0001193125-21-237889.txt : 20210805 0001193125-21-237889.hdr.sgml : 20210805 20210805170637 ACCESSION NUMBER: 0001193125-21-237889 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 211149352 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 10-Q 1 d192980d10q.htm 10-Q 10-Q
falseQ20001693415--12-312023-03-312023-03-31P1Y 0001693415 2021-06-30 0001693415 2020-12-31 0001693415 2021-01-01 2021-06-30 0001693415 2020-01-01 2020-06-30 0001693415 2021-04-01 2021-06-30 0001693415 2020-04-01 2020-06-30 0001693415 2018-03-31 2018-03-31 0001693415 2021-08-02 0001693415 2020-06-30 0001693415 2021-01-01 2021-03-31 0001693415 2020-01-01 2020-03-31 0001693415 2019-12-31 0001693415 2021-03-31 0001693415 2020-03-31 0001693415 tbio:LexingtonMassachusettsMember 2021-06-30 0001693415 tbio:MitResearchAgreementMember 2021-06-30 0001693415 tbio:SublicenseSecondAmendmentAgreementWithSanofiMember tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember 2021-06-30 0001693415 tbio:SanofiAgreementMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 tbio:AlbanyMolecularResearchIncamriMember tbio:SuiteRetentionAndDevelopmentAgreementMember 2021-06-30 0001693415 tbio:AzzurCleanroomsOnDemandBurlingtonLlcMember tbio:BurlingtonMassachusettsMember 2021-06-30 0001693415 tbio:WalthamMassachusettsMember 2021-06-30 0001693415 srt:MaximumMember tbio:SanofiCollaborationAndLicenseAgreementMember 2021-06-30 0001693415 tbio:SanofiAgreementMember srt:MaximumMember 2021-06-30 0001693415 srt:MinimumMember tbio:SanofiCollaborationAndLicenseAgreementMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:SublicenseSecondAmendmentAgreementWithSanofiMember tbio:SarsCov2LicensedFiledMember 2021-06-30 0001693415 tbio:FinancingReceivablesDueWithinOneYearMember 2021-06-30 0001693415 tbio:FinancingReceivablesDueAfterOneYearThroughTwoYearsMember 2021-06-30 0001693415 tbio:LaboratoryEquipmentMember 2021-06-30 0001693415 us-gaap:ComputerEquipmentMember 2021-06-30 0001693415 us-gaap:OfficeEquipmentMember 2021-06-30 0001693415 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001693415 us-gaap:ConstructionInProgressMember 2021-06-30 0001693415 tbio:AmendedSanofiAgreementMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001693415 tbio:ShiresMrtProgramMember tbio:SanofiAgreementMember 2021-06-30 0001693415 tbio:SuiteRetentionAndDevelopmentAgreementMember 2021-06-30 0001693415 tbio:ShiresMrtProgramMember 2021-06-30 0001693415 us-gaap:InProcessResearchAndDevelopmentMember tbio:MrtProductMember tbio:ShiresMrtProgramMember 2021-06-30 0001693415 tbio:SanofiCollaborationAndLicenseAgreementMember 2021-06-30 0001693415 tbio:ContingentConsiderationMember 2021-06-30 0001693415 tbio:EarnoutPaymentsMember tbio:ContingentConsiderationMember 2021-06-30 0001693415 tbio:MilestonePaymentsMember tbio:ContingentConsiderationMember 2021-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2021-06-30 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2021-06-30 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001693415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2021-06-30 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2021-06-30 0001693415 tbio:TwoThousandAndEighteenEmployeeStockPurchasePlanMember 2021-06-30 0001693415 tbio:OpenMarketSaleAgreementMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member tbio:ContingentConsiderationMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member tbio:ContingentConsiderationMember 2021-06-30 0001693415 tbio:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 tbio:AmendedSanofiAgreementMember tbio:SanofiPasteurIncMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:SanofiPasteurIncMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:MilestonePaymentThreeMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 tbio:WalthamMassachusettsMember 2020-12-31 0001693415 tbio:FinancingReceivablesDueWithinOneYearMember 2020-12-31 0001693415 tbio:FinancingReceivablesDueAfterOneYearThroughTwoYearsMember 2020-12-31 0001693415 tbio:LaboratoryEquipmentMember 2020-12-31 0001693415 us-gaap:ComputerEquipmentMember 2020-12-31 0001693415 us-gaap:OfficeEquipmentMember 2020-12-31 0001693415 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001693415 us-gaap:ConstructionInProgressMember 2020-12-31 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001693415 us-gaap:InProcessResearchAndDevelopmentMember tbio:ShiresMrtProgramMember tbio:MrtProductMember 2020-12-31 0001693415 tbio:ContingentConsiderationMember 2020-12-31 0001693415 tbio:EarnoutPaymentsMember tbio:ContingentConsiderationMember 2020-12-31 0001693415 tbio:MilestonePaymentsMember tbio:ContingentConsiderationMember 2020-12-31 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001693415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001693415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2020-12-31 0001693415 tbio:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:EmployeeStockOptionMember 2020-12-31 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001693415 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2021-04-01 2021-06-30 0001693415 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001693415 tbio:MitResearchAgreementMember 2021-04-01 2021-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2021-04-01 2021-06-30 0001693415 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001693415 srt:WeightedAverageMember us-gaap:RestrictedStockMember 2020-04-01 2020-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2020-04-01 2020-06-30 0001693415 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2020-04-01 2020-06-30 0001693415 tbio:MitResearchAgreementMember 2020-04-01 2020-06-30 0001693415 tbio:TwoThousandSixteenStockIncentivePlanMember 2021-01-01 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-06-30 0001693415 tbio:AlbanyMolecularResearchIncamriMember tbio:SuiteRetentionAndDevelopmentAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:AzzurCleanroomsOnDemandBurlingtonLlcMember tbio:BurlingtonMassachusettsMember 2021-01-01 2021-06-30 0001693415 us-gaap:OtherNoncurrentAssetsMember tbio:AlbanyMolecularResearchIncamriMember tbio:SuiteRetentionAndDevelopmentAgreementMember 2021-01-01 2021-06-30 0001693415 us-gaap:InProcessResearchAndDevelopmentMember tbio:MrtProductMember tbio:ShiresMrtProgramMember 2021-01-01 2021-06-30 0001693415 tbio:ContingentConsiderationMember 2021-01-01 2021-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember tbio:SecuritiesPurchaseAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:WalthamMassachusettsMember 2021-01-01 2021-06-30 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001693415 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001693415 tbio:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:EarnoutPaymentsMember srt:MinimumMember 2021-01-01 2021-06-30 0001693415 tbio:EarnoutPaymentsMember srt:MaximumMember 2021-01-01 2021-06-30 0001693415 tbio:MilestonePaymentsMember srt:MinimumMember 2021-01-01 2021-06-30 0001693415 tbio:MilestonePaymentsMember srt:MaximumMember 2021-01-01 2021-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2021-01-01 2021-06-30 0001693415 tbio:OpenMarketSaleAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:OriginalSanofiAgreementAndSecondSanofiAmendmentAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:MitResearchAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:SanofiAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:TwoThousandAndEighteenEmployeeStockPurchasePlanMember 2021-01-01 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:MilestonePaymentOneMember 2021-01-01 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:MilestonePaymentTwoMember 2021-01-01 2021-06-30 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001693415 us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0001693415 srt:WeightedAverageMember us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0001693415 tbio:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2020-01-01 2020-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2020-01-01 2020-06-30 0001693415 tbio:MitResearchAgreementMember 2020-01-01 2020-06-30 0001693415 tbio:SanofiAgreementMember 2020-01-01 2020-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001693415 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001693415 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001693415 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001693415 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-12-31 0001693415 us-gaap:InProcessResearchAndDevelopmentMember tbio:MrtProductMember tbio:ShiresMrtProgramMember 2020-01-01 2020-12-31 0001693415 tbio:OpenMarketSaleAgreementMember 2020-01-01 2020-12-31 0001693415 tbio:WalthamMassachusettsMember srt:MinimumMember 2020-01-01 2020-12-31 0001693415 tbio:WalthamMassachusettsMember srt:MaximumMember 2020-01-01 2020-12-31 0001693415 tbio:EarnoutPaymentsMember srt:MinimumMember 2020-01-01 2020-12-31 0001693415 tbio:EarnoutPaymentsMember srt:MaximumMember 2020-01-01 2020-12-31 0001693415 tbio:MilestonePaymentsMember srt:MinimumMember 2020-01-01 2020-12-31 0001693415 tbio:MilestonePaymentsMember srt:MaximumMember 2020-01-01 2020-12-31 0001693415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember srt:MinimumMember 2018-06-14 2018-06-15 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember srt:MaximumMember 2018-06-14 2018-06-15 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2018-06-14 2018-06-15 0001693415 tbio:LexingtonMassachusettsMember 2017-06-01 2017-06-30 0001693415 tbio:LexingtonMassachusettsMember 2017-06-30 0001693415 tbio:BiomedicalResearchModelsIncMember tbio:SuiteRetentionAndDevelopmentAgreementMember 2020-10-31 0001693415 tbio:AzzurCleanroomsOnDemandBurlingtonLlcMember tbio:BurlingtonMassachusettsMember 2020-10-31 0001693415 tbio:WalthamMassachusettsMember 2020-11-03 0001693415 tbio:RichmondGroupMember tbio:OfficeAndLaboratorySpaceMember 2021-04-30 0001693415 tbio:MitResearchAgreementMember 2019-09-01 2019-09-30 0001693415 tbio:MergerAgreementMember us-gaap:SubsequentEventMember 2021-08-02 0001693415 us-gaap:SubsequentEventMember tbio:MergerAgreementMember tbio:TerminationOfAgreementMember tbio:VectorMergerSubIncMember 2021-08-02 0001693415 tbio:SecondSanofiAmendmentAgreementMember 2020-07-20 2020-07-20 0001693415 tbio:AmendedSanofiAgreementMember 2021-03-31 0001693415 tbio:TwoThousandTwentyOneInducementStockIncentivePlanMember 2021-01-20 0001693415 tbio:BiomedicalResearchModelsIncMember tbio:SuiteRetentionAndDevelopmentAgreementMember 2020-10-01 2020-10-31 0001693415 tbio:LexingtonMassachusettsMember 2018-03-31 0001693415 tbio:WalthamMassachusettsMember 2020-11-03 2020-11-03 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2020-01-01 2020-01-01 0001693415 us-gaap:CommonStockMember 2021-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001693415 us-gaap:RetainedEarningsMember 2021-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001693415 us-gaap:CommonStockMember 2020-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001693415 us-gaap:RetainedEarningsMember 2020-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001693415 us-gaap:CommonStockMember 2020-12-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001693415 us-gaap:RetainedEarningsMember 2020-12-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001693415 us-gaap:CommonStockMember 2021-03-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001693415 us-gaap:RetainedEarningsMember 2021-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001693415 us-gaap:CommonStockMember 2019-12-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001693415 us-gaap:RetainedEarningsMember 2019-12-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001693415 us-gaap:CommonStockMember 2020-03-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001693415 us-gaap:RetainedEarningsMember 2020-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 iso4217:USD xbrli:shares utr:sqft xbrli:pure utr:Year utr:Month tbio:Subsidiary tbio:Disease iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
    
        
    
    
to
    
    
        
    
Commission File Number:
001-38550
 
 
Translate Bio, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
 
 
Delaware
 
61-1807780
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
   
29 Hartwell Avenue
Lexington, Massachusetts
 
02421
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (617)
945-7361
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.001 par value
 
TBIO
 
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    
Yes
  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    
Yes
  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer,
a
smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
       
Non-accelerated filer      Smaller reporting company  
Emerging growth company
 
  
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No
 
As of August 2, 2021, the registrant had 75,586,714 shares of common stock, $0.001 par value per share, outstanding.
 
 
 

Table of Contents
 
 
  
 
  
Page
 
PART I.
  
  
 
1
 
Item 1.
  
  
 
1
 
  
  
 
1
 
  
  
 
2
 
  
  
 
3
 
  
  
 
4
 
  
  
 
6
 
  
  
 
7
 
Item 2.
  
  
 
21
 
Item 3.
  
  
 
35
 
Item 4.
  
  
 
35
 
PART II.
  
  
 
36
 
Item 1.
  
  
 
36
 
Item 1A.
  
  
 
36
 
Item 6.
  
  
 
84
 
  
  
 
85
 
 
i

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
This Quarterly Report on
Form 10-Q contains
forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Quarterly Report
on Form 10-Q, including
statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this Quarterly Report on
Form 10-Q include,
among other things, statements about:
 
   
the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs;
 
   
our plans and expectations regarding our pending transaction with Sanofi, a French
société anonyme
, or Sanofi S.A., and our anticipated timeframe in which to complete the transaction, and if it is completed at all;
 
   
our estimates regarding expenses, future revenue, capital requirements and need for additional financing;
 
   
our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and investments and the period in which we expect that such cash, cash equivalents, and investments will enable us to fund such operating expenses and capital expenditure requirements;
 
   
our plans to develop our product candidates;
 
   
the timing of and our ability to submit applications and obtain and maintain regulatory approvals for our product candidates;
 
   
the potential advantages of our product candidates;
 
   
the rate and degree of market acceptance and clinical utility of our product candidates;
 
   
our estimates regarding the potential market opportunity for our product candidates;
 
   
our commercialization, marketing and manufacturing capabilities and strategy;
 
   
the impacts of the
COVID-19
pandemic;
 
   
our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;
 
   
our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;
 
   
the impact of government laws and regulations;
 
   
our competitive position;
 
   
developments relating to our competitors and our industry; and
 
   
our ability to establish collaborations or obtain additional funding.
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on
Form 10-Q, particularly
in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make, other than our pending transaction with Sanofi S.A.
 
ii

You should read this Quarterly Report on
Form 10-Q
and the documents that we reference herein and have filed or incorporated by reference hereto completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on
Form 10-Q are
made as of the date hereof, and we do not assume any obligation to update any forward-looking statements except as required by applicable law.
This Quarterly Report on
Form 10-Q
includes certain statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.
 
iii

PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
TRANSLATE BIO, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share amounts)
 
 
  
June 30,
 
 
December 31,
 
 
  
2021
 
 
2020
 
Assets
  
 
Current assets:
  
 
Cash and cash equivalents
   $ 249,471     $ 342,027  
Investments
     417,727       312,001  
Collaboration receivables
     24,030       26,598  
Prepaid expenses and other current assets
     20,958       11,741  
Restricted cash
     4,826       4,826  
    
 
 
   
 
 
 
Total current assets
     717,012       697,193  
Property and equipment, net
     18,249       15,372  
Right-of-use
assets, net
     68,123       72,957  
Goodwill
     21,359       21,359  
Intangible assets, net
     74,507       79,127  
Other assets
     5,620       3,928  
    
 
 
   
 
 
 
Total assets
   $ 904,870     $ 889,936  
    
 
 
   
 
 
 
Liabilities and Stockholders’ Equity
                
Current liabilities:
                
Accounts payable
   $ 13,736     $ 8,839  
Accrued expenses
     15,079       13,202  
Current portion of deferred revenue
     41,014       67,563  
Current portion of operating lease liability
     11,685       11,733  
Total current liabilities
     81,514       101,337  
Contingent consideration
     112,493       152,230  
Deferred revenue, net of current portion
     252,055       228,659  
Operating lease liability, net of current portion
     46,171       50,953  
    
 
 
   
 
 
 
Total liabilities
     492,233       533,179  
    
 
 
   
 
 
 
Commitments and contingencies (Notes 3 and 12)
                
Stockholders’ equity:
                
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of
June 30, 2021 and December 31, 2020; no shares issued and
outstanding as of June 30, 2021 and December 31, 2020
              —    
Common stock, $0.001 par value; 200,000,000 shares authorized as of
June 30, 2021 and December 31, 2020; 75,343,712 shares
and 75,029,625 shares
 
issued and outstanding as of
June 30, 2021 and December 31, 2020, respectively
     75       75  
Additional
paid-in
capital
     782,144       769,965  
Accumulated deficit
     (369,617 )     (413,283
Accumulated other comprehensive income
     35       —    
    
 
 
   
 
 
 
Total stockholders’ equity
     412,637       356,757  
    
 
 
   
 
 
 
Total liabilities and stockholders’ equity
   $ 904,870     $ 889,936  
    
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
1

TRANSLATE BIO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except share and per share amounts)
 
    
Three Months Ended June 30,
   
Six Months Ended June 30,
 
    
2021
    
2020
   
2021
   
2020
 
Collaboration revenue
   $ 72,649      $ 16,319     $ 107,249     $ 20,974  
Operating expenses:
                                 
Research and development
     40,477        29,002       81,617       50,442  
General and administrative
     11,921        8,601       22,738       16,060  
Change in fair value of contingent consideration
     4,242        15,347       (39,737     5,895  
    
 
 
    
 
 
   
 
 
   
 
 
 
Total operating expenses
     56,640        52,950       64,618       72,397  
    
 
 
    
 
 
   
 
 
   
 
 
 
Income (loss) from operations
     16,009        (36,631     42,631       (51,423
Other income, net
     154        343       308       853  
Income (loss) before income tax
es
     16,163        (36,288     42,939       (50,570
Income tax benefit
    
981
       —         727       —    
Net income (loss)
   $ 17,144      $ (36,288   $ 43,666     $ (50,570
    
 
 
    
 
 
   
 
 
   
 
 
 
Net income (loss) per share—basic
   $ 0.23      $ (0.58   $ 0.58     $ (0.83
    
 
 
    
 
 
   
 
 
   
 
 
 
Weighted average common shares outstanding—basic
     75,254,186        62,282,291       75,222,119       61,145,254  
    
 
 
    
 
 
   
 
 
   
 
 
 
Net income (loss) per share—diluted
   $ 0.21      $ (0.58   $ 0.55     $ (0.83
    
 
 
    
 
 
   
 
 
   
 
 
 
Weighted average common shares outstanding—diluted
     80,026,488        62,282,291       79,994,422       61,145,254  
    
 
 
    
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
2

TRANSLATE BIO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
(In thousands)
 
    
Three Months Ended June 30,
   
Six Months Ended June 30,
 
    
2021
   
2020
   
2021
    
2020
 
Net income (loss)
   $ 17,144     $ (36,288   $ 43,666      $ (50,570
Other comprehensive income (loss):
                                 
Unrealized gains (losses) on
available-for-sale
securities, net of tax of $0
     (42     (315     35        (201
    
 
 
   
 
 
   
 
 
    
 
 
 
Comprehensive income (loss)
   $ 17,102     $ (36,603   $ 43,701      $ (50,771
    
 
 
   
 
 
   
 
 
    
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
3

TRANSLATE BIO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)
(In thousands, except share amounts)
 
 
  
Common Stock
 
  
Additional
Paid-in
 
  
Accumulated
 
 
Accumulated
Other
Comprehensive
 
 
Total
Stockholders’
 
 
  
Shares
 
  
Amount
 
  
Capital
 
  
Deficit
 
 
Income
 
 
Equity
 
Balances at December 31, 2020
     75,029,625      $ 75      $ 769,965      $ (413,283   $        $ 356,757  
Exercise of stock options
     188,047        —          1,550        —         —         1,550  
Stock-based compensation expense
     —          —          3,984        —         —         3,984  
Unrealized gains on
available-for-sale
securities
     —          —          —          —         77       77  
Net income
     —          —          —          26,522       —         26,522  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balances at March 31, 2021
     75,217,672        75        775,499        (386,761     77       388,890  
Exercise of stock options
     98,852        —          819        —         —         819  
Issuance of common stock under employee stock purchase plan
     27,188        —          490        —         —         490  
Stock-based compensation expense
     —          —          5,336        —         —         5,336  
Unrealized losses on
available-for-sale
securities
     —          —          —          —         (42     (42
Net income
     —          —          —          17,144       —         17,144  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balances at June 30, 2021
     75,343,712      $ 75      $ 782,144      $ (369,617   $ 35     $ 412,637  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
4

TRANSLATE BIO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)
(In thousands, except share amounts)
 
 
  
Common Stock
 
  
Additional
Paid-in
 
  
Accumulated
 
 
Accumulated
Other
Comprehensive
 
 
Total
Stockholders’
 
 
  
Shares
 
  
Amount
 
  
Capital
 
  
Deficit
 
 
Income
 
 
Equity
 
Balances at December 31, 2019
     60,022,067      $ 60      $ 512,231      $ (359,496   $ 741     $ 153,536  
Exercise of stock options
     15,596        —          132        —         —         132  
Stock-based compensation expense
     —          —          3,172        —         —         3,172  
Unrealized gains on
available-for-sale
securities
     —          —          —          —         114       114  
Net loss
     —          —          —          (14,282     —         (14,282
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balances at March 31, 2020
     60,037,663        60        515,535        (373,778     855       142,672  
Issuance of common stock in connection with public offerings, net of underwriting discounts and commissions and offering costs
     8,544,982        9        153,602        —         —         153,611  
Exercise of stock options
     776,864        —          5,699        —         —         5,699  
Stock-based compensation expense
     —          —          6,014        —         —         6,014  
Unrealized
losses
 on
available-for-sale
securities
     —          —          —          —         (315     (315
Net loss
     —          —          —          (36,288     —         (36,288
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balances at June 30, 2020
     69,359,509      $ 69      $ 680,850      $ (410,066   $ 540     $ 271,393  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
5

TRANSLATE BIO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
 
  
Six Months Ended June 30,
 
 
  
2021
 
 
2020
 
Cash flows from operating activities:
  
 
Net income (loss)
   $ 43,666     $ (50,570
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
                
Depreciation and amortization expense
     6,471       5,617  
Stock-based compensation expense
     9,320       9,186  
Change in fair value of contingent consideration
     (39,737     5,895  
Changes in operating assets and liabilities:
                
Collaboration receivables
     2,568       (10,535
Prepaid expenses and other assets
     (8,521     1,472  
Right-of-use
assets
     6,210       270  
Long-term prepaid rent
     (2,395    
(7,381
)  
Accounts payable
     3,900       (2,783
Accrued expenses
     1,571       4,013  
Lease liability
     (6,206     (244
Deferred revenue
     (3,153     (6,429
    
 
 
   
 
 
 
Net cash provided by (used in) operating activities
     13,694       (51,489
    
 
 
   
 
 
 
Cash flows from investing activities:
                
Purchases of investments
     (185,690     (27,409
Sales and maturities of investments
     80,000       111,277  
Purchases of property and equipment
     (3,419     (4,446
    
 
 
   
 
 
 
Net cash provided by (used in) investing activities
     (109,109     79,422  
    
 
 
   
 
 
 
Cash flows from financing activities:
                
Proceeds from public offerings, net of underwriting discounts and commissions
     —         154,292  
Payments of public offering costs
     —         (443
Proceeds from option exercises
     2,369       5,831  
Proceeds from issuance of common stock under employee stock purchase plan
     490       —    
    
 
 
   
 
 
 
Net cash provided by financing activities
     2,859       159,680  
    
 
 
   
 
 
 
Net increase (decrease) in cash, cash equivalents and restricted cash:
     (92,556     187,613  
Cash, cash equivalents and restricted cash at beginning of period
     346,853       85,530  
    
 
 
   
 
 
 
Cash, cash equivalents and restricted cash at end of period
   $ 254,297     $ 273,143  
    
 
 
   
 
 
 
Cash, cash equivalents and restricted cash at end of period:
                
Cash and cash equivalents
   $ 249,471     $ 272,193  
Restricted cash
     4,826       950  
    
 
 
   
 
 
 
Total cash, cash equivalents and restricted cash at end of period
   $ 254,297     $ 273,143  
    
 
 
   
 
 
 
Purchases of property and equipment included in accounts payable and accrued expenses
   $ 1,707     $ 718  
Offering costs included in accrued expenses
   $ —       $ 238  
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
6

TRANSLATE BIO, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. Nature of the Business and Basis of Presentation
Translate Bio, Inc. (the “Company”) is a clinical-stage messenger RNA (“mRNA”) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Using its proprietary mRNA therapeutic platform (“MRT platform”), the Company creates mRNA that encodes functional proteins. The Company’s mRNA is designed to be delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The Company is primarily focused on applying its MRT platform to treat pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease. In addition, the Company is pursuing discovery efforts in diseases that affect the liver. The Company is also pursuing the applicability of its MRT platform for the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur Inc. (“Sanofi”), the vaccines global business unit of Sanofi, a French
société anonyme
(“Sanofi S.A.”)
The Company is developing mRNA therapeutics for the treatment of cystic fibrosis (“CF”) with two programs, MRT5005, a clinical-stage program, and a preclinical next-generation CF program. The Company is conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of single- and multiple-ascending doses of MRT5005. The clinical trial is investigating several groups receiving five once-weekly doses, as well as a group receiving five daily doses. Percent predicted forced expiratory volume in one second (“ppFEV
1
”) which is a well-defined and accepted endpoint measuring lung function, is also being measured at
pre-defined
timepoints throughout the trial as a safety measure. In 2019, the Company reported interim data from the single-ascending dose portion of the Phase 1/2 clinical trial through
one-month
follow up post dosing. In March 2021, the Company reported the second interim data analysis. In evaluating safety and tolerability, the primary outcome measure, data to date from the ongoing Phase 1/2 clinical trial suggested that repeat dosing of MRT5005 was generally safe and well tolerated. For patients receiving MRT5005, ppFEV
1
was not negatively impacted; there was no pattern of treatment-associated increases in ppFEV
1
. The clinical trial is ongoing with evaluation of the remaining dose groups, which include a 20 mg multiple-ascending dose group and the daily dosing cohort, and the Company anticipates reporting the interim findings from the clinical trial at the North American Cystic Fibrosis Conference, being held September 30, 2021 through October 2, 2021. The Company’s preclinical next-generation CF program incorporates mRNA codon optimization and advances in lipid nanoparticle chemistry. Positive preclinical data generated from the program support the planned initiation of investigational new drug (“IND”)-enabling studies in the second half of 2021. The Company is conducting translational studies with MRT5005 and a next-generation CF candidate to support and optimize future clinical development
.
The Company is leveraging its lung delivery platform and focusing its preclinical research efforts on identifying lead product candidates in additional pulmonary diseases with unmet medical needs, including primary ciliary dyskinesia (“PCD”), pulmonary arterial hypertension and respiratory infectious diseases. Positive preclinical data from our PCD program support the anticipated initiation of
IND-enabling
studies in the second half of 2021.
The Company has a collaboration with Sanofi to develop infectious disease vaccines using the Company’s mRNA technology. Under the collaboration, the Company and Sanofi are jointly conducting research and development activities to advance mRNA vaccines targeting up to seven infectious disease pathogens (see Note 3). Two of the target pathogens under development are
SARS-CoV-2,
which causes
COVID-19,
and influenza. MRT5500 has been selected as the lead candidate for a vaccine against
SARS-CoV-2.
A Phase 1/2 clinical trial to evaluate MRT5500 began in the first quarter of 2021 with interim data anticipated in the third quarter of 2021. A Phase 1 clinical trial evaluating MRT5400 and MRT5401, the Company’s investigational mRNA vaccine candidates against seasonal influenza, was initiated in June 2021 with interim data expected by the end of 2021.
Since early 2020, the outbreak of the novel strain of coronavirus named
SARS-CoV-2
has spread across the globe and the
COVID-19
pandemic has had wide-reaching impacts on the global economy and business operations. The
COVID-19
pandemic has had, and the Company expects it will continue to have, an impact on its operations, the operations of its collaborators, the operations of third-party contractors and other entities with which the Company interacts, as well as on the patients who may enroll in the Company’s clinical trials. The Company continues to actively monitor
COVID-19
trends and government guidance. The ultimate impacts of the
COVID-19
pandemic are still unknow
n
 and uncertain.
The Company is subject to risks common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently
 
7

under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sal
e
s.
The preparation of the accompanying condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the
COVID-19
pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning
COVID-19
and the actions taken in an effort to contain or to potentially treat or vaccinate against
COVID-19,
it as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of
COVID-19
within its financial statements and have determined them to be immaterial. There may be changes to those estimates in future periods. Actual results may differ from these estimates.
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its two wholly owned subsidiaries,
Translate Bio MA, Inc. and Translate Bio Securities Corporation, from their date of incorporation. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated balance sheet as of June 30, 2021, the unaudited condensed consolidated statements of operations and of comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020, the unaudited condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2021 and 2020 and the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The accompanying balance sheet as of December 31, 2020 has been derived from the Company’s audited financial statements for the year ended December 31, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form
10-K
that was filed with the SEC on March 1, 2021.
The accompanying unaudited interim condensed consolidated financial presentation has been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflects all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2021, the results of its operations for the three and six months ended June 30, 2021 and 2020, and its cash flows for the six months ended June 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2021 and 2020 are also unaudited. The results for the three and six months ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period.
Sales of Common Stock
The Company is a party to an Open Market Sale Agreement
SM
(the “Sales Agreement”) with Jefferies LLC under
 which the Company may issue and sell shares of common stock, from time to time, having an aggregate offering price of up to $
100.0
 million. During the year ended December 
31
,
2020
, the Company issued and sold
2,863,163
shares of its common stock pursuant to the Sales Agreement, resulting in gross proceeds of $
37.9 
million, before deducting commissions of $
1.1
 million and other offering expenses of $
0.2
 million. There were
no
shares issued or sold pursuant to the Sales Agreement during the six months ended June 
30
,
2021
. In the future, $
62.1
 million of shares of common stock remain available to be sold pursuant to the Sales Agreement, which sales, if any, would be made under the Company’s universal shelf registration statement on Form
S-3.
2. Summary of Significant Accounting Policies
The significant accounting policies and estimates used in preparation of the consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company’s Annual Report on Form
10-K.
During the six months ended June 30, 2021, there were no material changes to the Company’s significant accounting policies.
 
8

Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2016-13,
Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
. The guidance requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For
available-for-sale
debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements and disclosures.
In December 2019, the FASB issued ASU
No. 2019-12,
Income Taxes-Simplifying the Accounting for Income Taxes
. This new standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a
step-up
in the tax basis of goodwill. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements.
3. Collaboration Agreement
Sanofi Collaboration and License Agreement
In 2018, the Company entered into a collaboration and license agreement with Sanofi (the “Original Sanofi Agreement”) to develop mRNA vaccines for up to five infectious disease pathogens (the “Licensed Fields”). On March 26, 2020, the Company and Sanofi amended the Original Sanofi Agreement (the “First Sanofi Amendment”) to include vaccines against
SARS-CoV-2
as an additional Licensed Field, increasing the number of infectious disease pathogens to up to six. On June 22, 2020, the Company and Sanofi further amended the Original Sanofi Agreement to expand the scope of the collaboration and licenses granted to Sanofi (the “Second Sanofi Amendment”). The Original Sanofi Agreement, as amended by the First Sanofi Amendment and the Second Sanofi Amendment, is referred to as the “Amended Sanofi Agreemen
t
.”
Pursuant to the Amended Sanofi Agreement, the Company and Sanofi are jointly conducting research and development activities to advance mRNA vaccines targeting up to seven infectious disease pathogens. The term of the research collaboration (the “Collaboration Term”) expires in June 2022 with an option for Sanofi to extend the Collaboration Term for one additional year, followed by a technology transfer to Sanofi. If Sanofi elects to extend the Collaboration Term, the collaboration may be further expanded to jointly conduct research and development activities to advance mRNA vaccines for up to an additional three infectious disease pathogens, bringing the total to up to ten pathogens.
Under the terms of the Amended Sanofi Agreement, the Company has granted to Sanofi exclusive, worldwide licenses under applicable patents, patent applications,
know-how
and materials, including those arising under the collaboration, to develop, commercialize and manufacture mRNA vaccines to prevent, treat or cure diseases, disorders or conditions in humans caused by any infectious disease pathogen, with certain specified exceptions.
Pursuant to the Original Sanofi Agreement, Sanofi paid the Company an upfront payment of $45.0 million in 2018. Pursuant to the Second Sanofi Amendment, Sanofi paid the Company an additional upfront payment of $300.0 million in August 2020. If Sanofi chooses to exercise its option to extend the Collaboration Term for an additional year, Sanofi has agreed to pay the Company an additional payment of $75.0 million. The Amended Sanofi Agreement provides that the Company is eligible to receive aggregate potential payments of up to $1.9 billion upon the achievement of additional specified development, regulatory, manufacturing and commercialization milestones, inclusive of the fee to exercise the option to extend the Collaboration Term. In particular, the Company is entitled to receive development, regulatory and sales milestone payments of up to $148.0 million for each Licensed Field, other than the
SARS-CoV-2
Licensed Field, development, regulatory and sales milestone payments of up to $250.0 million in the
SARS-CoV-2
Licensed Field, and
one-time
manufacturing milestone payments of up to $200.0 million. In addition, the Company is entitled to receive a $10.0 million milestone payment from Sanofi following
completion
of the technology and process transfer. In March 2021, Sanofi paid the Company a milestone payment of $25.0 million upon the initiation of the Phase 1/2 clinical trial of MRT5500 and in June 2021, Sanofi paid the Company a milestone payment of $50.0 million upon the successful manufacture, release and delivery of clinical drug product to supply the Phase 1 clinical trial of MRT5400 and MRT5401. Additionally, in June 2021, the Company achieved a milestone of $4.0 million upon the start of the Phase 1 clinical trial of MRT5400 and MRT5401, which is included in collaboration receivables on the condensed consolidated balance sheet as of June 30, 2021.
 
9

Accounting for the Sanofi Collaboration
The Company recognizes revenue under Accounting Standards Codification (“ASC”) 606,
Revenue from Contracts with Customer
(“ASC 606”)
.
During the six months ended June 30, 2021, the Company increased the overall transaction price by
$108.7 million. The transaction price as of June 30, 2021 includes the upfront,
non-refundable
payments of $345.0 million for the transfer of the combined license, supply and development obligations under the Original Sanofi Agreement and Second Sanofi Amendment, the premium paid in consideration for common stock of $51.2 million under a securities purchase
agreement
entered into with an affiliate of Sanofi, an estimated $76.3 million in reimbursable employee costs, an estimated $167.8 million in reimbursable development costs including manufacturing costs and
out-of-pocket
costs paid to third parties and an estimated $212.0 million in milestone payments. Under ASC 606, at the end of each reporting period, the Company
re-evaluates
the variable consideration determined using either the expected value or most likely outcome approach and
re-evaluates
the probability that the consideration associated with each milestone or reimbursement will not be subject to a significant reversal in the cumulative amount of revenue recognized, and, if necessary, adjusts the estimate of the overall transaction price. The estimated collaboration budget is consistently
re-evaluated
and changes to the budget, if any, require approval by the Joint Steering Committee. If an approved change occurs, the Company will
re-evaluate
the transaction price which could potentially affect the cumulative amount of revenue recognized. Changes as a result of a contract modification or in the planned services under the Amended Sanofi Agreement may have an impact on the transaction price and on the Company’s measure of progress toward complete satisfaction of the performance obligation. The impact of changes during the six months ended June 30, 2021 resulted in a cumulative revenue
catch-up
adjustment of $20.5 million.
The following table summarizes the Company’s collaboration revenue (in thousands):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2021
    
2020
    
2021
    
2020
 
Collaboration revenue
   $ 72,649      $ 16,319      $ 107,249      $ 20,974  
The following table presents the balance of the Company’s contract liabilities (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Contract liabilities
                 
Deferred revenue
   $ 293,069      $ 296,222  
Deferred revenue is classified as short-term or long-term in the
conde
nsed
consolidated balance sheets based on the Company’s estimate of revenue that will be recognized within the next twelve months which is determined by the
cost-to-cost
input method which measures the extent of progress towards satisfying the performance obligation. As of June 30, 2021, the aggregate amount of the transaction price allocated to the remaining performance obligation is estimated to be approximately $597.0 million, which is expected to be recognized as revenue through 2024. Revenue recognized from contract liabilities at the beginning of the period was $29.8 million and $6.4 million during the six months ended June 30, 2021 and 2020, respectively.
4. Intangible Assets and Goodwill
Acquisition of Shire’s MRT Program
In December 2016, the Company entered into an asset purchase agreement (as amended in June 2018) with Shire Human Genetic Therapies, Inc. (“Shire”), a subsidiary of Takeda Pharmaceutical Company Ltd., pursuant to which Shire sold equipment to and assigned to the Company all of its rights to certain patent rights, permits, real property leases, contracts, regulatory documentation, books and records, and materials related to Shire’s mRNA therapy platform (the “MRT Program”), including its cystic fibrosis transmembrane conductance regulator program.
 
10

Intangible Assets, Net
The acquisition of Shire’s MRT Program was accounted for in accordance with the acquisition method of accounting for business combinations. The total purchase consideration transferred was allocated to the tangible and identifiable intangible assets acquired based on their estimated fair values. The tables below present the Company’s definite-lived intangible assets that are subject to amortization and indefinite-lived intangible assets:
 
           
June 30, 2021
 
    
Estimated Life
    
Gross Carrying

Amount
    
Accumulated

Amortization
    
Net Carrying

Amount
 
           
(In thousands)
 
Definite-lived intangible assets:
                                   
MRT
     6 years      $ 45,992      $ (13,776    $ 32,216  
             
 
 
    
 
 
    
 
 
 
Indefinite-lived intangible assets:
                                   
IPR&D—CF
     Indefinite        42,291        —          42,291  
             
 
 
    
 
 
    
 
 
 
Total intangible assets, net
            $ 88,283      $ (13,776    $ 74,507  
             
 
 
    
 
 
    
 
 
 
     
           
December 31, 2020
 
    
Estimated Life
    
Gross Carrying

Amount
    
Accumulated

Amortization
    
Net Carrying

Amount
 
           
(In thousands)
 
Definite-lived intangible assets:
                                   
MRT
     6 years      $ 45,992      $ (9,156    $ 36,836  
             
 
 
    
 
 
    
 
 
 
Indefinite-lived intangible assets:
                                   
IPR&D—CF
     Indefinite        42,291        —          42,291  
             
 
 
    
 
 
    
 
 
 
Total intangible assets, net
            $ 88,283      $ (9,156    $ 79,127  
             
 
 
    
 
 
    
 
 
 
Identifiable intangible assets acquired in the acquisition of Shire’s MRT Program consisted of
in-process
research and development (“IPR&D”), which included ongoing projects that could further the Company’s preclinical and clinical development activities related to CF and other potential rare diseases. As of the date of acquisition, the IPR&D was determined to be indefinite-lived.
Upon
commencement
of the Original Sanofi Agreement, the IPR&
D—M
RT intangible asset was reclassified from indefinite-lived to definite-lived intangible assets and the Company began amortization of this intangible asset. Amortization will be recorded over the intangible asset’s estimated life based on an economic consumption
model
. The Company recorded amortization expense of $2.6 million and $3.6 million during the three months ended June 30, 2021 and 2020, respectively, and $4.6 million and $4.3 million during the six months ended June 30, 2021 and 2020, respectively, related to the definite-lived MRT intangible asset. The estimated amortization expense for the remainder of the useful life is $11.8 million, $11.2 million, $11.1 
million
and $2.7 million for the years ending December 31, 2021, 2022, 2023 and 2024, respectively.
Indefinite-lived IPR&D is not subject to amortization, but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived IPR&D annually for impairment on October 1st. During the six months ended June 30, 2021 and 2020, the Company did not recognize any impairment charges related to indefinite-lived IPR&D.
 
11

Goodwill
The excess of the fair value of the consideration transferred over the fair value of identifiable assets acquired in the acquisition of Shire’s MRT Program was allocated to goodwill in the amount of $21.4 million. There have been no changes to the carrying amount of goodwill during the six months ended June 30, 2021. Goodwill is not subject to amortization, but is tested annually for impairment or more frequently if there are indicators of impairment. During the six months ended June 30, 202
1
and 20
20
, the Company did not recognize any impairment charges related to goodwill.
5. Fair Value of Financial Assets and Liabilities
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):
 
 
  
Fair Value Measurements

as of June 30, 2021 Using:
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Assets:
                                   
Money market funds
   $         $ 167,938      $         $ 167,938  
U.S. treasuries
               359,871                  359,871  
U.S. government agency bonds
               57,856                  57,856  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $         $ 585,665      $         $ 585,665  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Contingent consideration
   $         $         $ 112,493      $ 112,493  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $         $         $ 112,493      $ 112,493  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
  
Fair Value Measurements

as of December 31, 2020 Using:
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Assets:
  
  
  
  
Money market funds
   $ —        $ 273,827      $ —        $ 273,827  
U.S. treasuries
               292,001        —          292,001  
U.S. government agency bonds
     —          20,000        —          20,000  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ 585,828      $ —        $ 585,828  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Contingent consideration
   $ —        $ —        $ 152,230      $ 152,230  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ —        $ 152,230      $ 152,230  
    
 
 
    
 
 
    
 
 
    
 
 
 
During the six months ended June 30, 2021 and the year ended December 31, 2020, there were no transfers between Level 1, Level 2 and Level 3.
Cash equivalents as of June 30, 2021 and December 31, 2020 consisted of money market funds totaling $167.9 million and $273.8 million, respectively. The money market funds were valued using inputs observable in active markets for similar securities, which represent a Level 2 measurement in the fair value hierarchy. The Company’s investments as of June 30, 2021 and December 31, 2020 consisted of U.S. treasuries and U.S. government agency bonds and were clas
s
ified as
available-for-sale
securities. The U.S. treasuries and U.S. government agency bonds were valued using inputs observable in active markets for similar securities, which represent a Level 2 measurement in the fair value hierarchy. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such
available-for-sale
securities represent the investment of cash that is available for current operations.
The estimated amortized costs and fair value of the Company’s
available-for-sale
securities by contractual maturity are summarized as follows:
 
12

    
June 30, 2021
    
December 31, 2020
 
    
Amortized Cost
    
Fair Value
    
Amortized Cost
    
Fair Value
 
Due within one year
   $ 305,053      $ 305,095      $ 201,606      $ 201,596  
Due after one year through two years
     112,639        112,632        110,395        110,405  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
available-for-sale
securities
   $ 417,692      $ 417,727      $ 312,001      $ 312,001  
    
 
 
    
 
 
    
 
 
    
 
 
 
Valuation of Contingent Consideration
The contingent consideration liability related to the acquisition of Shire’s MRT Program in 2016 was classified as a Level 3 measurement within the fair value hierarchy. The Company may be required to pay future consideration to Shire contingent upon the achievement of potential future milestones and earnout payments.
The fair value of the liability to make potential future milestone and earnout payments was estimated by the Company at each reporting date based, in part, on the results of a valuation u
s
ing a discounted cash flow analysis based on various assumptions, including the amount and timing of cash flows, probability of achieving specified events, discount rate, and the period of time until earnout payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events.
The following table presents the unobservable inputs and fair value of the components of the contingent consideration (dollar amounts in thousands):
 
 
  
Unobservable Inputs
 
  
Fair Value at
 
 
  
Projected Year of Payment
 
  
June 30,
 
  
December 31,
 
 
  
 
 
  
2021
 
  
2020
 
Earnout payments
    
2027 -
 2039
     $ 103,093      $ 142,250  
Milestone payments
  
 
2027 - 2031
       9,400        9,980  
             
 
 
    
 
 
 
              $ 112,493      $ 152,230  
             
 
 
    
 
 
 
The discount rate used in the valuation was 10.8% and 11.0% as of June 30, 2021 and December 31, 2020, respectively.
The following table presents a roll-forward of the total acquisition-related contingent consideration liability (in thousands):
 
    
Fair Value
 
Balance as of December 31, 2020
   $ 152,230  
Decrease in fair value of contingent consideration
     (39,737
    
 
 
 
Balance as of June 30, 2021
   $ 112,493  
    
 
 
 
The change in the fair value of contingent consideration was due to a large decrease in the fair value of contingent consideration during the three months ended March 31, 2021 due to the previously announced results of the second interim data analysis from the Phase 1/2 clinical trial of MRT5005. This decrease was partially offset by an increase in the fair value of contingent consideration during the three months ended June 30, 2021 due to
the
time value of money due to the passage of time and a decrease in the discount rate.
6. Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Laboratory equipment
   $ 18,949      $ 12,710  
Computer equipment
     932        922  
Office equipment
     941        941  
Leasehold improvements
     5,557        5,730  
Construction in progress
     2,882        5,189  
    
 
 
    
 
 
 
       29,261        25,492  
Less: Accumulated depreciation and amortization
     (11,012      (10,120
    
 
 
    
 
 
 
     $ 18,249      $ 15,372  
    
 
 
    
 
 
 
 
13

Depreciation and amortization expense related to property and equipment was $1.0 million and $0.7 million during the three months ended June 30, 2021 and 2020, respectively, and $1.9 million and $1.4 million during the six months ended June 30, 2021 and 2020, respectively.
7. Accrued Expenses
Accrued expenses consisted of the following (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Accrued employee compensation and benefits
   $ 5,326      $ 5,600  
Accrued external research and development expenses
     4,420        2,805  
Accrued consultant and professional fees
     2,468        1,489  
Other
     2,865        3,308  
    
 
 
    
 
 
 
     $ 15,079      $ 13,202  
    
 
 
    
 
 
 
Included in other accrued expenses as of June 30, 2021 was $2.5 million related to a work agreement to perform a
build-out
of the Company’s office and laboratory space at 200 West Street in Waltham, Massachusetts (see Note 11).
8. Incentive Stock Options and Employee Stock Purchase Plan
2021 Inducement Stock Incentive Plan
On January 20, 2021, the Board of Directors adopted a 2021 Inducement Stock Incentive Plan (the “2021 Plan”), pursuant to which the Company may grant
non-statutory
stock options, restricted stock, restricted stock units and other stock-based awards with respect to an aggregate of
 
2,612,550 
shares of common stock. Awards under the 2021 Plan may only be granted to persons who (i) were not previously an employee or director of the Company or (ii) are commencing employment with the Company following a bona fide period of
non-employment,
in either case as an inducement material to the individual’s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4).
2018 Equity Incentive Plan
On March 7, 2018, the Company’s Board of Directors (the “Board of Directors”), subject to stockholder approval, adopted, and on June 15, 2018, the Company’s stockholders approved, the 2018 Equity Incentive Plan (the “2018 Plan”), which became effective on June 27, 2018. The 2018 Plan provides for the grant of incentive stock options,
non-qualified
stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The Company previously awarded grants under the 2016 Stock Incentive Plan (the “2016 Plan”). Upon the effectiveness of the 2018 Plan, no further awards will be made under the 2016 Plan, but awards outstanding under the 2016 Plan will continue to be governed by their existing terms
.
As of December 31, 2020, there were 7,457,171 shares of common stock reserved for issuance under the 2018 Plan. On January 1, 2021, the number of shares of common stock that may be issued under the 2018 Plan increased by 3,001,185 shares of common stock. During the six months ended June 30, 2021, a total of 12,848 shares issued under the 2016 Plan have been canceled and rolled over to the 2018 Plan, such that there is a total of 10,471,204 shares of common stock reserved for issuance under the 2018 Plan as of June 30, 2021. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, repurchased or are otherwise terminated by the Company under the 20
16
Plan will be added back to the shares of common stock available for issuance under the 2018 Plan.
The 2018 Plan is administered by the Board of Directors. The exercise prices, vesting periods and other restrictions are determined at the discretion of the Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the common stock on the date of grant. Stock options awarded under the 2018 Plan expire 10 years after the grant date, unless the Board of Directors sets a shorter term. Awards granted to employees, officers, members of the Board of Directors and consultants typically vest over a period of
one
to
four
years
.
Typically, unvested stock options are forfeited upon the recipient ceasing to provide services to the Company.
 
14

2018 Employee Stock Purchase Plan
On March 7, 2018, the Board of Directors, subject to stockholder approval, adopted, and on June 15, 2018, the Company’s stockholders approved the 2018 Employee Stock Purchase Plan (the “2018 ESPP”), which became effective on June 27, 2018. As of June 30, 2021, 870,096 shares of common stock were reserved for issuance under this plan.
As of June 30, 2021, 54,152 shares have been issued under the 2018 ESPP.
Stock Options
The following table summarizes the Company’s stock option activity since December 31, 2020 (in thousands, except share and per share amounts):
 
    
Number of

Shares
    
Weighted

Average

Exercise

Price
    
Weighted

Average

Remaining

Contractual

Term
    
Intrinsic

Value
 
                  
(in years)
        
Outstanding as of December 31, 2020
     9,557,391      $ 8.79        7.92      $ 93,256  
Granted
     3,126,560      $ 21.81                    
Exercised
     (286,899    $ 8.25                    
Forfeited
     (154,303    $ 14.68                    
    
 
 
                            
Outstanding as of June 30, 2021
     12,242,749      $ 12.06        8.07      $ 189,483  
    
 
 
                            
Exercisable as of June 30, 2021
     5,953,908      $ 8.14        7.07      $ 115,421  
Vested and expected to vest as of June 30, 2021
     12,242,749      $ 12.06        8.07      $ 189,483  
The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2021 and 2020 was $3.8 million and $10.7 million, respectively.
The weighted average grant-date fair value per share of stock options granted was $13.56 and $5.50 during the six months ended June 30, 2021 and 2020, respectively.
Stock Option Valuation
The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company completed its initial public offering in July 2018 and therefore lacks company-specific historical and implied volatility information before that date. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to
non-employees
is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors:
 
    
Six Months Ended June 30,
 
    
2021
   
2020
 
Risk-free interest rate
     1.03     0.79
Expected term (in years)
     6.1       6.1  
Expected volatility
     69.7     68.6
Expected dividend yield
     0     0
 
15

Stock-Based Compensation
Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands):
 
 
  
Three Months Ended June 30,
 
  
Six Months Ended June 30,
 
 
  
2021
 
  
2020
 
  
2021
 
  
2020
 
Research and development expenses
   $ 2,841      $ 4,091      $ 4,921      $ 5,545  
General and administrative expenses
     2,495        1,923        4,399        3,641  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ 5,336      $ 6,014      $ 9,320      $ 9,186  
    
 
 
    
 
 
    
 
 
    
 
 
 
As of June 30, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $57.4 million, which is expected to be recognized over a weighted average period of 2.9 years.
9. Income Taxes
The Company recognized an income tax
benefit
of $1.0 million and $0.7
million during the three and six months ended June 30, 2021,
respectively, due to the current period income before income taxes and the application of the annual effective tax rate. The annual effective tax rate
relates primarily to an expected income tax liability due to the acceleration of revenue recognition for tax purposes related to the Amended Sanofi Agreement. There was
no
 income tax benefit recognized during the three and six months ended June 30, 2020. Net operating losses generated in
2018
and years thereafter can be carried forward indefinitely. 
10. Net Income (Loss) per Share
Basic net income (loss) per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period, including any dilutive effect from outstanding stock options.
Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2021
    
2020
    
2021
    
2020
 
Basic net income (loss) per common share:
                                   
Numerator:
                                   
Net income (loss)
   $ 17,144      $ (36,288    $ 43,666      $ (50,570
Denominator:
                                   
Weighted average common shares outstanding—basic
     75,254,186        62,282,291        75,222,119        61,145,254  
Net income (loss) per share—basic
   $ 0.23      $ (0.58    $ 0.58      $ (0.83
Diluted net income (loss) per common share:
                                   
Numerator:
                                   
Net income (loss)
   $ 17,144      $ (36,288    $ 43,666      $ (50,570
Denominator:
                                   
Weighted average common shares
outstanding—diluted
     80,026,488        62,282,291        79,994,422        61,145,254  
Net income (loss) per share—diluted
   $ 0.21      $ (0.58    $ 0.55      $ (0.83
 
16

The Company excluded 3,790 shares and 11,149 shares of restricted common stock, presented on a weighted average basis, from the calculations of basic net loss per share attributable to common stockholders for the three and six months ended June 30, 2020, respectively, because those shares had not vested. As of June 30, 2021, there are no unvested shares of restricted common stock.
The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
 
    
Six Months Ended June 30,
 
    
2021
    
2020
 
Options to purchase common stock
     3,608,932        10,494,989  
Unvested restricted common stock
               1,691  
    
 
 
    
 
 
 
       3,608,932        10,496,680  
    
 
 
    
 
 
 
11. Leases
Suite Retention Agreements
In September 2019, the Company entered into a suite retention and development agreement with Curia Massachusetts, Inc. (“Curia”), formerly known as Albany Molecular Research, Inc., under which a series of cleanroom suites were built at Curia’s manufacturing facility in accordance with the Company’s objectives (“Curia Agreement”). The Curia Agreement continues for five years after the
build-out
is completed, and the Company has the right to extend for an additional three years. The Company has determined this is a lease under ASU
No. 2016-02,
Leases (Topic 842) (“ASC 842”). Under the Curia Agreement, the Company will finance $6.0 million of the costs of the
build-out
(“Build-Out
Costs”). If
Build-Out
Costs exceed $6.0 million, the Company and Curia will share overage costs equally, up to $11.0 million, and the Company will be responsible for any amounts exceeding $11.0 million. The Company had paid $12.8 million towards the
Build-Out
Costs prior to the lease commencement date which had been recorded within other long-term assets as prepaid rent as these represented payments for lessor owned assets. The Company anticipates making additional payments of $5.6 million related to the final
Build-Out
Costs, of which $3.2 million was paid as of June 30, 2021. These costs are included within the
right-of-use
(“ROU”) assets and lease liabilities recorded at the lease commencement date. Upon the
build-out
completion date of August 31, 2020 (“Curia Lease Commencement”), the Company determined that it gained control of the space, in accordance with ASC 842, which resulted in the recording of ROU assets and related lease liabilities of approximately $66.6 million and $53.8 million, respectively, with the difference being due to the elimination of previously recorded prepaid rent. Due to an increase in the final
Build-Out
Costs, the Company recorded an increase of $1.4 million to ROU assets and lease liabilities as of June 30, 2021. As of August 31, 2020, the Company began paying monthly fees of $1.0 million, which are subject to a 3% increase on January 1 of each calendar year following the first anniversary of the
build-out
completion. The option to extend the lease for an additional three years was not included in the lease liability as of June 30, 2021 as the Company is not reasonably certain it will exercise this option.
In October 2020, the Company entered into a suite retention agreement (the “Biomere Suite Retention Agreement”) with Biomedical Research Models, Inc. (“Biomere”) under which the Company will lease two exclusive procedure rooms and one housing and maintenance room in Biomere’s Worcester, Massachusetts facility. The lease term is 13 months
 
and commenced
 on December 1, 2020 (the “Biomere Lease Commencement”). The Company can terminate the Biomere Suite Retention Agreement for convenience, and without penalty, with 60 days’ written notice. The Biomere Suite Retention Agreement does not contain any lease incentives or renewal options. Upon the Biomere Lease Commencement, the Company determined that it gained control of the space, in accordance with ASC 842, which resulted in the recording of an ROU asset and lease liability of $0.3 million. As of the Biomere Lease Commencement, the Company began paying monthly fees of less than $0.1 million.
Real Estate Lease
In June 2017, the Company entered into an operating lease for office and laboratory space at its headquarters in Lexington, Massachusetts. The Company occupies approximately 59,000 square feet of space under a
10-year
lease agreement expiring in April 2028. The Company occupied this property in March 2018. Monthly lease payments include base rent charges of $0.2 million, which are subject to a 3% annual increase each year. In June 2017, in connection with this lease agreement, the Company issued a letter of credit collateralized by cash deposits of $1.0 million, which are classified as restricted cash
on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020.
 
17

Equipment Lease
In March 2018, the Company entered into an operating lease for communications equipment for use at its office and laboratory space in Lexington, Massachusetts. The term of the lease is five years, expiring in March 2023.
The Company excludes leases with an initial term of one year or less in the recognized ROU asset and lease liabilities. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842, lease and
non-lease
components are combined into a single lease component. The Company’s leases have remaining lease terms of up to seven years, excluding two five-year options to extend the real estate lease after the expiration of the initial term. The Company believes the Lexington real estate lease, together with the anticipated relocation to a space in Waltham, Massachusetts as described below, will be sufficient to meet its needs for the foreseeable future and that suitable additional space will be available as and when needed.
The components of lease cost were as follows (dollar amounts in thousands):
 
    
Six Months Ended June 30,
 
    
2021
   
2020
 
Lease cost
                
Operating lease cost
   $ 9,597     $ 1,346  
    
 
 
   
 
 
 
Total lease cost
   $ 9,597     $ 1,346  
    
 
 
   
 
 
 
Other information
                
Operating cash flows from operating leases
   $ 9,593     $ 1,320  
Operating lease liabilities arising from obtaining
right-of-use
assets
     1,376       —    
Weighted-average remaining lease term
     5 years       8 years  
Weighted-average discount rate
     12.0     17.5
Maturities of operating lease liabilities are as follows (in thousands):
 
    
June 30, 2021
    
December 31, 2020
 
2021
   $ 9,971      $ 18,067  
2022
     15,178        15,178  
2023
     15,591        15,591  
2024
     16,050        16,050  
2025
     12,029        12,029  
2026 and thereafter
     7,134        7,134  
    
 
 
    
 
 
 
Total future minimum lease payments
     75,953        84,049  
Less: imputed interest
     (18,097      (21,363
    
 
 
    
 
 
 
Present value of lease liabilities
   $ 57,856      $ 62,686  
    
 
 
    
 
 
 
 
18

As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate which are the rates incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2019 for operating leases that commenced prior to that date and for all subsequent leases the Company used an appropriate incremental borrowing rate upon commencement date.
In October 2020, the Company entered into a suite retention agreement with Azzur Cleanrooms-on-Demand – Burlington, LLC (“Azzur”) under which it will lease two exclusive cleanroom suites in Azzur’s Burlington, Massachusetts facility (the “Azzur Agreement”). The lease term is
 24
months and commenced on August 1, 2021, with the option to extend the term with three months’ notice prior to the termination date. Upon commencement, the Company will pay monthly fees of 
$0.4 
million, which are subject to a
4%
 increase on July 1, 2022. As of June 30, 2021, the Company’s commitment under this agreement is
$8.8 
million through June 2023. The Company can terminate the Azzur Agreement for convenience, and without penalty, with three months’ written notice. The Azzur Agreement does not contain any lease incentives or renewal options. The Company has determined this is a lease under ASC 842. As of June 30, 2021, the Company has determined that it does not have control of the space, as defined in ASC 842, during the build-out and as such, this Azzur Agreement was
 not
included in the ROU assets or lease liabilities on the Company’s condensed consolidated balance sheet.
On November 3, 2020 (the “Lease Commencement Date”), the Company entered into a
ten-year
lease agreement for approximately 138,444 square feet of office and laboratory space located at 200 West Street in Waltham, Massachusetts (the “Waltham Lease Agreement”). The Waltham Lease Agreement includes an extension option of one period of 10 years. The Waltham Lease Agreement includes a work agreement to perform a
build-out
arrangement, with a construction period from March 2021 to December 2021. Under the Waltham Lease Agreement, the Company has improvement allowances of $26.3 million, plus an additional tenant allowance of up to $15 per square foot, should the Company elect to use those. In April 2021, the Company entered into a contract with the Richmond Group for $36.8 million for the
build-out
of this office and laboratory space. The Company expects to spend between $10.5 million and $12.5 
million on the construction of lessor assets, which represents the cost of the project that exceeds the tenant allowances. The Company has paid
$2.3
million towards the construction of lessor assets, which is included in other long-term assets in the condensed consolidated balance sheet as of June 30, 2021. Initial base rent, which commences 12 months after the Lease Commencement Date, shall be
$5.7 million for the first year and approximately $8.0 million for the second year and thereafter shall be subject to a 3% annual increase. In December 2020, in connection with this Waltham Lease Agreement, the Company issued a letter of credit collateralized by cash deposits of $3.9 
million, which are classified as restricted cash on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020. The Company has determined this is a lease under ASC 842. As of June 30, 2021, the Company has determined that it does not have control of the space, as defined in ASC 842, during the
build-out
and as such, this Waltham Lease Agreement
was not
included in the ROU assets or lease liabilities on the Company’s condensed consolidated balance sheet
.
12. Commitments and Contingencies
Research, Supply and License Agreements
Roche Master Supply Agreement
The Company is a party to a master supply agreement with Roche Diagnostics Corporation (“Roche”) pursuant to which Roche will custom manufacture certain products for the Company. The agreement specifies a minimum purchase requirement for certain custom manufactured products through December 31, 2024. As of June 30, 2021, the Company’s purchase commitments under the agreement totaled $10.5 million, with $3.5 million committed as payments each year from 2022 to 2024. Research and development expenses related to this agreement totaled $1.3 million and $1.3 million during the three months ended June 30, 2021 and 2020, respectively, and $5.7 million and $2.6 million during the six months ended June 30, 2021 and 2020, respectively.
MIT Research Agreement
In September 2019, the Company entered into a research agreement with the Massachusetts Institute of Technology (“MIT”) pursuant to which the Company is obligated to reimburse MIT up to $4.1 million for specified direct and indirect costs to be incurred from January 2020 through December 2022 for specified research activities conducted for the Company (the “2019 MIT Agreement”). As of June 30, 2021 and 2020, the Company paid MIT $2.4 million and $1.2 million, respectively, towards the total committed amount. Research and development expenses related to this agreement were $0.3 million during each of the three months ended June 30, 2021 and 2020 and $0.7 million during each of the six months ended June 30, 2021 and 2020. There were no amounts payable by the Company under the agreement as of June 30, 2021. The 2019 MIT Agreement expires in December 2022 and may be extended thereafter by mutual agreement of the parties.
 
19

MIT Exclusive Patent License Agreement
The Company is a party to an exclusive patent license agreement with MIT pursuant to which the Company received an exclusive license under the licensed patent rights to develop, manufacture and commercialize any product containing both Certain RNA sequences and certain lipid products, referred to as a “licensed product”. Under the licensed patent rights, the Company is permitted to develop, manufacture and commercialize the licensed products for the delivery of coding RNA components to treat disease in humans.
The Company has the right to grant sublicenses under this license. The patent rights licensed to the Company by MIT include claims that cover certain of the Company’s customized lipid nanoparticles used for delivery of coding RNA components in its MRT platform, including products that may be developed under the Company’s collaboration with Sanofi.
The Company is also obligated to make milestone payments to MIT aggregating up to $1.375 million upon the achievement of specified clinical and regulatory milestones with respect to each licensed product and $1.250 
million upon the Company’s first commercial sale of each licensed product, and to pay royalties of a low single-digit percentage to MIT based on the Company’s, and any of its affiliates’ and sublicensees’, net sales of licensed products. The royalties are p
a
yable on a product-by-product and country-by-country basis, and may be reduced in specified circumstances. The Company’s obligation to make royalty payments extends with respect to a licensed product in a country until four years past the expiration of the last-to-expire patent or patent application licensed from MIT covering the licensed product in the country. In addition, the Company is obligated to pay MIT a low double-digit percentage of the portion of income from sublicensees that the Company ascribes to the MIT-licensed patents, excluding royalties on net sales and research support payments. Pursuant to such provision, during the six months ended June 30, 2021, the Company paid
 $
3.4
million to MIT which included
$
2.5 
million as MIT’s share of sublicense income with respect to the payments the Company received in 2020 under the Second Sanofi Amendment and the Securities Purchase Agreement and
 $0.9
million as MIT’s share of sublicense income with respect to the milestones the Company achieved in 2021 under the Amended Sanofi Agreement. Future amounts that the Company may owe to MIT will depend upon the relative value of the patents the Company licensed from MIT and sublicensed to Sanofi as compared to the other rights that the Company licensed to Sanofi. The determination of the relative value of such rights is subject to a process described in the Company’s license agreement with MIT. Additionally, in the quarter ended June 30, 2021, the Company paid a total of
 $0.7 million due to the achievement of specified milestones in accordance with the license agreement with MIT.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2021 and December 31, 2020.
Legal Proceedings
The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.
13. Subsequent Event
On August 2, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanofi S.A. and Vector Merger Sub, Inc., a Delaware corporation and
a
n indirect
wholly owned subsidiary of Sanofi S.A. (“Merger Sub”). On the terms and subject to the conditions of the Merger Agreement, Merger Sub will commence a cash tender offer (the “Tender Offer”) to acquire all of the outstanding shares of common stock of the Company for a purchase price of
 
$
38.00
per share, in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. Following the completion of the Tender Offer, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and as a
n
indirect
 w
holly owned subsidiary of Sanofi S.A. The Merger Agreement is subject to customary closing conditions, and is anticipated to close in the third quarter of 2021. If the Merger Agreement is terminated by the Company under specified circumstances, the Company will be required to pay Sanofi S.A. a termination fee of
 
$
96.0
 million.
 
20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes appearing elsewhere in this Quarterly Report on
Form 10-Q and
our audited financial statements and related notes included in our Annual Report on Form
10-K
for the year ended December 31, 2020, or the 2020 Annual Report, that was filed with the Securities and Exchange Commission, or SEC, on March 1, 2021. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. Among the important factors that could cause actual results to differ materially from those indicated by our forward-looking statements are those discussed under the heading “Risk Factors” in Part II, Item 1A. and elsewhere in this report, and in the 2020 Annual Report.
Objective
The purpose of this Management’s Discussion and Analysis is to better allow our investors to understand and view our company from our management’s perspective. We are providing an overview of our business and strategy, followed by a discussion of our financial condition and results of operations. As further discussed below, our vision is to continue building a leading messenger RNA, or mRNA, product company, leveraging our extensive experience with proprietary mRNA product development, delivery, manufacturing and process development. However, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. We believe that our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into 2024.
Pending Transaction with Sanofi S.A.
On August 2, 2021, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Sanofi, a French
société anonyme
, or Sanofi S.A., and Vector Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Sanofi S.A., or the Merger Sub. On the terms and subject to the conditions of the Merger Agreement, Merger Sub will commence a cash tender offer, or the Tender Offer, to acquire all of the outstanding shares of our common stock for $38.00 per share, in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. Following the completion of the Tender Offer, Merger Sub will merge with and into Translate Bio, Inc., with Translate Bio, Inc. continuing as the surviving corporation and as an indirect wholly owned subsidiary of Sanofi S.A. If the Merger Agreement is terminated by us under specified circumstances, we will be required to pay Sanofi S.A. a termination fee of $96.0 million. Although we anticipate closing the transaction in the third quarter of 2021, the closing of the Merger Agreement is subject to customary closing conditions, and we may not complete this pending transaction with Sanofi S.A. within the time frame we anticipate, or at all.
Business Overview
We are a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Using our proprietary mRNA therapeutic platform, or MRT platform, we create mRNA that encodes functional proteins. Our mRNA is designed to be delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. We believe the mRNA design, delivery and manufacturing capabilities of our MRT platform provide us with the most advanced platform for developing product candidates that deliver mRNA encoding functional proteins for therapeutic uses. We believe our MRT platform is broadly applicable across multiple diseases in which the production of a desirable protein can have a therapeutic effect. We are primarily focused on applying our MRT platform to treat pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease. In addition, we are pursuing discovery efforts in diseases that affect the liver. We are also pursuing the applicability of our MRT platform for the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur Inc., or Sanofi, the vaccine global business unit of Sanofi S.A.
We are developing mRNA therapeutics for the treatment of cystic fibrosis, or CF with two programs, MRT5005, a clinical-stage program, and a preclinical next-generation CF program. Our mRNA therapeutic candidates for CF are designed to deliver mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator, or CFTR, protein to the lung. We have designed our mRNA therapeutic candidates for CF to be inhaled via a handheld nebulizer. Once the inhaled treatment has entered the epithelial cells lining the patient’s lungs, our therapeutic mRNA uses the cells’ own machinery for translation and expression of fully functional CFTR protein, thereby restoring this essential ion channel, which we believe will address the pathology of CF directly. Currently approved CFTR modulating therapies are limited to patients with specific genetic mutations; therefore, there remains a significant unmet medical need for patients with CF who have genetic mutations
non-amenable
to currently approved CFTR modulating therapies. Additionally, patients treated with these current therapies still suffer from a long-term decline in lung function and exacerbations that require hospitalization. Our mRNA therapeutic candidates for CF are being developed to treat the underlying cause of CF, regardless of the specific genetic mutation, including in patients with limited or no CFTR protein.
 
21

Our clinical-stage CF candidate in development is MRT5005. We believe MRT5005 is the first mRNA product candidate to be administered via inhalation to patients with CF. The U.S. Food and Drug Administration, or FDA, has granted orphan drug designation, fast track designation and rare pediatric disease designation for MRT5005 for the treatment of CF.
We are conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of single- and multiple-ascending doses of MRT5005. The clinical trial is investigating several groups receiving five once-weekly doses, as well as a group receiving five daily doses. Percent predicted forced expiratory volume in one second, or ppFEV
1
, which is a well-defined and accepted endpoint measuring lung function, is also being measured at
pre-defined
timepoints throughout the trial as a safety measure. Target enrollment for each dose group consists of four patients total, three patients receiving MRT5005 and one receiving placebo. In evaluating safety and tolerability, the primary outcome measure, data to date from the ongoing Phase 1/2 clinical trial suggested that repeat dosing of MRT5005 was generally safe and well tolerated. For patients receiving MRT5005, ppFEV
1
was not negatively impacted; there was no pattern of treatment-associated increases in ppFEV
1
. There was no clinically relevant immunogenicity as measured by anti-CFTR antibodies,
anti-PEG
antibodies or
T-cell
sensitization to CFTR. Detection of mRNA and lipid in the blood suggests that MRT5005 crosses the mucus layer, delivering mRNA to the lung of CF patients.
The clinical trial is ongoing with the evaluation of the remaining dose groups, which include a 20 mg multiple-ascending dose group and the daily dosing cohort, and we anticipate reporting the interim findings from the clinical trial at the North American Cystic Fibrosis Conference, or NACFC, being held September 30, 2021 through October 2, 2021. We are conducting translational studies with MRT5005 and a next-generation CF candidate to support and optimize future clinical development, including research into dosing, formulation and nebulization. We have a next-generation CF discovery program that incorporates mRNA codon optimization and advances in lipid nanoparticle, or LNP, chemistry. Preclinical data generated demonstrates CFTR protein expression in the lungs of animals after the delivery of the next-generation CF product candidate using the intended inhaled route of administration. This and other preclinical data generated support the planned initiation of investigational new drug, or IND,-enabling studies in the second half of 2021. We anticipate reporting preclinical data for the next-generation CF program at NACFC.
We are leveraging our lung delivery platform and focusing our preclinical research efforts on identifying lead product candidates in additional pulmonary diseases with unmet medical need, including primary ciliary dyskinesia, or PCD, pulmonary arterial hypertension and respiratory infectious diseases.
We are developing a novel mRNA-based therapeutic designed to treat PCD, a rare genetic disease for which there is no cure. Mutations in the genes that cause PCD result in ineffective mucociliary clearance which can lead to lung disease. While PCD can result from a mutation in one of more than 30 genes involved in ciliary function, DNAI1 is one of the more frequently mutated genes. Our mRNA therapeutic candidate is designed to be delivered to the lungs, providing the cells the instructions to produce fully functional DNAI1 protein, which could potentially restore mucociliary clearance. In May 2021, we reported preclinical data from our PCD program including assessments of the level and distribution of protein expression as well as ciliary activity which suggests the potential for an mRNA therapeutic to correct ciliary function in people with PCD due to a mutation in the DNAI1 gene. These data support continued advancement of this program and we anticipate initiating
IND-enabling
studies in the second half of 2021.
Additionally, we have early discovery efforts ongoing in other areas of unmet medical need. Our research includes discovery efforts in diseases that affect the liver. We have also begun to explore ways to apply our mRNA and delivery platform expertise to diseases where the degradation of a protein would lead to therapeutic benefit. We believe that using mRNA to enable the production of a molecule that can help tag a target protein for destruction within the cell may have advantages over other protein degradation approaches, including the ability to reach previously undruggable therapeutic targets and increase target selectivity. We are also leveraging our mRNA technology to encode therapeutic antibodies.
Additionally, we are leveraging the broad applicability of our platform through a collaboration with Sanofi to develop infectious disease vaccines using our mRNA technology. In the case of vaccines, the mRNA instructs certain cells in the body to produce an antigen that will induce an immune response to an infectious pathogen. Under the collaboration with Sanofi, we are jointly conducting research and development activities to advance vaccines targeting up to seven infectious disease pathogens. As part of the ongoing vaccine development program, comprehensive
in vivo
studies have been conducted across several infectious disease targets. Multiple development candidates have been evaluated against distinct pathogens, all of which were well tolerated across all species tested. Multiple antigens have been tested with all demonstrating robust neutralization titers. Two of the target pathogens under development are a novel strain of coronavirus named
SARS-CoV-2,
which causes
COVID-19,
and influenza. After evaluation of multiple
COVID-19
vaccine candidates
in vivo
for immunogenicity and neutralizing antibody activity, MRT5500 was selected as the lead candidate for a vaccine against
SARS-CoV-2.
In October 2020 and in April 2021, preclinical data were reported demonstrating that MRT5500 induced potent neutralizing antibodies against
SARS-CoV-2
in mice and
non-human
primates, or NHPs. Two doses of MRT5500 in NHPs induced neutralizing antibody levels significantly higher than those observed in a panel of samples from
COVID-19
patients. Additionally, MRT5500 demonstrated protection against viral infection and disease progression in Syrian golden hamsters immunized with MRT5500 against a virus challenge. It was also demonstrated that MRT5500-immunized mice and NHPs exhibited a
Th1-biased
 
22

T-cell
response against
SARS-CoV-2.
Vaccine-associated enhanced respiratory disease, or VAERD, has generally not been reported to be associated with a
Th1-biased
T-cell
response and therefore these data suggest the potential for a reduced risk for VAERD. A Phase 1/2 clinical trial to evaluate MRT5500 began in March 2021 and interim data from this trial is expected in the third quarter of 2021. For information on risks related to our successful development of a vaccine against
COVID-19,
please see Part II, Item 1A – “Risk Factors – We and Sanofi may not be successful in our joint efforts to successfully develop in an expedited timeframe an mRNA vaccine against
SARS-CoV-2,”
included elsewhere in this Quarterly Report on Form
10-Q.
A Phase 1 clinical trial evaluating MRT5400 and MRT5401, our investigational mRNA vaccine candidates against seasonal influenza, was initiated in June 2021 with interim data expected by the end of 2021. Preclinical studies are ongoing for targets against additional viral and bacterial pathogens.
Our vision is to continue building a leading mRNA product company, leveraging our extensive experience with proprietary mRNA product development, delivery, manufacturing and process development. Our proprietary MRT platform has enabled us to focus on direct therapeutic approaches to treat specific genetic diseases with significant unmet medical need. We are primarily focused on applying our MRT platform to treat pulmonary diseases where the production of proteins can modify disease. We are also leveraging our platform’s broad applicability to other diseases, including liver diseases, as well as to preventing disease in the case of infectious disease vaccines. To realize our vision, we plan to advance multiple programs to clinical stage, add new pipeline programs and continue to innovate on the mRNA platform. In order to achieve these goals, we plan to increase our research and development investments, add key
in-house
capabilities, deepen our platform and delivery expertise as well as expand our infrastructure and facility size. We also plan to appropriately invest in manufacturing and commercial capabilities to support continued growth and advancement and our ultimate goal of delivering mRNA medicines to treat or prevent life-threatening or debilitating illnesses.
The successful development of our product candidates will require, among other things, that we develop sufficient mRNA manufacturing capabilities. To date, we have established
100-gram
single-batch production with our clinical-stage mRNA therapeutics platform.
Build-out
of a dedicated manufacturing space through a contract manufacturing partner was completed during the third quarter of 2020 and has the potential to accommodate multiple
250-gram
batches per month upon continued investments and third-party supplier arrangements. As it relates to development of a
COVID-19
vaccine, depending on the final human
COVID-19
vaccine dose and timing of
scale-up
activities, we estimate that we could have manufacturing capacity to produce
90-360 million
doses annually. We plan to further expand our mRNA manufacturing capabilities to increase production capacity, and will need to work with raw material and other third-party suppliers to achieve this goal.
Since our inception in 2011, we have devoted substantially all of our focus and financial resources to organizing and staffing our company, business planning, raising capital, acquiring or discovering product candidates and securing related intellectual property rights and conducting discovery, research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. Through June 30, 2021, we have funded our operations primarily through sales of equity securities and upfront and milestone payments received under a collaboration and license agreement with Sanofi and we have received proceeds of approximately $1.1 billion from such transactions.
We are a party to an Open Market Sale Agreement
SM
, or Sales Agreement, with Jefferies LLC, or Jefferies, under which we may issue and sell shares of our common stock, from time to time, having an aggregate offering price of up to $100.0 million. During the year ended December 31, 2020, we issued and sold 2,863,163 shares of our common stock pursuant to the Sales Agreement, resulting in gross proceeds of $37.9 million, before deducting commissions of $1.1 million and other offering expenses of $0.2 million. There were no shares issued or sold pursuant to the Sales Agreement during the six months ended June 30, 2021. In the future, $62.1 million of shares of common stock remain available to be sold pursuant to the Sales Agreement, which sales, if any, would be made under our universal shelf registration statement on Form
S-3,
or the 2020 Shelf.
Since our inception, we have incurred significant operating losses. Our ability to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. As of June 30, 2021, we had an accumulated deficit of $369.6 million. We expect to continue to incur significant expenses for at least the next several years as we advance our product candidates from discovery through preclinical development and clinical trials and seek regulatory approval. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection with the
in-licensing
or acquisition of additional product candidates.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties or grants from organizations and foundations. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential
in-licenses
or acquisitions.
 
23

Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of June 30, 2021, we had cash, cash equivalents and investments of $667.2 million. We believe that our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into 2024.
Sanofi Pasteur Collaboration and Licensing Agreement
In 2018, we entered into a collaboration and license agreement with Sanofi, or the Original Sanofi Agreement, to develop mRNA vaccines for up to five infectious disease pathogens, or the Licensed Fields. On March 26, 2020, we and Sanofi amended the Original Sanofi Agreement, or the First Sanofi Amendment, to include vaccines against
SARS-CoV-2
as an additional Licensed Field, increasing the number of infectious disease pathogens to up to six. On June 22, 2020, we and Sanofi further amended the Original Sanofi Agreement to expand the scope of the collaboration and licenses granted to Sanofi, or the Second Sanofi Amendment, which closed on July 20, 2020, the effective date. The Original Sanofi Agreement, as amended by the First Sanofi Amendment and the Second Sanofi Amendment, is referred to as the Amended Sanofi Agreement.
Pursuant to the Amended Sanofi Agreement, we and Sanofi are jointly conducting research and development activities to advance mRNA vaccines targeting up to seven infectious disease pathogens. The term of the research collaboration expires in June 2022, with an option for Sanofi to extend for one additional year. If Sanofi elects to extend the collaboration, the collaboration may be further expanded to jointly conduct research and development activities to advance mRNA vaccines for up to an additional three infectious disease pathogens, bringing the total to up to ten pathogens.
Under the terms of the Amended Sanofi Agreement, we have granted to Sanofi exclusive, worldwide licenses under applicable patents, patent applications,
know-how
and materials, including those arising under the collaboration, to develop, commercialize and manufacture mRNA vaccines to prevent, treat or cure diseases, disorders or conditions in humans caused by any infectious disease pathogen, with certain specified exceptions.
Business Impact of the
COVID-19
Pandemic
Since early 2020, the outbreak of the novel strain of coronavirus named
SARS-CoV-2
has spread across the globe and the
COVID-19
pandemic has had wide-reaching impacts on the global economy and business operations. The
COVID-19
pandemic has had, and we expect it may continue to have, an impact on our operations, the operations of our collaborators, the operations of third-party contractors and other entities, with which we interact, as well as on the patients who may enroll in our clinical trials. We actively continue to monitor
COVID-19
trends and government guidance. The ultimate impacts of the
COVID-19
pandemic are still unknown and uncertain. For additional information on risks posed by the
COVID-19
pandemic, please see Part II, Item 1A – “Risk Factors” included elsewhere in this Quarterly Report on Form
10-Q.
Components of Our Results of Operations
Revenue from Product Sales
To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales.
 
24

Collaboration Revenue
Since 2018, we have recognized revenue relating to the Amended Sanofi Agreement. Under revenue recognition guidance, we account for: (i) the license we conveyed to Sanofi with respect to the Licensed Fields, (ii) the licensed
know-how
to be conveyed to Sanofi with respect to the Licensed Fields, (iii) our obligations to perform research and development on the Licensed Fields, (iv) our obligation to transfer licensed materials to Sanofi, (v) our obligation to manufacture and supply certain
non-clinical
and clinical mRNA vaccines and materials containing mRNA until we transfer such manufacturing capabilities to Sanofi and (vi) the technology and process transfer as a single performance obligation. We recognize revenue using the
cost-to-cost
input method, which we believe best depicts the transfer of control to the customer. Under the
cost-to-cost
input method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. We recognize adjustments in revenue under the cumulative
catch-up
method. Under this method, the impact of this adjustment on revenue recorded to date is recognized in the period the adjustment is identified.
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include:
 
   
employee-related expenses, including salaries, related benefits and stock-based compensation expense for employees engaged in research and development functions;
 
   
expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with third parties, such as consultants and contract research organizations, or CROs;
 
   
the cost of manufacturing drug products for use in our preclinical studies and clinical trials, including under agreements with third parties, such as consultants and contract manufacturing organizations, or CMOs;
 
   
laboratory supplies;
 
   
facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance;
 
   
costs to fulfill our obligations under our collaboration with Sanofi;
 
   
costs related to compliance with regulatory requirements; and
 
   
payments made under third-party licensing agreements.
We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense when the services have been performed or the goods have been delivered, or when it is no longer expected that the goods will be delivered or the services rendered. Upfront payments, milestone payments (other than those deemed contingent consideration in a business combination) and annual maintenance fees under license agreements are expensed in the period in which they are incurred.
Our direct research and development expenses are tracked on a
program-by-program
basis and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include costs of laboratory supplies incurred for each program as well as fees incurred under license agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery and to manage our preclinical development, process development, manufacturing and clinical development activities.
 
25

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we conduct our clinical trials of MRT5005 for the treatment of patients with CF; expand our manufacturing capabilities; conduct research and development activities to advance mRNA vaccine candidates and develop an mRNA vaccine platform under the Amended Sanofi Agreement; prepare regulatory filings for our product candidates; continue to discover and develop additional product candidates; and potentially advance product candidates from our discovery program into later stages of clinical development. We expect to continue to devote a substantial portion of our resources to our discovery program for the foreseeable future.
The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:
 
   
the timing and progress of preclinical and clinical development activities, including delays resulting from the
COVID-19
pandemic;
 
   
the number and scope of preclinical and clinical programs we decide to pursue;
 
   
our ability to maintain our current research and development programs and to establish new ones;
 
   
establishing an appropriate safety profile with investigational new drug, or IND,-enabling studies;
 
   
successful patient enrollment in, and the initiation and completion of, clinical trials;
 
   
the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;
 
   
the receipt of regulatory approvals from applicable regulatory authorities;
 
   
the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;
 
   
the success of our collaboration with Sanofi;
 
   
our ability to establish new licensing or collaboration arrangements;
 
   
the performance of our future collaborators, if any;
 
   
establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
 
   
development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch, if approved;
 
   
obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
 
   
launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others; and
 
   
maintaining a continued acceptable safety profile of the product candidates following approval.
 
26

Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. If FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete clinical development of that product candidate. We may never obtain regulatory approval for any of our product candidates. Drug commercialization will take several years and millions of dollars in development costs.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries, related benefits and stock-based compensation expense for personnel in executive, finance and administrative functions. General and administrative expenses also include facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, as well as professional fees for legal, patent, consulting, recruiting fees, investor and public relations, accounting and audit services.
We anticipate that our general and administrative expenses will increase over the next several years as we anticipate increased accounting, audit, legal, regulatory, compliance, director and officer insurance and investor and public relations costs associated with being a public company.
Change in Fair Value of Contingent Consideration
In connection with our acquisition of the messenger RNA therapeutic platform, or MRT Program, from Shire Human Genetic Therapies, Inc., or Shire, a subsidiary of Takeda Pharmaceutical Company Ltd., we recognized contingent consideration liabilities for future potential milestone and earnout payment obligations. The contingent consideration was initially recorded at fair value on the acquisition date and is subsequently remeasured to fair value at each reporting date. Any changes in the fair value of the contingent consideration liabilities are recognized as operating income or expenses.
Other Income, Net
Other Income, Net
Other income, net primarily consists of income recognized in connection with our investments in money market funds, U.S. treasuries and U.S. government agency bonds.
Income Taxes
We recognized an income tax benefit of $1.0 million and $0.7 million during the three and six months ended June 30, 2021, respectively, due to the current period income before income taxes and the application of the annual effective tax rate. The annual effective tax rate relates primarily to an expected income tax liability due to the acceleration of revenue recognition for tax purposes related to the Amended Sanofi Agreement. There was no income tax benefit recognized during the three and six months ended June 30, 2020. Net operating losses generated in 2018 and years thereafter can be carried forward indefinitely.
As of December 31, 2020, we had U.S. federal net operating loss carryforwards of $239.3 million, of which $116.1 million will, if not utilized, begin to expire in 2031. As of December 31, 2020, we had U.S. state net operating loss carryforwards of $227.6 million, which will, if not utilized, begin to expire in 2031. As of December 31, 2020, we also had U.S. federal and state research and development tax credit carryforwards of $7.0 million and $4.3 million, respectively, which will, if not utilized, begin to expire in 2032 and 2028, respectively, and orphan drug tax credit carryforwards of $17.4 million, which begin to expire in 2037. We also have state investment tax credit carryforwards of $0.8 million, which will, if not utilized, begin to expire in 2020. As of December 31, 2020, we recorded a full valuation allowance against our net deferred tax assets.
 
27

Results of Operations
Comparison of the Three Months Ended June 30, 2021 and 2020
The following table summarizes our results of operations for the three months ended June 30, 2021 and 2020:
 
    
Three Months Ended June 30,
        
    
2021
    
2020
    
Change
 
    
(in thousands)
 
Collaboration revenue
   $ 72,649      $ 16,319      $ 56,330  
Operating expenses:
                          
Research and development
     40,477        29,002        11,475  
General and administrative
     11,921        8,601        3,320  
Change in fair value of contingent consideration
     4,242        15,347        (11,105
    
 
 
    
 
 
    
 
 
 
Total operating expenses
     56,640        52,950        3,690  
    
 
 
    
 
 
    
 
 
 
Income (loss) from operations
     16,009        (36,631      52,640  
Other income, net
     154        343        (189
    
 
 
    
 
 
    
 
 
 
Income (loss) before income taxes
     16,163        (36,288      52,451  
Income tax benefit
     981        —          981  
    
 
 
    
 
 
    
 
 
 
Net income (loss)
   $ 17,144      $ (36,288    $ 53,432  
    
 
 
    
 
 
    
 
 
 
Collaboration Revenue
Collaboration revenue was $72.6 million and $16.3 million for the three months ended June 30, 2021 and 2020, respectively, which was derived from the Sanofi collaboration. Revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. The transaction price increased in the three months ended June 30, 2021 compared to the same period in 2020. Although total expenses in the vaccine program decreased in the three months ended June 30, 2021 compared to the same period in 2020, revenue increased due to the increase in the transaction price. See “—Components of Our Results of Operations – Collaboration Revenue” above.
Research and Development Expenses
 
    
Three Months Ended June 30,
        
    
2021
    
2020
    
Change
 
    
(in thousands)
 
Direct external research and development expenses by program:
 
                 
Discovery program
   $ 8,234      $ 2,033      $ 6,201  
Vaccine program
     8,348        9,387        (1,039
MRT5005 program
     3,314        3,350        (36
Unallocated research and development expenses:
                          
Personnel related (including stock-based compensation)
     10,300        8,791        1,509  
Other
     10,281        5,441        4,840  
    
 
 
    
 
 
    
 
 
 
Total research and development expenses
   $ 40,477      $ 29,002      $ 11,475  
    
 
 
    
 
 
    
 
 
 
Research and development expenses were $40.5 million for the three months ended June 30, 2021, compared to $29.0 million for the three months ended June 30, 2020. The increase of $11.5 million was primarily due to continued development of our discovery program as well as increases in occupancy and personnel-related costs.
Direct external expenses of our discovery program increased by $6.2 million during the three months ended June 30, 2021 compared to the three months ended June 30, 2020 primarily due to increased costs related to our ongoing exploratory research and discovery efforts to identify next-generation CF candidates and lead product candidates in additional pulmonary diseases.
Direct external expenses of our vaccine program decreased by $1.0 million during the three months ended June 30, 2021 compared to the three months ended June 30, 2020 primarily due to decreased activities with the Sanofi collaboration.
 
28

Unallocated research and development expenses increased by $6.3 million during the three months ended June 30, 2021 compared to the three months ended June 30, 2020. The increase of $1.5 million in personnel-related costs was primarily related to an increase in headcount in the three months ended June 30, 2021 compared to the same period in 2020, partially offset by a decrease in stock-based compensation due to a stock option modification in the three months ended June 30, 2020. The increase of $4.8 million in other unallocated research and development expenses was due to an increase of $4.3 million in occupancy costs and an increase of $0.7 million in license fees due to payments owed to the Massachusetts Institute of Technology, or MIT, upon achievement of milestones under the Amended Sanofi Agreement, partially offset by a decrease of $0.6 million in amortization expense related to the definite-lived MRT intangible asset.
General and Administrative Expenses
General and administrative expenses were $11.9 million for the three months ended June 30, 2021, compared to $8.6 million for the three months ended June 30, 2020. The increase of $3.3 million was due to an increase of $1.7 million in personnel-related costs related to an increase in headcount in the three months ended June 30, 2021 compared to the same period in 2020 as well as an increase in stock-based compensation, an increase of $1.1 million in professional fees primarily consisting of increases in recruiting fees and consulting costs and an increase of $0.2 million in insurance fees.
Change in Fair Value of Contingent Consideration
During the three months ended June 30, 2021 and 2020, we recognized operating expenses of $4.2 million and $15.3 million, respectively, for changes in the fair value of the contingent consideration liabilities we recorded in connection with our acquisition of the MRT Program in December 2016. The contingent consideration liabilities relate to future potential milestone and earnout payment obligations. The expense recognized during the three months ended June 30, 2021 was attributed primarily to an increase in the fair value of the contingent consideration liability for future earnout payments that could become due. The increase in the fair value of contingent consideration was due to the time value of money due to the passage of time and a decrease in the discount rate during the three months ended June 30, 2021.
Benefit from Income Taxes
We recognized an income tax benefit of $1.0 million and $0 during the three months ended June 30, 2021 and 2020, respectively, due to the current period income before income taxes and the application of the annual effective tax rate. The annual effective tax rate relates primarily to an expected income tax liability due to the acceleration of revenue recognition for tax purposes related to the Amended Sanofi Agreement.
Comparison of the Six Months Ended June 30, 2021 and 2020
The following table summarizes our results of operations for the six months ended June 30, 2021 and 2020:
 
    
Six Months Ended June 30,
        
    
2021
    
2020
    
Change
 
    
(in thousands)
 
Collaboration revenue
   $ 107,249      $ 20,974      $ 86,275  
Operating expenses:
                          
Research and development
     81,617        50,442        31,175  
General and administrative
     22,738        16,060        6,678  
Change in fair value of contingent consideration
     (39,737      5,895        (45,632
    
 
 
    
 
 
    
 
 
 
Total operating expenses
     64,618        72,397        (7,779
    
 
 
    
 
 
    
 
 
 
Income (loss) from operations
     42,631        (51,423      94,054  
Other income, net
     308        853        (545
    
 
 
    
 
 
    
 
 
 
Income (loss) before income taxes
     42,939        (50,570      93,509  
Income tax benefit
     727        —          727  
    
 
 
    
 
 
    
 
 
 
Net income (loss)
   $ 43,666      $ (50,570    $ 94,236  
    
 
 
    
 
 
    
 
 
 
Collaboration Revenue
Collaboration revenue was $107.2 million and $21.0 million for the six months ended June 30, 2021 and 2020, respectively, which was derived from the Sanofi collaboration. Revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. The transaction price increased in the six months ended June 30, 2021 compared to the same period in 2020 resulting in an increase of revenue recognized. See “—Components of Our Results of Operations – Collaboration Revenue” above.
 
29

Research and Development Expenses
 
    
Six Months Ended June 30,
        
    
2021
    
2020
    
Change
 
    
(in thousands)
 
Direct external research and development expenses by program:
                          
Discovery program
   $ 16,850      $ 5,807      $ 11,043  
Vaccine program
     15,917        11,976        3,941  
MRT5005 program
     9,528        9,444        84  
Unallocated research and development expenses:
                          
Personnel related (including stock-based compensation)
     19,058        14,777        4,281  
Other
     20,264        8,438        11,826  
    
 
 
    
 
 
    
 
 
 
Total research and development expenses
   $ 81,617      $ 50,442      $ 31,175  
    
 
 
    
 
 
    
 
 
 
Research and development expenses were $81.6 million for the six months ended June 30, 2021, compared to $50.4 million for the six months ended June 30, 2020. The increase of $31.2 million was primarily due to continued development of our discovery program and our vaccine program associated with the Sanofi collaboration as well as increases in occupancy and personnel-related costs.
Direct external expenses of our discovery program increased by $11.0 million during the six months ended June 30, 2021 compared to the six months ended June 30, 2020 primarily due to increased costs related to our ongoing exploratory research and discovery efforts to identify next-generation CF candidates and identify lead product candidates in additional pulmonary diseases.
Direct external expenses of our vaccine program increased by $3.9 million during the six months ended June 30, 2021 compared to the six months ended June 30, 2020 primarily due to increased activities with the Sanofi collaboration.
Unallocated research and development expenses increased by $16.1 million during the six months ended June 30, 2021 compared to the six months ended June 30, 2020. The increase of $4.3 million in personnel-related costs was primarily related to an increase in headcount in the six months ended June 30, 2021 compared to the same period in 2020, partially offset by a decrease in stock-based compensation due to a stock option modification in the six months ended June 30, 2020. The increase of $11.8 million in other unallocated research and development expenses was due to an increase of $8.6 million in occupancy costs, an increase of $1.7 million in license fees due to payments owed to MIT upon achievement of milestones under the Amended Sanofi Agreement and an increase of $1.0 million in amortization expense related to the definite-lived MRT intangible asset.
General and Administrative Expenses
General and administrative expenses were $22.7 million for the six months ended June 30, 2021, compared to $16.1 million for the six months ended June 30, 2020. The increase of $6.7 million was primarily due to an increase of $3.6 million in professional fees primarily consisting of increases in recruiting fees, consulting costs, accounting fees and legal fees primarily associated with filing patent applications and prosecuting our intellectual property portfolio. Additionally, personnel-related costs increased by $2.4 million primarily related to an increase in headcount in the six months ended June 30, 2021 compared to the same period in 2020 as well as an increase in stock-based compensation and insurance fees increased by $0.3 million.
Change in Fair Value of Contingent Consideration
During the six months ended June 30, 2021 and 2020, we recognized operating income of $39.7 million and operating expense of $5.9 million, respectively, for changes in the fair value of the contingent consideration liabilities we recorded in connection with our acquisition of the MRT Program in December 2016. The contingent consideration liabilities relate to future potential milestone and earnout payment obligations. The income recognized during the six months ended June 30, 2021 was attributed primarily to a decrease in the fair value of the contingent consideration liability for future earnout payments that could become due. The decrease in the fair value of contingent consideration was due to the previously announced results of the second interim data analysis from the Phase 1/2 clinical trial of MRT5005 and the resulting decrease in the fair value of contingent consideration during the three months ended March 31, 2021. This decrease was partially offset by an increase in the fair value of contingent consideration due to the time value of money due to the passage of time and a decrease in the discount rate during the three months ended June 30, 2021.
 
30

Benefit from Income Taxes
We recognized an income tax benefit of $0.7 million and $0 during the six months ended June 30, 2021 and 2020, respectively, due to the current period income before income taxes and the application of the annual effective tax rate. The annual effective tax rate relates primarily to an expected income tax liability due to the acceleration of revenue recognition for tax purposes related to the Amended Sanofi Agreement.
Liquidity and Capital Resources
Since our inception through June 30, 2021, we have not generated any revenue from product sales, have generated collaboration revenue only from the Amended Sanofi Agreement and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. See “ —Funding Requirements” and Note 1 to the condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form
10-Q
for a further discussion of our liquidity.
Through June 30, 2021, we have funded our operations primarily through sales of equity securities and upfront and milestone payments received under the Amended Sanofi Agreement and we have received proceeds of approximately $1.1 billion from such transactions.
We are party to the Sales Agreement, with Jefferies, under which we may issue and sell shares of our common stock, from time to time, having an aggregate offering price of up to $100.0 million. Sales of common stock through Jefferies may be made by any method that is deemed an “at the market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell shares of our common stock based upon our instructions. We are not obligated to make any sales of our common stock under the Sales Agreement. During the year ended December 31, 2020, we issued and sold 2,863,163 shares of our common stock, resulting in gross proceeds of $37.9 million, before deducting commissions of $1.1 million and other offering expenses of $0.2 million. There were no shares issued or sold pursuant to the Sales Agreement during the six months ended June 30, 2021. In the future, $62.1 million of shares of common stock remain available to be sold pursuant to the Sales Agreement, which sales, if any, would be made under the 2020 Shelf.
Cash Flows
The following table summarizes our sources and uses of cash for each of the periods presented:
 
    
Six Months Ended June 30,
 
    
2021
    
2020
 
    
(in thousands)
 
Net cash provided by (used in) operating activities
   $ 13,694      $ (51,489
Net cash provided by (used in) investing activities
     (109,109      79,422  
Net cash provided by financing activities
     2,859        159,680  
    
 
 
    
 
 
 
Net increase (decrease) in cash, cash equivalents and restricted cash
   $ (92,556    $ 187,613  
    
 
 
    
 
 
 
Operating Activities
During the six months ended June 30, 2021, operating activities provided $13.7 million of cash, resulting from our net income of $43.7 million, partially offset by net
non-cash
charges of $23.9 million and net cash used in changes in our operating assets and liabilities of $6.0 million. Net
non-cash
charges for the six months ended June 30, 2021 primarily consisted of a $39.7 million decrease in the change in the fair value of contingent consideration, partially offset by a $9.3 million charge to stock-based compensation expense and a $6.5 million charge for depreciation and amortization expense. Net cash used in changes in our operating assets and liabilities consisted of a $8.5 million increase in prepaid expenses and other assets, a $6.2 million decrease in lease liability, a $3.2 million decrease in deferred revenue and a $2.4 million increase in long-term prepaid rent, partially offset by a $6.2 million decrease in
right-of-use
assets, a $3.9 million increase in accounts payable, a $2.6 million decrease in collaboration receivables and a $1.6 million increase in accrued expenses.
During the six months ended June 30, 2020, operating activities used $51.5 million of cash, resulting from our net loss of $50.6 million and net cash used in changes in our operating assets and liabilities of $21.6 million, partially offset by net
non-cash
charges of $20.7 million. Net cash used in changes in our operating assets and liabilities consisted of a $10.5 million increase in collaboration receivables, a $7.4 million increase in long-term prepaid rent, a $6.4 million decrease in deferred revenue and a $2.8 million decrease in accounts payable, partially offset by a $4.0 million increase in accrued expenses and a $1.5 million increase in
 
31

prepaid expenses and other assets. Net
non-cash
charges for the six months ended June 30, 2020 primarily consisted of a $9.2 million charge to stock-based compensation expense, a $5.9 million increase in the change in the fair value of contingent consideration which was primarily due to the time value of money due to the passage of time and a $5.6 million charge for depreciation and amortization expense.
Investing Activities
During the six months ended June 30, 2021, net cash used in investing activities was $109.1 million, consisting of $185.7 million of purchases of investments and $3.4 million of purchases of property and equipment, partially offset by $80.0 million of sales and maturities of investments.
During the six months ended June 30, 2020, net cash provided by investing activities was $79.4 million, consisting of $111.3 million of sales and maturities of investments, partially offset by $27.4 million of purchases of investments and $4.4 million of purchases of property and equipment.
Financing Activities
During the six months ended June 30, 2021, net cash provided by financing activities was $2.8 million, consisting primarily of proceeds from option exercises.
During the six months ended June 30, 2020, net cash provided by financing activities was $159.7 million, consisting of net cash proceeds of $153.8 million from public offerings of our common stock and $5.8 million in proceeds from option exercises.
Funding Requirements
We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue ongoing and initiate new clinical trials of and seek marketing approval for our product candidates. In addition, we expect to incur additional costs associated with operating as a public company. Our expenses will also increase if, and as, we:
 
   
continue the clinical development of MRT5005 for CF, MRT5500, the lead vaccine candidate against
SARS-CoV-2,
and MRT5400 and MRT5401, the investigational mRNA vaccine candidates against seasonal influenza;
 
   
continue the advancement of mRNA therapeutics for next-generation CF and PCD and continue the development of additional mRNA vaccine candidates against infectious diseases;
 
   
leverage our programs to advance our other product candidates, including those for the treatment of diseases that affect the liver, into preclinical and clinical development;
 
   
seek regulatory approvals for any product candidates that successfully complete clinical trials;
 
   
seek to discover and develop additional product candidates;
 
   
expand our manufacturing, operational, financial and management systems;
 
   
increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;
 
   
maintain, expand and protect our intellectual property portfolio;
 
   
acquire or
in-license
other product candidates and technologies;
 
   
incur additional legal, accounting and other expenses in operating as a public company; and
 
   
establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may not obtain marketing approval and intend to commercialize on our own or jointly.
 
32

We believe that our existing cash, cash equivalents and investments of $667.2 million as of June 30, 2021 will enable us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.
We will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, many of which are outside of our control, and we may be unable to raise financing when needed, or on terms favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, which could adversely affect our business prospects, and we may be unable to continue our operations. Because of numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Factors that may affect our planned future capital requirements and accelerate our need for additional working capital include the following:
 
   
the successful completion of our pending transaction with Sanofi S.A.;
 
   
the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;
 
   
the success of our collaboration with Sanofi;
 
   
the costs, timing and outcome of regulatory review of our product candidates;
 
   
the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
 
   
the costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch;
 
   
the ability to receive additional
non-dilutive
funding, including grants from organizations and foundations;
 
   
the impacts of the
COVID-19
pandemic and our response to it;
 
   
the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;
 
   
the cost and timing of hiring new employees to support our continued growth;
 
   
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
 
   
the ability to establish and maintain collaborations on favorable terms, if at all;
 
   
the extent to which we acquire or
in-license
other product candidates and technologies; and
 
   
the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any.
A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.
 
33

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties and grants from organizations and foundations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that could adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in increased fixed payment obligations.
If we raise funds through collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.
Cash Requirements from Contractual and Other Obligations
During the three months ended June 30, 2021, there were no material changes to our cash requirements from contractual and other obligations as of December 31, 2020 described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2020 Annual Report.
In April 2021, we entered into a contract with The Richmond Group, Inc. for $36.8 million for the
build-out
of the 200 West Street location in Waltham, Massachusetts. Under the lease agreement for the 200 West Street location, our landlord will reimburse us $26.3 million for tenant improvement allowances. We expect to spend between $10.5 million and $12.5 million towards
build-out
costs, which represents the cost of the project that exceeds the tenant improvement allowances, of which $2.3 million has been paid as of June 30, 2021.
Critical Accounting Policies and Significant Judgments and Estimates
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in our finance statements. We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates—which also would have been reasonable—could have been used. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 Annual Report.
 
34

Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We were a smaller reporting company, as defined in Rule
12b-2
under the Securities Exchange Act of 1934, as amended, for the fiscal year ended December 31, 2020 and are therefore not required to provide the information required under this item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures” as defined in Rules
13a-15(e)
and
15d-15(e)
under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer and principal financial and accounting officer, respectively, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2021. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2021.
Changes in Internal Control over Financial Reporting
There have been no changes in internal control over financial reporting (as defined in Rules
13a-15(f)
and
15d-15(f)
under the Exchange Act) during the three months ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
35

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
We are not currently subject to any material legal proceedings.
Item 1A. Risk Factors.
Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in this Quarterly Report on Form
10-Q,
including our financial statements and the related notes and in our other filings with the Securities and Exchange Commission, or SEC. If any of the following risks occur, our business, financial condition, results of operations and prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment.
Risks Related to the Pending Transaction with Sanofi S.A.
We may not complete the pending transaction with Sanofi, a French société anonyme, or Sanofi S.A., within the time frame we anticipate, or at all, which could have an adverse effect on our business, financial results and/or operations.
On August 2, 2021, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Sanofi S.A. and Vector Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Sanofi S.A., or the Merger Sub. On the terms and subject to the conditions of the Merger Agreement, Merger Sub will commence a cash tender offer, or the Tender Offer, to acquire all of the outstanding shares of our common stock for $38.00 per share, or the Offer Price, in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. Following the completion of the Tender Offer, Merger Sub will merge with and
into Translate
Bio, Inc., 
with Translate Bio, Inc
. continuing as the surviving corporation and as an indirect wholly owned subsidiary of Sanofi S.A., and each outstanding share of our common stock (other than shares of common stock held by us as treasury stock, or owned by Sanofi S.A. or any wholly owned subsidiary of Sanofi S.A. (other than Merger Sub) or held by stockholders who are entitled to demand, and who properly demand, appraisal rights under Delaware law) will be converted into the right to receive an amount in cash equal to the Offer Price, without interest, subject to any withholding of taxes required by applicable law.
The obligation of Merger Sub to purchase shares of our common stock tendered in the Tender Offer is subject to the conditions set forth in the Merger Agreement, including (1) that the number of shares validly tendered in accordance with the terms of the Tender Offer and not validly withdrawn, considered together with all other shares otherwise beneficially owned by Sanofi S.A. or any of its wholly owned subsidiaries (including Merger Sub) would represent one more than 50% of the total number of shares of our common stock outstanding at the time of the expiration of the Tender Offer, (2) the absence of any injunction or other order issued by a court of competent jurisdiction or law prohibiting consummation of the Tender Offer or the merger, (3) the expiration or early termination of the applicable waiting period (or any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (4) the accuracy of our representations and warranties, subject to materiality standards set forth in the Merger Agreement, (5) compliance by us in all material respects with our obligations under the Merger Agreement and (6) the absence of a Material Adverse Effect (as defined in the Merger Agreement). In addition, the Merger Agreement may be terminated under certain specified circumstances, including, but not limited to, a change in the recommendation of our board of directors or a termination of the Merger Agreement by us to enter into an agreement for a Superior Offer (as defined in the Merger Agreement). As a result, we cannot assure you that the transaction with Sanofi S.A. will be completed, or that, if completed, it will be exactly on the terms set forth in the Merger Agreement or within the expected time frame.
We have incurred and will continue to incur costs relating to the proposed transaction (including significant legal and financial advisory fees) and many of these costs are payable by us whether or not the proposed transaction is completed. If the transaction is not completed within the expected time frame or at all, we may be subject to a number of material risks. The price of our common stock may decline to the extent that current market prices reflect a market assumption that the transaction will be completed. We could be required to pay Sanofi S.A. a termination fee of $96.0 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. The failure to complete the transaction also may result in negative publicity and negatively affect our relationship with our stockholders, employees, collaborators, vendors, suppliers, regulators and other business partners. We may also be required to devote significant time and resources to litigation related to any failure to complete the merger or related to any enforcement proceeding commenced against us to perform our obligations under the Merger Agreement.
The announcement and pendency of the transaction with Sanofi S.A. could adversely affect our business, financial results and/or operations.
Our efforts to complete the transaction could cause substantial disruptions in, and create uncertainty surrounding, our business, which may materially adversely affect our results of operation and our business. For example, we may forego opportunities we may have otherwise pursued absent the proposed transaction. Uncertainty as to whether the transaction will be completed may also affect our ability to recruit prospective employees or to retain and motivate existing employees. Employee retention may be particularly challenging while the transaction is pending because employees may experience uncertainty about their roles
 
36

following the transaction. A substantial amount of our management’s and employees’ attention is being directed toward the completion of the transaction and thus is being diverted from our
day-to-day
operations. Uncertainty as to our future could adversely affect our business and our relationship with collaborators, vendors, suppliers, regulators and other business partners. For example, vendors, suppliers, collaborators and other counterparties may defer decisions concerning working with us, or seek to change existing business relationships with us. Changes to or termination of existing business relationships could adversely affect our results of operations and financial condition, as well as the market price of our common stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.
While the Merger Agreement is in effect, we are subject to restrictions on our business activities.
While the Merger Agreement is in effect, we are subject to restrictions on our business activities, generally requiring us to conduct our business in the ordinary course, consistent with past practice, and subjecting us to a variety of specified limitations absent Sanofi S.A.’s prior consent. These limitations include, among other things, restrictions on our ability to acquire other businesses and assets, dispose of our assets, make investments, enter into certain contracts, repurchase or issue securities, pay dividends, make capital expenditures, take certain actions relating to intellectual property, amend our organizational documents and incur indebtedness. These restrictions could prevent us from pursuing strategic business opportunities, taking actions with respect to our business that we may consider advantageous and responding effectively and/or timely to competitive pressures and industry developments, and may as a result materially and adversely affect our business, results of operations and financial condition.
The Merger Agreement limits our ability to pursue alternative transactions, which could deter a third party from proposing an alternative transaction.
The Merger Agreement contains provisions that, subject to certain exceptions, limit our ability to solicit, initiate or knowingly facilitate or knowingly encourage any inquiries or the making of any proposal or offer that constitutes, or would reasonably be expected to lead to, or engage in, continue or otherwise participate in any discussions or negotiations regarding, or furnish any non-public information in connection with, an alternative transaction. It is possible that these or other provisions in the Merger Agreement might discourage a potential competing acquirer that might have an interest in acquiring all or a significant part of the outstanding shares of our common stock from considering or proposing an acquisition or might result in a potential competing acquirer proposing to pay a lower per share price to acquire our common stock than it might otherwise have proposed to pay.
In certain instances, the Merger Agreement requires us to pay a termination fee to Sanofi S.A., which could require us to use available cash that would have otherwise been available for general corporate purposes.
Under the terms of the Merger Agreement, we may be required to pay Sanofi S.A. a termination fee of $96.0 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. If the Merger Agreement is terminated under such circumstances, the termination fee we may be required to pay under the Merger Agreement may require us to use available cash that would have otherwise been available for general corporate purposes and other uses. For these and other reasons, termination of the Merger Agreement could materially and adversely affect our business operations and financial condition, which in turn would materially and adversely affect the price of our common stock.
We have incurred, and will continue to incur, direct and indirect costs as a result of the pending transaction with Sanofi S.A
We have incurred, and will continue to incur, significant costs and expenses, including fees for professional services and other transaction costs, in connection with the pending transaction. We must pay a material portion of these costs and expenses whether or not the transaction is completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses, any of which could materially and adversely affect our business, prospects, financial condition and results of operations.
Certain of our directors and executive officers may have interests in the proposed transaction with Sanofi S.A. that are or were different from, or in conflict with or in addition to, those of our stockholders generally.
Certain of our directors and executive officers have interests in the proposed transaction with Sanofi S.A. that may differ from, or that are in addition, to their interests as our stockholders. Our board of directors was aware of these interests at the time it approved the Merger Agreement. These interests may cause our directors and officers to view the proposed transaction differently from how our stockholders may view it.
Risks Related to our Financial Position and Need for Additional Capital
We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.
Since inception, we have incurred significant losses. As of June 30, 2021, we had an accumulated deficit of $369.6 million. We have funded our operations to date primarily through sales of equity securities and upfront payments received under a collaboration and license agreement with Sanofi Pasteur, Inc., or Sanofi, the vaccines global business unit of Sanofi S.A. We expect that it could be several years, if ever, before we have a commercialized product candidate. We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if, and as, we:
 
   
continue the clinical development of MRT5005, for cystic fibrosis, or CF, MRT5500, the lead vaccine candidate against
SARS-CoV-2,
which causes
COVID-19,
and MRT5400 and MRT5401, the investigational mRNA vaccine candidates against seasonal influenza;
 
   
continue the advancement of mRNA therapeutics for next-generation CF and primary ciliary dyskinesia, or PCD, and continue the development of additional mRNA vaccine candidates against infectious diseases;
 
   
leverage our programs to advance our other product candidates, including those for the treatment of diseases that affect the liver, into preclinical and clinical development;
 
37

   
seek regulatory approvals for any product candidates that successfully complete clinical trials;
 
   
seek to discover and develop additional product candidates;
 
   
expand our manufacturing, operational, financial and management systems;
 
   
increase personnel, including personnel to support our research, clinical development, manufacturing and commercialization efforts and our operations as a public company;
 
   
maintain, expand and protect our intellectual property portfolio;
 
   
acquire or
in-license
other product candidates and technologies;
 
   
incur additional legal, accounting and other expenses in operating as a public company; and
 
   
establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly.
To become and remain profitable, we, or our collaborators, must develop and eventually commercialize product candidates with significant market potential. This will require us to succeed in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate sufficient revenue to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.
We have never generated revenue from product sales and may never be profitable.
We have never generated revenue from product sales. Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with our collaborative partners, to successfully develop and obtain the regulatory approvals necessary to commercialize our product candidates. We do not have any products approved for sale and do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate future revenue from product sales depends heavily on our, or our collaborators’, success in:
 
   
completing preclinical and clinical development of our product candidates and identifying and developing new product candidates;
 
   
seeking and obtaining marketing approvals for any of our product candidates;
 
   
launching and commercializing product candidates for which we obtain marketing approval by establishing a sales force, marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner;
 
   
achieving formulary status in hospitals and adequate coverage and reimbursement by government and third-party payors for our product candidates;
 
   
establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for our product candidates, if approved;
 
   
obtaining market acceptance of our product candidates as viable treatment options;
 
   
addressing any competing technological and market developments;
 
   
negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;
 
38

   
maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and
know-how;
 
   
defending against third-party interference or infringement claims, if any; and
 
   
attracting, hiring and retaining qualified personnel.
Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs in commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the Food and Drug Administration, or FDA, European Medicines Agency, or EMA, or other regulatory agencies to perform clinical trials or studies in addition to those that we currently anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.
Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring or discovering product candidates and securing related intellectual property rights, conducting discovery, research and development activities for our programs, undertaking preclinical studies, entering into licensing agreements and planning for potential commercialization. While we are conducting a Phase 1/2 clinical trial of MRT5005, we have not yet completed a clinical trial of any of our product candidates. We have not yet demonstrated the ability to obtain marketing approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any evaluation of our business to date or predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.
If we obtain marketing approval for any of our product candidates, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition.
We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain capital when needed may force us to delay, reduce or eliminate certain of our product development efforts or other operations.
We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue ongoing and initiate clinical trials of and seek marketing approval for our product candidates. These expenditures will include costs associated with our asset purchase agreement, as amended, with Shire Human Genetic Therapies, Inc., or Shire, a subsidiary of Takeda Pharmaceutical Company Ltd., referred to as the Shire Agreement. Under the terms of the Shire Agreement, we are obligated to make significant cash payments upon the achievement of specified commercial milestones, as well as earnout payments in connection with sales of products based on the compounds that we acquired from Shire.
We will require additional capital to advance MRT5005 and any other product candidates we develop through necessary clinical trials and clinical development. In addition, if we obtain marketing approval for any of our product candidates that we plan to commercialize ourselves, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain additional funding in connection with our continuing operations. We may raise this additional funding through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions and funding under government or other contracts. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.
We believe that our existing cash, cash equivalents and investments of $667.2 million as of June 30, 2021 will enable us to fund our operating expenses and capital expenditure requirements into 2024. If we are unable to obtain funding, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, which could adversely affect our business prospects, and we may be unable to continue operations. To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured.
 
39

Our estimates regarding our ability to fund our operating expenses and capital expenditure requirements with our existing cash and cash equivalents are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Our future funding requirements will depend on, and could increase significantly as a result of, many factors, including:
 
   
the successful completion of our pending transaction with Sanofi S.A.;
 
   
the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;
 
   
the success of our collaboration with Sanofi;
 
   
the costs, timing and outcome of regulatory review of our product candidates;
 
   
the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
 
   
the impacts of the
COVID-19
pandemic and our response to it;
 
   
the costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch;
 
   
the ability to receive additional
non-dilutive
funding, including grants from organizations and foundations;
 
   
the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;
 
   
the cost and timing of hiring new employees to support our continued growth;
 
   
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
 
   
our ability to establish and maintain collaborations on favorable terms, if at all;
 
   
the extent to which we acquire or
in-license
other product candidates and technologies; and
 
   
the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any.
Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that typically takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenue, if any, and any commercial milestones or royalty payments under any collaboration agreements that we enter into, including our collaboration with Sanofi, will be derived from or based on sales of products that may not be commercially available for many years, if at all. Accordingly, we will continue to rely on additional financing to achieve our business objectives.
Any additional fundraising efforts may divert our management from their
day-to-day
activities, which may adversely affect our ability to develop and commercialize our product candidates. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Our issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common stock to decline, and our stockholders may not agree with our financing plans or the terms of such financings.
Our failure to raise capital as and when needed would negatively impact our financial condition and our ability to pursue our business strategy, and we could be forced to delay, reduce or eliminate certain of our research and development programs or any future commercialization efforts.
 
40

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to technologies or product candidates.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through the combination of public or private equity offerings, debt financings, grants, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring debt, making capital expenditures or declaring dividends. In addition, debt financing would result in increased fixed payment obligations.
If we raise funds through collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we will be required to delay, reduce or eliminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
We may be required to make payments in connection with our acquisition of the MRT Program from Shire.
In December 2016, we acquired the mRNA therapeutic platform, or MRT Program, pursuant to the Shire Agreement. Under the Shire Agreement, we are obligated to make milestone payments to Shire of up to $60.0 million in the aggregate upon the occurrence of specified commercial milestones, including upon the first commercial sale of a product that includes or is composed of MRT compounds acquired from Shire, or MRT Product, for the treatment of cystic fibrosis, or CF, and upon the achievement of a specified level of annual net sales with respect to MRT Products. We are also obligated to make additional milestone payments of $10.0 million for each
non-CF
MRT Product upon the first commercial sale of a
non-CF
MRT Product; provided that such milestone payments will only be due once for any two
non-CF
MRT Products that contain the same MRT compounds, or once for
non-CF
MRT Products that are mRNA vaccines in certain infectious disease pathogens under our collaboration and license agreement with Sanofi, or Licensed Fields. Under the Shire Agreement, we are also obligated to pay a fixed, quarterly earnout payment of a
mid-single-digit
percentage of net sales of each MRT Product. The earnout period will begin on the date of the first commercial sale of MRT Products and will end, on a
product-by-product
and
country-by-country
basis, on the later of (1) the expiration of the last valid claim of the assigned patents covering the manufacture, use or composition of such product in such country of the applicable MRT Product and (2) 10 years after the first commercial sale of the MRT Product in such country. If these payments become due under the terms of the Shire Agreement, we may not have sufficient funds available to meet our obligations and our development efforts may be materially harmed. If a combination MRT Product that is a vaccine is sold, in certain circumstances, we would be obligated to pay Shire a royalty on a minimum portion of net sales.
We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards.
As of December 31, 2020, we had federal net operating loss carryforwards of $239.3 million, of which $116.1 million will, if not utilized, begin to expire in 2031. As of December 31, 2020, we had state net operating loss carryforwards of $227.6 million, which will, if not utilized, begin to expire in 2031. Our federal and state research and development tax credit carryforwards of $7.0 million and $4.3 million, respectively, will, if not utilized, begin to expire in 2032 and 2028, respectively, and orphan drug tax credit carryforwards of $17.4 million will, if not utilized, begin to expire in 2037. We also have state investment tax credit carryforwards of $0.8 million, which will, if not utilized, begin to expire in 2020. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset our future income tax liabilities.
In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a three-year period, the corporation’s ability to use its
pre-change
net operating loss carryforwards and other
pre-change
tax attributes to offset its post-change income may be limited. We have determined that we have experienced multiple Sections 382 and 383 ownership changes in the past and if a portion of our net operating loss and tax credit carryforwards are subject to an annual limitation under Section 382. In addition, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If an ownership change has occurred or occurs in the future and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.
 
41

There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. As described below in “Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,” the Tax Cuts and Jobs Act, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our net operating losses and other tax attributes.
Risks Related to the Development of Our Product Candidates
Our approach to the discovery and development of product candidates based on mRNA is unproven, and we do not know whether we will be able to successfully develop any products.
We focus on delivering mRNA encoding functional versions of proteins into cells without altering the underlying DNA. Our future success depends on the successful development of this novel therapeutic approach. Relatively few mRNA-based therapeutic product candidates have been tested in animals or humans, and the data underlying the feasibility of developing mRNA-based therapeutic products is both preliminary and limited. While
COVID-19
vaccines relying on mRNA have been approved by the FDA and EMA and are commercially available, to date, no product that utilizes mRNA as a therapeutic has been approved in the United States or Europe. We have not yet succeeded and may not succeed in demonstrating the efficacy and safety of any of our product candidates in clinical trials or in obtaining marketing approval thereafter. We have not yet completed a clinical trial of any product candidate and we have not yet assessed safety of any product candidate in humans. As such, there may be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time.
As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our MRT platform, or any similar or competitive mRNA platforms, will result in the development and regulatory approval of any products. There can be no assurance that any development problems we experience in the future related to our MRT platform or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all. For example, in September 2019 we discontinued the development of MRT5201, a liver targeted treatment for ornithine transcarbamylase, or OTC, deficiency, and terminated our Phase 1/2 clinical trial for MRT5201 in patients with OTC deficiency.
We and Sanofi may not be successful in our joint efforts to successfully develop in an expedited timeframe an mRNA vaccine against
SARS-CoV-2.
We have a collaboration with Sanofi to develop infectious disease vaccines using our messenger RNA, or mRNA, technology, including mRNA vaccines against
SARS-CoV-2.
Pursuant to the collaboration, we are leveraging our mRNA platform and Sanofi’s vaccine expertise to develop mRNA vaccines for infectious diseases, which includes a goal of discovering, developing and advancing rapidly into the clinic a
SARS-CoV-2
vaccine candidate.
Although MRT5500 has been selected as the lead
COVID-19
vaccine candidate, and a Phase 1/2 clinical trial to evaluate MRT5500 began in the first quarter of 2021, the development of a
SARS-CoV-2
vaccine candidate is still in its early stages. MRT5500 may not be safe and may not successfully prevent
COVID-19
in a timely manner, if at all. In order to obtain regulatory approval to market a new biological product such as a
SARS-CoV-2
vaccine, proof of safety, purity and potency must be demonstrated in humans. To satisfy these requirements, one or more adequate and well-controlled clinical trials will have to be conducted. We cannot predict if any applicable regulatory bodies will accept the proposed clinical program or if the outcome of the preclinical testing and studies will ultimately support the further development of MRT5500. As a result, we cannot be sure that MRT5500 will be able to be advanced into clinical trials on the expected timeline, if at all, and we cannot be sure that applicable regulatory authorities will allow clinical trials to begin. Moreover, even though a clinical trial for MRT5500 has been initiated, development efforts may not be successful, and clinical trials conducted may not demonstrate sufficient safety, purity and potency necessary to obtain the requisite regulatory approvals for MRT5500.
The timing and success of any clinical trials will also depend on our ability to enroll subjects in the clinical trials. Vaccines for
COVID-19
have been approved by the FDA and EMA and are available in the United States and Europe. In addition, several other companies are pursuing the development of a vaccine for
COVID-19,
and subject enrollment may be affected by availability of the authorized available vaccines and other clinical trials of competing vaccine candidates. Subject enrollment may also be affected by other factors, including variations in the incidence of
COVID-19
at the time of the trial and the perceived risks and benefits of the
 
42

clinical trial among potential subjects. Our inability to enroll a sufficient number of subjects for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in demonstrating safety and potency in later trials.    
Further, while the FDA and other regulatory authorities have authority to expedite review and approval of various products, including vaccines, it is unclear how the FDA or such other authorities will exercise these powers with respect to our vaccine candidate, if at all. For example, while the FDA issued an Emergency Use Authorization, or EUA, for the first
COVID-19
vaccine, it is unclear whether it will do so for future
COVID-19
vaccine candidates. An EUA allows for the manufacture, research and distribution of drugs, biologics and medical devices that have not been approved or licensed by the agency under the standard requirements that typically govern the development of new medical products. The extent to which the FDA relies on the EUA process, or other expedited regulatory mechanisms for the study and review of vaccine candidates, remains unclear and will be subject to a number of different factors. As a result, even if our vaccine candidate shows promising results in preclinical and clinical studies, its approval under an EUA or expedited licensing processes is not assured and the need for authorization from the FDA may result in delays.
If the
COVID-19
pandemic is effectively contained or the risk of
SARS-CoV-2
infection is diminished or eliminated before we can successfully develop and manufacture an mRNA vaccine against
SARS-CoV-2,
Sanofi could
de-prioritize
its support for the joint development of such a vaccine. We are also committing financial resources and personnel to the development of MRT5500,
which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties surrounding the longevity and extent of coronavirus as a global health concern. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could rapidly dissipate or against which our vaccine, if developed, may not be partially or fully effective. In addition, other companies have developed an FDA approved a vaccine for
COVID-19,
and it is possible that
SARS-CoV-2
could be effectively contained before or shortly after we are able to receive authorization for our vaccine candidate.
The failure to successfully develop, manufacture and commercialize MRT5500 could have an adverse effect on our business, prospects, financial condition and results of operations and cause us reputational harm, any of which could cause our stock price to decline.
We have never obtained marketing approval for a product candidate, and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.
We are a clinical-stage company and have not received approval from the FDA, EMA or other regulatory authority to market any product candidate. The regulatory review process may be more expensive or take longer than we expect, and we may be required to conduct additional studies and/or trials beyond those we anticipate. If it takes us longer to develop and/or obtain regulatory approval for our product candidates than we expect, such delays could materially and adversely affect our business, financial condition, results of operations and prospects.
If we are unable to complete satisfactorily the clinical development of, obtain marketing approval for or successfully commercialize any product candidate, particularly MRT5005, either alone or with a future collaborator, or if we experience significant delays in doing so, our business would be substantially harmed.
We do not currently have products approved for sale and are investing a significant portion of our efforts and financial resources in the development of MRT5005. As a consequence of the
COVID-19
pandemic, we announced that enrollment and dosing in the ongoing Phase 1/2 clinical trial in patients with CF was paused in April 2020 and then resumed in September 2020. The uncertain environment associated with the
COVID-19
pandemic could result in additional disruptions in enrollment, affecting our timing to report data. The
COVID-19
pandemic also may continue to impact our clinical trials. Our prospects are substantially dependent on our ability, or that of any future collaborator, to develop and obtain marketing approval for, and successfully commercialize, MRT5005.
The success of MRT5005 will depend on several factors, including the following:
 
   
successful patient enrollment in and completion of clinical trials;
 
   
a safety, tolerability and efficacy profile that is satisfactory to the FDA, EMA or other regulatory authorities for marketing approval;
 
   
timely receipt of marketing approvals from applicable regulatory authorities;
 
43

   
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
 
   
establishment and maintenance of arrangements with third-party manufacturers for both clinical and any future commercial manufacturing, if approved;
 
   
adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales, if approved;
 
   
obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally;
 
   
protection of our rights in our intellectual property portfolio;
 
   
successful launch of commercial sales following any marketing approval;
 
   
a continued acceptable safety profile following any marketing approval;
 
   
commercial acceptance by hospitals, the patient community, the medical community and third-party payors;
 
   
the availability of coverage and adequate reimbursement from third-party payors;
 
   
the performance of our future collaborators, if any; and
 
   
our ability to compete with other therapies.
Many of these factors are beyond our control, including clinical development, the regulatory review process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. The failure to successfully develop, receive marketing approval for and commercialize any product candidate, particularly MRT5005, on our own or with any future collaborator, could have an adverse effect on our business, prospects, financial condition and results of operations and cause us reputational harm, any of which could cause our stock price to decline.
Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If the initiation or completion of clinical trials of our product candidates, particularly MRT5005, is prolonged or delayed, we or any future collaborators may be unable to obtain required regulatory approvals, and therefore will be unable to commercialize our product candidates on a timely basis or at all, which will adversely affect our business.
Before obtaining marketing approval for our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates. Clinical testing is expensive, time-consuming, difficult to design and implement and uncertain as to outcome. We cannot guarantee that the clinical trials, such as the Phase 1/2 clinical trial for MRT5500, the Phase 1 clinical trial for MRT5400 and MRT5401 and our Phase 1/2 clinical trial of MRT5005 in patients with CF, will be conducted as planned, completed on schedule, if at all, or yield positive results. As a consequence of the
COVID-19
pandemic, we announced that enrollment and dosing in the ongoing Phase 1/2 clinical trial in patients with CF was paused in April 2020 and then resumed in September 2020. The uncertain environment associated with the
COVID-19
pandemic could result in additional disruptions in enrollment, affecting our timing to report data. The
COVID-19
pandemic also may continue to impact our clinical trials.
A clinical trial failure can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:
 
   
delays in reaching a consensus with regulatory authorities or collaborators on trial design;
 
   
delays in reaching agreement on acceptable terms with CROs and clinical trial sites;
 
   
delays in opening clinical trial sites or obtaining required institutional review board or independent ethics committee approval at each clinical trial site;
 
   
delays in recruiting suitable subjects or a sufficient number of subjects to participate in our clinical trials;
 
44

   
imposition of a clinical hold by regulatory authorities, including upon submission of an IND, or as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;
 
   
failure by us, any CROs we engage, clinical investigators or any other third parties to adhere to clinical trial requirements;
 
   
failure to perform the clinical trial in accordance with good clinical practices, or GCP, or applicable regulatory requirements in the European Union, the United States, or other countries;
 
   
delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;
 
   
delays or failures in demonstrating the comparability of product manufactured at one facility or with one process to product manufactured at another facility or with another process, including clinical trials to demonstrate such comparability;
 
   
delays in having patients complete participation in a trial or return for post-treatment
follow-up;
 
   
clinical trial sites or subjects dropping out of a trial;
 
   
selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;
 
   
occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;
 
   
occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; and
 
   
changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.
Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional trials to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.
We have experienced delays in enrollment and dosing in our ongoing Phase 1/2 clinical trial in patients with CF as a consequence of the
COVID-19
pandemic. We could also encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards of the institutions in which such trials are conducted or their ethics committees, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA or other foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidates belong.
Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or early termination of the development of our product candidates.
Preclinical drug development is uncertain. Some or all of our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.
In order to obtain FDA approval to market a new biological product, we must demonstrate proof of safety, purity and potency or efficacy in humans. To satisfy these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support an investigational new drug, or IND, in the United States. We cannot be certain of the timely completion or outcome of our preclinical testing and studies, and we cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of these product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for any preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.
 
45

Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per product candidate. Delays associated with product candidates for which we are conducting preclinical testing and studies ourselves may cause us to incur additional operating expenses. Moreover, we may be affected by delays associated with the preclinical testing and studies of certain product candidates conducted by our potential partners over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:
 
   
inability to generate sufficient preclinical or other
in vivo
or
in vitro
data to support the initiation of clinical trials; and
 
   
delays in reaching a consensus with regulatory agencies on study design.
Moreover, even if we do initiate clinical trials for other product candidates, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate sufficient safety, purity and potency or efficacy necessary to obtain the requisite regulatory approvals for any of our product candidates or product candidates employing our technology. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in future trials.
Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.
Results from preclinical studies are not necessarily predictive of clinical trial results, results from early clinical trials are not necessarily predictive of later clinical trial results and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or successful advancement through initial clinical trials.
There can be no assurance that the success we achieved in preclinical studies of MRT5005, MRT5500, MRT5400 and MRT5401 or may achieve in preclinical studies of other product candidates will result in success in clinical trials of these product candidates. In addition, we cannot assure you that we will be able to achieve the same or similar success in our preclinical studies and clinical trials of our other product candidates.
For example, our preclinical studies in animal models have been conducted using human mRNA, which differs from animal mRNA, making it difficult for us to use animal models to assess whether our product candidates are safe or effective in humans. Preclinical studies conducted in mice, rats and
non-human
primates are not always indicative of clinical trial outcomes in humans.
While we are conducting a Phase 1/2 clinical trial of MRT5005, we have not completed any clinical trials evaluating any of our product candidates or proposed delivery modes, including the use of lipid nanoparticles that are customized for delivery to specific tissues.
There is a high failure rate for drugs and biologic products proceeding through preclinical studies and clinical trials. Any product candidates we develop may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical studies and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could materially and adversely affect our business, financial condition, results of operations and prospects.
We have experienced and may in the future experience difficulty enrolling and dosing patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.
Identifying, qualifying and enrolling patients to participate in clinical trials of our product candidates is critical to our success, and we may not be able to identify, recruit, enroll and dose a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. The timing of our clinical trials depends on our ability to recruit patients to participate as well as to subsequently dose these patients and complete required
follow-up
periods. We depend on Sanofi to
 
46

design and conduct clinical trials for our vaccine candidates. As a result, we may not control the manner or time schedule in which these clinical trials are conducted, which may negatively impact our business operations. In addition, we anticipate competition enrolling patients for the anticipated future clinical trials of MRT5500 as
COVID-19
vaccines are available and many other companies are conducting or plan to conduct similar trials. In contrast, because our clinical trial of MRT5005 is focused on indications with relatively small patient populations, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate as a consequence to the
COVID-19
pandemic or otherwise. Many CF clinical trial sites place importance on the review, ranking and sanctioning of CF patient advocacy groups. If CF patient advocacy groups do not timely sanction or highly rate our clinical trials, or prioritize trials of other sponsors over our trials, we may not be able to enroll sufficient patients to conduct our trials at their member sites, or it may take longer to conduct these trials.
As a consequence of the
COVID-19
pandemic, we announced that enrollment and dosing had been paused in our ongoing Phase 1/2 clinical trial in patients with CF in April 2020. Even though we were able to resume in September 2020 and complete enrollment and dosing in this trial for the second interim data analysis as well as continue to enroll and dose in the remaining dose groups, we may encounter slower than expected enrollment or dosing delays due to the CF patient population, or CF advocacy groups may provide additional guidance for the safety of the CF population, which may delay the trial. The uncertain environment associated with the
COVID-19
pandemic could result in additional disruptions in enrollment, affecting our timing to report data. The
COVID-19
pandemic also may continue to impact our clinical trial of MRT5005. In addition, we may experience enrollment delays related to increased or unforeseen regulatory, legal and logistical requirements at certain clinical trial sites. For example, a delay in the manufacturing of clinical trial material for the Phase 1/2 clinical trial of MRT5500 resulted in a delay in the initiation of the trial. These delays could be caused by regulatory reviews by regulatory authorities and contractual discussions with individual clinical trial sites. Any delays in enrolling and/or dosing patients in our planned clinical trials could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.
Patient enrollment may be affected if our competitors have ongoing clinical trials for product candidates for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in our competitors’ clinical trials. Patient enrollment may also be affected by other factors, including:
 
   
coordination between us, CROs and any future collaborators in our efforts to enroll and administer the clinical trial;
 
   
size of the patient population and process for identifying patients;
 
   
design of the trial protocol;
 
   
eligibility and exclusion criteria;
 
   
perceived risks and benefits of the product candidate under study;
 
   
availability of competing commercially available therapies and other competing product candidates’ clinical trials;
 
   
time of year in which the trial is initiated or conducted;
 
   
variations in the seasonal incidence of the target indication;
 
   
severity of the disease under investigation;
 
   
ability to obtain and maintain subject consent;
 
   
ability to enroll and treat patients in a timely manner;
 
   
risk that enrolled subjects will drop out before completion of the trial;
 
   
proximity and availability of clinical trial sites for prospective patients;
 
   
patient referral practices of physicians; and
 
   
ability to monitor subjects adequately during and after treatment.
 
47

Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which could cause the value of our company to decline and limit our ability to obtain additional financing.
We may not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programs or product candidates for which there is a greater likelihood of commercial success.
Our success depends upon our ability to identify, develop and commercialize product candidates based on our MRT platform. If we do not successfully develop and eventually commercialize products, we will not be able to generate product revenue, resulting in significant harm to our financial position and adverse effects to our share price. Research programs to identify new product candidates require substantial technical, financial and human resources. Although our product candidates are currently in preclinical or clinical development, we may fail to identify other potential product candidates for clinical development.
Additionally, because we have limited financial and managerial resources, we may forego or delay pursuit of opportunities for certain programs or product candidates or for indications that later prove to have greater commercial potential. For example, we currently intend to focus our capital resources primarily on the clinical development of MRT5005 and the development of vaccines.
However, the development of MRT5005, MRT5500, MRT5400 or MRT5401 may ultimately prove to be unsuccessful or less successful than another product candidate in our pipeline that we might have chosen to pursue on a more aggressive basis with our capital resources. Our estimates regarding the potential market for our product candidates could be inaccurate, and our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaborative arrangement.
If any of these events occur, we may be forced to abandon or delay our development efforts with respect to a particular product candidate, or we may fail to develop a potentially successful product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.
We may fail to demonstrate safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities.
If the results of any of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:
 
   
be delayed in obtaining marketing approval for our product candidates, if at all;
 
   
obtain approval for indications or patient populations that are not as broad as intended or desired;
 
   
obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
 
   
be subject to changes in the way the product is administered;
 
   
be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;
 
   
have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS;
 
   
be subject to the addition of labeling statements, such as contraindications or warnings, including a black box warning;
 
   
be sued; or
 
   
experience damage to our reputation.
 
48

If serious adverse or undesirable side effects are identified during the development of our product candidates or proposed delivery modes, we may abandon or limit our development of such product candidates.
If our product candidates or proposed delivery modes are associated with undesirable side effects or have unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause side effects or raise other safety issues that delayed or prevented further development of the compound. Further, given the relatively small patient populations for which we are developing MRT5005, we expect to have to evaluate long-term exposure to establish the safety and tolerability of this product candidate in a chronic dose setting. The adverse effects from long-term exposure, as well as exposure in general, to our product candidates are unknown because they are a new class of therapeutics that have not previously been evaluated in a clinical trial. The risk of adverse or undesirable side effects therefore remains a significant concern, and we cannot assure you that these or other risks will not occur in any of our current or future clinical trials of MRT5005 or other product candidates that we may develop.
If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenue from such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business, financial condition, results of operations and prospects.
Because we are developing product candidates for the treatment of diseases in which there is little clinical experience using new technologies, there is increased risk that the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.
During the regulatory review process, we will need to identify success criteria and endpoints such that the FDA, the EMA or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates we may develop. Because our initial focus is to identify and develop product candidates to treat diseases in which there is little clinical experience using new technologies, there is heightened risk that the FDA, the EMA or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA determines that our success criteria is sufficiently validated and clinically meaningful, we may not achieve the
pre-specified
endpoints to a degree of statistical significance.
This may be a particularly significant risk for many of the genetically defined diseases for which we plan to develop product candidates because many of these diseases have small patient populations, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations. Further, even if we do achieve the
pre-specified
criteria, the results may be unpredictable or inconsistent with the results of the
non-primary
endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. The EMA and other regulatory authorities may make similar comments with respect to these endpoints and data. Any product candidate we may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval.
We may conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.
We may conduct one or more of our clinical trials with one or more trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP. The FDA must be able to validate the data from the trial through an onsite inspection, if necessary. The trial population must also have a similar profile to the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful, except to the extent the disease being studied does not typically occur in the United States. In addition, while these clinical trials are subject to the applicable local laws, whether the FDA accepts the data will depend upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt the development of MRT5005, MRT5500, MRT5400, MRT5401 or any future product candidates.
 
49

In addition, conducting clinical trials outside the United States could have a significant adverse impact on us. Risks inherent in conducting international clinical trials include:
 
   
clinical practice patterns and standards of care that vary widely among countries;
 
   
non-U.S.
regulatory authority requirements that could restrict or limit our ability to conduct our clinical trials;
 
   
administrative burdens of conducting clinical trials under multiple
non-U.S.
regulatory authority schema;
 
   
foreign exchange fluctuations; and
 
   
diminished protection of intellectual property in some countries.
The manufacture of mRNA-based therapeutics is complex and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter difficulties, our ability to provide product candidates for clinical trials or products, if approved, to patients could be delayed or halted.
The manufacture of mRNA-based therapeutics is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and our third-party manufacturers must comply with current Good Manufacturing Practices, or cGMP, regulations and guidelines for the manufacturing of our product candidates used in preclinical studies and clinical trials and, if approved, marketed products. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up and validating initial production. Furthermore, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities where our product candidates are made, such manufacturing facilities may be closed for an extended period of time to investigate and remedy the contamination. In addition, the recent increase in large scale demand for the manufacture of mRNA
COVID-19
vaccines may impact our ability to obtain the raw materials required to manufacture our mRNA products. Shortages of raw materials may also extend the period of time required to develop our product candidates.
We cannot assure you that any disruptions or other issues relating to the manufacture of any of our product candidates will not occur in the future. For example, in November 2020, we announced a delay in the manufacturing of our clinical material for the Phase 1/2 clinical trial of MRT5500, which caused a delay in the initiation of the trial. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could delay or impede the development and commercialization of any of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.
The manufacture, scale, validation and production of a potential
SARS-CoV-2
vaccine candidate is complex and uncertain. We may encounter difficulties, and our ability to develop and provide a vaccine, if approved, could be delayed, interrupted or halted.
To date, we have produced multiple mRNA constructs and have established 100 gram single-batch production with our clinical-stage mRNA therapeutics platform.
Build-out
of a dedicated manufacturing space through a contract manufacturing partner was completed during the third quarter of 2020 and has the potential to accommodate multiple
250-gram
batches per month upon continued investments and third-party supplier arrangements. As it relates to development of MRT5500, depending on the final human dose and timing of
scale-up
activities, we estimate that we could have manufacturing capacity to produce
90-360 million
doses annually. However, the manufacture of mRNA-based therapeutics is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We may face difficulties in production of MRT5500, including scaling up and validating production, potential shortages of raw materials, a failure by our contract manufacturer to comply with guidelines, specifications and regulations necessary for the manufacture of any vaccine candidate we seek to manufacture, and other disruptions relating to the manufacture of any potential
SARS-CoV-2
vaccine candidates.
 
50

We will also require substantial capital to commence and continue production of MRT5500, which capital may not be available in the time frame or amount needed. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials of MRT5500, increase the cost associated with the related clinical trial program and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. For example, a delay in the manufacturing of clinical trial material for the Phase 1/2 clinical trial of MRT5500 resulted in a delay in the initiation of the trial. Any adverse developments affecting clinical or commercial manufacturing of MRT5500 or approved vaccine may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in supply.
If the market opportunities for our product candidates are smaller than we believe they are, even assuming approval of a product candidate, our business may suffer.
Our product candidates are based on novel therapeutic approaches. As such, physicians, hospitals, third-party payors and patients may not accept our product candidates as treatment options, even if approved. While we believe there are commercial opportunities for our product candidates, we cannot be sure that is the case, particularly given the novelty of mRNA-based therapeutics.
Our projections of both the number of people affected by disease within our target indications, as well as the subset of these people who could benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations and market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or reach, which would adversely affect our results of operations and our business.
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
The biotechnology and pharmaceutical industries are highly competitive, characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face and will continue to face competition from third parties that use mRNA, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecules. The competition is likely to come from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.
Our competitors also include companies that are or will be developing other mRNA technology methods as well as small molecules, biologics and nucleic acid-based therapies for the same indications that we are targeting with our mRNA-based therapeutics.
Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even greater concentration of resources among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products faster or earlier than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, new data from clinical-stage products continue to emerge. Technologies developed by our competitors may render our product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors’ products. In addition, the availability of our competitors’ products could limit the demand and the prices we are able to charge for any products that we may develop and commercialize.
 
51

If approved for the treatment of CF, MRT5005 would compete with Kalydeco, Orkambi, Symdeko and Trikafta, each of which is marketed by Vertex Pharmaceuticals Incorporated, or Vertex. Vertex also has several cystic fibrosis transmembrane conductance, or CFTR, modulator compounds in clinical development, each of which is currently in a Phase 2 clinical trial.
Our other potential competitors for CF include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. Examples include AbbVie, Inc., Eloxx Pharmaceuticals Ltd, Yumanity Therapeutics, Inc., Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Companies are developing gene-based medicines that modulate or affect CFTR function for the treatment of CF. These products are currently in the preclinical stage but could enter Phase 1 clinical trials within the next year. Companies developing mRNA products for CF include Arcturus Therapeutics Holdings Inc., ReCode Therapeutics, Inc. and Moderna, Inc. (in collaboration with Vertex). Companies developing gene editing or gene therapy products for CF include CRISPR Therapeutics AG (in collaboration with Vertex), 4D Molecular Therapeutics, Spirovant Sciences, Inc. and Boehringer Ingelheim International GmbH.
Large and established companies, such as Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, Pfizer, Inc., Johnson & Johnson and AstraZeneca plc, among others, compete in the vaccine market. In addition, some of our mRNA competitors, Moderna, Inc. and BioNTech AG, have also developed
COVID-19
vaccines using mRNA technology and other mRNA competitors, such as CureVac AG and Arcturus Therapeutics Holdings, Inc., are developing
COVID-19
vaccines. Currently, several of our competitors have developed
COVID-19
vaccines that have received emergency use approval by the FDA or conditional marketing authorization from the EMA and are being administered throughout the United States, Europe and other parts of the world. Competitors are also developing influenza vaccines using mRNA technology; Moderna, Inc., has an influenza vaccine program which has started Phase 1 clinical studies while Pfizer, Inc. (in collaboration with BioNTech AG) and Arcturus Therapeutics Holdings, Inc. both have influenza vaccine programs in the preclinical stage.
Risks Related to Dependence on Third Parties
We have an existing collaboration with Sanofi and we are highly dependent on the efforts of Sanofi to advance our vaccine development program, including the vaccines against
SARS-CoV-2
and influenza. If our collaboration with Sanofi is not successful, our business could be adversely affected.
We currently have a collaboration and license agreement with Sanofi to develop mRNA vaccines for infectious disease pathogens, including
SARS-CoV-2
and influenza. MRT5500 has been selected as the lead candidate for a vaccine against
SARS-CoV-2.
MRT5400 and MRT5401 are our vaccine candidates against influenza. Sanofi may not be successful in its efforts to develop or commercialize our vaccine candidates, which could adversely affect our business. In addition, Sanofi could decide not to pursue or prioritize our vaccine candidates, or disputes may arise over certain obligations, which could have an adverse effect on our ability to develop and commercialize any affected product candidate.
We have limited control over the amount and timing of resources that Sanofi dedicates to the development or commercialization of our vaccine candidates. Our ability to generate revenue from our arrangement with Sanofi will depend on Sanofi’s ability to successfully perform the functions assigned to Sanofi.
Our collaboration with Sanofi may pose several risks, including the following:
 
   
Sanofi has significant discretion in determining the efforts and resources that it will apply to our collaboration;
 
   
Sanofi may not perform its obligations as expected;
 
   
The clinical trials conducted as part of our collaboration with Sanofi may not be successful;
 
   
Sanofi may not pursue development and/or commercialization of any vaccine candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in Sanofi’s strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;
 
   
Sanofi has final decision-making authority for conducting clinical trials, and this may result in Sanofi delaying clinical trials, providing insufficient funding for clinical trials, stopping a clinical trial or abandoning a vaccine candidate, repeating or conducting new clinical trials or requiring a new formulation of a vaccine candidate for clinical testing;
 
52

   
We may not have access to, or may be restricted from disclosing, certain information regarding vaccine candidates being developed or commercialized under our collaboration with Sanofi and, consequently, may have limited ability to inform our stockholders about the status of such vaccine candidates;
 
   
Sanofi has an existing collaboration with GlaxoSmithKline plc to develop a
SARS-CoV-2
vaccine candidate that could compete with MRT5500, and Sanofi could further independently develop, or develop with third parties, products that compete directly or indirectly with any of our vaccine candidates if Sanofi believes that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
 
   
Sanofi may view vaccine candidates developed in collaboration with us as competitive with their own product candidates or products, which may cause Sanofi to cease to devote resources to the commercialization of our vaccine candidates;
 
   
Sanofi may not commit sufficient resources to the marketing and distribution of any such of our vaccine candidates that achieve regulatory approval;
 
   
Disagreements with Sanofi, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any of our vaccine candidates, may cause delays or termination of the research, development, manufacture or commercialization of such vaccine candidates, may lead to additional responsibilities for us with respect to such vaccine candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive. Moreover, in certain circumstances, there could be a misalignment between our contractual obligations to Sanofi and any upstream contractual obligations we may owe to our licensors or other third parties;
 
   
Sanofi may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation. For example, Sanofi has the first right to enforce or defend certain of our intellectual property rights under our collaboration with respect to products in Licensed Fields, and although we may have the right to assume the enforcement and defense of such intellectual property rights if Sanofi does not, our ability to do so may be compromised by Sanofi’s actions;
 
   
Disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaboration with Sanofi;
 
   
Sanofi may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
 
   
Sanofi may terminate our collaboration for convenience after a specified notice period and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable vaccine candidates.
If our collaboration with Sanofi does not result in the successful development and commercialization of vaccines, or if Sanofi terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under our agreement with Sanofi, our development of vaccine candidates could be delayed and we may need additional resources to develop our vaccine candidates.
In addition, if Sanofi terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation among the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report on Form
10-Q
also apply to Sanofi’s activities.
We may enter into additional collaborations with third parties, and if we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.
As part of our strategy, we intend to seek to enter into collaborations with third parties for one or more of our programs or product candidates. Our likely collaborators for any other collaboration arrangements include large and
mid-size
pharmaceutical companies and biotechnology companies.
We face significant competition in attracting appropriate collaborators to advance the development of any product candidates for which we may seek a collaboration. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or other regulatory authorities, the potential market for the subject product candidate, the
 
53

costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also have the opportunity to collaborate on other product candidates or technologies for similar indications and will have to evaluate whether such a collaboration could be more attractive than one with us.
Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical companies has reduced the number of potential future collaborators. Even if we are able to successfully enter into collaborations with third parties for one or more of our programs or product candidates, such collaborations may be subject to risks similar to those described above under the risk factor captioned “We have an existing collaboration with Sanofi and we are highly dependent on the efforts of Sanofi to advance our vaccine development program, including the vaccines against
SARS-CoV-2
and influenza. If our collaboration with Sanofi is not successful, our business could be adversely affected
.
We may not be able to negotiate collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue, which could have an adverse effect on our business, prospects, financial condition and results of operations.
Under the Shire Agreement, prior to the first dosing of a patient with a CFTR MRT Product in a Phase 3 clinical trial, Shire has a
90-day
right of first negotiation before we may grant rights or sell assets relating to our CFTR MRT Products to a third party. Shire may exercise the right of first negotiation for a period of 30 days following Shire’s receipt of written notice from us notifying Shire of the offer from a third party to acquire, license or commercialize grant rights or sell assets relating to our CF program.
We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.
We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. In addition, we currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience. In addition, as a consequence of the
COVID-19
pandemic, some of these parties may be unable to perform their engagements satisfactorily or at all. If any of our relationships with these third parties terminate, we may not be able to enter into alternative arrangements on commercially reasonable terms, if at all. Switching or including additional third parties involves increased cost and requires management’s time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays may occur in our product development activities. Although we seek to carefully manage our relationships with our third parties, we could encounter similar challenges or delays in the future and these challenges or delays could have a material adverse impact on our business, financial condition and prospects. The
COVID-19
pandemic also may continue to impact our clinical trials.
Our reliance on third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. We and these third parties are required to comply with GCP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable regulatory authorities, for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Similar requirements are applicable outside the United States. Failure to comply can result in fines, adverse publicity and civil and criminal sanctions.
 
54

Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical,
non-clinical
and preclinical programs. If these third parties do not successfully satisfy their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our preclinical studies or clinical trials may be extended, delayed or terminated, and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products. As a result, our results of operations and the commercial prospects for our products would be harmed, our costs could increase and our ability to generate revenue could be impaired.
Our reliance on third parties to manufacture our product candidates and any future products increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
We do not own or operate manufacturing facilities for the production of clinical or commercial supplies of the product candidates that we are developing or evaluating in our research program. Although we have a suite retention and development agreement under which a series of cleanroom suites were built at Curia Massachusetts, Inc., or Curia, (f/k/a Albany Molecular Research, Inc.) manufacturing facility in accordance with our objectives, we do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates. We have limited personnel with experience in drug manufacturing and lack the resources and capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on third parties for supply of our product candidates, and we outsource to third parties all manufacturing of our product candidates in preparation for our clinical trials.
In order to conduct clinical trials of our product candidates, we will need to have them manufactured in potentially large quantities. Our third-party manufacturers may be unable to meet this increased demand in a timely or cost-effective manner, or at all. In addition, as a consequence of the
COVID-19
pandemic, our third-party manufacturers may experience delays or other interruptions with their manufacturing capabilities and may be unable to perform satisfactorily, or at all. In addition, quality issues may arise during
scale-up
activities and at any other time. For example, ongoing data on the stability of our products may shorten the expiry of our products and lead to clinical trial material supply shortages, and potentially clinical trial delays. If these third-party manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.
Our use of third-party manufacturers increases the risk of delays in production or insufficient supplies of our product candidates as we transfer our manufacturing technology to these manufacturers and as they gain experience manufacturing our product candidates. For example, Curia, a third-party manufacturer, manufactures certain portions of our product candidates. Although we were closely involved with the design and construction of the cleanroom suites, we may still experience delays in the development services provided by Curia. Such delays could materially adversely affect our business.
Even after a third-party manufacturer has gained significant experience in manufacturing our product candidates or even if we believe we have succeeded in optimizing the manufacturing process, there can be no assurance that such manufacturer will produce sufficient quantities of our product candidates in a timely manner or continuously over time, or at all.
In the future, we may be unable to enter into such agreements with third-party manufacturers for commercial supplies of our product candidates, or may be unable to do so on acceptable terms. Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, including:
 
   
reliance on the third party for regulatory compliance and quality assurance;
 
   
the possible breach of the manufacturing agreement by the third party;
 
   
the possible misappropriation of our proprietary information, including our trade secrets and
know-how;
and
 
   
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
 
55

Third-party manufacturers may not be able to comply with cGMP requirements or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and/or criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.
Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP requirements, particularly for the development of mRNA-based therapeutics, and that might be capable of manufacturing for us.
If the third parties that we engage to supply any materials or manufacture product for our preclinical tests and clinical trials should cease to do so for any reason, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers, and we may be unable to obtain replacement supplies on terms that are favorable to us. For example, we rely on one third-party supplier of the handheld nebulizer that patients in our clinical trials use to administer MRT5005. The failure of our supplier to provide sufficient quantities, acceptable quality and timely delivery of the nebulizer at an acceptable price, or an interruption in the delivery of goods from such supplier, could delay or otherwise adversely affect our clinical trials of MRT5005, and harm our business and prospects. The use of an alternative manufacturer of the nebulizer could involve significant delays and other costs and regulatory challenges, and may not be available to us on reasonable terms, if at all. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.
Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.
Risks Related to the Commercialization of our Product Candidates
If we are unable to establish sales, medical affairs and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any product revenue.
We do not currently have a sales and marketing organization and have never commercialized a product. To successfully commercialize any products that may result from our development programs, we will need to develop these capabilities, either on our own or with others. The establishment and development of our own commercial and medical science liaison teams or the engagement of a contract sales force will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We have entered into a collaboration with Sanofi and may also seek to enter into future collaborations with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our collaborators do not commit sufficient resources to commercialize our products, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many well-funded and profitable pharmaceutical and biotechnology companies that currently have extensive and experienced medical affairs, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing, sales and medical affairs functions, we may be unable to compete successfully against these more established companies.
Our efforts to educate the medical community and third-party payors about the benefits of our product candidates may require significant resources and may never be successful. If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals or third-party payors, we will not be able to generate significant revenue from such product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.
The hospital formulary approval and insurance coverage and reimbursement status of newly approved products, including vaccines, is uncertain. Failure to obtain or maintain adequate hospital formulary approval and/or insurance coverage and reimbursement for our products, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.
We expect that hospital formulary approval and insurance coverage and reimbursement by government and other third-party payors of our products, including vaccines, if approved, will be essential for most patients to be able to access these treatments. Accordingly, sales of our product candidates, if approved, will depend substantially on the extent to which the costs of our product candidates will be paid by hospitals or will be reimbursed by government authorities, private health coverage insurers and other third- party payors. Hospital formulary approval and insurance coverage and reimbursement by other third-party payors may depend upon several factors, including the third-party payor’s determination that use of a product is:
 
56

   
a covered benefit under the applicable health plan;
 
   
safe, effective and medically necessary;
 
   
appropriate for the specific patient population;
 
   
cost-effective; and
 
   
neither experimental nor investigational.
Obtaining hospital formulary approval and insurance coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that will require us to provide to the hospitals and payors supporting scientific, clinical and cost-effectiveness data. We may not be able to provide data sufficient to gain acceptance with respect to hospital formulary approval and insurance coverage and reimbursement. If hospital formulary approval, insurance coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our product candidates.
There is significant uncertainty related to hospital formulary approval and insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. It is difficult to predict what third-party payors will decide with respect to the insurance coverage and reimbursement for our product candidates.
Outside the United States, international operations generally are subject to extensive government price controls and other market regulations, and increasing emphasis on cost-containment initiatives in the European Union, Canada and other countries may put pricing pressure on us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines and vaccines under such systems are substantially lower than in the United States. Other countries may use different methods to keep the cost of medical products artificially low. Foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenue.
Moreover, hospitals and government and other third-party payors in the United States and abroad have increasingly taken measures to cap or reduce health care costs. For example, governmental and other third-party payors may attempt to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward reducing hospital costs, managed health care, the increasing influence of health maintenance organizations and additional legislative changes.
The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community.
Even with the requisite approvals from the FDA in the United States, EMA in the European Union and other regulatory authorities internationally, the commercial success of our product candidates, if approved, will significantly depend on the acceptance of physicians, hospitals and health care payors of our product candidates as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, hospitals, health care payors and others in the medical community. If these commercialized products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including:
 
   
the efficacy and safety of such product candidates as demonstrated in clinical trials;
 
   
the potential and perceived advantages of our product candidates over other treatments;
 
   
the cost-effectiveness of treatment relative to alternative treatments;
 
57

   
the clinical indications for which the product candidate is approved by the FDA, the EMA or other regulatory body;
 
   
the willingness of physicians to prescribe new therapies over the existing standard of care and future new therapies;
 
   
the willingness of the target patient population to try new therapies;
 
   
the prevalence and severity of any side effects;
 
   
product labeling or product insert requirements of the FDA, EMA or other regulatory authorities, including any limitations or warnings contained in a product’s approved labeling, including any black box warning;
 
   
relative convenience and ease of administration;
 
   
our ability to educate the medical community and third-party payors about the benefit of our product candidates;
 
   
the strength of marketing and distribution support;
 
   
the timing of market introduction of competitive products;
 
   
any restrictions on the use of our products together with other medications;
 
   
publicity concerning our products or competing products and treatments; and
 
   
sufficient third-party payor insurance coverage and adequate reimbursement.
Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after we begin to commercialize the product.
If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
We expect that we will be subject to additional risks in commercializing our product candidates outside the United States, including:
 
   
different regulatory requirements for approval of drugs and biologics in foreign countries;
 
   
reduced protection for intellectual property rights;
 
   
unexpected changes in tariffs, trade barriers and regulatory requirements;
 
   
economic weakness, including inflation, or political instability in foreign economies and markets;
 
   
different pricing and reimbursement regimes;
 
   
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
 
   
foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
 
   
workforce uncertainty in countries where labor unrest is more common than in the United States;
 
   
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
 
   
business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters, including earthquakes, typhoons, floods and fires.
 
58

Risks Related to Our Business Operations
The COVID-19
pandemic has adversely disrupted, and may continue to adversely disrupt, our operations, including our ability to complete our ongoing clinical trials, and may have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business, operations and ability to raise capital.
In December 2019, a novel strain of coronavirus named
SARS-CoV-2,
which causes
COVID-19,
was reported and in March 2020, the World Health Organization declared the outbreak of
COVID-19
a global pandemic. The
COVID-19
pandemic has continued to spread, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which the ongoing
COVID-19
pandemic impacts our operations or those of the third parties on which we rely will depend on many factors, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, additional or modified government actions, new information that may emerge concerning the severity and impact of
COVID-19,
and the actions to contain
COVID-19
or address its impact in the short and long term.
In April 2020, our enrollment and dosing were paused in our ongoing Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis, or CF, as a consequence of the
COVID-19
pandemic. Although we were able to resume enrollment and dosing in September 2020 and then announce our second interim data analysis in March 2021, the uncertain environment associated with the
COVID-19
pandemic could result in additional disruptions in enrollment, affecting our timing to report data.
Any negative impact that the
COVID-19
pandemic has on recruiting or retaining patients in our clinical trials for MRT5005, MRT5500, MRT5400 or MRT5401, the ability of our suppliers to provide materials for our product candidates, or the regulatory review process could cause additional delays with respect to product development activities, which could materially and adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, affect our ability to raise additional capital, and have a material adverse effect on our financial results.
The COVID-19
pandemic continues to rapidly evolve and its ultimate scope, duration and effects are unknown. The extent of the impact of the disruptions to our business, preclinical studies and clinical trials as a result of the
COVID-19
pandemic will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.
The pandemic has caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could adversely impact any future plans to raise capital. The trading prices of our stock and that of other biopharmaceutical companies have been highly volatile as a result of the economic volatility. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the
COVID-19
pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.
Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general conditions in the U.S. and global economy and financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our products, if any, and could adversely impact our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for any current or future approved products. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. We expect that the
COVID-19
pandemic will continue to disrupt the financial markets and may adversely impact economies worldwide.
Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are
“at-will”
employees.
 
59

Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, is also critical to our success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. In addition, given the recent development of mRNA
COVID-19
vaccines, there is an increased demand for employees with mRNA manufacturing skills. Furthermore, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects.
If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer.
If we are successful in executing our business strategy, we will need to expand our managerial, operational, financial and other systems and resources to manage our operations, continue our research and development activities and, in the longer term, build a commercial infrastructure to support commercialization of any of our product candidates that are approved for sale. Future growth would impose significant added responsibilities on members of management. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and product candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas and to attract and retain sufficient numbers of talented employees. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals.
Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop.
We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and may face an even greater risk if we commercialize any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
 
   
decreased demand for any product candidates that we may develop;
 
   
loss of revenue;
 
   
substantial monetary awards to trial participants or patients;
 
   
significant time and costs to defend the related litigation;
 
   
withdrawal of clinical trial participants;
 
   
the inability to commercialize any product candidates that we may develop; and
 
   
injury to our reputation and significant negative media attention.
Our insurance coverage may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.
 
60

Our internal computer systems, or those of any collaborators, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
Our internal computer systems and those of any collaborators, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. In addition, we may not have adequate insurance coverage to provide compensation for any losses associated with such events.
We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company, including personal information of our employees. In addition, outside parties may attempt to penetrate our systems or those of our vendors or fraudulently induce our employees or employees of our vendors to disclose sensitive information to gain access to our data. Like other companies, we may experience threats to our data and systems, including malicious codes and viruses, and other cyber-attacks. The number and complexity of these threats continue to increase over time. If a material breach of our security or that of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed, we could lose business and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely.
Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including
non-compliance
with regulatory standards and requirements and insider trading laws.
We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include failures to:
 
   
comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions;
 
   
provide accurate information to the FDA, the EMA and other regulatory authorities;
 
   
comply with health care fraud and abuse laws and regulations in the United States and abroad;
 
   
comply with the U.S. Foreign Corrupt Practices Act, or FCPA, or other anti-corruption laws and regulations;
 
   
comply with U.S. federal securities laws relating to trading in our common stock;
 
   
report financial information or data accurately; or
 
   
disclose unauthorized activities to us.
In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations regulate a wide range of pricing, discounting, marketing and promotional practices, as well as sales and customer incentive programs and other business arrangements. Other forms of misconduct could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, EMA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct and expect to implement other internal controls applicable to all of our employees, consultants and contractors, but it is not always possible to identify and deter third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, we may be subject to civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion
 
61

from participation in government health care programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of
non-compliance
with these laws and the curtailment or restructuring of our operations, any of which could have a significant impact on our business, financial condition, results of operations and prospects.
Risks Related to Our Intellectual Property
If we are unable to obtain and maintain patent protection for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.
Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and technology that are important to our business.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents that protect our technology or product candidates or that effectively prevent others from commercializing competitive technologies and product candidates being issued. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications on inventions claimed in our patent or patent application on or before March 15, 2013, an interference proceeding in the United States can be initiated by such third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs.
The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.
Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the United States Patent and Trademark Office, or USPTO, and various government patent agencies outside of the United States over the lifetime of our licensed patents and/or applications and any patent rights we own or may own in the future. We rely, in part, on our outside counsel or our licensing partners to pay these fees due to the USPTO and to
non-U.S.
patent agencies. The USPTO and various
non-U.S.
government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
non-compliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.
Filing, prosecuting and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a
non-infringing
manner.
 
62

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
Our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an
FDA-approved
reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this
12-year
period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full Biologics License Application, or BLA, for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company’s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.
We believe that any of our product candidates approved as a biological product under a BLA should qualify for the
12-year
period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for
non-biological
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.
Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, and these decisions have narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors’ ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future decisions by the U.S. Congress, the federal courts and the USPTO, as well as similar bodies in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that may weaken our and our licensors’ ability to obtain new patents or to enforce existing patents and patents we and our licensors or any collaborators may obtain in the future.
Patent reform legislation enacted in the United States in 2011 could increase the uncertainties and costs surrounding the prosecution of our and our licensors’ patent applications and the enforcement or defense of our or our licensors’ issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a “first to invent” system to a “first inventor to file” system. The USPTO has developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular the first inventor to file provisions, became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors’ patent applications and the enforcement or defense of our or our licensors’ issued patents, all of which could have a material adverse effect on our business and financial condition.
 
63

Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, and, if we fail to comply with our obligations under these arrangements, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.
We are a party to several intellectual property license agreements, including agreements with the Massachusetts Institute of Technology, or MIT, that are important to our business, and may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. In that event, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly.
Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, development and commercialization timelines, milestone payments, royalties and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.
For example, our license agreement with MIT imposes specified diligence, annual payment, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under the license agreement, MIT may have the right to terminate the license agreement, in which event we might not be able to market, and may be required to transfer to MIT our rights in, any product that is covered by the MIT agreement, including products that may be developed under our collaboration with Sanofi. Termination of the license agreement may also result in our having to negotiate a new or reinstated license with less favorable terms, which would have a material adverse impact on our business.
In our existing license agreements, and we expect in future agreements, patent prosecution of our licensed technology is in certain cases controlled solely by the licensor, and we are in certain cases required to reimburse the licensor for their costs of patent prosecution. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products covered by the intellectual property. Further, in each of our license agreements, we are responsible for bringing any actions against any third party for infringing the patents we have licensed. Certain of our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products and minimum yearly diligence obligations in developing and commercializing the product. Disputes may arise regarding intellectual property subject to a licensing agreement, including:
 
   
the scope of rights granted under the license agreement and other interpretation-related issues;
 
   
the extent to which our technology and processes infringe the intellectual property of the licensor that is not subject to the licensing agreement;
 
   
the sublicensing of patent and other rights under any collaborative development relationships;
 
   
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
 
   
the inventorship or ownership of inventions and
know-how
resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
 
   
the priority of invention of patented technology.
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.
In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
 
64

We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful.
Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. Countering infringement or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
In addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop or license.
Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.
If we or one of our licensing partners initiates legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or
non-enablement.
In addition, patent validity challenges may, under certain circumstances, be based upon
non-statutory
obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
re-examination,
post grant review,
inter partes
review and equivalent proceedings in foreign jurisdictions. For example, as of August 2, 2021, four of our patents issued in Europe are under opposition, including one with claims of similar scope as U.S. Patent 10,143,758. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.
In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how
that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary
know-how,
information or technology that is not covered by patents. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot
 
65

guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
Our commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference proceedings, post grant review and
inter partes
review before the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent.
If we are found to infringe a third party’s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be
non-exclusive,
thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.
Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects.
While we are presently unaware of any claims or material assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example, a third party may claim an ownership interest in one or more of our, or our licensors’, patents or other proprietary or intellectual property rights. A third party could bring legal actions against us and seek monetary damages or enjoin clinical testing, manufacturing or marketing of the affected product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.
 
66

If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.
Trade secrets and
know-how
can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or
know-how
owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual’s assignee. Such assignment or license may not be available on commercially reasonable terms or at all.
Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds similar to those of our employees to attempt to independently reverse engineer or otherwise duplicate our antibody technologies to replicate our success.
We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or
know-how
of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.
In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to
 
67

establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.
Intellectual property rights do not necessarily address all potential threats.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:
 
   
others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license or may own in the future;
 
   
we, or any partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;
 
   
we, or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
 
   
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;
 
   
it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;
 
   
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
 
   
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
 
   
we may not develop additional proprietary technologies that are patentable;
 
   
the patents of others may have an adverse effect on our business; and
 
   
we may choose not to file a patent for certain trade secrets or
know-how,
and a third party may subsequently file a patent covering such intellectual property.
Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.
Risks Related to Regulatory Approval and Other Legal Compliance Matters
The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities and the complexity and novelty of the proposed product. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. Further, as set forth above in the risk factor captioned “We and Sanofi may not be successful in our joint efforts to successfully develop in an expedited timeframe an mRNA vaccine against
SARS-CoV-2,
substantial uncertainty and potential delay surrounds the use of emergency authorization processes to approve products, including vaccines, by the FDA and comparable regulatory authorities in other jurisdictions. The extent to which the FDA and other regulatory authorities rely on such emergency procedures is uncertain and subject to a number of different factors. As a result, even if the FDA and comparable regulatory authorities have indicated that they will rely on these emergency procedures to review our product candidates, including our vaccine candidates, approval of such products under these procedures may be substantially delayed and is not assured.
 
68

Our product candidates could fail to receive regulatory approval for many reasons, including the following:
 
   
the FDA may disagree with the design or implementation of our clinical trials;
 
   
we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe, pure and potent or effective for its proposed indication;
 
   
results of clinical trials may not meet the level of statistical significance required by the FDA for approval;
 
   
we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
 
   
the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;
 
   
data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or other submission or to obtain regulatory approval in the United States;
 
   
the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
 
   
the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.
This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. We may also experience delays as a consequence of the
COVID-19
pandemic. The FDA has substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA.
Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.
The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drug products are subject to extensive regulation by the FDA, EMA and other regulatory authorities, and regulations may differ from country to country. We, and any future collaborators, are not permitted to market our product candidates in the United States or in other countries until we, or they, receive approval of a BLA from the FDA, approval of a marketing authorization application, or MAA, from the EMA, or marketing approval from other applicable regulatory authorities. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States, Europe or in any other jurisdiction. We have not yet been successful at conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of a BLA and EMA approval of an MAA.
In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.
Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any future collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.
 
69

Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad and may limit our ability to generate revenue from product sales.
In order to market and sell our products in the European Union and many other jurisdictions, we, and any future collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We, and any future collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.
In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining
non-U.S.
regulatory approvals and compliance with
non-U.S.
regulatory requirements could result in significant delays, difficulties and costs for us and any future collaborators and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we or any future collaborators fail to obtain the
non-U.S.
approvals required to market our product candidates outside the United States or if we or any future collaborators fail to comply with applicable
non-U.S.
regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected.
Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the recent withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom withdrew from the European Union, effective December 31, 2020. On December 24, 2020, the United Kingdom and European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the Trade and Cooperation Agreement would prevent us from commercializing any product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for any product candidates, which could significantly and materially harm our business.
We, or any future collaborators, may not be able to obtain and maintain orphan drug exclusivity for our product candidates in the United States and Europe.
Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. In November 2015, the FDA granted orphan drug designation to MRT5005 for the treatment of CF. We may seek orphan drug designations for MRT5005 for other indications or for other of our product candidates. There can be no assurances that we will be able to obtain such designations.
Even if we, or any future collaborators, obtain orphan drug designation for a product candidate as we have obtained for MRT5005 for the treatment of CF, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the United States and 10 years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.
Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. For example, the concept of what constitutes the “same drug” for purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA has issued recent draft guidance suggesting that it would not consider two genetic medicine products to be different drugs solely based on minor differences in the transgenes or vectors. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.
 
70

On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA’s
pre-existing
regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.
Although we have received fast track designation for MRT5005 for CF, such designation may not actually lead to a faster development or regulatory review or approval process. In addition, we may not receive such designation for other product candidates.
If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet needs for this condition, the treatment sponsor may apply for FDA fast track designation. We have received fast track designation for MRT5005 for CF. However, even though we received fast track designation, fast track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development, regulatory review or approval process with fast track designation compared to conventional FDA procedures. Additionally, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA’s priority review procedures. In addition, if we seek fast track designation for other product candidates, we may not receive it from the FDA.
The FDA has granted a Rare Pediatric Disease Designation, or RPDD, for MRT5005 and we may seek the same designation for one or more of our other product candidates. However, a BLA for one or more of our product candidates may not meet the eligibility criteria for a priority review voucher upon approval nor does this designation mean that our product candidates, including MRT5005, will be subject to a faster development and regulatory review process.
With enactment of the Food and Drug Administration Safety and Innovation Act in 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications that meet the criteria specified in the law. This provision is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a “rare pediatric disease” may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application.
For the purposes of this program, a “rare pediatric disease” is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (b) rare disease or conditions within the meaning of the Orphan Drug Act. In March 2020, the FDA granted Rare Pediatric Designation for MRT5005 for the treatment of CF. The FDA may, however, determine that a BLA for this product candidate or our other product candidates do not meet the eligibility criteria for a priority review voucher upon approval.
While the opportunity to receive a priority review voucher was meant to expire for those companies that had not received a designation by September 30, 2020, Congress authorized an extension of the program in late 2020. Specifically, on December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, the FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers.
 
71

A breakthrough therapy designation by the FDA for a product candidate may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive marketing approval.
We may seek a breakthrough therapy designation for one or more product candidates. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.
Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.
Even if we, or any future collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.
Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved labeling. Thus, we, and any future collaborators, will not be able to promote any products we develop for indications or uses for which they are not approved.
In addition, manufacturers of approved products and those manufacturers’ facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our third-party manufacturers, any future collaborators and their third-party manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.
Accordingly, assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates, we, and any future collaborators, and our respective third-party manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.
If we, and any future collaborators, are not able to comply with post-approval regulatory requirements, we, and any future collaborators, could have the marketing approvals for our products withdrawn by regulatory authorities and our, or any future collaborators’, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.
Any of our product candidates for which we, or any future collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.
Any of our product candidates for which we, or any future collaborators, obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS.
 
72

The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding
off-label
use and if we, or any future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for
off-label
marketing. Violation of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.
In addition, later discovery of previously unknown side effects or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:
 
   
restrictions on such products, manufacturers or manufacturing processes;
 
   
restrictions on the labeling or marketing of a product;
 
   
restrictions on product distribution or use;
 
   
requirements to conduct post-marketing studies or clinical trials;
 
   
warning letters or untitled letters;
 
   
withdrawal of the products from the market;
 
   
refusal to approve pending applications or supplements to approved applications that we submit;
 
   
recall of products;
 
   
restrictions on coverage by third-party payors;
 
   
fines, restitution or disgorgement of profits or revenue;
 
   
suspension or withdrawal of marketing approvals, including license revocation;
 
   
refusal to permit the import or export of products;
 
   
product seizure; and
 
   
injunctions or the imposition of civil or criminal penalties.
Our relationships with health care providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings.
Health care providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, health care providers and physicians may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following:
 
   
Anti-Kickback Statute
—the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing any remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal health care program, such as Medicare and Medicaid;
 
73

   
False Claims Act
—the federal civil and criminal false claims laws impose criminal and civil penalties, including, in some cases, through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal health care program or knowingly making a false statement or record material to payment of a false claim or knowingly avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant
per-claim
penalties;
 
   
HIPAA
—the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any health care benefit program or making false statements relating to health care matters, and apply regardless of the payor (e.g., public or private);
 
   
HIPAA and HITECH
—HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information;
 
   
Transparency Requirements
—federal transparency laws, including the federal Physician Payments Sunshine Act, require applicable manufacturers of covered drugs to annually report payments and other transfers of value to physicians and teaching hospitals and ownership or investment interests held by physicians and their family members; and
 
   
Analogous State and Foreign Laws
—analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving health care items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions.
Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not
pre-empted
by HIPAA, thus complicating compliance efforts.
Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion of drugs from government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of
non-compliance
with these laws and the curtailment or restructuring of our operations. If any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs.
The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States, such as the U.K. Bribery Act 2010, or the Bribery Act. Infringement of these laws could result in substantial fines and imprisonment.
Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.
 
74

Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.
Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act—which went into effect on January 1, 2020—is creating similar risks and obligations as those created by GDPR, though the Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.
Given the breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.
 
75

Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.
In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the health care system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.
In March 2010, President Obama signed into law the ACA. Among the provisions of the ACA of importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any of our product candidates, are the following:
 
   
an annual,
non-deductible
fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;
 
   
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
 
   
expansion of federal health care fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;
 
   
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50%
point-of-sale
discounts off negotiated prices;
 
   
extension of manufacturers’ Medicaid rebate liability;
 
   
expansion of eligibility criteria for Medicaid programs;
 
   
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
 
   
new requirements to report certain financial arrangements with physicians and teaching hospitals;
 
   
a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and
 
   
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of 2% per fiscal year starting in 2013 and that, due to subsequent legislative amendments to the statute, will stay in effect through 2029. The CARES Act and other
COVID-19
relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 3, 2021, and extended the sequester by one year, through 2030. The American Taxpayer Relief Act of 2012 reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws and any new health care reform measures may result in additional reductions in Medicare and other health care funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.
Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, will become effective in 2019. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the
ACA-mandated
“Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019, to increase from 50 to 70 percent the
point-of-
sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole.” The Congress may consider other legislation to replace elements of the ACA during the next Congressional session.
 
76

We expect that these health care reforms, as well as other health care reform measures that may be adopted in the future, may result in additional reductions in Medicare, Medicaid and other health care funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare, Medicaid or other government programs may result in a similar reduction in payments from private payors.
The Trump Administration also took executive actions to undermine or delay implementation of the ACA. President Trump signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One Executive Order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the Administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.
Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the Court of Appeals for the Fifth Circuit affirmed the lower court’s ruling that the individual mandate portion of the ACA is unconstitutional. On January 21, 2020, the U.S. Supreme Court declined to review this decision on an expedited basis, but on March 3, 2020, the Court agreed to hear the case through its normal procedures. The Supreme Court heard oral argument in this case on November 10, 2020, and a decision dismissing the lawsuit was released on June 17, 2021. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.
The cost of prescription pharmaceuticals has also been the subject of considerable discussion in the United States. To date, there have been several recent U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.
In addition, on July 24, 2020, President Trump issued four executive orders intended to lower the costs of prescription drug products. Several of these orders are reflected in recently promulgated regulations, and one of these regulations is currently subject to a nationwide preliminary injunction. It remains to be seen whether these orders and resulting regulations will remain in force during the Biden Administration.
At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.
Finally, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent product labeling and post-marketing testing and other requirements.
 
77

Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues from the sales of drugs and vaccines, if any.
In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals and vaccines is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug or vaccine. To obtain reimbursement or pricing approval in some countries, we, or our future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug or vaccine to other available therapies. If reimbursement of our drugs or vaccines is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.
We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition.
Our operations are subject to anti-corruption laws, including the FCPA, the Bribery Act, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.
We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws.
There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by U.S., U.K. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.
 
78

We maintain workers’ compensation insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.
Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.
Risks Related to Ownership of Our Common Stock
Our executive officers, directors and principal stockholders maintain the ability to control all matters submitted to stockholders for approval.
We believe our executive officers, directors and stockholders which own more than 5% of our outstanding common stock, in the aggregate, beneficially own more than a majority of our capital stock. We also have one stockholder who holds approximately 24% of our outstanding common stock. If these stockholders were to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and business affairs. For example, these persons, if they act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in management of our company that other stockholders disagree with.
A substantial number of shares of our common stock may be sold into the market in the near future, including pursuant to our Sales Agreement with Jefferies LLC, or Jefferies, or our universal shelf registration statement, which could result in dilution to our stockholders and/or cause the market price of our common stock to drop significantly, even if our business is performing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to certain restrictions under U.S. securities laws. A significant number of our total outstanding shares are restricted from resale but may be sold into the market in the near future. Moreover, holders of a substantial number of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.
In July 2020, we issued and sold 4,884,434 shares of common stock to an affiliate of Sanofi, or the Sanofi Investor, in connection with the Second Sanofi Amendment. We registered these shares on a registration statement in August 2020, covering the resale by the Sanofi Investor of the common stock purchased in the private placement and have agreed to keep the registration statement effective until the date the shares covered by the registration statement have been sold or can be sold without restriction pursuant to Rule 144 of the Securities Act of 1933, as amended, or the Securities Act. The Sanofi Investor will not, and will cause its affiliates not to, sell or transfer the shares without our prior written approval, subject to specified conditions, until January 2022. In June 2020, we completed a public offering in which we issued and sold 5,681,819 shares of common stock and a stockholder sold
 
79

6,824,992 shares of common stock registered under our universal shelf registration statement. Furthermore, we have registered an aggregate of 19,656,367 shares of our common stock on Form
S-8
to be issued to our employees under certain employee benefit plans. Registered shares can be freely sold in the public market, subject only to volume limitations applicable to affiliates.
We currently have on file with the SEC a universal shelf registration statement which allows us to offer and sell an indeterminate amount of registered common stock, preferred stock, debt securities, warrants and/or units from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale. We are a party to an Open Market Sale Agreement
SM
, or Sales Agreement, with Jefferies, pursuant to which, from time to time, we may offer and sell through Jefferies up to $100.0 million of common stock pursuant to one or more “at the market” offerings. During the year ended December 31, 2020, pursuant to the Sales Agreement, we issued and sold 2,863,163 shares of our common stock, for gross proceeds of $37.9 million, before deducting commissions of $1.1 million and other offering expenses of $0.2 million. There were no shares issued or sold pursuant to the Sales Agreement during the six months ended June 30, 2021. In the future, $62.1 million of our common stock remain available to be sold pursuant to the Sales Agreement. Sales of a substantial number of shares of our common stock, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.
Sales of substantial amounts of shares of our common stock or other securities our stockholders, by Jefferies pursuant to the Sales Agreement, under our universal shelf registration statement or otherwise could also dilute our stockholders.
If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.
The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analyst will provide favorable coverage. A lack of research coverage or adverse coverage may negatively impact the market price of our common stock. In addition, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.
The price of our common stock is volatile and may fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
Our stock price is volatile. The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:
 
   
results of preclinical studies and clinical trials of our product candidates or those of our competitors;
 
   
public announcements about the scientific community’s evolving understanding of the
COVID-19
pandemic and the potential effectiveness of vaccines, treatments, public health measures and other approaches to addressing the disease;
 
   
the success of competitive products or technologies;
 
   
commencement or termination of collaborations;
 
   
regulatory or legal developments in the United States and other countries;
 
   
developments or disputes concerning patent applications, issued patents or other proprietary rights;
 
   
the recruitment or departure of key personnel;
 
   
the level of expenses related to any of our product candidates or clinical development programs;
 
   
the results of our efforts to discover, develop, acquire or
in-license
additional product candidates;
 
   
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
 
   
variations in our financial results or those of companies that are perceived to be similar to us;
 
80

   
changes in the structure of health care payment systems; 
 
   
market conditions in the pharmaceutical and biotechnology sectors;
 
   
the entry into significant acquisitions, strategic partnerships or divestitures by us or our competitors;
 
   
significant sales of our common stock, including sales by our directors, executive officers or 5% stockholders;
 
   
general economic, industry and market conditions, such as the impact of the
COVID-19
pandemic on our industry and market conditions; and
 
   
the other factors described in this “Risk Factors” section.
If any of the foregoing matters were to occur, or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management’s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.
We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and requirements.
As a public company, and particularly as we ceased to be an emerging growth company, or EGC, as of December 31, 2020, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and the Nasdaq Stock Market have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. In addition, as we ceased to be an EGC, we are now required to comply with auditor attestation requirements, increased disclosure obligations and other reporting requirements, which has increased our costs for the 2021 fiscal year. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm may reveal deficiencies in our internal control over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.
Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we continue to dedicate internal resources, continue to engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
 
81

Provisions in our certificate of incorporation and bylaws and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:
 
   
establish a classified board of directors such that not all members of the board are elected at one time;
 
   
allow the authorized number of our directors to be changed only by resolution of our board of directors;
 
   
limit the manner in which stockholders can remove directors from the board;
 
   
establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;
 
   
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
 
   
limit who may call stockholder meetings;
 
   
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or
so-called
“poison pill,” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
 
   
require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation or bylaws.
Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.
Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders.
Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to us or our stockholders, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or our bylaws or governed by the internal affairs doctrine. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act of 1934, as amended, or any other claim for which federal courts have exclusive jurisdiction. This provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, other employees or other stockholders, which may discourage such lawsuits against us and our directors, officers, other employees or other stockholders. Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.
 
82

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future, and investors seeking cash dividends should not purchase shares of our common stock.
General Risk Factors
Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.
Recent changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Act, which significantly reformed the Code. The Tax Act, among other things, contained significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income and elimination of net operating loss carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits.
As part of Congress’s response to the
COVID-19
pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, and the CARES Act was enacted on March 27, 2020. Both contain numerous tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of the
80%-of-income
limitation on the use of net operating losses, which was enacted as part of the Tax Act. It also provides that net operating losses arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible to be carried back up to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30 to 50% of adjusted taxable income.
Regulatory guidance under the Tax Act, the FFCR Act and the CARES Act is and continues to be forthcoming, and such guidance could ultimately increase or lessen impact of these laws on our business and financial condition. It is also possible that Congress will enact additional legislation in connection with the
COVID-19
pandemic, some of which could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the FFCR Act or the CARES Act.
 
83

Item 6. Exhibits.
 
Exhibit
Number
  
Description
10.1*+    Second Amended and Restated Director Compensation Plan, adopted June 16, 2021.
10.2*+    Letter Agreement, dated March 22, 2021, by and between the Registrant and Brendan Smith.
10.3*+    Consulting Agreement, dated June 16, 2021, by and between the Registrant and Daniel Lynch.
31.1*    Certification of Principal Executive Officer pursuant to Rules 13aa-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*    Certification of Principal Financial Officer pursuant to Rules 13aa-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**    Certification of Principal Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**    Certification of Principal Financial Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*    Inline XBRL Instance Document– the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH†    Inline XBRL Taxonomy Extension Schema Document
101.CAL†    Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF†    Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB†    Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE†    Inline XBRL Taxonomy Extension Presentation Linkbase Document
104†    Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
 
*
Filed herewith.
**
Furnished herewith.
+
Indicates a management contract or compensatory arrangement.
Submitted electronically herewith.
 
84

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
   
Translate Bio, Inc.
Date: August 5, 2021     By:   /s/ Ronald C. Renaud, Jr.
     
Ronald C. Renaud, Jr.
     
Chief Executive Officer
Date: August 5, 2021     By:   /s/ Brendan Smith
     
Brendan Smith
     
Chief Financial Officer and Treasurer
 
85
EX-10.1 2 d192980dex101.htm EX-10.1 EX-10.1

EXHIBIT 10.1

TRANSLATE BIO, INC.

SECOND AMENDED AND RESTATED

DIRECTOR COMPENSATION POLICY

Adopted on June 16, 2021

The non-employee directors of Translate Bio, Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of the Company.

Director Compensation

Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Company’s affairs. We also seek to align the interests of our directors and our stockholders and we have chosen to do so by compensating our non-employee directors with a mix of cash and equity-based compensation.

Cash Compensation

The fees that will be paid to our non-employee directors for service on the Board, and for service on each committee of the Board on which the director is then a member, and the fees that will be paid to the chairperson of the Board, if one is then appointed, and the chairperson of each committee of the Board will be as follows:

 

     Member Annual
Fee
     Chair Incremental
Annual Fee
 

Board of Directors

   $ 40,000      $ 30,000  

Lead Independent Director

   $ 25,000        n/a  

Audit Committee

   $ 7,500      $ 7,500  

Compensation Committee

   $ 5,000      $ 5,000  

Nominating and Corporate Governance Committee

   $ 3,750      $ 3,750  

The foregoing fees will be payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on our Board, on such committee or in such position, and no fee shall be payable in respect of any period prior to the completion of our initial public offering.


Equity Compensation

Initial Grants

Upon initial election to our Board, with respect to each non-employee director who is elected to our Board after the IPO, such non-employee director will be granted, automatically and without the need for any further action by the Board, an initial equity award of an option to purchase 40,000 shares of our common stock. The initial award shall have a term of ten years from the date of the award and shall vest and become exercisable in equal monthly installments beginning one month following the date of grant of the award and ending on the three-year anniversary of the date of grant of the award, subject to the director’s continued service as a director, employee or consultant through each applicable vesting date. The exercise price shall be the closing price of our common stock on the date of grant.

Annual Grants

Each non-employee director will be granted, automatically and without the need for any further action by the Board, an equity award on the date of our annual meeting of stockholders for such year of an option to purchase 20,000 shares of our common stock. The annual award shall have a term of ten years from the date of the award, and shall vest and become exercisable in full on the one-year anniversary of the date of the award, (or, if earlier, the date of our next annual meeting of stockholders following the date of grant), subject to the director’s continued service as a director, employee or consultant through each applicable vesting date. The exercise price shall be the closing price of our common stock on the date of grant.

Accelerated Vesting

The vesting of each option granted from and after the IPO to a non-employee director shall accelerate as to 100% of the shares subject to the option in the event that (i) there is a Change of Control of the Company (as defined in the applicable option agreement) and (ii) either the non-employee director (A) is required to resign his or her position as a non-employee director as a condition to the closing of the Change in Control, (B) is removed from his or her position as a non-employee director in connection with the Change in Control or (C) is not nominated to serve on the Board of the Company or the acquiring or succeeding entity at the next annual meeting of stockholders of the Company or the acquiring or succeeding entity following the Change of Control.

Adjustments

The foregoing share amounts shall be automatically adjusted in the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event effecting our common stock, or any distribution to holders of our common stock other than an ordinary cash dividend, including without limitation any reverse stock split of the common stock effected by the Company in connection with the IPO.

 

2


The initial awards and the annual awards shall be subject to the terms and conditions of our 2018 Equity Incentive Plan, or any successor plan, and the terms of the option agreements entered into with each non-employee director in connection with such awards.

Expenses

Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each non-employee director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board and committees thereof or in connection with other business related to the Board, and each non-employee director shall also be reimbursed for his or her reasonable out-of-pocket business expenses authorized by the Board or a committee of the Board that are incurred in connection with attendance at various conferences or meetings with management of the Company, in accordance with the Company’s travel policy, as it may be in effect from time to time.

 

3

EX-10.2 3 d192980dex102.htm EX-10.2 EX-10.2

EXHIBIT 10.2

 

LOGO    29 Hartwell Avenue
   Lexington, MA 02421
   P (617) 945 7361

March 19, 2021

Brendan Smith

35 Park Street

Charlestown, MA 02129

Re: Employment Agreement

Dear Brendan:

On behalf of Translate Bio, Inc., a Delaware corporation (the “Company”), I am pleased to offer you the position of the Company’s Chief Financial Officer & Corporate Strategy. Please note this offer is also contingent upon the successful completion of references and routine background checks and work authorization.

 

1.

Position. Your position with the Company is Chief Financial Officer & Corporate Strategy and you report to Ron Renaud, Chief Executive Officer. You agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company’s interests and the performance of your duties as an employee of the Company and not to engage in any other business activities without prior approval of the Company.

 

2.

Start Date. Your employment with the Company will begin on or before April 19, 2021. For purposes of this Agreement, the actual first day of your employment with the Company shall be referred to as the “Start Date”.

 

3.

Base Salary. The Company will pay you a salary at the bi-weekly rate of $15,576.93 (which is equivalent to an annualized rate of $405,000.00 per year), payable in accordance with the Company’s standard payroll schedule and subject to applicable tax and other withholdings as required by law. Such base salary may be subject to periodic review and adjustments at the Company’s sole discretion.

 

4.

Discretionary Bonus. You will be eligible to receive an annual cash discretionary bonus of up to 45% of your base salary (the “bonus”) in accordance with the terms of the applicable bonus plan. Your 2021 bonus will not be prorated based on your start date. The amount, if any, of the cash bonus payment, and the Company’s determination of your performance, corporate objectives and business conditions at the Company are all within the sole discretion of the Company. Eligibility for and earning of the bonus, which is also a retention incentive that you remain employed by the Company, requires the you be employed for the full period covered by the bonus as well as on the date the bonus is to be paid. Your eligibility for the bonus is also contingent on approval by the Board of Directors of the Company (the “Board”). The Company expects to review your job performance on an annual basis and to discuss with you the criteria which the Company will use to assess your performance for bonus purposes. The Company also may make adjustments in the targeted amount of your bonus in the Company’s sole discretion.

 

LOGO


5.

Benefits. You will be eligible to participate in the Company’s employee benefits and insurance programs generally made available from time to time to its full-time employees, in accordance with, and provided you are eligible under, the plan documents governing those programs. You will also be eligible for up to 20 of days of paid vacation per year which shall accrue on a prorated basis, in accordance with the Company’s vacation policy as in effect from time to time. The Company reserves the right to modify or terminate any or all of its benefit plans or policies at any time at its discretion.

 

6.

Incentive Equity Awards. Subject to approval by the Board, and as a material inducement to you entering into employment with the Company, the Company will grant to you an option to purchase 201,800 shares of the Company’s common stock at a price per share equal to the fair market value per share of the Company’s common stock on the date of grant (the “Proposed Grant”). The Proposed Grant will be subject to a vesting schedule as follows: one quarter of the shares subject to the option will vest on the first anniversary of the Start Date, and following that, 1/36th of the remaining shares subject to the option will vest on a monthly basis, contingent on your continued employment with the Company. In connection with your ongoing employment, the Company may propose to the Board from time to time, that a stock option grant be made to you of Company’ common stock pursuant to the Company’s 2018 Equity Incentive Plan (an “Additional Grant”). Any Proposed Grant or Additional Grant will be subject to the terms and conditions of an Option Agreement to be entered into by you and the Company. Your ownership of the common stock will be subject to a vesting schedule and will be contingent on your continued employment or continuous service as a consultant or advisor with the Company.

The Board may also, in its discretion, award you additional stock option grants or other equity awards subject to time based and/or performance based vesting. The terms of the equity incentive plan and any associated award agreement (collectively the “Equity Documents”) shall apply to any equity grant. In the event of any conflict between the terms set forth in this Agreement and the terms of the Equity Documents, the terms of the Equity Documents shall control.

 

7.

Severance. Without otherwise limiting the “at-will” nature of your employment, in the event your employment is terminated by the Company without Cause (as defined below) or you terminate for Good Reason, you shall be entitled to the base salary that has accrued and to which you are entitled as of the effective date of such termination, and further, subject to the conditions set forth in the second paragraph of this Severance section, the Company shall, for a period of nine (9) months following your termination date: (i) continue to pay you, in accordance with the Company’s regularly established payroll procedure, your base salary as Severance; and (ii) provided you are eligible for and timely elect to continue receiving group medical insurance pursuant to the “COBRA” law, continue to pay the share of the premium for health coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage, unless the Company’s provision of such COBRA payments will violate the non-discrimination requirements of applicable law, in which case this benefit will not apply. If, in the twelve months following a Change of Control, the Company terminates your employment without Cause or you terminate for Good Reason, the Company, subject to the conditions set forth in the second paragraph of this Severance section, will: (a) extend the Severance benefits described in (i) and (ii) above for an additional three (3) months, such that the total severance benefit period shall be

 

2


  twelve (12) months; (b) accelerate the vesting of all unvested stock options, restricted stock or other equity awards held by you as of the date your employment is terminated such that 100% of such options, restricted stock or equity award shall become fully vested and, if applicable, exercisable effective as of such date (except as described in the next paragraph); and (c) pay to you a bonus amount equal to 1x your target annual bonus for the year in which termination of employment occurs.

Notwithstanding the foregoing, you will not be entitled to receive any severance benefits unless, within sixty (60) days following the date of termination, you (i) have executed a severance and release of claims agreement in a form prescribed by the Company or persons affiliated with the Company (which will include, at a minimum, a release of all releasable claims and non-disparagement and cooperation obligations). Any severance payments shall commence on the first payroll period following the date the release becomes effective (the “Payment Date”). Notwithstanding the foregoing, if the 60th day following the date of termination occurs in the calendar year following the calendar year of the termination, then the Payment Date shall be no earlier than January 1st of such subsequent calendar year. Any stock options, restricted stock or equity award that would vest as a result of the prior paragraph will be treated as only provisionally vested and will only actually become exercisable and/or alienable if and when you satisfy the release requirements, and any such provisionally vested portion will be deemed null and void retroactive to your date of termination if you either notify the Company that you will not execute or will revoke the release or the period for providing the release expires without your complying with the release requirements. The Company may choose instead to provide to you any provisionally vested portions of these awards, subject to your undertaking to repay the Company in the manner determined by the Company at such time if you fail to satisfy the release requirements thereafter.

For purposes of this Agreement, “Cause” shall mean a finding by the Company in its sole discretion of any of the following: (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross negligence, willful misconduct, theft, fraud or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) your material breach of any written agreement between you and the Company; (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendre; or (vi) continued nonperformance of your responsibilities, provided that, if the Company determines that such nonperformance can be cured, the Company has provided you with notice of such nonperformance and you have been provided with a reasonable opportunity to cure not to exceed thirty (30) days.

For purposes of this Agreement, “Good Reason” shall mean that you have complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following actions undertaken by the Company without your express prior written consent: (i) the material diminution in your responsibilities, authority and function; (ii) a material reduction in your base salary, provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your base salary that is pursuant to a salary reduction program affecting substantially all of the senior level employees of the Company and that does not adversely affect you to a greater extent than other similarly situated employees; (iii) a material breach of your Agreement or any other written agreement between you and the Company; or (v) a change in the geographic location at which you must regularly report to work and perform services to a location that is more than fifty (50) miles from Lexington, Massachusetts, except for required travel on the Company’s business. “Good Reason Process” means that (i) you have reasonably determined in good faith that a “Good Reason” condition has occurred; (ii) you have notified the Company in writing of the first

 

3


occurrence of the Good Reason condition within sixty (60) days of the first occurrence of such condition; (iii) you have cooperated in good faith with the Company’s efforts, for a period not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within sixty (60) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

For purposes of this Agreement, “Change in Control” shall mean any: (i) merger or consolidation in which the Company is a constituent party or a subsidiary of the Company is a constituent party and the Company issues equity securities pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in which the equity ownership of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for equity securities that represent, immediately following such merger or consolidation, at least a majority, by both voting power and equity ownership, of (a) the surviving or resulting entity, or (b) if the surviving or resulting entity is a wholly owned subsidiary of another entity immediately following such merger or consolidation, the parent entity of such surviving or resulting entity (provided that all capital stock issuable upon exercise of options outstanding immediately prior to such merger or consolidation or upon conversion of convertible securities outstanding prior to such merger or consolidation shall be deemed to be outstanding immediately prior to such merger or consolidation and, if applicable, converted or exchanged in such merger or consolidation on the same terms as the actual outstanding capital stock are converted or exchanged); (ii) sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Company; (iii) any transfer of the Company’s equity securities, or securities exchangeable for or convertible into the Company’s equity securities, if, immediately following the transfer, any one or more persons (other than the Company’s equity holders as of immediately prior to the transfer) own a majority of the equity ownership or otherwise control a majority of the voting power of the Company; or (iv) any transfer of a subsidiary of the Company’s equity securities, or securities exchangeable for or convertible into equity securities of such subsidiary, if, immediately following the transfer, any one or more persons ( other than the Company’s equity holders as of immediately prior to the transfer) own a majority of the equity ownership or otherwise control a majority of the voting power of such subsidiary; provided that, where required for compliance with Section 409A, the event described in clauses (i)-(iv) is also a change in control event as set forth in Treas. Reg. Section 1.409A-3(i)(5).

 

8.

Parachute Treatment. Notwithstanding any other provision of this Agreement to the contrary, if payments and benefits provided for under this Agreement together with any payments or benefits under any other agreement or arrangement between the Company or any of its affiliates and you are considered “excess parachute payments” under Section 280G of the Internal Revenue Code (the “Code”), then such excess parachute payments plus any other payments made by the Company and its affiliates that you are entitled to receive that are considered excess parachute payments shall be limited to the greatest amount that may be paid to you under Section 280G of the Code without causing any loss of deduction to the Company under such Code Section, but only if, by reason of

 

4


  such reduction, the “Net After Tax Benefit” (as defined below) to you shall exceed the net after tax benefit if such reduction was not made. “Net After Tax Benefit” for purposes of this Agreement shall mean the sum of (i) the total amounts payable to you that would constitute an “excess parachute payment” within the meaning of Section 280G of the Code, less (ii) the amount of federal, state and other income taxes payable with respect to the foregoing calculated at the maximum marginal tax rate for each year in which the foregoing shall be paid to you (based upon the rate in effect for such year as set forth in the Code at the time of termination of your employment or the change in control), less (iii) the amount of excise taxes imposed with respect to the payments and benefits described above by Section 4999 of the Code. The determination of whether payments would be considered excess parachute payments and the calculation of all the amounts referred to in this section shall be made reasonably and in good faith by the parties, provided, that if the parties cannot agree, then such determination (and supporting calculations) shall be made by attorneys, accountants, or an executive compensation consulting firm each as selected by the Company at the expense of the Company (the “280G Service Providers”). Any determination by the 280G Service Providers made in good faith shall be binding upon the Company and you.

 

9.

Tax Acknowledgement. All forms of compensation referred to in this Agreement are subject to all applicable federal, state and/or local withholding and/or payroll taxes, and the Company may withhold from any amounts payable to you in order to comply with such withholding obligations and you shall be responsible for all applicable taxes with respect to such compensation. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its board of directors related to tax liabilities arising from your compensation. You further acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the compensation set forth in this Agreement.

 

10.

409A Compliance. This Agreement is intended to provide payments that are exempt from or compliant with Section 409A, and should be interpreted consistent with that intent. The attached exhibit entitled “Payments Subject to Section 409A” is hereby appended to the Agreement as Attachment A and, if applicable, replaces any previous such attachment concerning the same subject matter.

 

11.

Confidential Information and Restricted Activities. By signing this Agreement, you represent that you have carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on you pursuant to the Company’s Non-Competition, Non-Solicit, Confidentiality and Invention Assignment Agreement (the “Restrictive Covenant Agreement”) attached as Attachment B, the terms of which are incorporated by reference herein. You agree without reservation that these restraints are necessary for the reasonable and proper protection of the Company and its affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. You further agree that, if were you to breach any of the covenants contained in this Agreement or the Restrictive Covenant Agreement, in addition to the Company’s other legal and equitable remedies, the Company may suspend or cease any Termination Benefits to which you might otherwise be entitled. Any such suspension or termination of the Termination Benefits by the Company in the event of a breach by you shall not affect your ongoing obligations to the Company.

 

5


12.

Interpretation, Amendment, Enforcement and Complete Agreement. This Agreement, the Employee Non-Competition, Non-Solicit, Confidentiality and Invention Assignment Agreement which you previously executed and which you reaffirm, and any plans and agreements applicable to the incentive equity awards referred in Section 5 of this Agreement constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, amendments, representations or understandings (whether written, oral or implied) between you and the Company. This Agreement shall be amended only by a writing signed by the Chief Executive Officer of the Company and you. The terms of this Agreement will be governed by statutes and common law of The Commonwealth or Massachusetts without regard to the conflict of laws provisions. You and the Company hereby irrevocably submit to and acknowledge and recognize the exclusive personal jurisdiction of the federal and state courts located in The Commonwealth of Massachusetts (which courts for purposes of this Agreement, are the only courts of competent jurisdiction) in connection with any dispute or any claim related to this Agreement or the subject matter hereof.

 

13.

At-Will Employment. Your employment with the Company will be on an “at will” basis. In other words, you or the Company may terminate your employment for any reason and at any time, with or without cause. Although your job duties, title, compensation and benefits, as well as the Company’s benefit plans and personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and the Company.

[remainder of page intentionally left blank]

 

6


Please acknowledge, by signing below, that you have accepted this Agreement.

 

Very truly yours,
TRANSLATE BIO, INC.
By:  

/s/ Ronald C. Renaud, Jr.

  Ronald C. Renaud, Jr.
  Chief Executive Officer

The foregoing correctly sets forth the terms of my employment by Translate Bio. I have read and accept the terms of this Agreement. I am not relying on any representations pertaining to my employment other than those set forth above.

Accepted and Agreed as of March 22, 2021

 

/s/ Brendan Smith

Brendan Smith

 

7


Attachment A

Payments Subject to Section 409A

1. Subject to this Attachment A, any severance payments that may be due under the letter agreement shall begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the termination of your employment. The following rules shall apply with respect to distribution of the severance payments, if any, to be provided to you under the letter agreement, as applicable:

 

  a.

It is intended that each installment of the severance payments under the letter agreement shall be treated as a separate “payment” for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”). Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments except to the extent specifically permitted or required by Section 409A.

 

  b.

If, as of the date of your “separation from service” from the Company, you are not a “specified employee” (within the meaning of Section 409A), then each installment of the severance payments shall be made on the dates and terms set forth in the letter agreement.

 

  c.

If, as of the date of your “separation from service” from the Company, you are a “specified employee” (within the meaning of Section 409A), then:

 

  i.

Each installment of the severance payments due under the letter agreement that is paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section l.409A-l(b)(4) to the maximum extent permissible under Section 409A and shall be paid on the dates and terms set forth in the letter agreement; and

 

  ii.

Each installment of the severance payments due under the letter agreement that is not described in this Attachment A, Section I (c)(i) and that would, absent this subsection, be paid within the six-month period following your “separation from service” from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which the separation from service occurs.


2. The determination of whether and when your separation from service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1 (h). Solely for purposes of this Attachment A, Section 2, “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414( c) of the Internal Revenue Code of 1986, as amended.

3. The Company makes no representation or warranty and shall have no liability to you or to any other person if any of the provisions of the letter agreement (including this Attachment) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.

EX-10.3 4 d192980dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (this “Agreement”), made this 16th day of June, 2021 (the “Effective Date”), is entered into by and between Translate Bio, Inc., a Delaware corporation (the “Company”), and Daniel S. Lynch, an individual residing at 18 Marlborough St, Boston, MA 02116 (the “Consultant”).

INTRODUCTION

Consultant is currently serving a three year term on the board of directors of the Company as a director and chairman of the board, which such term ending on June 16, 2021 (the “Term End Date”). The Company and the Consultant desire to establish the terms and conditions under which the Consultant shall continue service to the Company from and after Term End Date. In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties agree as follows:

1. Services. In the role of senior advisor to the Company, the Consultant agrees to provide such advisory services to the Company as may be reasonably requested from time to time by the Company, including strategic advice and special projects.

2. Term. This Agreement shall commence on the Term End Date and shall continue until the Consultant’s service is terminated in accordance with the provisions of Section 4 (such period, the “Consultation Period”).

3. Compensation.

3.1 Consulting Fee. During the Consultation Period, the Company shall pay to the Consultant consulting fees of $8,333.33 per month ($100,000 on an annual basis), payable in arrears on the last day of each month. Payment for any partial month of service during the Consultation Period shall be prorated.

3.2 Equity. During the Consultation Period, any equity awards previously granted by the Company to the Consultant shall continue to vest and be exercisable, and the commencement of the Consultation Period immediately following the Term End Date shall be deemed not to create a cessation of service that would cause such awards either (y) to cease to vest or (z) to cease to be exercisable after a set period of time following the Term End Date.

3.3 Expenses. The Company shall reimburse the Consultant for all reasonable documented out of pocket expenses incurred or paid by the Consultant in connection with, or related to, the performance of his duties, responsibilities or services under this Agreement, including Consultant’s travel and lodging expenses, upon presentation by the Consultant of documentation, expense statements, vouchers and/or such other supporting information as the Company may reasonably request. The Consultant shall submit to the Company itemized monthly statements of such expenses incurred in the previous month. The Company shall pay to the Consultant amounts shown on each such statement within thirty (30) days after receipt thereof. The Company shall pay the reasonable and documented fees and expenses of Moulton Law Group, PLLC, counsel for the Consultant, incurred in connection with the preparation and negotiation of this Agreement, not to exceed $2,500.


3.4 Benefits. The Consultant shall not be entitled to participate in any health or dental benefit programs that the Company establishes and makes available to its employees, and shall not be entitled to participate in any other benefit programs that the Company establishes and makes available to its employees, if any.

3.5 Taxes. The Consultant acknowledges and agrees that the Consultant is obligated to report as income all compensation received by the Consultant pursuant to this Agreement, and the Consultant agrees to and acknowledge the obligation to pay all taxes including without limitation all federal and state income tax, social security taxes and unemployment, disability insurance and workers’ compensation applicable to the Consultant. The Consultant shall indemnify and hold the Company harmless from any liability for, or assessment of, any such taxes imposed on the Company by relevant taxing authorities.

4. Termination. This Agreement may be terminated by either the Company or the Consultant upon not less than ninety (90) days’ prior written notice to the other party; provided, however, that either party may terminate this Agreement immediately upon written notice to the other party in the event such other party has materially breached this Agreement. In the event of any termination of this Agreement, the Consultant shall be entitled to payment of consulting fees hereunder and for expenses paid or incurred hereunder prior to the effective date of termination.

5. Cooperation. The Company shall provide such access to its information and property as may be reasonably required in order to permit the Consultant to perform his obligations hereunder. The Consultant shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and property.

6. Proprietary Information, Inventions, and Non-Compete.

6.1 Proprietary Information.

(a) The Consultant acknowledges that his relationship with the Company is one of high trust and confidence and that in the course of his service to the Company he will have access to and contact with Proprietary Information. The Consultant shall not disclose any Proprietary Information to any person or entity other than employees, officers, directors, lawyers, accountants and consultants of the Company or use the same for any purposes (other than in the performance of his duties as a consultant of the Company) without written approval by an officer of the Company, either during or after the Consultation Period, unless and until such Proprietary Information has become public knowledge without fault by the Consultant.

 

- 2 -


(b) For purposes of this Agreement, Proprietary Information shall mean, by way of illustration and not limitation, all information, whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential nature, owned, possessed or used by the Company, concerning the Company’s business, business relationships or financial affairs, including, without limitation, any Invention, formula, vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical or research data, clinical data, know-how, computer program, software, software documentation, hardware design, technology, product, processes, methods, techniques, formulas, compounds, projects, developments, marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost, customer, supplier or personnel information or employee list that is communicated to, learned of, developed or otherwise acquired by the Consultant in the course of performing his duties as a consultant of the Company.

(c) The Consultant’s obligations under this Section 6.1 shall not apply to any information that (i) is or becomes known to the general public under circumstances involving no breach by the Consultant or others of the terms of this Section 6.1, (ii) is generally disclosed to third parties by the Company without restriction on such third parties, or (iii) is approved for release by written authorization of an officer of the Company.

(d) The Consultant agrees that all files, documents, letters, memoranda, reports, records, data sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Consultant or others, which shall come into his custody or possession, shall be and are the exclusive property of the Company to be used by the Consultant only in the performance of his duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Consultant shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) the termination of this Agreement. After such delivery, the Consultant shall not retain any such materials or copies thereof or any such tangible property.

(e) The Consultant agrees that his obligation not to disclose or to use information and materials of the types set forth in paragraphs (b) and (d) above, and his obligation to return materials and tangible property set forth in paragraph (d) above extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Consultant.

(f) The Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. The Consultant agrees to be bound by all such obligations and restrictions that are known to him and to take all action necessary to discharge the obligations of the Company under such agreements.

 

- 3 -


(g) Pursuant to the federal Defend Trade Secrets Act of 2016, the Consultant shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this Agreement shall be interpreted or applied to prohibit the Consultant from making any good faith report to any governmental agency or other governmental entity concerning any acts or omissions that the Consultant believes to constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law or regulation.

6.2 Inventions.

(a) All inventions, creations, discoveries, computer programs, data, developments, technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by the Consultant, solely or jointly with others or under his direction and whether during normal business hours or otherwise, (i) during the Consultation Period if made, conceived, reduced to practice, created, written, designed or developed in the course of Consultant’s performance of duties pursuant to this Agreement or (ii) during or after the Consultation Period if resulting or directly derived from Proprietary Information (collectively under clauses (i) and (ii), “Inventions”), shall be the sole property of the Company. The Consultant hereby assigns and transfers and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. However, this paragraph shall not apply to Inventions which do not relate to the business or research and development conducted or planned to be conducted by the Company at the time such Invention is created, made, conceived or reduced to practice and which are made and conceived by the Consultant not during normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Proprietary Information.

(b) Upon the request of the Company and at the Company’s expense, the Consultant shall execute such further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. The Consultant also hereby waives all claims to moral rights in any Inventions.

 

- 4 -


(c) The Consultant shall promptly disclose to the Company all Inventions and shall maintain adequate and current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the Company at all times.

7. Other Agreements. The Consultant represents that his performance of all of the terms of this Agreement do not and will not breach any agreement with any third party to which the Consultant is a party (including, without limitation, any nondisclosure or non-competition agreement), and that the Consultant will not disclose to the Company or induce the Company to use any trade secrets, confidential or proprietary information or material belonging to any current or previous employer or others.

8. Non-Exclusivity. The Consultant retains the right to be employed or engaged by other companies and to contract with other companies or entities for his consulting services without restriction.

9. Remedies. The Consultant acknowledges that any breach of the provisions of Section 6 shall result in serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that, in addition to any other remedy it may have, the Company shall be entitled to enforce the specific performance of this Agreement by the Consultant and to seek and obtain both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages or posting a bond.

10. Independent Contractor Status. The Consultant shall perform all services under this Agreement as an “independent contractor” and not as an employee of the Company.

11. Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or three days after deposit in the United States Post Office, by registered or certified mail (return receipt requested), postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 11.

12. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.

13. Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement.

14. Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Consultant.

15. Non-Assignability of Contract by the Consultant. This Agreement is personal to the Consultant and the Consultant shall not have the right to assign any of his rights or delegate any of his duties without the express written consent of the Company. Any non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be void and shall constitute a breach and a default by the Consultant.

 

- 5 -


16. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction.

17. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any entity with which, or into which, the Company may be merged or consolidated or which may succeed to its assets or business; provided, however, that the obligations of the Consultant are personal and shall not be assigned by him.

18. Interpretation. If any restriction set forth in Section 6 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

19. Survival. Section 4 and Sections 6 through 21 shall survive the termination of this Agreement.

20. Section 409A.

20.1 To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Consultant’s termination of service, then such payments or benefits shall be payable only upon the Consultant’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).

20.2 The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

20.3 The Company makes no representation or warranty and shall have no liability to the Consultant or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 

- 6 -


21. Miscellaneous.

21.1 No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. No waiver of any term or condition of this Agreement shall be valid or binding on either Party unless the same shall have been mutually assented to in writing by both Parties. The failure of either Party to enforce at any time any of the provisions of this Agreement, or the failure to require at any time performance by the other Party of any of the provisions of this Agreement, shall in no way be construed to be a present or future waiver of such provisions, nor in any way affect the right of either Party to enforce each and every such provision thereafter. The express waiver by either Party of any provision, condition or requirement of this Agreement shall not constitute a waiver of any future obligation to comply with such provision, condition or requirement.

21.2 The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.

21.3 In the event that any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.

[Remainder of Page Intentionally Left Blank]

 

- 7 -


IN WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as of the day and year set forth above.

 

TRANSLATE BIO, INC.
By:  

/s/ Paul Burgess

Name: Paul Burgess
Title: Chief Operating Officer and Chief Legal Officer
CONSULTANT

/s/ Daniel S. Lynch

Daniel S. Lynch

[Signature Page to Consulting Agreement]

EX-31.1 5 d192980dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ronald C. Renaud, Jr., certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Translate Bio, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 5, 2021     By:   /s/ Ronald C. Renaud, Jr.
      Ronald C. Renaud, Jr.
      Chief Executive Officer
EX-31.2 6 d192980dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brendan Smith, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Translate Bio, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 5, 2021     By:   /s/ Brendan Smith
      Brendan Smith
      Chief Financial Officer and Treasurer
EX-32.1 7 d192980dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Translate Bio, Inc. (the “Company”) for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), the undersigned, Ronald C. Renaud, Jr., Chief Executive Officer, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:

 

  (1)

The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 5, 2021     By:  

/s/ Ronald C. Renaud, Jr.

      Ronald C. Renaud, Jr.
      Chief Executive Officer
EX-32.2 8 d192980dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Translate Bio, Inc. (the “Company”) for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), the undersigned, Brendan Smith, Chief Financial Officer and Treasurer, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:

 

  (1)

The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 5, 2021     By:  

/s/ Brendan Smith

      Brendan Smith
      Chief Financial Officer and Treasurer
EX-101.SCH 9 tbio-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Condensed Consolidated Statements of Cash flows link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Collaboration Agreement link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Net Income (Loss) per Share link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Subsequent Event link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Collaboration Agreement (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Net Income (Loss) per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Collaboration Agreement - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Collaboration Agreement - Summary of Collaboration Revenue (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Collaboration Agreement - Balance of Contract Liabilities Related to Collaboration Agreements (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Intangible Assets and Goodwill - Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Total Acquisition Related Contingent Consideration Liability (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Property and Equipment, Net - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Accrued Expenses - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock-Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Net Income (Loss) per Share - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Net Income (Loss) per Share - Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Leases - Schedule of Lease Cost (Details) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Subsequent Event - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 tbio-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 tbio-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 tbio-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 tbio-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 14 g192980g0802235630934.jpg GRAPHIC begin 644 g192980g0802235630934.jpg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g192980g0802235631164.jpg GRAPHIC begin 644 g192980g0802235631164.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ H[444 9-KXFT>]U V%O=[[H$@Q^6XQ MCKR1CM6M7'WEK=?VGXHDB@F_>6*+"RJ?F8!N%/:^)7_ ZV\SOJ*\^L-+N[RWT*WOH[ M]8Q'=>>"[JV<_*'(J&YAU5M*TAY(M1FN(D=?*P^&(?"Y92"K8 P3D4?5U>W- M_6O^0OK3M?E_K3_,[^"]M[FXN((I TMNP65<'Y21D?I2WEY;V%LUS=2".%/O M,03C\JXR^MM2\W67BM[H1275NTJPY#R1!!O"'N?I692B*! M,;G()QGZ5PNL66KC6I8X4N0JB-;!XED81@#GD,%!SUW=:V/%;W%[X:O;..WN M7N83%N9(CASD$E/7&*E4%>.NC*>(ERR=M4;-OKVF7=H+JWNA+"9!%E48D,>Q M&,C\:TJ\[M;?4/L5VT<-\TW^$?^13TW_KE_4U,DD>KD^.KXBK*-5W217\6^*!X7M;>H?\+=7_H$M_P!_?_K4?\+=7_H$M_W]_P#K5Y?175_9^'_E_,XO[4Q7 M\WX(]0_X6ZO_ $"6_P"_O_UJU?#OQ#77]:ATX:>8?,#'?YF<8!/]*\:KJ_AS M_P CM9_[LG_H)K*O@:$:4I):I&V&S'$SK1C*6C:Z(]SK@[WXD+:7UQ;'3BWD MR,F[S.N#BN\[5X)K7_(=U#_KXD_]"->#%7.[.,75PT(ND[79W'_"T$_Z!K?] M_*/^%H)_T#6_[^5YS15\J/!_MC&?S_@CT;_A:"?] UO^_E'_ M!/^@:W_?R MO.:*.5!_;&,_G_!'N^A:K_;6DQ7PB\KS"1LSG&#BJGBKQ$/#.F)>&W,^Z01[ M0V.N?\*K^ _^12M?]Y__ $(UE?%;_D5X?^OE?Y&JP\(SK1C+9L^H=>?U)5;^ M]RIF7_PMU?\ H$M_W]_^M1_PMU?^@2W_ ']_^M7E]%>]_9^'_E_,\'^U,5_- M^"/4/^%NK_T"6_[^_P#UJ/\ A;J_] EO^_O_ -:O+Z*/[/P_\OYA_:F*_F_! M'L.A_$E=9UFVT\:<8O.;&_S,XKO:\#\"_P#(YZ;_ -=/Z&O?*\C,*,*-11@K M:'N99B*E>DY5'=W.-UOQXNC:M-8FQ,GEX^;?C.1FL[_A:"?] UO^_E<(RT3?1'HW_"T$_P"@:W_?RC_A:"?] UO^ M_E>C?\+03_H&M_W\KI_#/B$>(K.6<6YA\M]N"V#UZF PM*K3H?\+=7_ *!+?]_?_K5-:_%9;F[A@_LME\QPN?-Z9_"O*:N:5_R%[/\ MZ[+_ #I2P&'2;Y?S*AF>*H?\+=7_H$M M_P!_?_K4?\+=7_H$M_W]_P#K5Y?11_9^'_E_,/[4Q7\WX(]2C^+2O(B?V4PW M,!GS?7\*])B?S(D?&-R@XKYHM_\ CYA_WU_G7TK;?\>L7^X/Y5YN88>G1Y>1 M6N>OE>*JU^;VCO:QA^)_$X\.+;L;8S><2.&QC%<[_P +03_H&M_W\I?BA_JK M#_>:O.*X(Q31YF99EB:&)E3IRLE;HNQZ-_PM!/\ H&M_W\H_X6@G_0-;_OY7 MG-%/E1P_VQC/Y_P1Z-_PM!/^@:W_ '\K6\/>-EU[5!9"R,64+;M^>E>1UUGP M[_Y&@?\ 7%J3BK'3@\TQ53$0A*6C?9'KC':I/H,UYM-\65AGDB_LICL8KGS> MN#]*](D_U;?0U\U7O_'_ ''_ %U;^==V7X>G6QFF*JT%'V;M>YZ3_P MMU?^@2W_ ']_^M1_PMU?^@2W_?W_ .M7E]%>G_9^'_E_,\C^U,5_-^"/4/\ MA;J_] EO^_O_ -:C_A;J_P#0);_O[_\ 6KR^BC^S\/\ R_F']J8K^;\$?1^B M:E_;&CVU^(_+\Y-VS.<52\3>(1X=M(9S;F;S'VX#8Q4?@G_D3M-_ZY"L?XF_ M\@>T_P"NQ_E7S]2*51Q6USWL17G#!.K%^]9,J?\ "T$_Z!K?]_*/^%H)_P! MUO\ OY7G-%'*CY?^V,9_/^"/1O\ A:"?] UO^_E'_"T$_P"@:W_?RO.:*.5! M_;&,_G_!'J^A^/%UG5HK$6)B\S/S;\XQ795XSX&_Y&RU^C?RKV:HDK,^CRC$ MU<1034S+%1FX\VS[(]0_X6ZO_ $"6_P"_O_UJ M/^%NK_T"6_[^_P#UJ\OHJO[/P_\ +^9']J8K^;\$>H?\+=7_ *!+?]_?_K5W M/AW6?[?T6'41#Y/F$C9G.,'%?.U>\?#^)H?!=@&&-P+CZ$DUPX_"TJ--."L[ MGHY9C*]>JXU'=6-G5K_^R]*N+TQ^9Y*[MN<9YKB?^%H)_P! UO\ OY74^+O^ M14U#_KG_ %%>(5Y<4F99QCJ^'JQC2=DT>C?\+03_ *!K?]_*/^%H)_T#6_[^ M5YS156:TL?3YC7G1H<\'9W-S_A;J_P#0);_O[_\ M6H_X6ZO_ $"6_P"_O_UJ\OHKV?[/P_\ +^9X/]J8K^;\$>H?\+=7_H$M_P!_ M?_K4?\+=7_H$M_W]_P#K5Y?11_9^'_E_,/[4Q7\WX(]W\(^+AXI%T1:&W^SE M>K9SG/\ A6[J-W]@TRZO-F_R(FDVYQG SBO._A#]W5?K'_[-7?ZY!)H?\+=7_ *!+?]_?_K5Z7$_FPI)C&Y0(+T11 I O,LN.%'^->S:;IMKI-DEI:1A(T'XD^I]Z)2L:Y9EC MQ+]I4^!?B-L=)L]/TY;&"%1 %P01G=ZD^M>9^,/"#Z1(U[9*6L6.64=8C_A7 M::GXVTK2]=@TN:3+.<2R _+$>V?\\5T3I'<0E6"R1NN"#R"#2<9PLY+<^AQ. M$P^+INE&UX]NA\\U[?X1_P"13TW_ *Y?U->?^,/"#Z/(U[9*6L6/('6(_P"% M>@>$?^13TW_KE_4TI.Z/*R?#U,/BITZBUM^IRGQ<_P"05IW_ %\'_P!!->35 MZS\7/^05IW_7P?\ T$UY-7T.7?[NOF8YK_O3^04445W'G!75_#G_ )':S_W9 M/_037*5U?PY_Y':S_P!V3_T$UAB?X,_1G1@_]XAZH]S[5X)K7_(=U#_KXD_] M"->]UX+K8*Z]J ((/VA^O^\:^7AN>IQ#_#AZLH4445H?*A1110![)X#_ .12 MM?\ >?\ ]"-97Q6_Y%>'_KY7^1K6\" CPE:9!&2QY_WC63\5O^17A_Z^5_D: MO"?[Q'U/MW_R+E_A7Y'C=%%%?4'RP4444 =%X%_Y'/3?^NG]#7OE>!^!?^1S MTW_KI_0U[Y7@9K_%7H?2Y-_ ?J>;?$K27%Q!JD:DHR^7(1V/8UY_7T%>6<%_ M:26UP@>*088&O)M?\$W^E2M+;(US:9R&499?J*X(RZ'FYQETU4=>FKI[^1RU M%*RLAPRE3Z$8J:VL[F[D$=O!)*QZ!5S5G@*+;LD0JI9@J@DDX %>V^%-+;2? M#]O;N,2L/,<>YKG?"?@9K.5+_5%!E7F.'KM/J?>N]K.4KGU>39?.C>M45F]D MS_P"NR_SJG5S2O^0O9_\ 79?YU<_A9-/XT?25>1?$3_D: M#_UQ7^M>NUY%\1/^1H/_ %Q7^M?(PW/H<]_W7YHY.BBBM3XT**** /2/A?\ MZC4/]Y?Y5V^HV4>I:=<64I(29"A(ZC-<1\+_ /4:A_O+_*O020.M9-M2NC[C M*DG@H)^?YL^>?$7AV[\.:@UO<*6B)S%*!PX_QK'KZ-UK1;37=/>TNXPRL/E; MNI]17A/B+P]=^'=0:WN%)C/,'?/#X?R,BB MBNG\(>$;CQ)=AW#1V,9_>28^]["NRI4C3BY2>APTJ4ZLU""U8O@[PE<^(;Y9 MG#1V43 O)C[Q'85[HBA$5!T48%0V=G;Z=9QVUM&L<,8PH%6*^:Q6)E7G?HMC MZW!X2.&A9;O<\]^*'^JL/]YJ\XKT?XH?ZJP_WFKSBLH['RF6%=9\._^1H'_7%JY.NL^'?_ "- _P"N+4I;';E_^]4_5'KIKLP%>%&,Y2\C MZG,L-/$2A"'G^AP6E^%]8U@!K.R=HS_RT;Y5_.N@7X6ZZ4R9+93Z;Z]E1$B0 M(BA5 P !@"@R(#@NH/IFG/-*K?NI(F&3T(KWVVSP74O ^OZ8C22V9EC'5H3N MKG2""0001U!KZ=X(]:XWQ?X%M=:@>ZLHUAOU&05&!)[&M\/F=WRU5\SFQ.3V MCS47\C3\$_\ (G:;_P!UE/4& ML/XF_P#('M/^NQ_E7EU?XLO5G9C%;+FO[J_0\NHHHIGQ 4444 ='X&_Y&RU^ MC?RKV:O&? W_ "-EK]&_E7LU93W/K\A_W9^O^1Y+\3_#\D%^NLP(3#, LV!] MUAW_ !KSNOIBYMH+VVDM[B-9(9!AE(R"*\KU_P"%]U#*\VCN)H3SY+G#+]#W MKV<#CH=T5K2>&-E%75'#5I/E47]QB:+I-QK>JPV-NI)=OF8#[J]S7T/9 MVT=E90VT0Q'$@11["LGPUX6L?#5H4MQOGW^+O\ D5-0_P"N?]17B%RXX ]![UZ7J7@W3KS14L88Q"\(_=2 <@^ M_KFFY)'%AR6MU&4D0_@1 MZBHK3_C]@_ZZ+_,570X5%QGRR5FF?0*?ZM?H*\7^*'_(W'_K@E>T)_JU^@KQ M?XH?\CDW5PEI:RW$N?+B0NV/0=:^9Q_P#O$OE^1]=EK2PD6_/\ MSB?'/@==7C?4=.0+?*,N@X$H_P :\>='CD:.12KJ<,I&"#7TO;W$-W;I/!(L MD3C*LIX-<1XY\#KJR/J6G(%OE&70<"4?XUTX''6[6UCA=KAFV",#G/IBO9_!7@N+0+<7=VJ MR:A(.3U$8]!_C7IXG%1H1N]^AY.#P<\3.RT2W8O@OP7%X?MQ=70634)!\S=H MQZ#_ !KL*K7U];Z=9R75U((XD&23_*IT<21JXZ,,BOFZM2527/+<^KHTZ=*/ MLX=#RWXF_P#(?M?^O8?^A-7%5VOQ-_Y#]K_U[#_T)JXJJCL?$YG_ +W4]0HH MHIG %%%% 'ONF:9:Z38I:6D82-1^+'U/O7+>./&J:' UC8N&U"1>2.D0]3[^ ME3^-?&,7AZT^SVY5]0E7Y%_YYC^\?\*\3GGEN9WGGD:261MSNQR2:[<#@O:/ MVE3;\S[+'XZ-"/L:._Y#9)'ED:21B[LD:I+F G;!,Q^ MX?[I]J\YHKV*U"%:')(\+#XF="ISQ_X<^FY(XYXFCD57C<8((R"*CLK.&PLX M[6W7;%&,*,]!FO./ 'CC/EZ/JDO/W;>=CU_V2?Y&O3J^9KT)T9\LCZW#UJ>( MBJL-_P O(\Z^+G_(*T[_ *^#_P"@FO)J]9^+G_(*T[_KX/\ Z":\FKWLN_W= M?,^G\@HHHKN/."NK^'/_([6?^[)_P"@FN4KJ_AS_P CM9_[LG_H)K#$ M_P &?HSHP?\ O$/5'N=6)X96CD0HZG#*PP0:U3N?$8[ U,)4Y9:KHQE=?X/\(/J\JWMXI6Q4 M\#O(?3Z4GA#P@^L2K>7BE+%#P.\A]![5ZQ'''#$L<:!$0850, "IE+HCTLJR MKVEJU9>[T7?_ ( 1QI#&L<:!$4850. *XCXK?\BO#_U\K_(UVZ2)*"8V# '! M(/>N(^*W_(KP_P#7RO\ (UK@_P"/'U/H,=_NT[=CQNBCVK6LO#.M:BNZUTZ= MU/\ $5P*^GE.,5>3L?'PA*;M%7,FBN@E\$>(X4+MIDI _N\UB3V\]M(8YX7B M<=5=<&E&I"?PNY4Z52'Q1:-WP+_R.>F_]=/Z&O?*\#\"_P#(YZ;_ -=/Z&O? M*\/-?XJ]#Z')OX#]3D4\8PV?C"\T;4'$<>5\B4] 2!\IKK00PR""#7A/Q!_Y M'6^_X#_Z"*70_'FLZ(BPB07-N.D7NI3C.GO9:$0S14ZLJ=79-ZGM MLNG64S;I;2!SZE!4D-M!;C$,,=P?%NV*?O],E#?[#@BJU]\6G9"MC MIVUNS2MT_ 5RK 8ANW*=?]H81>\G^!Z/J&HVNEVU+7)_-O[EI,?=0<*OT%>E_";_D"7O\ UW'\ MJZ*V"5##N4M9:&%#,'B,2H1TCK\S;\?_ /(EW_\ NC^=>%P02W4Z001M)*YP MJJ.2:]X\<02W/A*\AA1GD!FL&DU32XR;8G,L2C_5^X]JXG2O\ D+V?_79?YU](,JR( M58!E88(/((KR_P 2^!FT[6K;5-,C)M3.IEB4?ZOGJ/:O5P>.YH^SJ;]&>=CL MNY9JM26G5'J5>1?$3_D:#_UQ7^M>NUY%\1/^1H/_ %Q7^M>1#0:Y+X7_P"HU#_> M7^5=9XF_Y%K4/^N)K)_$?:8#_D7+T?ZG/^#O&*ZDB6%^X6[481STD'^-='K> MB6FNZ>]I=H""/E;NI]17A2.T;JZ,593D$'D&O5/!WC!=31;"^<+=J,*YZ2#_ M !JM8OFBO6[*RMM-L MX[:VC6*&,8 %6#@#)KSGQGXSW>9IFFR<=)IE/Z"M:V)J8AKFZ'?)8?+:;GW^ M_P!!_BSQEYER-,TV3Y=X6:53UYZ"O0(/^/:+_<'\J^?H/^/F+_?'\Z^@;?\ MX]HO]P?RK"2L<5Z/\4/]58?[S5YQ5QV/ M$SC_ 'R7R_(****H\L*ZSX=_\C0/^N+5R==9\._^1H'_ %Q:E+8[@[L?05=KR#QWK+ZCKCVRL?L]L=BC/!;N:RBKL^PS M#&+"T>=;O1#=9\F>*]7TN13'=/)&.L1[CVKQ* MK^C:G+I&J07D3$;&^8>J]Q2E&YW8#,ZN'FE-WB>]=.E]>Q>&O#5OH%G@ /=./WDN/T'M6DI6/EL MOR^>+GKI%;L\Q\0^%[SP^\9E_>0N.)%' /H:PJ^@KRS@O[62VN8Q)$XP0:\= M\3^&)] N\@%[1S^[DQT]C[THRN=.9Y4\/^\I?#^0_P #?\C9:_1OY5[-7C/@ M;_D;+7Z-_*O9JF>YZF0_[L_7_(\]T?QD-/UF[T[46/V?SV$[\M#U6(;:GD9Z$L^ MPR5TFV>B>)?&%IHL+10LLUX1\J Y"^YJ?P922>M>R> _^11M/J_\ Z$:7?6L3&<_A2^_473=-MM*LH[6UC"1H/Q)]34-M MKNG7FI3Z?!=(]S!]] ?Y>M<9X[\="R632M+D!N"-LTRG_5^P]Z\MM+ZYL;U+ MRWF9)T;<'!YS[UZ&'RZ56#G)V["Q&9T\/-4J:NEO_P ][\1^'+;7[+8X"7" M#]U+CD'T/M7D,NGW.EZS':W4921)5^AY'(KU'PAXOM_$=ILD*QWT8_>1YZ^X M]JT-=\/VVMQ1EP$N(F#1R@+?%#_D;C_UP2NS+/X_R-[_^@FOFZZ?PGXLET*X$$Y9[%S\R]T/J*YY1ZH\7*LT=%JC5 M?N]'V_X!ZA'H.FQ:P^JI:H+QUVE\?K]?>K5[>V^G6DESI[>-QU+!T[Q^)[+ M]1/$WB:X\07?>.T0_NXL_J?>O9K;_CUB_P!P?RKY[KZ$MO\ CUB_W!_*B:L> M?D=:=:I5G-W;M^IYA\3?^0_:_P#7L/\ T)JXJNU^)O\ R'[7_KV'_H35Q57' M8\7,_P#>ZGJ%%%%,X HHHH H7=W/?7_\ @K_D3-*_ZX#^9KRL MU7[N/J>SDK?M9+R.9^+@_P")3IQ_Z>#_ .@FO)J]Q^(VEOJ7A.5HEW26KB< M=2!P?T)_*O#JURR2="W8RS>#6(OW04445Z!Y85U?PX!/C:TQV20G_ODURE>A M_"G2WEU6YU)E/EP1^6I]6;_ZW\ZYL9)1H2;['7@(.6)@EW_(];[5X[I7C*;P M[XJU&WN"TFGR7\9W'D?X5[%VKYQU[_D8=2_Z^I/_ $(UY.74XU.>,MK' MN9K6G14)P>MSZ)MKF&\MH[BWD62*0;E93D$5AZQX/T[6-1AO)5*.I_>!/^6@ M]#7E_@SQE-X>N1;7):33I#\R]3&?4?X5[9;7,-W;1W$$BR12+N5E.017-B<- M+#RL]NC-J%:CCJ5IJ]MT.BBC@B6*) D:#"JHP *X/QSXY73$?3=-D#7C#$D@ MY$0_QIWCGQPNEH^FZ:X:]88>0;]Y4VZ( MY,QS!4U[&EOU?8]T^'C,_@VU=V+,SN22>2=QJI\2K2>^T.TM;:,R32W:JJCN M<&K/PY_Y$JS_ -Y__0C74LBLRLR@E3D$CI7)4J>SQ+FNC9WTZ?M<)&#ZI'(> M%_ -AHT*3WJ)(;'0;;S+I\NWW(E^\U>> MW_Q%U:X<_9$BMH^W&YOSK&SZ]EO\SUBL[5=#T_6K=H;Z MV20$<-CYE^AKRV+Q[K\3AFN4D'HZ#%==H'Q M=0E6VU!!;3-PKY^1C_2I2E% MW1%+-L)B'[-Z7[G.V?A"X\->/--=29;*24^7+CD'!X/O7J]-94D"D@-@Y!(Z M'UIU:5Z\JS3ENCNP^'A034-F[GA'Q!_Y'6^_X#_Z"*YBNG^(/_(ZWW_ ?_01 M7,5])AOX,?1'R6+_ (\_5A1116YSA7KOPF_Y E[_ -=Q_*O(J]=^$W_($O?^ MNX_E7!F7^[OY'I93_O*]&>@U7O;VWT^TDN;F01Q(,DFEO+N&PM)+FX<)%&,L MQKQWQ/XGGU^[P"8[-#^[CSU]S[U\ZE<]O,,?#"0[R>R$\3>)KC7[O )2T0_N MX_7W/O6!116R5CXFM6G6FYS=VST/P9XSVF/3-3DX^[#,Q_0UZ+P1ZBOG>O1/ M!?C(YCTO4I,Y^6&9C^AK.4>J/H<5Z/\4/\ 56'^\U]:?BSP=)HI^U6 M8:2S/!SR4/O[5ZCIVG6VE626MK&$C0?B3ZFK$D<=Q"T;JKQN,$'D$5/.[GK4 M\CI?5^27QOK_ %T/GFNL^'?_ "- _P"N+4[Q?X0?1Y6O+-2]DYY'>,^A]J;\ M._\ D:!_UQ:J;NCQ,-AZF'QT*=1:W1ZXQPI/H*^?[]R^H7+GDF5B?SKW]_\ M5M]#7S]=_P#'[/\ ]=&_G4P/5XA?NT_G^A#1116A\N%%%% 'N/A60R^&-/9N MOE 5C_$"RN-0L["UMHR\KSX 'TK5\(?\BKI__7(5M8!() R.E8WLS[Y457PD M:[NW 4?=7NY]!3M9UFTT/ M3WO+R0*BCY5[L?05X3XB\17?B+46N;ABL8.(H@>$'^-=F$PDJ\KOX3#$XFE@ M:2ITUKT7ZL]7\)>.;?Q$SV\ZK;W8)*IGAU]O>NGO;*WU"TDMKF,21.,$&OFV M">6VG2:&1HY4.Y64X(->T>"O&L6O0+:7;+'J"#D=I!ZBM\;@?9^_3V_(RP&8 M*NO95M_S,K3?#,_A_P <6I&7M)-WER8]NA]Z]'I" <9 ..E+7F-W/0PN%AAD MXPV;N>"ZU_R'+[_KLW\ZH5?UK_D.7W_79OYU0K9;'P5;^)+U84444&05[+X# M_P"11M/J_P#Z$:\:KV7P'_R*-I]7_P#0C43V/7Z?JCI*\\\=^.A8K)I M>ER W)&)9E/^K]A[UU7BRYFL_"NHW%O(8Y4B^5AU'(%?/;,68LQ)8G))[UWY M=A8U7[26RZ'KYKC)44J<-WU L68LQ)).23WI***]\^:)[*]N-/O([JUE,QR([Z,?O8L]?<>U>$5Z/I*O%?BA_R-Q_ZX)7M"$E%)ZD5XW\4X63Q3'(1\LE MNI!^A(KR,L_C_(]O-]<-\T[_^@FOFZ^A+;_CUB_P!P?RJ)GT?#V]3Y?J>8?$W_ )#]K_U[#_T)JXJO0/'> MG7.J^+;*TM(R\CVP^@&YN3[5T&A>!]-TJ-7N$6ZNNI=Q\H/L*%))&-;+JV+Q ME1QT5]SRB'3[RX&8;69QZJAI)K&[M_\ 76TL?^\A%?0"HJ*%10JCH ,"D>-) M%*R(K*>H89%+G.K_ %>C;^)KZ'SQ17KFO>!-/U*-I;)5M;K&1M'R-]1VKRZ[ MTV\LKN2VGMY%EC.&&W-6I)GC8S+ZV%?O:I]4<_1117U@@HHHH *]_P#!7_(F M:5_UP'\S7@%>_P#@K_D3-*_ZX#^9KR\U_A1]3V]>GZYKT6ARV+7 Q;SR&-W_ +G&0?I6 MJCI-&'1E=&&00<@BO)P^)G0ES1/7Q-&CBTZ3>L?P/F2BOH"_\&:!J3F2?3HQ M(>K1Y0G\JK6WP^\-VT@<6'F$=I')'Y5ZRS6E;5.YX[R6M?22L>0:!X:U#Q#= MK%:Q$1 _O)F'RH/K_2O=M$T>VT+2XK"U7Y$'+'J[=R:MP6\-K"L4$211KT1% M K)E\16Y\1VVC0%9)7#-,0>$ 4G'UKS<5C)XAVV1Z>&PM+!*\G[ST^_HC;[ M5\XZ]_R,.I?]?4G_ *$:^CNU?..O?\C#J7_7U)_Z$:ZLI^.1S9W_ X>IGUO M:/XNU71-/N+*UE'E2CY=W/EGU6L&BO9G",U:2N>!3J3IOF@[,<[M([.[%G8Y M9B?_T(UT6H7L6G:?/=S'"1(6/O7._#G_D2K/\ MWG_]"-,^(L[1>&-BG EF53].O]*^4Q'\>7JSZY571P2J+I']#S#5-3N-6U"6 M\N6)=SP.RCL!5.BB@^%E*4Y.4G=L****"3U3X?>()-0LWTZY)-R-[@BO9JRDK,^VR?$2K8915Z[\)O\ D"7O_7C.@\;?\BG>_[H_G M7B]>T>-O^13O?]T?SKQ>O AL1G_^\1]/U844459X05;TS_D*6O\ UU7^=5*M MZ9_R%+7_ *ZK_.A[&E/XUZGOU>1?$3_D:3_UQ7^M>NUS5SX7BU'Q2VIWJAX( MXU6.,_Q,.Y]JRB[,^VS/#3Q-%4X=T>>:-X.U765$JQB"W/\ RUEX!^@[UU<' MPQM0@\_4)6;OL0 5W?RQIV55'T K'NO%N@V">-9(G&&5AD&A\T7:2)KY/A:T;T='Y:HX/ MX7_ZC4/]Y?Y5UGB;_D6M0_ZXFJ?AWP]_8%Y?K$K.C#4IT<"Z<]TG^IX71116I\.%%%% $D'_'Q%_OC^=?0-O\ \>T7^X/Y M5\_0?\?$7^^/YU] V_\ Q[1?[@_E6?+]3F/%V@7&OW>GP1?+$C M,99/[H_QK?TW3;;2;)+6UC"1J/Q)]35RO._'?CH62R:7I<@-R1B693_J_8>] M71I3K2Y(GL550PTI8B6[_JR$\=^.A9B32M+D!N",2S*?N>P]ZPO!'CF32YET M_4Y&>S<_)*QR8R?7VKA"2S%F)))R2>])7T$<#25+V;7S/GIYC6E6]JG\O(^F M66&[MB"%EAD7GN&!KD],\)MHGBX7=J"UC)&P [QGTKCO WCAM*D33=2D+63' M$I2H8U1J?:B_FO\ @ _^K;Z& MOGZ[_P"/V?\ ZZ-_.OH%_P#5M]#7S]=_\?L__71OYUE \OB':G\_T(:***T/ MF HHHH ]N\(?\BKI_P#UR%7-8UBTT/3I+R\DVHHX'=CZ"J?A#_D5=/\ ^N0K MF?BS_P @2R_Z[G^5%"FJE50?4^\]JZ6"4UNHH\[\1^([SQ'J!N+@E8E.(H@> M$'^-8U%%?4PA&$>6.Q\G4J2J20:CHI[DIM.Z M/;?!7C2+7X!:715-0C7D=I!ZBNQKPGX>_P#(Z6?T;^5>[5\WCZ,:56T=F?6Y M;B)UZ-Y[K0\%UK_D.7W_ %V;^=4*OZU_R'+[_KLW\ZH5BMCXFM_$EZL****# M(*]E\!_\BC:?5_\ T(UXU7LO@/\ Y%&T^K_^A&HGL>YD'^\OT_5$OC7_ )$W M4_\ KE_45X!7O_C7_D3=3_ZY?U%> 5[65?PI>IUYU_%CZ?J%%%%>H>,%36?_ M !_6_P#UU3^8J&IK/_C^M_\ KJG\Q2>Q4/B1]+1_ZM?H*XOXD>'WU;1TO;=" MUQ9Y)4=60]?RZ_G7:1_ZM?H*8MQ#)<26X<&6, NG< ]*^3I5)4IJ<>A]K6I1 MJTW3EU/F:BO6_%'PUCOYGO-'=()F.7@;A&/L>U>?W7@_Q!:.5DTJX./XHUW# M\Q7T='%TJJNG8^4KX&O1E9QNNZ,2GQ123RI%$A>1R%50.236]8^!_$-_(%73 MI8E/\$=#_L#P];VCX\X_O)B/[QZ_ET_"KNO?\B_J'_7N_\ Z":MI_Y%_4/^O=__ $$U\Y.;G)RENSZB48PH.,=DFCP:BBBM M#\["BBB@ KZ$MO\ CUB_W!_*OGNOH2V_X]8O]P?RJ)GTG#V]3Y?J MXA=-9?W 1C]V,T6:_D 9A\L2?WW M/0?Y]*\"U#4;K5;Z2\O)3+-(#P3K^]+2)ZF/QRPJY8+WF>BW?Q M<^?87"R ?>7HRGW':KYC1CDHI/J17SCI.K7>BZA'>V4A21 M#R.SCT/J*]ZTCQ#8ZKI-M?+,D?G)DHSA'Y@UY&,P3H.\=4SV\#CXXE6EI M)'SQ1117TA\H%%%% !7O_@K_ )$S2O\ K@/YFO *]_\ !7_(F:5_UP'\S7EY MK_"CZGLY+_%EZ?J8?Q/_ .098_\ 7<_^@FN0T'Q=J.A8B1A/:Y_U,AX'T/:N MO^)__(,L?^NY_P#037F->+%71Q9K6J4<KVGQ(TB9!]ICGMW[@KN M'YBIIOB)H,:Y22:4^BQ$?SQ7D5%/D0EGN*2MI]QVFM?$2]OD:'3XOLD9X+DY M<_T%4? ;%O&%LS$EBLA))Y/RFN9KIO /_(WVO^Z__H)H:21A0Q57$8NG*J[Z MK\SV/M7SCKW_ ",.I?\ 7U)_Z$:^CNU?..O?\C#J7_7U)_Z$:]'*?CD>]G?\ M.'J9]%%%>X?.A1110![G\.?^1*L_]Y__ $(U7^)7_(NP_P#7PO\ (U8^'/\ MR)5G_O/_ .A&J_Q*_P"1=A_Z^%_D:^5Q'\>7JSZBO_R+7_A1Y31112/B0HHH MH WO!O\ R-EA_O\ ]*]KKQ3P;_R-EA_O_P!*]KK.>Y]=D'^[R]?T1X1\0?\ MD=;[_@/_ *"*YBNG^(/_ ".M]_P'_P!!%/B_X\_5A1116YSA M7KOPF_Y E[_UW'\J\BKUWX3?\@2]_P"NX_E7!F7^[OY'I93_ +RO1G0>-O\ MD4[W_='\Z\7KVCQM_P BG>_[H_G7B]>!#8C/_P#>(^GZL****L\(*MZ9_P A M2U_ZZK_.JE6],_Y"EK_UU7^=#V-*?QKU/?JK:A?V^F6,MY=.$AB7K>M/[FPN(['596FM M&.U96.6C^I[BN"HJ:U&%6/+-%4,14H3YH,^G5970,I!4C(([UE^)O^1:U#_K MB:Q/AQJSZEX96*5MTEJWE9/<=JV_$W_(M:A_UQ-?+5*;IU'!]#ZV555<,YKJ MG^1X71115GY\%%%% $D'_'Q%_OC^=?0-O_Q[1?[@_E7S]!_Q\1?[X_G7T#;_ M /'M%_N#^59S/IN'O^7GR_4X[XB>([K1-,B@L_DENB5\WN@]O>O%V8LQ9B2Q M.23WKU#XN?ZO3?\ >:O+J^@RZ$5032U9EFTY2Q#BWH@HHHKO/,"O2_ACXCO) M+O\ L6<^; $+Q,QY3';Z5YI79_##_D;U_P"N#_TKEQL(RH2OT.W+YRCB(\KW M9[2_^K;Z&OGZ[_X_9_\ KHW\Z^@7_P!6WT-?/UW_ ,?L_P#UT;^=?-0.SB': MG\_T(:***T/F HHHH ]N\(?\BKI__7(5S/Q9_P"0)9?]=S_*NF\(?\BKI_\ MUR%!FG\9>A]-DW\!^IX+K7_ "'+[_KL MW\ZH5?UK_D.7W_79OYU0KC6Q\A6_B2]6%%%%!D%>R^ _^11M/J__ *$:\:KV M7P'_ ,BC:?5__0C43V/7Z?JB7QK_P B;J?_ %R_J*\ KW_QK_R)NI_] M9^,-5NM&\;+=VC[7$* J>C#T->F1_ZM?H*\E^ M(O\ R-!_ZXI7R$=SZ3.9RAAE*+LTT=KHGC?3-614FD6UN3UCD. 3['O73*RL M,JP(/H:^=ZGBOKN 8ANIXQZ)(0/T-4X=CS:&?SC&U6-_-:'O\DT4*%Y9%11U M+' %<=X@\?V=E&\&F,MS/N)^/?\ "O+YKJXN/]?/++_ON6_G45"AW(Q& M?5)QY:4>7SW9Z5\-KB:[FU:XN)&DED9"S-U)YKK]>_Y%_4/^O=__ $$UQ?PN M^[J7UC_K7::]_P B_J'_ %[O_P"@FI>YZV7MO+TWV?YL\&HHHK4^*"BBB@ K MZ$MO^/6+_<'\J^>Z^A+;_CUB_P!P?RJ)GTG#V]3Y?J>7_%R\]^"P5\':6K @B$9!&#U M-%%>;F33;$(C,1,?NC/\)KS7[-/_P \)?\ O@T4 M5Y$7H>?F]-2Q;;\OR#[-/_SPE_[X-'V:?_GA+_WP:**=SS/91#[-/_SPE_[X M-=)X$AE3Q;:L\3J-K\E2!]TT44-Z'5@J26)@_-?F>P=J^=M=MYSX@U(B"4@W M,F"$/]XT45WY6[2D?0YO%2A&_$O_?!HHKV>=G@ M^R0?9KC_ )X2_P#?!H^S7'_/"7_O@T44<[#V2/3P]$$5F/GKPHSV-%%?,UW^^EZL^CK1_P"$]K^Z>6?9I_\ GA+_ -\& MC[-/_P \)?\ O@T45-SX_P!E$/LT_P#SPE_[X-'V:?\ YX2_]\&BBBX>RB;G M@Z"9/%5B6BD4!^I4^E>T445$MSZG(XJ-"27?]$>&>/X)G\9WS+#(P.WD(2/N MBN9^S7'_ #PE_P"^#117TV'F_91]$>5BJ:=:;\V'V:X_YX2_]\&C[-%%Z&>>04J\6^P?9I_ M^>$O_?!H^S3_ //"7_O@T455SQ?91#[-/_SPE_[X-6M-MYQJEJ3#(!YJ_P ! M]:**+ETZ4>='O5>,?$V*:3Q:2L9QOV:X M_P">$O\ WP:/LUQ_SPE_[X-%%>]SL^;]D@^S7'_/"7_O@T?9KC_GA+_WP:** M.=A[)'J'PF22.WU(2(Z9=&]0 !),)P!117SN-=\1(^DPRM@; M>3_4\0^S3_\ /"7_ +X-'V:?_GA+_P!\&BBL;GQWLHA]FG_YX2_]\&C[-/\ M\\)?^^#111)D_0/LUQ_ MSPE_[X-'V:X_YX2_]\&BBNOG9P^R0?9KC_GA+_WP:['X9PRQ^+5+Q2*/)?EE M(HHK#%2;HR]#IP=-*O!^9[,_^K;Z&O [NWG-Y/B&3_6-_ ?6BBOG(L[<^@I* M%_/]"'[-/_SPE_[X-'V:?_GA+_WP:**JY\Y[*(?9I_\ GA+_ -\&C[-/_P \ M)?\ O@T447#V43VKPD"OA:P# @B(9!%31;,(C,?./"C/:BBM<([8B) M]E57^PV\E^AY+]FN/^>$O_?!H^S7'_/"7_O@T45]'SL^:]D@^S7'_/"7_O@T M?9KC_GA+_P!\&BBCG8>R1TWP_@F3QE9L\4BKAN2I Z5[G117AYF[U5Z'T64Q M4:+2[GA.LV\QUJ](AD(,SP^!59/"=JK*5.7X(Q_$ M:**F3T/9R2"CB&UV_5$OC,%O!^IJH))BX &3U%>"?9KC_GA+_P!\&BBO8RR3 M5-^IU9O!2JQOV#[-$O\ WP:**]+G9Y/LD'V:X_YX M2_\ ?!J:TMIQ?6Y\B7_6K_ ?4444G-V*C27,CZ1C_P!6OT%>4?$.&5_$Y*1N MP\E>0I-%%?*QW/>SF*EA;/NCE/LT_P#SPE_[X-'V:?\ YX2_]\&BBKN?)>RB M'V:?_GA+_P!\&C[-/_SPE_[X-%%%P]E$]#^&,;QKJ6]&7)3&X8]:['703H&H M DFW? '^Z:**A[GU^ 5L EY/]3PO[-/_P \)?\ O@T?9I_^>$O_ 'P:**NY M\A[*(?9I_P#GA+_WP:/LT_\ SPE_[X-%%%P]E$/LT_\ SPE_[X->_P!M_P > MT7^X/Y445,F?0Y#!1=2WE^IY-\5HI9/$=J4B=A]D'*J3_$U<)]FN/^>$O_?! MHHKZ+!R:H1.;'4T\1)^8?9KC_GA+_P!\&C[- XML 16 d192980d10q_htm.xml IDEA: XBRL DOCUMENT 0001693415 2021-06-30 0001693415 2020-12-31 0001693415 2021-01-01 2021-06-30 0001693415 2020-01-01 2020-06-30 0001693415 2021-04-01 2021-06-30 0001693415 2020-04-01 2020-06-30 0001693415 2018-03-31 2018-03-31 0001693415 2021-08-02 0001693415 2020-06-30 0001693415 2021-01-01 2021-03-31 0001693415 2020-01-01 2020-03-31 0001693415 2019-12-31 0001693415 2021-03-31 0001693415 2020-03-31 0001693415 tbio:LexingtonMassachusettsMember 2021-06-30 0001693415 tbio:MitResearchAgreementMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:SublicenseSecondAmendmentAgreementWithSanofiMember 2021-06-30 0001693415 tbio:SanofiAgreementMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 tbio:SuiteRetentionAndDevelopmentAgreementMember tbio:AlbanyMolecularResearchIncamriMember 2021-06-30 0001693415 tbio:BurlingtonMassachusettsMember tbio:AzzurCleanroomsOnDemandBurlingtonLlcMember 2021-06-30 0001693415 tbio:WalthamMassachusettsMember 2021-06-30 0001693415 srt:MaximumMember tbio:SanofiCollaborationAndLicenseAgreementMember 2021-06-30 0001693415 srt:MaximumMember tbio:SanofiAgreementMember 2021-06-30 0001693415 srt:MinimumMember tbio:SanofiCollaborationAndLicenseAgreementMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:SublicenseSecondAmendmentAgreementWithSanofiMember tbio:SarsCov2LicensedFiledMember 2021-06-30 0001693415 tbio:FinancingReceivablesDueWithinOneYearMember 2021-06-30 0001693415 tbio:FinancingReceivablesDueAfterOneYearThroughTwoYearsMember 2021-06-30 0001693415 tbio:LaboratoryEquipmentMember 2021-06-30 0001693415 us-gaap:ComputerEquipmentMember 2021-06-30 0001693415 us-gaap:OfficeEquipmentMember 2021-06-30 0001693415 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001693415 us-gaap:ConstructionInProgressMember 2021-06-30 0001693415 tbio:AmendedSanofiAgreementMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001693415 tbio:ShiresMrtProgramMember tbio:SanofiAgreementMember 2021-06-30 0001693415 tbio:SuiteRetentionAndDevelopmentAgreementMember 2021-06-30 0001693415 tbio:ShiresMrtProgramMember 2021-06-30 0001693415 tbio:ShiresMrtProgramMember us-gaap:InProcessResearchAndDevelopmentMember tbio:MrtProductMember 2021-06-30 0001693415 tbio:SanofiCollaborationAndLicenseAgreementMember 2021-06-30 0001693415 tbio:ContingentConsiderationMember 2021-06-30 0001693415 tbio:ContingentConsiderationMember tbio:EarnoutPaymentsMember 2021-06-30 0001693415 tbio:ContingentConsiderationMember tbio:MilestonePaymentsMember 2021-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2021-06-30 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2021-06-30 0001693415 tbio:TwoThousandAndEighteenEmployeeStockPurchasePlanMember 2021-06-30 0001693415 tbio:OpenMarketSaleAgreementMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel1Member tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel2Member tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 us-gaap:FairValueInputsLevel3Member tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001693415 tbio:AmendedSanofiAgreementMember tbio:SanofiPasteurIncMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:SanofiPasteurIncMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:MilestonePaymentThreeMember 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 tbio:WalthamMassachusettsMember 2020-12-31 0001693415 tbio:FinancingReceivablesDueWithinOneYearMember 2020-12-31 0001693415 tbio:FinancingReceivablesDueAfterOneYearThroughTwoYearsMember 2020-12-31 0001693415 tbio:LaboratoryEquipmentMember 2020-12-31 0001693415 us-gaap:ComputerEquipmentMember 2020-12-31 0001693415 us-gaap:OfficeEquipmentMember 2020-12-31 0001693415 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001693415 us-gaap:ConstructionInProgressMember 2020-12-31 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001693415 tbio:ShiresMrtProgramMember us-gaap:InProcessResearchAndDevelopmentMember tbio:MrtProductMember 2020-12-31 0001693415 tbio:ContingentConsiderationMember 2020-12-31 0001693415 tbio:ContingentConsiderationMember tbio:EarnoutPaymentsMember 2020-12-31 0001693415 tbio:ContingentConsiderationMember tbio:MilestonePaymentsMember 2020-12-31 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2020-12-31 0001693415 us-gaap:FairValueInputsLevel3Member tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 tbio:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001693415 us-gaap:EmployeeStockOptionMember 2020-12-31 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001693415 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2021-04-01 2021-06-30 0001693415 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001693415 tbio:MitResearchAgreementMember 2021-04-01 2021-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2021-04-01 2021-06-30 0001693415 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001693415 srt:WeightedAverageMember us-gaap:RestrictedStockMember 2020-04-01 2020-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2020-04-01 2020-06-30 0001693415 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2020-04-01 2020-06-30 0001693415 tbio:MitResearchAgreementMember 2020-04-01 2020-06-30 0001693415 tbio:TwoThousandSixteenStockIncentivePlanMember 2021-01-01 2021-06-30 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-06-30 0001693415 tbio:SuiteRetentionAndDevelopmentAgreementMember tbio:AlbanyMolecularResearchIncamriMember 2021-01-01 2021-06-30 0001693415 tbio:BurlingtonMassachusettsMember tbio:AzzurCleanroomsOnDemandBurlingtonLlcMember 2021-01-01 2021-06-30 0001693415 us-gaap:OtherNoncurrentAssetsMember tbio:SuiteRetentionAndDevelopmentAgreementMember tbio:AlbanyMolecularResearchIncamriMember 2021-01-01 2021-06-30 0001693415 tbio:ShiresMrtProgramMember us-gaap:InProcessResearchAndDevelopmentMember tbio:MrtProductMember 2021-01-01 2021-06-30 0001693415 tbio:ContingentConsiderationMember 2021-01-01 2021-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember tbio:SecuritiesPurchaseAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:WalthamMassachusettsMember 2021-01-01 2021-06-30 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001693415 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001693415 tbio:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2021-01-01 2021-06-30 0001693415 srt:MinimumMember tbio:EarnoutPaymentsMember 2021-01-01 2021-06-30 0001693415 srt:MaximumMember tbio:EarnoutPaymentsMember 2021-01-01 2021-06-30 0001693415 srt:MinimumMember tbio:MilestonePaymentsMember 2021-01-01 2021-06-30 0001693415 srt:MaximumMember tbio:MilestonePaymentsMember 2021-01-01 2021-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2021-01-01 2021-06-30 0001693415 tbio:OpenMarketSaleAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:OriginalSanofiAgreementAndSecondSanofiAmendmentAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:MitResearchAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:SanofiAgreementMember 2021-01-01 2021-06-30 0001693415 tbio:TwoThousandAndEighteenEmployeeStockPurchasePlanMember 2021-01-01 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:MilestonePaymentOneMember 2021-01-01 2021-06-30 0001693415 tbio:MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember tbio:MilestonePaymentTwoMember 2021-01-01 2021-06-30 0001693415 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001693415 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001693415 us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0001693415 srt:WeightedAverageMember us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0001693415 tbio:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001693415 tbio:OTCDeficiencyProgramMember 2020-01-01 2020-06-30 0001693415 tbio:RocheDiagnosticsCorporationMasterSupplyAgreementMember 2020-01-01 2020-06-30 0001693415 tbio:MitResearchAgreementMember 2020-01-01 2020-06-30 0001693415 tbio:SanofiAgreementMember 2020-01-01 2020-06-30 0001693415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001693415 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001693415 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001693415 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001693415 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001693415 us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-12-31 0001693415 tbio:ShiresMrtProgramMember us-gaap:InProcessResearchAndDevelopmentMember tbio:MrtProductMember 2020-01-01 2020-12-31 0001693415 tbio:OpenMarketSaleAgreementMember 2020-01-01 2020-12-31 0001693415 srt:MinimumMember tbio:WalthamMassachusettsMember 2020-01-01 2020-12-31 0001693415 srt:MaximumMember tbio:WalthamMassachusettsMember 2020-01-01 2020-12-31 0001693415 srt:MinimumMember tbio:EarnoutPaymentsMember 2020-01-01 2020-12-31 0001693415 srt:MaximumMember tbio:EarnoutPaymentsMember 2020-01-01 2020-12-31 0001693415 srt:MinimumMember tbio:MilestonePaymentsMember 2020-01-01 2020-12-31 0001693415 srt:MaximumMember tbio:MilestonePaymentsMember 2020-01-01 2020-12-31 0001693415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001693415 srt:MinimumMember tbio:TwoThousandEighteenStockIncentivePlanMember 2018-06-14 2018-06-15 0001693415 srt:MaximumMember tbio:TwoThousandEighteenStockIncentivePlanMember 2018-06-14 2018-06-15 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2018-06-14 2018-06-15 0001693415 tbio:LexingtonMassachusettsMember 2017-06-01 2017-06-30 0001693415 tbio:LexingtonMassachusettsMember 2017-06-30 0001693415 tbio:SuiteRetentionAndDevelopmentAgreementMember tbio:BiomedicalResearchModelsIncMember 2020-10-31 0001693415 tbio:BurlingtonMassachusettsMember tbio:AzzurCleanroomsOnDemandBurlingtonLlcMember 2020-10-31 0001693415 tbio:WalthamMassachusettsMember 2020-11-03 0001693415 tbio:OfficeAndLaboratorySpaceMember tbio:RichmondGroupMember 2021-04-30 0001693415 tbio:MitResearchAgreementMember 2019-09-01 2019-09-30 0001693415 us-gaap:SubsequentEventMember tbio:MergerAgreementMember 2021-08-02 0001693415 tbio:VectorMergerSubIncMember tbio:TerminationOfAgreementMember us-gaap:SubsequentEventMember tbio:MergerAgreementMember 2021-08-02 0001693415 tbio:SecondSanofiAmendmentAgreementMember 2020-07-20 2020-07-20 0001693415 tbio:AmendedSanofiAgreementMember 2021-03-31 0001693415 tbio:TwoThousandTwentyOneInducementStockIncentivePlanMember 2021-01-20 0001693415 tbio:SuiteRetentionAndDevelopmentAgreementMember tbio:BiomedicalResearchModelsIncMember 2020-10-01 2020-10-31 0001693415 tbio:LexingtonMassachusettsMember 2018-03-31 0001693415 tbio:WalthamMassachusettsMember 2020-11-03 2020-11-03 0001693415 tbio:TwoThousandEighteenStockIncentivePlanMember 2020-01-01 2020-01-01 0001693415 us-gaap:CommonStockMember 2021-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001693415 us-gaap:RetainedEarningsMember 2021-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001693415 us-gaap:CommonStockMember 2020-06-30 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001693415 us-gaap:RetainedEarningsMember 2020-06-30 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001693415 us-gaap:CommonStockMember 2020-12-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001693415 us-gaap:RetainedEarningsMember 2020-12-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001693415 us-gaap:CommonStockMember 2021-03-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001693415 us-gaap:RetainedEarningsMember 2021-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001693415 us-gaap:CommonStockMember 2019-12-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001693415 us-gaap:RetainedEarningsMember 2019-12-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001693415 us-gaap:CommonStockMember 2020-03-31 0001693415 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001693415 us-gaap:RetainedEarningsMember 2020-03-31 0001693415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 iso4217:USD shares utr:sqft pure utr:Year utr:Month tbio:Subsidiary tbio:Disease iso4217:USD shares false Q2 0001693415 --12-31 2023-03-31 2023-03-31 P1Y 10-Q true 2021-06-30 2021 false 001-38550 Translate Bio, Inc. DE 61-1807780 29 Hartwell Avenue Lexington MA 02421 617 945-7361 Common Stock TBIO NASDAQ Yes Yes Large Accelerated Filer false false false 75586714 249471000 342027000 417727000 312001000 24030000 26598000 20958000 11741000 4826000 4826000 717012000 697193000 18249000 15372000 68123000 72957000 21359000 21359000 74507000 79127000 5620000 3928000 904870000 889936000 13736000 8839000 15079000 13202000 41014000 67563000 11685000 11733000 81514000 101337000 112493000 152230000 252055000 228659000 46171000 50953000 492233000 533179000 0.001 0.001 10000000 10000000 0 0 0 0 0 0.001 0.001 200000000 200000000 75343712 75343712 75029625 75029625 75000 75000 782144000 769965000 -369617000 -413283000 35000 412637000 356757000 904870000 889936000 72649000 16319000 107249000 20974000 40477000 29002000 81617000 50442000 11921000 8601000 22738000 16060000 4242000 15347000 -39737000 5895000 56640000 52950000 64618000 72397000 16009000 -36631000 42631000 -51423000 154000 343000 308000 853000 16163000 -36288000 42939000 -50570000 -981000 -727000 17144000 -36288000 43666000 -50570000 0.23 -0.58 0.58 -0.83 75254186 62282291 75222119 61145254 0.21 -0.58 0.55 -0.83 80026488 62282291 79994422 61145254 17144000 -36288000 43666000 -50570000 0 0 0 0 -42000 -315000 35000 -201000 17102000 -36603000 43701000 -50771000 75029625 75000 769965000 -413283000 0 356757000 188047 1550000 1550000 3984000 3984000 77000 77000 26522000 26522000 75217672 75000 775499000 -386761000 77000 388890000 98852 819000 819000 27188 490000 490000 5336000 5336000 -42000 -42000 17144000 17144000 75343712 75000 782144000 -369617000 35000 412637000 60022067 60000 512231000 -359496000 741000 153536000 15596 132000 132000 3172000 3172000 114000 114000 -14282000 -14282000 60037663 60000 515535000 -373778000 855000 142672000 8544982 9000 153602000 153611000 776864 5699000 5699000 6014000 6014000 -315000 -315000 -36288000 -36288000 69359509 69000 680850000 -410066000 540000 271393000 43666000 -50570000 6471000 5617000 9320000 9186000 -39737000 5895000 2568000 -10535000 8521000 -1472000 -6210000 -270000 2395000 7381000 3900000 -2783000 1571000 4013000 -6206000 -244000 -3153000 -6429000 13694000 -51489000 185690000 27409000 80000000 111277000 3419000 4446000 -109109000 79422000 154292000 443000 2369000 5831000 490000 2859000 159680000 -92556000 187613000 346853000 85530000 254297000 273143000 249471000 272193000 4826000 950000 254297000 273143000 1707000 718000 238000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Nature of the Business and Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Translate Bio, Inc. (the “Company”) is a clinical-stage messenger RNA (“mRNA”) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Using its proprietary mRNA therapeutic platform (“MRT platform”), the Company creates mRNA that encodes functional proteins. The Company’s mRNA is designed to be delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The Company is primarily focused on applying its MRT platform to treat pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease. In addition, the Company is pursuing discovery efforts in diseases that affect the liver. The Company is also pursuing the applicability of its MRT platform for the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur Inc. (“Sanofi”), the vaccines global business unit of Sanofi, a French <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">société anonyme</div></div> (“Sanofi S.A.”) </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company is developing mRNA therapeutics for the treatment of cystic fibrosis (“CF”) with two programs, MRT5005, a clinical-stage program, and a preclinical next-generation CF program. The Company is conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of single- and multiple-ascending doses of MRT5005. The clinical trial is investigating several groups receiving five once-weekly doses, as well as a group receiving five daily doses. Percent predicted forced expiratory volume in one second (“ppFEV<div style="font-size: 85%; vertical-align: bottom;;display:inline;;font-size:9.4px">1</div>”) which is a well-defined and accepted endpoint measuring lung function, is also being measured at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-defined</div> timepoints throughout the trial as a safety measure. In 2019, the Company reported interim data from the single-ascending dose portion of the Phase 1/2 clinical trial through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-month</div> follow up post dosing. In March 2021, the Company reported the second interim data analysis. In evaluating safety and tolerability, the primary outcome measure, data to date from the ongoing Phase 1/2 clinical trial suggested that repeat dosing of MRT5005 was generally safe and well tolerated. For patients receiving MRT5005, ppFEV<div style="font-size: 85%; vertical-align: bottom;;display:inline;;font-size:9.4px">1</div> was not negatively impacted; there was no pattern of treatment-associated increases in ppFEV<div style="font-size: 85%; vertical-align: bottom;;display:inline;;font-size:9.4px">1</div>. The clinical trial is ongoing with evaluation of the remaining dose groups, which include a 20 mg multiple-ascending dose group and the daily dosing cohort, and the Company anticipates reporting the interim findings from the clinical trial at the North American Cystic Fibrosis Conference, being held September 30, 2021 through October 2, 2021. The Company’s preclinical next-generation CF program incorporates mRNA codon optimization and advances in lipid nanoparticle chemistry. Positive preclinical data generated from the program support the planned initiation of investigational new drug (“IND”)-enabling studies in the second half of 2021. The Company is conducting translational studies with MRT5005 and a next-generation CF candidate to support and optimize future clinical development<div style="display:inline;">.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company is leveraging its lung delivery platform and focusing its preclinical research efforts on identifying lead product candidates in additional pulmonary diseases with unmet medical needs, including primary ciliary dyskinesia (“PCD”), pulmonary arterial hypertension and respiratory infectious diseases. Positive preclinical data from our PCD program support the anticipated initiation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies in the second half of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has a collaboration with Sanofi to develop infectious disease vaccines using the Company’s mRNA technology. Under the collaboration, the Company and Sanofi are jointly conducting research and development activities to advance mRNA vaccines targeting up to seven infectious disease pathogens (see Note 3). Two of the target pathogens under development are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> which causes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and influenza. MRT5500 has been selected as the lead candidate for a vaccine against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2.</div></div> A Phase 1/2 clinical trial to evaluate MRT5500 began in the first quarter of 2021 with interim data anticipated in the third quarter of 2021. A Phase 1 clinical trial evaluating MRT5400 and MRT5401, the Company’s investigational mRNA vaccine candidates against seasonal influenza, was initiated in June 2021 with interim data expected by the end of 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since early 2020, the outbreak of the novel strain of coronavirus named <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> has spread across the globe and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had wide-reaching impacts on the global economy and business operations. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had, and the Company expects it will continue to have, an impact on its operations, the operations of its collaborators, the operations of third-party contractors and other entities with which the Company interacts, as well as on the patients who may enroll in the Company’s clinical trials. The Company continues to actively monitor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> trends and government guidance. The ultimate impacts of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic are still unknow<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div> and uncertain. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sal<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div>s. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the accompanying condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions taken in an effort to contain or to potentially treat or vaccinate against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> it as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> within its financial statements and have determined them to be immaterial. There may be changes to those estimates in future periods. Actual results may differ from these estimates. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its two wholly owned subsidiaries, <div style="letter-spacing: 0px; top: 0px;;display:inline;">Translate Bio MA, Inc. and Translate Bio Securities Corporation, from their date of incorporation. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated balance sheet as of June 30, 2021, the unaudited condensed consolidated statements of operations and of comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020, the unaudited condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2021 and 2020 and the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The accompanying balance sheet as of December 31, 2020 has been derived from the Company’s audited financial statements for the year ended December 31, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> that was filed with the SEC on March 1, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited interim condensed consolidated financial presentation has been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflects all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2021, the results of its operations for the three and six months ended June 30, 2021 and 2020, and its cash flows for the six months ended June 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2021 and 2020 are also unaudited. The results for the three and six months ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales of Common Stock </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to an Open Market Sale Agreement<div style=";display:inline;vertical-align: super;;font-size:9.2px">SM</div> (the “Sales Agreement”) with Jefferies LLC under</div></div> which the Company may issue and sell shares of common stock, from time to time, having an aggregate offering price of up to $</div>100.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> million. During the year ended December </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">, the Company issued and sold </div>2,863,163<div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> shares of its common stock pursuant to the Sales Agreement, resulting in gross proceeds of $</div>37.9 <div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">million, before deducting commissions of $</div>1.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> million and other offering expenses of $</div>0.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> million. There were </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> shares issued or sold pursuant to the Sales Agreement during the six months ended June </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">. In the future, $</div>62.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"> million of shares of common stock remain available to be sold pursuant to the Sales Agreement, which sales, if any, would be made under the Company’s universal shelf registration statement on Form </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">S-3.</div></div> 2 100000000.0 2863163 37900000 1100000 200000 0 62100000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The significant accounting policies and estimates used in preparation of the consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> During the six months ended June 30, 2021, there were no material changes to the Company’s significant accounting policies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div>. The guidance requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements and disclosures. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes-Simplifying the Accounting for Income Taxes</div></div>. This new standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in the tax basis of goodwill. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div>. The guidance requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements and disclosures. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes-Simplifying the Accounting for Income Taxes</div></div>. This new standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in the tax basis of goodwill. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Collaboration Agreement </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sanofi Collaboration and License Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2018, the Company entered into a collaboration and license agreement with Sanofi (the “Original Sanofi Agreement”) to develop mRNA vaccines for up to five infectious disease pathogens (the “Licensed Fields”). On March 26, 2020, the Company and Sanofi amended the Original Sanofi Agreement (the “First Sanofi Amendment”) to include vaccines against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> as an additional Licensed Field, increasing the number of infectious disease pathogens to up to six. On June 22, 2020, the Company and Sanofi further amended the Original Sanofi Agreement to expand the scope of the collaboration and licenses granted to Sanofi (the “Second Sanofi Amendment”). The Original Sanofi Agreement, as amended by the First Sanofi Amendment and the Second Sanofi Amendment, is referred to as the “Amended Sanofi Agreemen<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>.” </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Amended Sanofi Agreement, the Company and Sanofi are jointly conducting research and development activities to advance mRNA vaccines targeting up to seven infectious disease pathogens. The term of the research collaboration (the “Collaboration Term”) expires in June 2022 with an option for Sanofi to extend the Collaboration Term for one additional year, followed by a technology transfer to Sanofi. If Sanofi elects to extend the Collaboration Term, the collaboration may be further expanded to jointly conduct research and development activities to advance mRNA vaccines for up to an additional three infectious disease pathogens, bringing the total to up to ten pathogens. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the Amended Sanofi Agreement, the Company has granted to Sanofi exclusive, worldwide licenses under applicable patents, patent applications, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials, including those arising under the collaboration, to develop, commercialize and manufacture mRNA vaccines to prevent, treat or cure diseases, disorders or conditions in humans caused by any infectious disease pathogen, with certain specified exceptions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Original Sanofi Agreement, Sanofi paid the Company an upfront payment of $45.0 million in 2018. Pursuant to the Second Sanofi Amendment, Sanofi paid the Company an additional upfront payment of $300.0 million in August 2020. If Sanofi chooses to exercise its option to extend the Collaboration Term for an additional year, Sanofi has agreed to pay the Company an additional payment of $75.0 million. The Amended Sanofi Agreement provides that the Company is eligible to receive aggregate potential payments of up to $1.9 billion upon the achievement of additional specified development, regulatory, manufacturing and commercialization milestones, inclusive of the fee to exercise the option to extend the Collaboration Term. In particular, the Company is entitled to receive development, regulatory and sales milestone payments of up to $148.0 million for each Licensed Field, other than the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> Licensed Field, development, regulatory and sales milestone payments of up to $250.0 million in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2</div></div> Licensed Field, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> manufacturing milestone payments of up to $200.0 million. In addition, the Company is entitled to receive a $10.0 million milestone payment from Sanofi following <div style="letter-spacing: 0px; top: 0px;;display:inline;">completion </div>of the technology and process transfer. In March 2021, Sanofi paid the Company a milestone payment of $25.0 million upon the initiation of the Phase 1/2 clinical trial of MRT5500 and in June 2021, Sanofi paid the Company a milestone payment of $50.0 million upon the successful manufacture, release and delivery of clinical drug product to supply the Phase 1 clinical trial of MRT5400 and MRT5401. Additionally, in June 2021, the Company achieved a milestone of $4.0 million upon the start of the Phase 1 clinical trial of MRT5400 and MRT5401, which is included in collaboration receivables on the condensed consolidated balance sheet as of June 30, 2021. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Sanofi Collaboration </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue under Accounting Standards Codification (“ASC”) 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customer</div></div> (“ASC 606”)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>During the six months ended June 30, 2021, the Company increased the overall transaction price by</div> $108.7 million. The transaction price as of June 30, 2021 includes the upfront, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payments of $345.0 million for the transfer of the combined license, supply and development obligations under the Original Sanofi Agreement and Second Sanofi Amendment, the premium paid in consideration for common stock of $51.2 million under a securities purchase <div style="letter-spacing: 0px; top: 0px;;display:inline;">agreement </div>entered into with an affiliate of Sanofi, an estimated $76.3 million in reimbursable employee costs, an estimated $167.8 million in reimbursable development costs including manufacturing costs and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs paid to third parties and an estimated $212.0 million in milestone payments. Under ASC 606, at the end of each reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the variable consideration determined using either the expected value or most likely outcome approach and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability that the consideration associated with each milestone or reimbursement will not be subject to a significant reversal in the cumulative amount of revenue recognized, and, if necessary, adjusts the estimate of the overall transaction price. The estimated collaboration budget is consistently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> and changes to the budget, if any, require approval by the Joint Steering Committee. If an approved change occurs, the Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price which could potentially affect the cumulative amount of revenue recognized. Changes as a result of a contract modification or in the planned services under the Amended Sanofi Agreement may have an impact on the transaction price and on the Company’s measure of progress toward complete satisfaction of the performance obligation. The impact of changes during the six months ended June 30, 2021 resulted in a cumulative revenue <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment of $20.5 million. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company’s collaboration revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaboration revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,649</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,319</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107,249</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the balance of the Company’s contract liabilities (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,069</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">296,222</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred revenue is classified as short-term or long-term in the <div style="letter-spacing: 0px; top: 0px;;display:inline;">conde<div style="letter-spacing: 0px; top: 0px;;display:inline;">nsed </div></div>consolidated balance sheets based on the Company’s estimate of revenue that will be recognized within the next twelve months which is determined by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> input method which measures the extent of progress towards satisfying the performance obligation. As of June 30, 2021, the aggregate amount of the transaction price allocated to the remaining performance obligation is estimated to be approximately $597.0 million, which is expected to be recognized as revenue through 2024. Revenue recognized from contract liabilities at the beginning of the period was $29.8 million and $6.4 million during the six months ended June 30, 2021 and 2020, respectively. </div> 5 6 7 3 10 45000000.0 300000000.0 75000000.0 1900000000 148000000.0 250000000.0 200000000.0 10000000.0 25000000.0 50000000.0 4000000.0 -108700000 345000000.0 51200000 76300000 167800000 212000000.0 20500000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company’s collaboration revenue (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaboration revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,649</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,319</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107,249</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 72649000 16319000 107249000 20974000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the balance of the Company’s contract liabilities (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,069</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">296,222</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 293069000 296222000 597000000.0 29800000 6400000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Intangible Assets and Goodwill </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of Shire’s MRT Program </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2016, the Company entered into an asset purchase agreement (as amended in June 2018) with Shire Human Genetic Therapies, Inc. (“Shire”), a subsidiary of Takeda Pharmaceutical Company Ltd., pursuant to which Shire sold equipment to and assigned to the Company all of its rights to certain patent rights, permits, real property leases, contracts, regulatory documentation, books and records, and materials related to Shire’s mRNA therapy platform (the “MRT Program”), including its cystic fibrosis transmembrane conductance regulator program. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible Assets, Net </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The acquisition of Shire’s MRT Program was accounted for in accordance with the acquisition method of accounting for business combinations. The total purchase consideration transferred was allocated to the tangible and identifiable intangible assets acquired based on their estimated fair values. The tables below present the Company’s definite-lived intangible assets that are subject to amortization and indefinite-lived intangible assets: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 53%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MRT</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,776</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,216</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D—CF</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Indefinite</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets, net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,776</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,507</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MRT</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,156</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36,836</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D—CF</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Indefinite</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets, net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,156</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,127</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Identifiable intangible assets acquired in the acquisition of Shire’s MRT Program consisted of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (“IPR&amp;D”), which included ongoing projects that could further the Company’s preclinical and clinical development activities related to CF and other potential rare diseases. As of the date of acquisition, the IPR&amp;D was determined to be indefinite-lived. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon <div style="letter-spacing: 0px; top: 0px;;display:inline;">commencement </div>of the Original Sanofi Agreement, the IPR&amp;<div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">D—M</div>RT intangible asset was reclassified from indefinite-lived to definite-lived intangible assets and the Company began amortization of this intangible asset. Amortization will be recorded over the intangible asset’s estimated life based on an economic consumption <div style="letter-spacing: 0px; top: 0px;;display:inline;">model</div>. The Company recorded amortization expense of $2.6 million and $3.6 million during the three months ended June 30, 2021 and 2020, respectively, and $4.6 million and $4.3 million during the six months ended June 30, 2021 and 2020, respectively, related to the definite-lived MRT intangible asset. The estimated amortization expense for the remainder of the useful life is $11.8 million, $11.2 million, $11.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million </div>and $2.7 million for the years ending December 31, 2021, 2022, 2023 and 2024, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived IPR&amp;D is not subject to amortization, but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived IPR&amp;D annually for impairment on October 1st. During the six months ended June 30, 2021 and 2020, the Company did not recognize any impairment charges related to indefinite-lived IPR&amp;D. </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The excess of the fair value of the consideration transferred over the fair value of identifiable assets acquired in the acquisition of Shire’s MRT Program was allocated to goodwill in the amount of $21.4 million. There have been no changes to the carrying amount of goodwill during the six months ended June 30, 2021. Goodwill is not subject to amortization, but is tested annually for impairment or more frequently if there are indicators of impairment. During the six months ended June 30, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div> and 20<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div>, the Company did not recognize any impairment charges related to goodwill. </div></div> The tables below present the Company’s definite-lived intangible assets that are subject to amortization and indefinite-lived intangible assets: <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 53%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MRT</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,776</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,216</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D—CF</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Indefinite</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets, net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,776</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,507</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="12" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Carrying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MRT</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,156</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36,836</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D—CF</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Indefinite</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets, net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,156</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,127</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> P6Y 45992000 13776000 32216000 42291000 42291000 88283000 13776000 74507000 P6Y 45992000 9156000 36836000 42291000 42291000 88283000 9156000 79127000 2600000 3600000 4600000 4300000 11800000 11200000 11100000 2700000 21400000 0 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Fair Value of Financial Assets and Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:84%;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as of June 30, 2021 Using:</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167,938</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167,938</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasuries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359,871 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,856</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,856 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,665</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,665</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:84%;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as of December 31, 2020 Using:</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> </tr> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">273,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">273,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasuries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,828</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,828</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the six months ended June 30, 2021 and the year ended December 31, 2020, there were no transfers between Level 1, Level 2 and Level 3. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Cash equivalents as of June 30, 2021 and December 31, 2020 consisted of money market funds totaling $167.9 million and $273.8 million, respectively. The money market funds were valued using inputs observable in active markets for similar securities, which represent a Level 2 measurement in the fair value hierarchy. The Company’s investments as of June 30, 2021 and December 31, 2020 consisted of U.S. treasuries and U.S. government agency bonds and were clas<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>ified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. The U.S. treasuries and U.S. government agency bonds were valued using inputs observable in active markets for similar securities, which represent a Level 2 measurement in the fair value hierarchy. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities represent the investment of cash that is available for current operations.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The estimated amortized costs and fair value of the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities by contractual maturity are summarized as follows:</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due within one year</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,053</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,095</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,606</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,596</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after one year through two years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,639</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,632</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,395</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,405</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">417,692</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">417,727</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Valuation of Contingent Consideration </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The contingent consideration liability related to the acquisition of Shire’s MRT Program in 2016 was classified as a Level 3 measurement within the fair value hierarchy. The Company may be required to pay future consideration to Shire contingent upon the achievement of potential future milestones and earnout payments. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the liability to make potential future milestone and earnout payments was estimated by the Company at each reporting date based, in part, on the results of a valuation u<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div>ing a discounted cash flow analysis based on various assumptions, including the amount and timing of cash flows, probability of achieving specified events, discount rate, and the period of time until earnout payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the unobservable inputs and fair value of the components of the contingent consideration (dollar amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:84%;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Inputs</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Projected Year of Payment</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnout payments</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2027 -</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> 2039</div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap; text-align: left;"/> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,093</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">142,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone payments</div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2027 - 2031</div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,400</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,980</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The discount rate used in the valuation was 10.8% and 11.0% as of June 30, 2021 and December 31, 2020, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a roll-forward of the total acquisition-related contingent consideration liability (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"> <tr style="font-size: 0px;"> <td style="width: 87%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in fair value of contingent consideration</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,737</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The change in the fair value of contingent consideration was due to a large decrease in the fair value of contingent consideration during the three months ended March 31, 2021 due to the previously announced results of the second interim data analysis from the Phase 1/2 clinical trial of MRT5005. This decrease was partially offset by an increase in the fair value of contingent consideration during the three months ended June 30, 2021 due to <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> time value of money due to the passage of time and a decrease in the discount rate. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:84%;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as of June 30, 2021 Using:</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167,938</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167,938</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasuries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359,871 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,856</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,856 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,665</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,665</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:84%;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">as of December 31, 2020 Using:</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> <td style="vertical-align: bottom;"/> </tr> <tr style="font-size: 0px;"> <td style="width: 67%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">273,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">273,827</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasuries</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency bonds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,828</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585,828</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 0 167938000 0 167938000 0 359871000 0 359871000 0 57856000 0 57856000 0 585665000 0 585665000 0 0 112493000 112493000 0 0 112493000 112493000 273827000 273827000 0 292001000 292001000 20000000 20000000 585828000 585828000 152230000 152230000 152230000 152230000 0 0 0 0 0 0 0 0 0 0 0 0 167900000 273800000 <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due within one year</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,053</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,095</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,606</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,596</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due after one year through two years</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,639</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,632</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,395</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,405</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">417,692</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">417,727</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">312,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 305053000 305095000 201606000 201596000 112639000 112632000 110395000 110405000 417692000 417727000 312001000 312001000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the unobservable inputs and fair value of the components of the contingent consideration (dollar amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:84%;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Inputs</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Projected Year of Payment</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnout payments</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2027 -</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> 2039</div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap; text-align: left;"/> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,093</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">142,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone payments</div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2027 - 2031</div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,400</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,980</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 2027 2027 2039 2039 103093000 142250000 2027 2027 2031 2031 9400000 9980000 112493000 152230000 10.8 11.0 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a roll-forward of the total acquisition-related contingent consideration liability (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"> <tr style="font-size: 0px;"> <td style="width: 87%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152,230</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease in fair value of contingent consideration</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,737</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">112,493</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 152230000 -39737000 112493000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Property and Equipment, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,949</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">922</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,557</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,189</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,492</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation and amortization</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,012</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,120</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,249</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense related to property and equipment was $1.0 million and $0.7 million during the three months ended June 30, 2021 and 2020, respectively, and $1.9 million and $1.4 million during the six months ended June 30, 2021 and 2020, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,949</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">922</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Office equipment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,557</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,189</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,492</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation and amortization</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,012</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,120</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,249</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 18949000 12710000 932000 922000 941000 941000 5557000 5730000 2882000 5189000 29261000 25492000 11012000 10120000 18249000 15372000 1000000.0 700000 1900000 1400000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Accrued Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued employee compensation and benefits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,326</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued external research and development expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued consultant and professional fees</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,468</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,865</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,079</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,202</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Included in other accrued expenses as of June 30, 2021 was $2.5 million related to a work agreement to perform a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-out</div> of the Company’s office and laboratory space at 200 West Street in Waltham, Massachusetts (see Note 11). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued employee compensation and benefits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,326</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued external research and development expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,805</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued consultant and professional fees</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,468</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,865</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,079</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,202</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 5326000 5600000 4420000 2805000 2468000 1489000 2865000 3308000 15079000 13202000 2500000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Incentive Stock Options and Employee Stock Purchase Plan </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Inducement Stock Incentive Plan </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On January 20, 2021, the Board of Directors adopted a 2021 Inducement Stock Incentive Plan (the “2021 Plan”), pursuant to which the Company may grant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options, restricted stock, restricted stock units and other stock-based awards with respect to an aggregate of<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>2,612,550 <br/> shares of common stock. Awards under the 2021 Plan may only be granted to persons who (i) were not previously an employee or director of the Company or (ii) are commencing employment with the Company following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employment,</div> in either case as an inducement material to the individual’s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4).</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Equity Incentive Plan </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March 7, 2018, the Company’s Board of Directors (the “Board of Directors”), subject to stockholder approval, adopted, and on June 15, 2018, the Company’s stockholders approved, the 2018 Equity Incentive Plan (the “2018 Plan”), which became effective on June 27, 2018. The 2018 Plan provides for the grant of incentive stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The Company previously awarded grants under the 2016 Stock Incentive Plan (the “2016 Plan”). Upon the effectiveness of the 2018 Plan, no further awards will be made under the 2016 Plan, but awards outstanding under the 2016 Plan will continue to be governed by their existing terms<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, there were 7,457,171 shares of common stock reserved for issuance under the 2018 Plan. On January 1, 2021, the number of shares of common stock that may be issued under the 2018 Plan increased by 3,001,185 shares of common stock. During the six months ended June 30, 2021, a total of 12,848 shares issued under the 2016 Plan have been canceled and rolled over to the 2018 Plan, such that there is a total of 10,471,204 shares of common stock reserved for issuance under the 2018 Plan as of June 30, 2021. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, repurchased or are otherwise terminated by the Company under the 20<div style="letter-spacing: 0px; top: 0px;;display:inline;">16</div> Plan will be added back to the shares of common stock available for issuance under the 2018 Plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2018 Plan is administered by the Board of Directors. The exercise prices, vesting periods and other restrictions are determined at the discretion of the Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the common stock on the date of grant. Stock options awarded under the 2018 Plan expire 10 years after the grant date, unless the Board of Directors sets a shorter term. Awards granted to employees, officers, members of the Board of Directors and consultants typically vest over a period of <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden23924511">on</span>e</div> to <div style="letter-spacing: 0px; top: 0px;;display:inline;">four</div> years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Typically, unvested stock options are forfeited upon the recipient ceasing to provide services to the Company. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Employee Stock Purchase Plan </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 7, 2018, the Board of Directors, subject to stockholder approval, adopted, and on June 15, 2018, the Company’s stockholders approved the 2018 Employee Stock Purchase Plan (the “2018 ESPP”), which became effective on June 27, 2018. As of June 30, 2021, 870,096 shares of common stock were reserved for issuance under this plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June 30, 2021, 54,152 shares have been issued under the 2018 ESPP. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company’s stock option activity since December 31, 2020 (in thousands, except share and per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,557,391</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.92</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,126,560</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.81</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(286,899</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(154,303</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.68</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,242,749</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.06</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189,483</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,953,908</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,421</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,242,749</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.06</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189,483</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2021 and 2020 was $3.8 million and $10.7 million, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant-date fair value per share of stock options granted was $13.56 and $5.50 during the six months ended June 30, 2021 and 2020, respectively. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Option Valuation </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company completed its initial public offering in July 2018 and therefore lacks company-specific historical and implied volatility information before that date. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 77%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.03</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.79</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69.7</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68.6</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,841</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,091</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,921</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,545</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,495</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,923</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,399</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 68%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,336</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,014</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,320</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,186</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June 30, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $57.4 million, which is expected to be recognized over a weighted average period of 2.9 years. </div></div> 2612550 7457171 3001185 12848 10471204 1 P10Y P4Y 870096 54152 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company’s stock option activity since December 31, 2020 (in thousands, except share and per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,557,391</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.92</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,126,560</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.81</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(286,899</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.25</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(154,303</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.68</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,242,749</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.06</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189,483</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,953,908</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,421</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest as of June 30, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,242,749</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.06</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.07</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189,483</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 9557391 8.79 P7Y11M1D 93256000 3126560 21.81 286899 8.25 154303 14.68 12242749 12.06 P8Y25D 189483000 5953908 8.14 P7Y25D 115421000 12242749 12.06 P8Y25D 189483000 3800000 10700000 13.56 5.50 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 77%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.03</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.79</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69.7</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68.6</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> 0.0103 0.0079 P6Y1M6D P6Y1M6D 0.697 0.686 0 0 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,841</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,091</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,921</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,545</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,495</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,923</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,399</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,641</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 68%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,336</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,014</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,320</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,186</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 2841000 4091000 4921000 5545000 2495000 1923000 4399000 3641000 5336000 6014000 9320000 9186000 57400000 P2Y10M24D <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">The Company recognized an income tax <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">benefit</div> of $1.0 million and $0.7<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> million during the three and six months ended June 30, 2021, </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively, due to the current period income before income taxes and the application of the annual effective tax rate. The annual effective tax rate </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> relates primarily to an expected income tax liability due to the acceleration of revenue recognition for tax purposes related to the Amended Sanofi Agreement. There was</div></div></div> no<div style="letter-spacing: 0px; top: 0px;;display:inline;"> income tax benefit recognized during the three and six months ended June 30, 2020. Net operating losses generated in <div style="letter-spacing: 0px; top: 0px;;display:inline;">2018</div> and years thereafter can be carried forward indefinitely. </div> </div></div> -1000000.0 -700000 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Net Income (Loss) per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period, including any dilutive effect from outstanding stock options. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per common share:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,144</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,288</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,570</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares outstanding—basic</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,254,186</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,282,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,222,119</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,145,254</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share—basic</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.23</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.58</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.58</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.83</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per common share:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,144</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,288</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,570</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares <br/> outstanding—diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,026,488</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,282,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,994,422</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,145,254</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share—diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.58</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.55</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.83</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company excluded 3,790 shares and 11,149 shares of restricted common stock, presented on a weighted average basis, from the calculations of basic net loss per share attributable to common stockholders for the three and six months ended June 30, 2020, respectively, because those shares had not vested. As of June 30, 2021, there are no unvested shares of restricted common stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,608,932</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,494,989</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,691</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 75%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,608,932</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,496,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per common share:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,144</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,288</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,570</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares outstanding—basic</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,254,186</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,282,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,222,119</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,145,254</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share—basic</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.23</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.58</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.58</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.83</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per common share:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,144</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,288</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,666</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,570</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares <br/> outstanding—diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,026,488</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,282,291</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,994,422</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,145,254</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share—diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.58</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.55</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.83</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> 17144000 -36288000 43666000 -50570000 75254186 62282291 75222119 61145254 0.23 -0.58 0.58 -0.83 17144000 -36288000 43666000 -50570000 80026488 62282291 79994422 61145254 0.21 -0.58 0.55 -0.83 3790 11149 0 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,608,932</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,494,989</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested restricted common stock</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,691</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 75%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,608,932</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,496,680</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 3608932 10494989 0 1691 3608932 10496680 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Leases </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Suite Retention Agreements </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2019, the Company entered into a suite retention and development agreement with Curia Massachusetts, Inc. (“Curia”), formerly known as Albany Molecular Research, Inc., under which a series of cleanroom suites were built at Curia’s manufacturing facility in accordance with the Company’s objectives (“Curia Agreement”). The Curia Agreement continues for five years after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-out</div> is completed, and the Company has the right to extend for an additional three years. The Company has determined this is a lease under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-02,</div> Leases (Topic 842) (“ASC 842”). Under the Curia Agreement, the Company will finance $6.0 million of the costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-out</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“Build-Out</div> Costs”). If <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Build-Out</div> Costs exceed $6.0 million, the Company and Curia will share overage costs equally, up to $11.0 million, and the Company will be responsible for any amounts exceeding $11.0 million. The Company had paid $12.8 million towards the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Build-Out</div> Costs prior to the lease commencement date which had been recorded within other long-term assets as prepaid rent as these represented payments for lessor owned assets. The Company anticipates making additional payments of $5.6 million related to the final <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Build-Out</div> Costs, of which $3.2 million was paid as of June 30, 2021. These costs are included within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (“ROU”) assets and lease liabilities recorded at the lease commencement date. Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-out</div> completion date of August 31, 2020 (“Curia Lease Commencement”), the Company determined that it gained control of the space, in accordance with ASC 842, which resulted in the recording of ROU assets and related lease liabilities of approximately $66.6 million and $53.8 million, respectively, with the difference being due to the elimination of previously recorded prepaid rent. Due to an increase in the final <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Build-Out</div> Costs, the Company recorded an increase of $1.4 million to ROU assets and lease liabilities as of June 30, 2021. As of August 31, 2020, the Company began paying monthly fees of $1.0 million, which are subject to a 3% increase on January 1 of each calendar year following the first anniversary of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-out</div> completion. The option to extend the lease for an additional three years was not included in the lease liability as of June 30, 2021 as the Company is not reasonably certain it will exercise this option. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In October 2020, the Company entered into a suite retention agreement (the “Biomere Suite Retention Agreement”) with Biomedical Research Models, Inc. (“Biomere”) under which the Company will lease two exclusive procedure rooms and one housing and maintenance room in Biomere’s Worcester, Massachusetts facility. The lease term is 13 months<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">and commenced</div> on December 1, 2020 (the “Biomere Lease Commencement”). The Company can terminate the Biomere Suite Retention Agreement for convenience, and without penalty, with 60 days’ written notice. The Biomere Suite Retention Agreement does not contain any lease incentives or renewal options. Upon the Biomere Lease Commencement, the Company determined that it gained control of the space, in accordance with ASC 842, which resulted in the recording of an ROU asset and lease liability of $0.3 million. As of the Biomere Lease Commencement, the Company began paying monthly fees of less than $0.1 million. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Real Estate Lease </div></div></div></div></div> <div style="text-indent: 0px;;font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2017, the Company entered into an operating lease for office and laboratory space at its headquarters in Lexington, Massachusetts. The Company occupies approximately 59,000 square feet of space under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-year</div> lease agreement expiring in April 2028. The Company occupied this property in March 2018. Monthly lease payments include base rent charges of $0.2 million, which are subject to a 3% annual increase each year. In June 2017, in connection with this lease agreement, the Company issued a letter of credit collateralized by cash deposits of $1.0 million, which are classified as restricted cash <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equipment Lease </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2018, the Company entered into an operating lease for communications equipment for use at its office and laboratory space in Lexington, Massachusetts. The term of the lease is five years, expiring in <span style="-sec-ix-hidden:hidden23928727">March</span> <span style="-sec-ix-hidden:hidden23928728">2023</span>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company excludes leases with an initial term of one year or less in the recognized ROU asset and lease liabilities. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842, lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components are combined into a single lease component. The Company’s leases have remaining lease terms of up to seven years, excluding two five-year options to extend the real estate lease after the expiration of the initial term. The Company believes the Lexington real estate lease, together with the anticipated relocation to a space in Waltham, Massachusetts as described below, will be sufficient to meet its needs for the foreseeable future and that suitable additional space will be available as and when needed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows (dollar amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease cost</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,597</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,597</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other information</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,593</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,320</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease liabilities arising from obtaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,376</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average remaining lease term</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average discount rate</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,971</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,067</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,591</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,591</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026 and thereafter</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,134</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,134</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total future minimum lease payments</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,953</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,049</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,097</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,363</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,856</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,686</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate which are the rates incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2019 for operating leases that commenced prior to that date and for all subsequent leases the Company used an appropriate incremental borrowing rate upon commencement date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In October 2020, the Company entered into a suite retention agreement with Azzur Cleanrooms-on-Demand – Burlington, LLC (“Azzur”) under which it will lease two exclusive cleanroom suites in Azzur’s Burlington, Massachusetts facility (the “Azzur Agreement”). The lease term is</div> 24 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">months and commenced on August 1, 2021, with the option to extend the term with three months’ notice prior to the termination date. Upon commencement, the Company will pay monthly fees of </div>$0.4 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million, which are subject to a</div> 4%<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> increase on July 1, 2022. As of June 30, 2021, the Company’s commitment under this agreement is</div> $8.8 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million through June 2023. The Company can terminate the Azzur Agreement for convenience, and without penalty, with three months’ written notice. The Azzur Agreement does not contain any lease incentives or renewal options. The Company has determined this is a lease under ASC 842. As of June 30, 2021, the Company has determined that it does not have control of the space, as defined in ASC 842, during the build-out and as such, this Azzur Agreement was</div> not <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">included in the ROU assets or lease liabilities on the Company’s condensed consolidated balance sheet. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November 3, 2020 (the “Lease Commencement Date”), the Company entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">ten-year</div> lease agreement for approximately 138,444 square feet of office and laboratory space located at 200 West Street in Waltham, Massachusetts (the “Waltham Lease Agreement”). The Waltham Lease Agreement includes an extension option of one period of 10 years. The Waltham Lease Agreement includes a work agreement to perform a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">build-out</div> arrangement, with a construction period from March 2021 to December 2021. Under the Waltham Lease Agreement, the Company has improvement allowances of $26.3 million, plus an additional tenant allowance of up to $15 per square foot, should the Company elect to use those. In April 2021, the Company entered into a contract with the Richmond Group for $36.8 million for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">build-out</div> of this office and laboratory space. The Company expects to spend between $10.5 million and $12.5 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million on the construction of lessor assets, which represents the cost of the project that exceeds the tenant allowances. The Company has paid </div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$2.3 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million towards the construction of lessor assets, which is included in other long-term assets in the condensed consolidated balance sheet as of June 30, 2021. Initial base rent, which commences 12 months after the Lease Commencement Date, shall be </div></div> $5.7 million for the first year and approximately $8.0 million for the second year and thereafter shall be subject to a 3% annual increase. In December 2020, in connection with this Waltham Lease Agreement, the Company issued a letter of credit collateralized by cash deposits of $3.9 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million, which are classified as restricted cash on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020. The Company has determined this is a lease under ASC 842. As of June 30, 2021, the Company has determined that it does not have control of the space, as defined in ASC 842, during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">build-out</div> and as such, this Waltham Lease Agreement</div> was not <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">included in the ROU assets or lease liabilities on the Company’s condensed consolidated balance sheet<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div> P5Y the Company has the right to extend for an additional three years. P3Y 6000000.0 6000000.0 11000000.0 11000000.0 12800000 5600000 3200000 66600000 53800000 1400000 1000000.0 0.03 P13M 300000 300000 100000 59000 P10Y 200000 0.03 1000000.0 P5Y P7Y <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows (dollar amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended June 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease cost</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,597</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,597</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other information</div></div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,593</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,320</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease liabilities arising from obtaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,376</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average remaining lease term</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8 years</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average discount rate</div></div> </td> <td style="vertical-align: bottom; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> 9597000 1346000 9597000 1346000 9593000 1320000 1376000 P5Y P8Y 0.120 0.175 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,971</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,067</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,591</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,591</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026 and thereafter</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,134</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,134</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total future minimum lease payments</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,953</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,049</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,097</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,363</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,856</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,686</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 9971000 18067000 15178000 15178000 15591000 15591000 16050000 16050000 12029000 12029000 7134000 7134000 75953000 84049000 18097000 21363000 57856000 62686000 P24M 400000 0.04 8800000 0 0 138444 P10Y 26300000 15 36800000 10500000 12500000 2300000 5700000 8000000.0 0.03 3900000 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Commitments and Contingencies </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research, Supply and License Agreements </div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Roche Master Supply Agreement </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a master supply agreement with Roche Diagnostics Corporation (“Roche”) pursuant to which Roche will custom manufacture certain products for the Company. The agreement specifies a minimum purchase requirement for certain custom manufactured products through December 31, 2024. As of June 30, 2021, the Company’s purchase commitments under the agreement totaled $10.5 million, with $3.5 million committed as payments each year from 2022 to 2024. Research and development expenses related to this agreement totaled $1.3 million and $1.3 million during the three months ended June 30, 2021 and 2020, respectively, and $5.7 million and $2.6 million during the six months ended June 30, 2021 and 2020, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MIT Research Agreement </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2019, the Company entered into a research agreement with the Massachusetts Institute of Technology (“MIT”) pursuant to which the Company is obligated to reimburse MIT up to $4.1 million for specified direct and indirect costs to be incurred from January 2020 through December 2022 for specified research activities conducted for the Company (the “2019 MIT Agreement”). As of June 30, 2021 and 2020, the Company paid MIT $2.4 million and $1.2 million, respectively, towards the total committed amount. Research and development expenses related to this agreement were $0.3 million during each of the three months ended June 30, 2021 and 2020 and $0.7 million during each of the six months ended June 30, 2021 and 2020. There were no amounts payable by the Company under the agreement as of June 30, 2021. The 2019 MIT Agreement expires in December 2022 and may be extended thereafter by mutual agreement of the parties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MIT Exclusive Patent License Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to an exclusive patent license agreement with MIT pursuant to which the Company received an exclusive license under the licensed patent rights to develop, manufacture and commercialize any product containing both Certain RNA sequences and certain lipid products, referred to as a “licensed product”. Under the licensed patent rights, the Company is permitted to develop, manufacture and commercialize the licensed products for the delivery of coding RNA components to treat disease in humans. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has the right to grant sublicenses under this license. The patent rights licensed to the Company by MIT include claims that cover certain of the Company’s customized lipid nanoparticles used for delivery of coding RNA components in its MRT platform, including products that may be developed under the Company’s collaboration with Sanofi. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is also obligated to make milestone payments to MIT aggregating up to $1.375 million upon the achievement of specified clinical and regulatory milestones with respect to each licensed product and $1.250 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million upon the Company’s first commercial sale of each licensed product, and to pay royalties of a low single-digit percentage to MIT based on the Company’s, and any of its affiliates’ and sublicensees’, net sales of licensed products. The royalties are p<div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>yable on a product-by-product and country-by-country basis, and may be reduced in specified circumstances. The Company’s obligation to make royalty payments extends with respect to a licensed product in a country until four years past the expiration of the last-to-expire patent or patent application licensed from MIT covering the licensed product in the country. In addition, the Company is obligated to pay MIT a low double-digit percentage of the portion of income from sublicensees that the Company ascribes to the MIT-licensed patents, excluding royalties on net sales and research support payments. Pursuant to such provision, during the six months ended June 30, 2021, the Company paid</div> $<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">3.4 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million to MIT which included</div> $</div>2.5 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million as MIT’s share of sublicense income with respect to the payments the Company received in 2020 under the Second Sanofi Amendment and the Securities Purchase Agreement and</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> $0.9 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million as MIT’s share of sublicense income with respect to the milestones the Company achieved in 2021 under the Amended Sanofi Agreement. Future amounts that the Company may owe to MIT will depend upon the relative value of the patents the Company licensed from MIT and sublicensed to Sanofi as compared to the other rights that the Company licensed to Sanofi. The determination of the relative value of such rights is subject to a process described in the Company’s license agreement with MIT. Additionally, in the quarter ended June 30, 2021, the Company paid a total of</div> $0.7 million due to the achievement of specified milestones in accordance with the license agreement with MIT.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification Agreements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2021 and December 31, 2020. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal Proceedings </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. </div></div></div> 2024-12-31 10500000 3500000 3500000 3500000 1300000 1300000 5700000 2600000 4100000 2022-12 2400000 1200000 300000 300000 700000 700000 0 2022-12 1375000 1250000 3400000 2500000 900000 700000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Subsequent Event </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 2, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanofi S.A. and Vector Merger Sub, Inc., a Delaware corporation and<div style="background-color:#ffffff;;display:inline;"> a</div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">n indirect</div></div><div style="background-color:#ffffff;;display:inline;"> wholly owned subsidiary of Sanofi S.A. (“Merger Sub”). On the terms and subject to the conditions of the Merger Agreement, Merger Sub will commence a cash tender offer (the “Tender Offer”) to acquire all of the outstanding shares of common stock of the Company for a purchase price of</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;"> </div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">$</div></div><div style="background-color:#ffffff;;display:inline;">38.00</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">per share, in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. Following the completion of the Tender Offer, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and as a</div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">n </div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">indirect</div></div></div><div style="background-color:#ffffff;;display:inline;"> w</div>holly owned subsidiary of Sanofi S.A. The Merger Agreement is subject to customary closing conditions, and is anticipated to close in the third quarter of 2021. If the Merger Agreement is terminated by the Company under specified circumstances, the Company will be required to pay Sanofi S.A. a termination fee of<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>96.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million.</div></div> 38.00 96000000.0 XML 17 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
6 Months Ended
Jun. 30, 2021
Aug. 02, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q2  
Document Transition Report false  
Entity File Number 001-38550  
Document Quarterly Report true  
Entity Registrant Name Translate Bio, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 61-1807780  
Entity Address, Address Line One 29 Hartwell Avenue  
Entity Address, City or Town Lexington  
Entity Address, Postal Zip Code 02421  
Trading Symbol TBIO  
City Area Code 617  
Local Phone Number 945-7361  
Entity Central Index Key 0001693415  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Title of 12(b) Security Common Stock  
Entity Address, State or Province MA  
Entity Interactive Data Current Yes  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   75,586,714
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 249,471 $ 342,027
Investments 417,727 312,001
Collaboration receivables 24,030 26,598
Prepaid expenses and other current assets 20,958 11,741
Restricted cash 4,826 4,826
Total current assets 717,012 697,193
Property and equipment, net 18,249 15,372
Right-of-use assets, net 68,123 72,957
Goodwill 21,359 21,359
Intangible assets, net 74,507 79,127
Other assets 5,620 3,928
Total assets 904,870 889,936
Current liabilities:    
Accounts payable 13,736 8,839
Accrued expenses 15,079 13,202
Current portion of deferred revenue 41,014 67,563
Current portion of operating lease liability 11,685 11,733
Total current liabilities 81,514 101,337
Contingent consideration 112,493 152,230
Deferred revenue, net of current portion 252,055 228,659
Operating lease liability, net of current portion 46,171 50,953
Total liabilities 492,233 533,179
Commitments and contingencies (Notes 3 and 12)
Stockholders' equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020; no shares issued and outstanding as of June 30, 2021 and December 31, 2020 0  
Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 75,343,712 shares and 75,029,625 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively 75 75
Additional paid-in capital 782,144 769,965
Accumulated deficit (369,617) (413,283)
Accumulated other comprehensive income 35  
Total stockholders' equity 412,637 356,757
Total liabilities and stockholders' equity $ 904,870 $ 889,936
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares Issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 75,343,712 75,029,625
Common stock, shares outstanding 75,343,712 75,029,625
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Collaboration revenue $ 72,649 $ 16,319 $ 107,249 $ 20,974
Operating expenses:        
Research and development 40,477 29,002 81,617 50,442
General and administrative 11,921 8,601 22,738 16,060
Change in fair value of contingent consideration 4,242 15,347 (39,737) 5,895
Total operating expenses 56,640 52,950 64,618 72,397
Income (loss) from operations 16,009 (36,631) 42,631 (51,423)
Other income, net 154 343 308 853
Income (loss) before income taxes 16,163 (36,288) 42,939 (50,570)
Income tax benefits 981 0 727 0
Net income (loss) $ 17,144 $ (36,288) $ 43,666 $ (50,570)
Net income (loss) per share—basic $ 0.23 $ (0.58) $ 0.58 $ (0.83)
Weighted average common shares outstanding—basic 75,254,186 62,282,291 75,222,119 61,145,254
Net income (loss) per share—diluted $ 0.21 $ (0.58) $ 0.55 $ (0.83)
Weighted average common shares outstanding—diluted 80,026,488 62,282,291 79,994,422 61,145,254
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ 17,144 $ (36,288) $ 43,666 $ (50,570)
Other comprehensive income (loss):        
Unrealized gains (losses) on available-for-sale securities, net of tax of $0 (42) (315) 35 (201)
Comprehensive income (loss) $ 17,102 $ (36,603) $ 43,701 $ (50,771)
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Statement of Comprehensive Income [Abstract]        
Unrealized gains (losses) on available-for-sale securities, net of tax $ 0 $ 0 $ 0 $ 0
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Beginning balances at Dec. 31, 2019 $ 153,536 $ 60 $ 512,231 $ (359,496) $ 741
Beginning balance, Shares at Dec. 31, 2019   60,022,067      
Exercise of stock options 132   132    
Exercise of stock options, Shares   15,596      
Stock-based compensation expense 3,172   3,172    
Unrealized gains (losses) on available-for-sale securities 114       114
Net income (loss) (14,282)     (14,282)  
Ending balances at Mar. 31, 2020 142,672 $ 60 515,535 (373,778) 855
Ending balance, shares at Mar. 31, 2020   60,037,663      
Beginning balances at Dec. 31, 2019 153,536 $ 60 512,231 (359,496) 741
Beginning balance, Shares at Dec. 31, 2019   60,022,067      
Unrealized gains (losses) on available-for-sale securities (201)        
Net income (loss) (50,570)        
Ending balances at Jun. 30, 2020 271,393 $ 69 680,850 (410,066) 540
Ending balance, shares at Jun. 30, 2020   69,359,509      
Beginning balances at Mar. 31, 2020 142,672 $ 60 515,535 (373,778) 855
Beginning balance, Shares at Mar. 31, 2020   60,037,663      
Issuance of common stock in connection with public offerings, net of underwriting discounts and commissions and offering costs 153,611 $ 9 153,602    
Issuance of common stock in connection with public offerings, net of underwriting discounts and commissions and offering costs, Shares   8,544,982      
Exercise of stock options 5,699   5,699    
Exercise of stock options, Shares   776,864      
Stock-based compensation expense 6,014   6,014    
Unrealized gains (losses) on available-for-sale securities (315)       (315)
Net income (loss) (36,288)     (36,288)  
Ending balances at Jun. 30, 2020 271,393 $ 69 680,850 (410,066) 540
Ending balance, shares at Jun. 30, 2020   69,359,509      
Beginning balances at Dec. 31, 2020 356,757 $ 75 769,965 (413,283) 0
Beginning balance, Shares at Dec. 31, 2020   75,029,625      
Exercise of stock options 1,550   1,550    
Exercise of stock options, Shares   188,047      
Stock-based compensation expense 3,984   3,984    
Unrealized gains (losses) on available-for-sale securities 77       77
Net income (loss) 26,522     26,522  
Ending balances at Mar. 31, 2021 388,890 $ 75 775,499 (386,761) 77
Ending balance, shares at Mar. 31, 2021   75,217,672      
Beginning balances at Dec. 31, 2020 356,757 $ 75 769,965 (413,283) 0
Beginning balance, Shares at Dec. 31, 2020   75,029,625      
Unrealized gains (losses) on available-for-sale securities 35        
Net income (loss) 43,666        
Ending balances at Jun. 30, 2021 412,637 $ 75 782,144 (369,617) 35
Ending balance, shares at Jun. 30, 2021   75,343,712      
Beginning balances at Mar. 31, 2021 388,890 $ 75 775,499 (386,761) 77
Beginning balance, Shares at Mar. 31, 2021   75,217,672      
Exercise of stock options 819   819    
Exercise of stock options, Shares   98,852      
Issuance of common stock under employee stock purchase plan 490   490    
Issuance of common stock under employee stock purchase plan, Shares   27,188      
Stock-based compensation expense 5,336   5,336    
Unrealized gains (losses) on available-for-sale securities (42)       (42)
Net income (loss) 17,144     17,144  
Ending balances at Jun. 30, 2021 $ 412,637 $ 75 $ 782,144 $ (369,617) $ 35
Ending balance, shares at Jun. 30, 2021   75,343,712      
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash flows - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Cash flows from operating activities:        
Net income (loss) $ 17,144 $ (36,288) $ 43,666 $ (50,570)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:        
Depreciation and amortization expense     6,471 5,617
Stock-based compensation expense     9,320 9,186
Change in fair value of contingent consideration 4,242 15,347 (39,737) 5,895
Changes in operating assets and liabilities:        
Collaboration receivables     2,568 (10,535)
Prepaid expenses and other assets     (8,521) 1,472
Right-of-use assets     6,210 270
Long-term prepaid rent     (2,395) (7,381)
Accounts payable     3,900 (2,783)
Accrued expenses     1,571 4,013
Deferred revenue     (3,153) (6,429)
Lease liability     (6,206) (244)
Net cash provided by (used in) operating activities     13,694 (51,489)
Cash flows from investing activities:        
Purchases of investments     (185,690) (27,409)
Sales and maturities of investments     80,000 111,277
Purchases of property and equipment     (3,419) (4,446)
Net cash provided by (used in) investing activities     (109,109) 79,422
Cash flows from financing activities:        
Proceeds from public offerings, net of underwriting discounts and commissions       154,292
Payments of public offering costs       (443)
Proceeds from option exercises     2,369 5,831
Proceeds from issuance of common stock under employee stock purchase plan      490  
Net cash provided by financing activities     2,859 159,680
Net increase (decrease) in cash, cash equivalents and restricted cash:     (92,556) 187,613
Cash, cash equivalents and restricted cash at beginning of period     346,853 85,530
Cash, cash equivalents and restricted cash at end of period 254,297 273,143 254,297 273,143
Cash, cash equivalents and restricted cash at end of period:        
Cash and cash equivalents 249,471 272,193 249,471 272,193
Restricted cash 4,826 950 4,826 950
Total cash, cash equivalents and restricted cash at end of period $ 254,297 $ 273,143 254,297 273,143
Supplemental disclosure of non-cash investing and financing activities:        
Purchases of property and equipment included in accounts payable and accrued expenses     $ 1,707 718
Offering costs included in accrued expenses       $ 238
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of the Business and Basis of Presentation
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business and Basis of Presentation
1. Nature of the Business and Basis of Presentation
Translate Bio, Inc. (the “Company”) is a clinical-stage messenger RNA (“mRNA”) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Using its proprietary mRNA therapeutic platform (“MRT platform”), the Company creates mRNA that encodes functional proteins. The Company’s mRNA is designed to be delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The Company is primarily focused on applying its MRT platform to treat pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease. In addition, the Company is pursuing discovery efforts in diseases that affect the liver. The Company is also pursuing the applicability of its MRT platform for the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur Inc. (“Sanofi”), the vaccines global business unit of Sanofi, a French
société anonyme
(“Sanofi S.A.”)
The Company is developing mRNA therapeutics for the treatment of cystic fibrosis (“CF”) with two programs, MRT5005, a clinical-stage program, and a preclinical next-generation CF program. The Company is conducting a Phase 1/2 clinical trial to evaluate the safety and tolerability of single- and multiple-ascending doses of MRT5005. The clinical trial is investigating several groups receiving five once-weekly doses, as well as a group receiving five daily doses. Percent predicted forced expiratory volume in one second (“ppFEV
1
”) which is a well-defined and accepted endpoint measuring lung function, is also being measured at
pre-defined
timepoints throughout the trial as a safety measure. In 2019, the Company reported interim data from the single-ascending dose portion of the Phase 1/2 clinical trial through
one-month
follow up post dosing. In March 2021, the Company reported the second interim data analysis. In evaluating safety and tolerability, the primary outcome measure, data to date from the ongoing Phase 1/2 clinical trial suggested that repeat dosing of MRT5005 was generally safe and well tolerated. For patients receiving MRT5005, ppFEV
1
was not negatively impacted; there was no pattern of treatment-associated increases in ppFEV
1
. The clinical trial is ongoing with evaluation of the remaining dose groups, which include a 20 mg multiple-ascending dose group and the daily dosing cohort, and the Company anticipates reporting the interim findings from the clinical trial at the North American Cystic Fibrosis Conference, being held September 30, 2021 through October 2, 2021. The Company’s preclinical next-generation CF program incorporates mRNA codon optimization and advances in lipid nanoparticle chemistry. Positive preclinical data generated from the program support the planned initiation of investigational new drug (“IND”)-enabling studies in the second half of 2021. The Company is conducting translational studies with MRT5005 and a next-generation CF candidate to support and optimize future clinical development
.
The Company is leveraging its lung delivery platform and focusing its preclinical research efforts on identifying lead product candidates in additional pulmonary diseases with unmet medical needs, including primary ciliary dyskinesia (“PCD”), pulmonary arterial hypertension and respiratory infectious diseases. Positive preclinical data from our PCD program support the anticipated initiation of
IND-enabling
studies in the second half of 2021.
The Company has a collaboration with Sanofi to develop infectious disease vaccines using the Company’s mRNA technology. Under the collaboration, the Company and Sanofi are jointly conducting research and development activities to advance mRNA vaccines targeting up to seven infectious disease pathogens (see Note 3). Two of the target pathogens under development are
SARS-CoV-2,
which causes
COVID-19,
and influenza. MRT5500 has been selected as the lead candidate for a vaccine against
SARS-CoV-2.
A Phase 1/2 clinical trial to evaluate MRT5500 began in the first quarter of 2021 with interim data anticipated in the third quarter of 2021. A Phase 1 clinical trial evaluating MRT5400 and MRT5401, the Company’s investigational mRNA vaccine candidates against seasonal influenza, was initiated in June 2021 with interim data expected by the end of 2021.
Since early 2020, the outbreak of the novel strain of coronavirus named
SARS-CoV-2
has spread across the globe and the
COVID-19
pandemic has had wide-reaching impacts on the global economy and business operations. The
COVID-19
pandemic has had, and the Company expects it will continue to have, an impact on its operations, the operations of its collaborators, the operations of third-party contractors and other entities with which the Company interacts, as well as on the patients who may enroll in the Company’s clinical trials. The Company continues to actively monitor
COVID-19
trends and government guidance. The ultimate impacts of the
COVID-19
pandemic are still unknow
n
 and uncertain.
The Company is subject to risks common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently
under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sal
e
s.
The preparation of the accompanying condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the
COVID-19
pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning
COVID-19
and the actions taken in an effort to contain or to potentially treat or vaccinate against
COVID-19,
it as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of
COVID-19
within its financial statements and have determined them to be immaterial. There may be changes to those estimates in future periods. Actual results may differ from these estimates.
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its two wholly owned subsidiaries,
Translate Bio MA, Inc. and Translate Bio Securities Corporation, from their date of incorporation. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated balance sheet as of June 30, 2021, the unaudited condensed consolidated statements of operations and of comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020, the unaudited condensed consolidated statements of stockholders’ equity for the three and six months ended June 30, 2021 and 2020 and the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The accompanying balance sheet as of December 31, 2020 has been derived from the Company’s audited financial statements for the year ended December 31, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form
10-K
that was filed with the SEC on March 1, 2021.
The accompanying unaudited interim condensed consolidated financial presentation has been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflects all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2021, the results of its operations for the three and six months ended June 30, 2021 and 2020, and its cash flows for the six months ended June 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2021 and 2020 are also unaudited. The results for the three and six months ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period.
Sales of Common Stock
The Company is a party to an Open Market Sale Agreement
SM
(the “Sales Agreement”) with Jefferies LLC under
 which the Company may issue and sell shares of common stock, from time to time, having an aggregate offering price of up to $
100.0
 million. During the year ended December 
31
,
2020
, the Company issued and sold
2,863,163
shares of its common stock pursuant to the Sales Agreement, resulting in gross proceeds of $
37.9 
million, before deducting commissions of $
1.1
 million and other offering expenses of $
0.2
 million. There were
no
shares issued or sold pursuant to the Sales Agreement during the six months ended June 
30
,
2021
. In the future, $
62.1
 million of shares of common stock remain available to be sold pursuant to the Sales Agreement, which sales, if any, would be made under the Company’s universal shelf registration statement on Form
S-3.
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
The significant accounting policies and estimates used in preparation of the consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company’s Annual Report on Form
10-K.
During the six months ended June 30, 2021, there were no material changes to the Company’s significant accounting policies.
 
Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2016-13,
Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
. The guidance requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For
available-for-sale
debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements and disclosures.
In December 2019, the FASB issued ASU
No. 2019-12,
Income Taxes-Simplifying the Accounting for Income Taxes
. This new standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a
step-up
in the tax basis of goodwill. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements.
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreement
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Sanofi Collaboration and License Agreement
3. Collaboration Agreement
Sanofi Collaboration and License Agreement
In 2018, the Company entered into a collaboration and license agreement with Sanofi (the “Original Sanofi Agreement”) to develop mRNA vaccines for up to five infectious disease pathogens (the “Licensed Fields”). On March 26, 2020, the Company and Sanofi amended the Original Sanofi Agreement (the “First Sanofi Amendment”) to include vaccines against
SARS-CoV-2
as an additional Licensed Field, increasing the number of infectious disease pathogens to up to six. On June 22, 2020, the Company and Sanofi further amended the Original Sanofi Agreement to expand the scope of the collaboration and licenses granted to Sanofi (the “Second Sanofi Amendment”). The Original Sanofi Agreement, as amended by the First Sanofi Amendment and the Second Sanofi Amendment, is referred to as the “Amended Sanofi Agreemen
t
.”
Pursuant to the Amended Sanofi Agreement, the Company and Sanofi are jointly conducting research and development activities to advance mRNA vaccines targeting up to seven infectious disease pathogens. The term of the research collaboration (the “Collaboration Term”) expires in June 2022 with an option for Sanofi to extend the Collaboration Term for one additional year, followed by a technology transfer to Sanofi. If Sanofi elects to extend the Collaboration Term, the collaboration may be further expanded to jointly conduct research and development activities to advance mRNA vaccines for up to an additional three infectious disease pathogens, bringing the total to up to ten pathogens.
Under the terms of the Amended Sanofi Agreement, the Company has granted to Sanofi exclusive, worldwide licenses under applicable patents, patent applications,
know-how
and materials, including those arising under the collaboration, to develop, commercialize and manufacture mRNA vaccines to prevent, treat or cure diseases, disorders or conditions in humans caused by any infectious disease pathogen, with certain specified exceptions.
Pursuant to the Original Sanofi Agreement, Sanofi paid the Company an upfront payment of $45.0 million in 2018. Pursuant to the Second Sanofi Amendment, Sanofi paid the Company an additional upfront payment of $300.0 million in August 2020. If Sanofi chooses to exercise its option to extend the Collaboration Term for an additional year, Sanofi has agreed to pay the Company an additional payment of $75.0 million. The Amended Sanofi Agreement provides that the Company is eligible to receive aggregate potential payments of up to $1.9 billion upon the achievement of additional specified development, regulatory, manufacturing and commercialization milestones, inclusive of the fee to exercise the option to extend the Collaboration Term. In particular, the Company is entitled to receive development, regulatory and sales milestone payments of up to $148.0 million for each Licensed Field, other than the
SARS-CoV-2
Licensed Field, development, regulatory and sales milestone payments of up to $250.0 million in the
SARS-CoV-2
Licensed Field, and
one-time
manufacturing milestone payments of up to $200.0 million. In addition, the Company is entitled to receive a $10.0 million milestone payment from Sanofi following
completion
of the technology and process transfer. In March 2021, Sanofi paid the Company a milestone payment of $25.0 million upon the initiation of the Phase 1/2 clinical trial of MRT5500 and in June 2021, Sanofi paid the Company a milestone payment of $50.0 million upon the successful manufacture, release and delivery of clinical drug product to supply the Phase 1 clinical trial of MRT5400 and MRT5401. Additionally, in June 2021, the Company achieved a milestone of $4.0 million upon the start of the Phase 1 clinical trial of MRT5400 and MRT5401, which is included in collaboration receivables on the condensed consolidated balance sheet as of June 30, 2021.
 
Accounting for the Sanofi Collaboration
The Company recognizes revenue under Accounting Standards Codification (“ASC”) 606,
Revenue from Contracts with Customer
(“ASC 606”)
.
During the six months ended June 30, 2021, the Company increased the overall transaction price by
$108.7 million. The transaction price as of June 30, 2021 includes the upfront,
non-refundable
payments of $345.0 million for the transfer of the combined license, supply and development obligations under the Original Sanofi Agreement and Second Sanofi Amendment, the premium paid in consideration for common stock of $51.2 million under a securities purchase
agreement
entered into with an affiliate of Sanofi, an estimated $76.3 million in reimbursable employee costs, an estimated $167.8 million in reimbursable development costs including manufacturing costs and
out-of-pocket
costs paid to third parties and an estimated $212.0 million in milestone payments. Under ASC 606, at the end of each reporting period, the Company
re-evaluates
the variable consideration determined using either the expected value or most likely outcome approach and
re-evaluates
the probability that the consideration associated with each milestone or reimbursement will not be subject to a significant reversal in the cumulative amount of revenue recognized, and, if necessary, adjusts the estimate of the overall transaction price. The estimated collaboration budget is consistently
re-evaluated
and changes to the budget, if any, require approval by the Joint Steering Committee. If an approved change occurs, the Company will
re-evaluate
the transaction price which could potentially affect the cumulative amount of revenue recognized. Changes as a result of a contract modification or in the planned services under the Amended Sanofi Agreement may have an impact on the transaction price and on the Company’s measure of progress toward complete satisfaction of the performance obligation. The impact of changes during the six months ended June 30, 2021 resulted in a cumulative revenue
catch-up
adjustment of $20.5 million.
The following table summarizes the Company’s collaboration revenue (in thousands):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2021
    
2020
    
2021
    
2020
 
Collaboration revenue
   $ 72,649      $ 16,319      $ 107,249      $ 20,974  
The following table presents the balance of the Company’s contract liabilities (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Contract liabilities
                 
Deferred revenue
   $ 293,069      $ 296,222  
Deferred revenue is classified as short-term or long-term in the
conde
nsed
consolidated balance sheets based on the Company’s estimate of revenue that will be recognized within the next twelve months which is determined by the
cost-to-cost
input method which measures the extent of progress towards satisfying the performance obligation. As of June 30, 2021, the aggregate amount of the transaction price allocated to the remaining performance obligation is estimated to be approximately $597.0 million, which is expected to be recognized as revenue through 2024. Revenue recognized from contract liabilities at the beginning of the period was $29.8 million and $6.4 million during the six months ended June 30, 2021 and 2020, respectively.
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets and Goodwill
6 Months Ended
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
4. Intangible Assets and Goodwill
Acquisition of Shire’s MRT Program
In December 2016, the Company entered into an asset purchase agreement (as amended in June 2018) with Shire Human Genetic Therapies, Inc. (“Shire”), a subsidiary of Takeda Pharmaceutical Company Ltd., pursuant to which Shire sold equipment to and assigned to the Company all of its rights to certain patent rights, permits, real property leases, contracts, regulatory documentation, books and records, and materials related to Shire’s mRNA therapy platform (the “MRT Program”), including its cystic fibrosis transmembrane conductance regulator program.
Intangible Assets, Net
The acquisition of Shire’s MRT Program was accounted for in accordance with the acquisition method of accounting for business combinations. The total purchase consideration transferred was allocated to the tangible and identifiable intangible assets acquired based on their estimated fair values. The tables below present the Company’s definite-lived intangible assets that are subject to amortization and indefinite-lived intangible assets:
 
           
June 30, 2021
 
    
Estimated Life
    
Gross Carrying

Amount
    
Accumulated

Amortization
    
Net Carrying

Amount
 
           
(In thousands)
 
Definite-lived intangible assets:
                                   
MRT
     6 years      $ 45,992      $ (13,776    $ 32,216  
             
 
 
    
 
 
    
 
 
 
Indefinite-lived intangible assets:
                                   
IPR&D—CF
     Indefinite        42,291        —          42,291  
             
 
 
    
 
 
    
 
 
 
Total intangible assets, net
            $ 88,283      $ (13,776    $ 74,507  
             
 
 
    
 
 
    
 
 
 
     
           
December 31, 2020
 
    
Estimated Life
    
Gross Carrying

Amount
    
Accumulated

Amortization
    
Net Carrying

Amount
 
           
(In thousands)
 
Definite-lived intangible assets:
                                   
MRT
     6 years      $ 45,992      $ (9,156    $ 36,836  
             
 
 
    
 
 
    
 
 
 
Indefinite-lived intangible assets:
                                   
IPR&D—CF
     Indefinite        42,291        —          42,291  
             
 
 
    
 
 
    
 
 
 
Total intangible assets, net
            $ 88,283      $ (9,156    $ 79,127  
             
 
 
    
 
 
    
 
 
 
Identifiable intangible assets acquired in the acquisition of Shire’s MRT Program consisted of
in-process
research and development (“IPR&D”), which included ongoing projects that could further the Company’s preclinical and clinical development activities related to CF and other potential rare diseases. As of the date of acquisition, the IPR&D was determined to be indefinite-lived.
Upon
commencement
of the Original Sanofi Agreement, the IPR&
D—M
RT intangible asset was reclassified from indefinite-lived to definite-lived intangible assets and the Company began amortization of this intangible asset. Amortization will be recorded over the intangible asset’s estimated life based on an economic consumption
model
. The Company recorded amortization expense of $2.6 million and $3.6 million during the three months ended June 30, 2021 and 2020, respectively, and $4.6 million and $4.3 million during the six months ended June 30, 2021 and 2020, respectively, related to the definite-lived MRT intangible asset. The estimated amortization expense for the remainder of the useful life is $11.8 million, $11.2 million, $11.1 
million
and $2.7 million for the years ending December 31, 2021, 2022, 2023 and 2024, respectively.
Indefinite-lived IPR&D is not subject to amortization, but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived IPR&D annually for impairment on October 1st. During the six months ended June 30, 2021 and 2020, the Company did not recognize any impairment charges related to indefinite-lived IPR&D.
Goodwill
The excess of the fair value of the consideration transferred over the fair value of identifiable assets acquired in the acquisition of Shire’s MRT Program was allocated to goodwill in the amount of $21.4 million. There have been no changes to the carrying amount of goodwill during the six months ended June 30, 2021. Goodwill is not subject to amortization, but is tested annually for impairment or more frequently if there are indicators of impairment. During the six months ended June 30, 202
1
and 20
20
, the Company did not recognize any impairment charges related to goodwill.
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Assets and Liabilities
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value of Financial Assets and Liabilities
5. Fair Value of Financial Assets and Liabilities
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):
 
 
  
Fair Value Measurements

as of June 30, 2021 Using:
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Assets:
                                   
Money market funds
   $ —        $ 167,938      $ —        $ 167,938  
U.S. treasuries
     —          359,871        —          359,871  
U.S. government agency bonds
     —          57,856        —          57,856  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ 585,665      $ —        $ 585,665  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Contingent consideration
   $ —        $ —        $ 112,493      $ 112,493  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ —        $ 112,493      $ 112,493  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
  
Fair Value Measurements

as of December 31, 2020 Using:
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Assets:
  
  
  
  
Money market funds
   $ —        $ 273,827      $ —        $ 273,827  
U.S. treasuries
     —          292,001        —          292,001  
U.S. government agency bonds
     —          20,000        —          20,000  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ 585,828      $ —        $ 585,828  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Contingent consideration
   $ —        $ —        $ 152,230      $ 152,230  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ —        $ 152,230      $ 152,230  
    
 
 
    
 
 
    
 
 
    
 
 
 
During the six months ended June 30, 2021 and the year ended December 31, 2020, there were no transfers between Level 1, Level 2 and Level 3.
Cash equivalents as of June 30, 2021 and December 31, 2020 consisted of money market funds totaling $167.9 million and $273.8 million, respectively. The money market funds were valued using inputs observable in active markets for similar securities, which represent a Level 2 measurement in the fair value hierarchy. The Company’s investments as of June 30, 2021 and December 31, 2020 consisted of U.S. treasuries and U.S. government agency bonds and were clas
s
ified as
available-for-sale
securities. The U.S. treasuries and U.S. government agency bonds were valued using inputs observable in active markets for similar securities, which represent a Level 2 measurement in the fair value hierarchy. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such
available-for-sale
securities represent the investment of cash that is available for current operations.
The estimated amortized costs and fair value of the Company’s
available-for-sale
securities by contractual maturity are summarized as follows:
 
    
June 30, 2021
    
December 31, 2020
 
    
Amortized Cost
    
Fair Value
    
Amortized Cost
    
Fair Value
 
Due within one year
   $ 305,053      $ 305,095      $ 201,606      $ 201,596  
Due after one year through two years
     112,639        112,632        110,395        110,405  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
available-for-sale
securities
   $ 417,692      $ 417,727      $ 312,001      $ 312,001  
    
 
 
    
 
 
    
 
 
    
 
 
 
Valuation of Contingent Consideration
The contingent consideration liability related to the acquisition of Shire’s MRT Program in 2016 was classified as a Level 3 measurement within the fair value hierarchy. The Company may be required to pay future consideration to Shire contingent upon the achievement of potential future milestones and earnout payments.
The fair value of the liability to make potential future milestone and earnout payments was estimated by the Company at each reporting date based, in part, on the results of a valuation u
s
ing a discounted cash flow analysis based on various assumptions, including the amount and timing of cash flows, probability of achieving specified events, discount rate, and the period of time until earnout payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events.
The following table presents the unobservable inputs and fair value of the components of the contingent consideration (dollar amounts in thousands):
 
 
  
Unobservable Inputs
 
  
Fair Value at
 
 
  
Projected Year of Payment
 
  
June 30,
 
  
December 31,
 
 
  
 
 
  
2021
 
  
2020
 
Earnout payments
    
2027 -
 2039
     $ 103,093      $ 142,250  
Milestone payments
  
 
2027 - 2031
       9,400        9,980  
             
 
 
    
 
 
 
              $ 112,493      $ 152,230  
             
 
 
    
 
 
 
The discount rate used in the valuation was 10.8% and 11.0% as of June 30, 2021 and December 31, 2020, respectively.
The following table presents a roll-forward of the total acquisition-related contingent consideration liability (in thousands):
 
    
Fair Value
 
Balance as of December 31, 2020
   $ 152,230  
Decrease in fair value of contingent consideration
     (39,737
    
 
 
 
Balance as of June 30, 2021
   $ 112,493  
    
 
 
 
The change in the fair value of contingent consideration was due to a large decrease in the fair value of contingent consideration during the three months ended March 31, 2021 due to the previously announced results of the second interim data analysis from the Phase 1/2 clinical trial of MRT5005. This decrease was partially offset by an increase in the fair value of contingent consideration during the three months ended June 30, 2021 due to
the
time value of money due to the passage of time and a decrease in the discount rate.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, Net
6 Months Ended
Jun. 30, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net
6. Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Laboratory equipment
   $ 18,949      $ 12,710  
Computer equipment
     932        922  
Office equipment
     941        941  
Leasehold improvements
     5,557        5,730  
Construction in progress
     2,882        5,189  
    
 
 
    
 
 
 
       29,261        25,492  
Less: Accumulated depreciation and amortization
     (11,012      (10,120
    
 
 
    
 
 
 
     $ 18,249      $ 15,372  
    
 
 
    
 
 
 
Depreciation and amortization expense related to property and equipment was $1.0 million and $0.7 million during the three months ended June 30, 2021 and 2020, respectively, and $1.9 million and $1.4 million during the six months ended June 30, 2021 and 2020, respectively.
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses
6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
Accrued Expenses
7. Accrued Expenses
Accrued expenses consisted of the following (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Accrued employee compensation and benefits
   $ 5,326      $ 5,600  
Accrued external research and development expenses
     4,420        2,805  
Accrued consultant and professional fees
     2,468        1,489  
Other
     2,865        3,308  
    
 
 
    
 
 
 
     $ 15,079      $ 13,202  
    
 
 
    
 
 
 
Included in other accrued expenses as of June 30, 2021 was $2.5 million related to a work agreement to perform a
build-out
of the Company’s office and laboratory space at 200 West Street in Waltham, Massachusetts (see Note 11).
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Incentive Stock Options and Employee Stock Purchase Plan
6 Months Ended
Jun. 30, 2021
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Incentive Stock Options and Employee Stock Purchase Plan
8. Incentive Stock Options and Employee Stock Purchase Plan
2021 Inducement Stock Incentive Plan
On January 20, 2021, the Board of Directors adopted a 2021 Inducement Stock Incentive Plan (the “2021 Plan”), pursuant to which the Company may grant
non-statutory
stock options, restricted stock, restricted stock units and other stock-based awards with respect to an aggregate of
 
2,612,550 
shares of common stock. Awards under the 2021 Plan may only be granted to persons who (i) were not previously an employee or director of the Company or (ii) are commencing employment with the Company following a bona fide period of
non-employment,
in either case as an inducement material to the individual’s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4).
2018 Equity Incentive Plan
On March 7, 2018, the Company’s Board of Directors (the “Board of Directors”), subject to stockholder approval, adopted, and on June 15, 2018, the Company’s stockholders approved, the 2018 Equity Incentive Plan (the “2018 Plan”), which became effective on June 27, 2018. The 2018 Plan provides for the grant of incentive stock options,
non-qualified
stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The Company previously awarded grants under the 2016 Stock Incentive Plan (the “2016 Plan”). Upon the effectiveness of the 2018 Plan, no further awards will be made under the 2016 Plan, but awards outstanding under the 2016 Plan will continue to be governed by their existing terms
.
As of December 31, 2020, there were 7,457,171 shares of common stock reserved for issuance under the 2018 Plan. On January 1, 2021, the number of shares of common stock that may be issued under the 2018 Plan increased by 3,001,185 shares of common stock. During the six months ended June 30, 2021, a total of 12,848 shares issued under the 2016 Plan have been canceled and rolled over to the 2018 Plan, such that there is a total of 10,471,204 shares of common stock reserved for issuance under the 2018 Plan as of June 30, 2021. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, repurchased or are otherwise terminated by the Company under the 20
16
Plan will be added back to the shares of common stock available for issuance under the 2018 Plan.
The 2018 Plan is administered by the Board of Directors. The exercise prices, vesting periods and other restrictions are determined at the discretion of the Board of Directors, except that the exercise price per share of options may not be less than 100% of the fair market value of the common stock on the date of grant. Stock options awarded under the 2018 Plan expire 10 years after the grant date, unless the Board of Directors sets a shorter term. Awards granted to employees, officers, members of the Board of Directors and consultants typically vest over a period of
one
to
four
years.
Typically, unvested stock options are forfeited upon the recipient ceasing to provide services to the Company.
2018 Employee Stock Purchase Plan
On March 7, 2018, the Board of Directors, subject to stockholder approval, adopted, and on June 15, 2018, the Company’s stockholders approved the 2018 Employee Stock Purchase Plan (the “2018 ESPP”), which became effective on June 27, 2018. As of June 30, 2021, 870,096 shares of common stock were reserved for issuance under this plan.
As of June 30, 2021, 54,152 shares have been issued under the 2018 ESPP.
Stock Options
The following table summarizes the Company’s stock option activity since December 31, 2020 (in thousands, except share and per share amounts):
 
    
Number of

Shares
    
Weighted

Average

Exercise

Price
    
Weighted

Average

Remaining

Contractual

Term
    
Intrinsic

Value
 
                  
(in years)
        
Outstanding as of December 31, 2020
     9,557,391      $ 8.79        7.92      $ 93,256  
Granted
     3,126,560      $ 21.81                    
Exercised
     (286,899    $ 8.25                    
Forfeited
     (154,303    $ 14.68                    
    
 
 
                            
Outstanding as of June 30, 2021
     12,242,749      $ 12.06        8.07      $ 189,483  
    
 
 
                            
Exercisable as of June 30, 2021
     5,953,908      $ 8.14        7.07      $ 115,421  
Vested and expected to vest as of June 30, 2021
     12,242,749      $ 12.06        8.07      $ 189,483  
The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2021 and 2020 was $3.8 million and $10.7 million, respectively.
The weighted average grant-date fair value per share of stock options granted was $13.56 and $5.50 during the six months ended June 30, 2021 and 2020, respectively.
Stock Option Valuation
The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company completed its initial public offering in July 2018 and therefore lacks company-specific historical and implied volatility information before that date. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to
non-employees
is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors:
 
    
Six Months Ended June 30,
 
    
2021
   
2020
 
Risk-free interest rate
     1.03     0.79
Expected term (in years)
     6.1       6.1  
Expected volatility
     69.7     68.6
Expected dividend yield
     0     0
 
Stock-Based Compensation
Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands):
 
 
  
Three Months Ended June 30,
 
  
Six Months Ended June 30,
 
 
  
2021
 
  
2020
 
  
2021
 
  
2020
 
Research and development expenses
   $ 2,841      $ 4,091      $ 4,921      $ 5,545  
General and administrative expenses
     2,495        1,923        4,399        3,641  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ 5,336      $ 6,014      $ 9,320      $ 9,186  
    
 
 
    
 
 
    
 
 
    
 
 
 
As of June 30, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $57.4 million, which is expected to be recognized over a weighted average period of 2.9 years.
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
6 Months Ended
Jun. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes
9. Income Taxes
The Company recognized an income tax
benefit
of $1.0 million and $0.7
million during the three and six months ended June 30, 2021,
respectively, due to the current period income before income taxes and the application of the annual effective tax rate. The annual effective tax rate
relates primarily to an expected income tax liability due to the acceleration of revenue recognition for tax purposes related to the Amended Sanofi Agreement. There was
no
 income tax benefit recognized during the three and six months ended June 30, 2020. Net operating losses generated in
2018
and years thereafter can be carried forward indefinitely. 
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income (Loss) per Share
6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Net Income (Loss) per Share
10. Net Income (Loss) per Share
Basic net income (loss) per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period, including any dilutive effect from outstanding stock options.
Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2021
    
2020
    
2021
    
2020
 
Basic net income (loss) per common share:
                                   
Numerator:
                                   
Net income (loss)
   $ 17,144      $ (36,288    $ 43,666      $ (50,570
Denominator:
                                   
Weighted average common shares outstanding—basic
     75,254,186        62,282,291        75,222,119        61,145,254  
Net income (loss) per share—basic
   $ 0.23      $ (0.58    $ 0.58      $ (0.83
Diluted net income (loss) per common share:
                                   
Numerator:
                                   
Net income (loss)
   $ 17,144      $ (36,288    $ 43,666      $ (50,570
Denominator:
                                   
Weighted average common shares
outstanding—diluted
     80,026,488        62,282,291        79,994,422        61,145,254  
Net income (loss) per share—diluted
   $ 0.21      $ (0.58    $ 0.55      $ (0.83
 
The Company excluded 3,790 shares and 11,149 shares of restricted common stock, presented on a weighted average basis, from the calculations of basic net loss per share attributable to common stockholders for the three and six months ended June 30, 2020, respectively, because those shares had not vested. As of June 30, 2021, there are no unvested shares of restricted common stock.
The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
 
    
Six Months Ended June 30,
 
    
2021
    
2020
 
Options to purchase common stock
     3,608,932        10,494,989  
Unvested restricted common stock
     —          1,691  
    
 
 
    
 
 
 
       3,608,932        10,496,680  
    
 
 
    
 
 
 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Leases
6 Months Ended
Jun. 30, 2021
Leases [Abstract]  
Leases
11. Leases
Suite Retention Agreements
In September 2019, the Company entered into a suite retention and development agreement with Curia Massachusetts, Inc. (“Curia”), formerly known as Albany Molecular Research, Inc., under which a series of cleanroom suites were built at Curia’s manufacturing facility in accordance with the Company’s objectives (“Curia Agreement”). The Curia Agreement continues for five years after the
build-out
is completed, and the Company has the right to extend for an additional three years. The Company has determined this is a lease under ASU
No. 2016-02,
Leases (Topic 842) (“ASC 842”). Under the Curia Agreement, the Company will finance $6.0 million of the costs of the
build-out
(“Build-Out
Costs”). If
Build-Out
Costs exceed $6.0 million, the Company and Curia will share overage costs equally, up to $11.0 million, and the Company will be responsible for any amounts exceeding $11.0 million. The Company had paid $12.8 million towards the
Build-Out
Costs prior to the lease commencement date which had been recorded within other long-term assets as prepaid rent as these represented payments for lessor owned assets. The Company anticipates making additional payments of $5.6 million related to the final
Build-Out
Costs, of which $3.2 million was paid as of June 30, 2021. These costs are included within the
right-of-use
(“ROU”) assets and lease liabilities recorded at the lease commencement date. Upon the
build-out
completion date of August 31, 2020 (“Curia Lease Commencement”), the Company determined that it gained control of the space, in accordance with ASC 842, which resulted in the recording of ROU assets and related lease liabilities of approximately $66.6 million and $53.8 million, respectively, with the difference being due to the elimination of previously recorded prepaid rent. Due to an increase in the final
Build-Out
Costs, the Company recorded an increase of $1.4 million to ROU assets and lease liabilities as of June 30, 2021. As of August 31, 2020, the Company began paying monthly fees of $1.0 million, which are subject to a 3% increase on January 1 of each calendar year following the first anniversary of the
build-out
completion. The option to extend the lease for an additional three years was not included in the lease liability as of June 30, 2021 as the Company is not reasonably certain it will exercise this option.
In October 2020, the Company entered into a suite retention agreement (the “Biomere Suite Retention Agreement”) with Biomedical Research Models, Inc. (“Biomere”) under which the Company will lease two exclusive procedure rooms and one housing and maintenance room in Biomere’s Worcester, Massachusetts facility. The lease term is 13 months
 
and commenced
 on December 1, 2020 (the “Biomere Lease Commencement”). The Company can terminate the Biomere Suite Retention Agreement for convenience, and without penalty, with 60 days’ written notice. The Biomere Suite Retention Agreement does not contain any lease incentives or renewal options. Upon the Biomere Lease Commencement, the Company determined that it gained control of the space, in accordance with ASC 842, which resulted in the recording of an ROU asset and lease liability of $0.3 million. As of the Biomere Lease Commencement, the Company began paying monthly fees of less than $0.1 million.
Real Estate Lease
In June 2017, the Company entered into an operating lease for office and laboratory space at its headquarters in Lexington, Massachusetts. The Company occupies approximately 59,000 square feet of space under a
10-year
lease agreement expiring in April 2028. The Company occupied this property in March 2018. Monthly lease payments include base rent charges of $0.2 million, which are subject to a 3% annual increase each year. In June 2017, in connection with this lease agreement, the Company issued a letter of credit collateralized by cash deposits of $1.0 million, which are classified as restricted cash
on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020.
 
Equipment Lease
In March 2018, the Company entered into an operating lease for communications equipment for use at its office and laboratory space in Lexington, Massachusetts. The term of the lease is five years, expiring in March 2023.
The Company excludes leases with an initial term of one year or less in the recognized ROU asset and lease liabilities. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842, lease and
non-lease
components are combined into a single lease component. The Company’s leases have remaining lease terms of up to seven years, excluding two five-year options to extend the real estate lease after the expiration of the initial term. The Company believes the Lexington real estate lease, together with the anticipated relocation to a space in Waltham, Massachusetts as described below, will be sufficient to meet its needs for the foreseeable future and that suitable additional space will be available as and when needed.
The components of lease cost were as follows (dollar amounts in thousands):
 
    
Six Months Ended June 30,
 
    
2021
   
2020
 
Lease cost
                
Operating lease cost
   $ 9,597     $ 1,346  
    
 
 
   
 
 
 
Total lease cost
   $ 9,597     $ 1,346  
    
 
 
   
 
 
 
Other information
                
Operating cash flows from operating leases
   $ 9,593     $ 1,320  
Operating lease liabilities arising from obtaining
right-of-use
assets
     1,376       —    
Weighted-average remaining lease term
     5 years       8 years  
Weighted-average discount rate
     12.0     17.5
Maturities of operating lease liabilities are as follows (in thousands):
 
    
June 30, 2021
    
December 31, 2020
 
2021
   $ 9,971      $ 18,067  
2022
     15,178        15,178  
2023
     15,591        15,591  
2024
     16,050        16,050  
2025
     12,029        12,029  
2026 and thereafter
     7,134        7,134  
    
 
 
    
 
 
 
Total future minimum lease payments
     75,953        84,049  
Less: imputed interest
     (18,097      (21,363
    
 
 
    
 
 
 
Present value of lease liabilities
   $ 57,856      $ 62,686  
    
 
 
    
 
 
 
 
As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate which are the rates incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2019 for operating leases that commenced prior to that date and for all subsequent leases the Company used an appropriate incremental borrowing rate upon commencement date.
In October 2020, the Company entered into a suite retention agreement with Azzur Cleanrooms-on-Demand – Burlington, LLC (“Azzur”) under which it will lease two exclusive cleanroom suites in Azzur’s Burlington, Massachusetts facility (the “Azzur Agreement”). The lease term is
 24
months and commenced on August 1, 2021, with the option to extend the term with three months’ notice prior to the termination date. Upon commencement, the Company will pay monthly fees of 
$0.4 
million, which are subject to a
4%
 increase on July 1, 2022. As of June 30, 2021, the Company’s commitment under this agreement is
$8.8 
million through June 2023. The Company can terminate the Azzur Agreement for convenience, and without penalty, with three months’ written notice. The Azzur Agreement does not contain any lease incentives or renewal options. The Company has determined this is a lease under ASC 842. As of June 30, 2021, the Company has determined that it does not have control of the space, as defined in ASC 842, during the build-out and as such, this Azzur Agreement was
 not
included in the ROU assets or lease liabilities on the Company’s condensed consolidated balance sheet.
On November 3, 2020 (the “Lease Commencement Date”), the Company entered into a
ten-year
lease agreement for approximately 138,444 square feet of office and laboratory space located at 200 West Street in Waltham, Massachusetts (the “Waltham Lease Agreement”). The Waltham Lease Agreement includes an extension option of one period of 10 years. The Waltham Lease Agreement includes a work agreement to perform a
build-out
arrangement, with a construction period from March 2021 to December 2021. Under the Waltham Lease Agreement, the Company has improvement allowances of $26.3 million, plus an additional tenant allowance of up to $15 per square foot, should the Company elect to use those. In April 2021, the Company entered into a contract with the Richmond Group for $36.8 million for the
build-out
of this office and laboratory space. The Company expects to spend between $10.5 million and $12.5 
million on the construction of lessor assets, which represents the cost of the project that exceeds the tenant allowances. The Company has paid
$2.3
million towards the construction of lessor assets, which is included in other long-term assets in the condensed consolidated balance sheet as of June 30, 2021. Initial base rent, which commences 12 months after the Lease Commencement Date, shall be
$5.7 million for the first year and approximately $8.0 million for the second year and thereafter shall be subject to a 3% annual increase. In December 2020, in connection with this Waltham Lease Agreement, the Company issued a letter of credit collateralized by cash deposits of $3.9 
million, which are classified as restricted cash on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020. The Company has determined this is a lease under ASC 842. As of June 30, 2021, the Company has determined that it does not have control of the space, as defined in ASC 842, during the
build-out
and as such, this Waltham Lease Agreement
was not
included in the ROU assets or lease liabilities on the Company’s condensed consolidated balance sheet
.
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
12. Commitments and Contingencies
Research, Supply and License Agreements
Roche Master Supply Agreement
The Company is a party to a master supply agreement with Roche Diagnostics Corporation (“Roche”) pursuant to which Roche will custom manufacture certain products for the Company. The agreement specifies a minimum purchase requirement for certain custom manufactured products through December 31, 2024. As of June 30, 2021, the Company’s purchase commitments under the agreement totaled $10.5 million, with $3.5 million committed as payments each year from 2022 to 2024. Research and development expenses related to this agreement totaled $1.3 million and $1.3 million during the three months ended June 30, 2021 and 2020, respectively, and $5.7 million and $2.6 million during the six months ended June 30, 2021 and 2020, respectively.
MIT Research Agreement
In September 2019, the Company entered into a research agreement with the Massachusetts Institute of Technology (“MIT”) pursuant to which the Company is obligated to reimburse MIT up to $4.1 million for specified direct and indirect costs to be incurred from January 2020 through December 2022 for specified research activities conducted for the Company (the “2019 MIT Agreement”). As of June 30, 2021 and 2020, the Company paid MIT $2.4 million and $1.2 million, respectively, towards the total committed amount. Research and development expenses related to this agreement were $0.3 million during each of the three months ended June 30, 2021 and 2020 and $0.7 million during each of the six months ended June 30, 2021 and 2020. There were no amounts payable by the Company under the agreement as of June 30, 2021. The 2019 MIT Agreement expires in December 2022 and may be extended thereafter by mutual agreement of the parties.
MIT Exclusive Patent License Agreement
The Company is a party to an exclusive patent license agreement with MIT pursuant to which the Company received an exclusive license under the licensed patent rights to develop, manufacture and commercialize any product containing both Certain RNA sequences and certain lipid products, referred to as a “licensed product”. Under the licensed patent rights, the Company is permitted to develop, manufacture and commercialize the licensed products for the delivery of coding RNA components to treat disease in humans.
The Company has the right to grant sublicenses under this license. The patent rights licensed to the Company by MIT include claims that cover certain of the Company’s customized lipid nanoparticles used for delivery of coding RNA components in its MRT platform, including products that may be developed under the Company’s collaboration with Sanofi.
The Company is also obligated to make milestone payments to MIT aggregating up to $1.375 million upon the achievement of specified clinical and regulatory milestones with respect to each licensed product and $1.250 
million upon the Company’s first commercial sale of each licensed product, and to pay royalties of a low single-digit percentage to MIT based on the Company’s, and any of its affiliates’ and sublicensees’, net sales of licensed products. The royalties are p
a
yable on a product-by-product and country-by-country basis, and may be reduced in specified circumstances. The Company’s obligation to make royalty payments extends with respect to a licensed product in a country until four years past the expiration of the last-to-expire patent or patent application licensed from MIT covering the licensed product in the country. In addition, the Company is obligated to pay MIT a low double-digit percentage of the portion of income from sublicensees that the Company ascribes to the MIT-licensed patents, excluding royalties on net sales and research support payments. Pursuant to such provision, during the six months ended June 30, 2021, the Company paid
 $
3.4
million to MIT which included
$
2.5 
million as MIT’s share of sublicense income with respect to the payments the Company received in 2020 under the Second Sanofi Amendment and the Securities Purchase Agreement and
 $0.9
million as MIT’s share of sublicense income with respect to the milestones the Company achieved in 2021 under the Amended Sanofi Agreement. Future amounts that the Company may owe to MIT will depend upon the relative value of the patents the Company licensed from MIT and sublicensed to Sanofi as compared to the other rights that the Company licensed to Sanofi. The determination of the relative value of such rights is subject to a process described in the Company’s license agreement with MIT. Additionally, in the quarter ended June 30, 2021, the Company paid a total of
 $0.7 million due to the achievement of specified milestones in accordance with the license agreement with MIT.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2021 and December 31, 2020.
Legal Proceedings
The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Event
6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
Subsequent Event
13. Subsequent Event
On August 2, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanofi S.A. and Vector Merger Sub, Inc., a Delaware corporation and
a
n indirect
wholly owned subsidiary of Sanofi S.A. (“Merger Sub”). On the terms and subject to the conditions of the Merger Agreement, Merger Sub will commence a cash tender offer (the “Tender Offer”) to acquire all of the outstanding shares of common stock of the Company for a purchase price of
 
$
38.00
per share, in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. Following the completion of the Tender Offer, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and as a
n
indirect
 w
holly owned subsidiary of Sanofi S.A. The Merger Agreement is subject to customary closing conditions, and is anticipated to close in the third quarter of 2021. If the Merger Agreement is terminated by the Company under specified circumstances, the Company will be required to pay Sanofi S.A. a termination fee of
 
$
96.0
 million.
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Recently Adopted Accounting Pronouncement
Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2016-13,
Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
. The guidance requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For
available-for-sale
debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements and disclosures.
In December 2019, the FASB issued ASU
No. 2019-12,
Income Taxes-Simplifying the Accounting for Income Taxes
. This new standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a
step-up
in the tax basis of goodwill. The Company adopted this new standard as of the required effective date of January 1, 2021, and its adoption had no impact on the Company’s condensed consolidated financial statements.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreement (Tables)
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Collaboration Revenue
The following table summarizes the Company’s collaboration revenue (in thousands):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2021
    
2020
    
2021
    
2020
 
Collaboration revenue
   $ 72,649      $ 16,319      $ 107,249      $ 20,974  
Balance of Contract Liabilities Related to Collaboration Agreements
The following table presents the balance of the Company’s contract liabilities (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Contract liabilities
                 
Deferred revenue
   $ 293,069      $ 296,222  
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets and Goodwill (Tables)
6 Months Ended
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets The tables below present the Company’s definite-lived intangible assets that are subject to amortization and indefinite-lived intangible assets:
           
June 30, 2021
 
    
Estimated Life
    
Gross Carrying

Amount
    
Accumulated

Amortization
    
Net Carrying

Amount
 
           
(In thousands)
 
Definite-lived intangible assets:
                                   
MRT
     6 years      $ 45,992      $ (13,776    $ 32,216  
             
 
 
    
 
 
    
 
 
 
Indefinite-lived intangible assets:
                                   
IPR&D—CF
     Indefinite        42,291        —          42,291  
             
 
 
    
 
 
    
 
 
 
Total intangible assets, net
            $ 88,283      $ (13,776    $ 74,507  
             
 
 
    
 
 
    
 
 
 
     
           
December 31, 2020
 
    
Estimated Life
    
Gross Carrying

Amount
    
Accumulated

Amortization
    
Net Carrying

Amount
 
           
(In thousands)
 
Definite-lived intangible assets:
                                   
MRT
     6 years      $ 45,992      $ (9,156    $ 36,836  
             
 
 
    
 
 
    
 
 
 
Indefinite-lived intangible assets:
                                   
IPR&D—CF
     Indefinite        42,291        —          42,291  
             
 
 
    
 
 
    
 
 
 
Total intangible assets, net
            $ 88,283      $ (9,156    $ 79,127  
             
 
 
    
 
 
    
 
 
 
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Assets and Liabilities (Tables)
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):
 
 
  
Fair Value Measurements

as of June 30, 2021 Using:
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Assets:
                                   
Money market funds
   $ —        $ 167,938      $ —        $ 167,938  
U.S. treasuries
     —          359,871        —          359,871  
U.S. government agency bonds
     —          57,856        —          57,856  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ 585,665      $ —        $ 585,665  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Contingent consideration
   $ —        $ —        $ 112,493      $ 112,493  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ —        $ 112,493      $ 112,493  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
 
  
Fair Value Measurements

as of December 31, 2020 Using:
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Assets:
  
  
  
  
Money market funds
   $ —        $ 273,827      $ —        $ 273,827  
U.S. treasuries
     —          292,001        —          292,001  
U.S. government agency bonds
     —          20,000        —          20,000  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ 585,828      $ —        $ 585,828  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Contingent consideration
   $ —        $ —        $ 152,230      $ 152,230  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ —        $ —        $ 152,230      $ 152,230  
    
 
 
    
 
 
    
 
 
    
 
 
 
Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity
    
June 30, 2021
    
December 31, 2020
 
    
Amortized Cost
    
Fair Value
    
Amortized Cost
    
Fair Value
 
Due within one year
   $ 305,053      $ 305,095      $ 201,606      $ 201,596  
Due after one year through two years
     112,639        112,632        110,395        110,405  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
available-for-sale
securities
   $ 417,692      $ 417,727      $ 312,001      $ 312,001  
    
 
 
    
 
 
    
 
 
    
 
 
 
Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration
The following table presents the unobservable inputs and fair value of the components of the contingent consideration (dollar amounts in thousands):
 
 
  
Unobservable Inputs
 
  
Fair Value at
 
 
  
Projected Year of Payment
 
  
June 30,
 
  
December 31,
 
 
  
 
 
  
2021
 
  
2020
 
Earnout payments
    
2027 -
 2039
     $ 103,093      $ 142,250  
Milestone payments
  
 
2027 - 2031
       9,400        9,980  
             
 
 
    
 
 
 
              $ 112,493      $ 152,230  
             
 
 
    
 
 
 
Schedule of Total Acquisition Related Contingent Consideration Liability
The following table presents a roll-forward of the total acquisition-related contingent consideration liability (in thousands):
 
    
Fair Value
 
Balance as of December 31, 2020
   $ 152,230  
Decrease in fair value of contingent consideration
     (39,737
    
 
 
 
Balance as of June 30, 2021
   $ 112,493  
    
 
 
 
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Laboratory equipment
   $ 18,949      $ 12,710  
Computer equipment
     932        922  
Office equipment
     941        941  
Leasehold improvements
     5,557        5,730  
Construction in progress
     2,882        5,189  
    
 
 
    
 
 
 
       29,261        25,492  
Less: Accumulated depreciation and amortization
     (11,012      (10,120
    
 
 
    
 
 
 
     $ 18,249      $ 15,372  
    
 
 
    
 
 
 
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses consisted of the following (in thousands):
 
 
  
June 30,
 
  
December 31,
 
 
  
2021
 
  
2020
 
Accrued employee compensation and benefits
   $ 5,326      $ 5,600  
Accrued external research and development expenses
     4,420        2,805  
Accrued consultant and professional fees
     2,468        1,489  
Other
     2,865        3,308  
    
 
 
    
 
 
 
     $ 15,079      $ 13,202  
    
 
 
    
 
 
 
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Incentive Stock Options and Employee Stock Purchase Plan (Tables)
6 Months Ended
Jun. 30, 2021
Summary of Stock Option Activity
The following table summarizes the Company’s stock option activity since December 31, 2020 (in thousands, except share and per share amounts):
 
    
Number of

Shares
    
Weighted

Average

Exercise

Price
    
Weighted

Average

Remaining

Contractual

Term
    
Intrinsic

Value
 
                  
(in years)
        
Outstanding as of December 31, 2020
     9,557,391      $ 8.79        7.92      $ 93,256  
Granted
     3,126,560      $ 21.81                    
Exercised
     (286,899    $ 8.25                    
Forfeited
     (154,303    $ 14.68                    
    
 
 
                            
Outstanding as of June 30, 2021
     12,242,749      $ 12.06        8.07      $ 189,483  
    
 
 
                            
Exercisable as of June 30, 2021
     5,953,908      $ 8.14        7.07      $ 115,421  
Vested and expected to vest as of June 30, 2021
     12,242,749      $ 12.06        8.07      $ 189,483  
Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees and directors:
 
    
Six Months Ended June 30,
 
    
2021
   
2020
 
Risk-free interest rate
     1.03     0.79
Expected term (in years)
     6.1       6.1  
Expected volatility
     69.7     68.6
Expected dividend yield
     0     0
Summary of Stock-Based Compensation Expense
Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands):
 
 
  
Three Months Ended June 30,
 
  
Six Months Ended June 30,
 
 
  
2021
 
  
2020
 
  
2021
 
  
2020
 
Research and development expenses
   $ 2,841      $ 4,091      $ 4,921      $ 5,545  
General and administrative expenses
     2,495        1,923        4,399        3,641  
    
 
 
    
 
 
    
 
 
    
 
 
 
     $ 5,336      $ 6,014      $ 9,320      $ 9,186  
    
 
 
    
 
 
    
 
 
    
 
 
 
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income (Loss) per Share (Tables)
6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders
Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
 
    
Three Months Ended June 30,
    
Six Months Ended June 30,
 
    
2021
    
2020
    
2021
    
2020
 
Basic net income (loss) per common share:
                                   
Numerator:
                                   
Net income (loss)
   $ 17,144      $ (36,288    $ 43,666      $ (50,570
Denominator:
                                   
Weighted average common shares outstanding—basic
     75,254,186        62,282,291        75,222,119        61,145,254  
Net income (loss) per share—basic
   $ 0.23      $ (0.58    $ 0.58      $ (0.83
Diluted net income (loss) per common share:
                                   
Numerator:
                                   
Net income (loss)
   $ 17,144      $ (36,288    $ 43,666      $ (50,570
Denominator:
                                   
Weighted average common shares
outstanding—diluted
     80,026,488        62,282,291        79,994,422        61,145,254  
Net income (loss) per share—diluted
   $ 0.21      $ (0.58    $ 0.55      $ (0.83
Schedule of Potential Securities Excluded from Computation of Earnings Per Share
The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
 
    
Six Months Ended June 30,
 
    
2021
    
2020
 
Options to purchase common stock
     3,608,932        10,494,989  
Unvested restricted common stock
     —          1,691  
    
 
 
    
 
 
 
       3,608,932        10,496,680  
    
 
 
    
 
 
 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Tables)
6 Months Ended
Jun. 30, 2021
Leases [Abstract]  
Schedule of Lease Cost
The components of lease cost were as follows (dollar amounts in thousands):
 
    
Six Months Ended June 30,
 
    
2021
   
2020
 
Lease cost
                
Operating lease cost
   $ 9,597     $ 1,346  
    
 
 
   
 
 
 
Total lease cost
   $ 9,597     $ 1,346  
    
 
 
   
 
 
 
Other information
                
Operating cash flows from operating leases
   $ 9,593     $ 1,320  
Operating lease liabilities arising from obtaining
right-of-use
assets
     1,376       —    
Weighted-average remaining lease term
     5 years       8 years  
Weighted-average discount rate
     12.0     17.5
Schedule of maturities of operating lease liabilities
Maturities of operating lease liabilities are as follows (in thousands):
 
    
June 30, 2021
    
December 31, 2020
 
2021
   $ 9,971      $ 18,067  
2022
     15,178        15,178  
2023
     15,591        15,591  
2024
     16,050        16,050  
2025
     12,029        12,029  
2026 and thereafter
     7,134        7,134  
    
 
 
    
 
 
 
Total future minimum lease payments
     75,953        84,049  
Less: imputed interest
     (18,097      (21,363
    
 
 
    
 
 
 
Present value of lease liabilities
   $ 57,856      $ 62,686  
    
 
 
    
 
 
 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of the Business and Basis of Presentation - Additional Information (Detail)
$ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2021
USD ($)
Subsidiary
shares
Dec. 31, 2020
USD ($)
shares
Initial Public Offering [Line Items]    
Number of wholly owned subsidiaries | Subsidiary 2  
Stock available to be sold under sales agreement $ 62.1  
Open Market Sale Agreement [Member]    
Initial Public Offering [Line Items]    
Payments of other offering expenses   $ 0.2
Payment of issuance commissions   1.1
Issuance of common, shares | shares 0  
Gross proceeds from issuance of public offering   $ 37.9
Market sale aggreement of common stock $ 100.0  
Issuance of common, shares | shares   2,863,163
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreement - Additional Information (Detail)
$ in Millions
6 Months Ended
Jul. 20, 2020
USD ($)
Jun. 30, 2021
USD ($)
Disease
Jun. 30, 2020
USD ($)
Mar. 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized as a cumulative catch-up adjustment   $ 20.5    
Sanofi Collaboration And License Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum number of infectious disease pathogens for vaccine development   10    
Sanofi Collaboration And License Agreement [Member] | Maximum [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of infectious disease pathogens for vaccine development | Disease   7    
Sanofi Collaboration And License Agreement [Member] | Minimum [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of infectious disease pathogens for vaccine development | Disease   3    
Second Sanofi Amendment Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Additional Upfront Payment $ 300.0      
Original Sanofi Agreement And Second Sanofi Amendment Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Increase in transaction price   $ 108.7    
Non-refundable upfront payment   345.0    
Amended Sanofi Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Milestone payments achieved   50.0   $ 25.0
Collaboration receivable milestone payments achieved   4.0    
Sanofi Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Remaining performance obligation, expected to be recognized as revenue   $ 597.0    
Number of infectious disease pathogens for vaccine development | Disease   5    
Upfront payment received   $ 45.0    
Technology and process transfer milestone payment receivable   10.0    
Estimated reimbursable employee cost   76.3    
Estimated reimbursable development cost   167.8    
Estimated milestone payments   212.0    
Revenue recognized from contract liabilities   $ 29.8 $ 6.4  
Sanofi Agreement [Member] | Maximum [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of infectious disease pathogens for vaccine development | Disease   6    
Sublicense Second Amendment Agreement With Sanofi [Member] | Massachusetts Institute Of Technology Exclusive Patent License Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Additional Upfront Payment Receivable   $ 75.0    
Milestone payment receivable upon the achievement of additional specified regulatory development manufacturing and commercial milestones   1,900.0    
Lumpsum or one time manufacturing milestone amount receivable   200.0    
Maximum development and regulatory milestone payment receivable   148.0    
Sars Cov2 Licensed Filed [Member] | Sublicense Second Amendment Agreement With Sanofi [Member] | Massachusetts Institute Of Technology Exclusive Patent License Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum development and regulatory milestone payment receivable   250.0    
Additional Paid-in Capital [Member] | Securities Purchase Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Shares issued during the period value   $ 51.2    
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreement - Summary of Collaboration Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Collaboration revenue $ 72,649 $ 16,319 $ 107,249 $ 20,974
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreement - Balance of Contract Liabilities Related to Collaboration Agreements (Detail) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Contract liabilities    
Deferred revenue $ 293,069 $ 296,222
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets and Goodwill - Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets (Detail) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2021
Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]    
Definite-lived intangible assets, accumulated amortization $ (13,776) $ (9,156)
Indefinite-lived intangible assets, gross carrying amount/net carrying amount 42,291 42,291
Total intangible assets, gross carrying amount 88,283 88,283
Total intangible assets, net carrying amount $ 74,507 $ 79,127
In-Process Research and Development [Member] | MRT Product [Member] | Shire's MRT Program [Member]    
Finite Lived Intangible Assets [Line Items]    
Definite-lived intangible assets, estimated life 6 years 6 years
Definite-lived intangible assets, gross carrying amount $ 45,992 $ 45,992
Definite-lived intangible assets, accumulated amortization (13,776) (9,156)
Definite-lived intangible assets, net carrying amount $ 32,216 $ 36,836
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets and Goodwill - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]          
Goodwill, Impairment Charges     $ 0 $ 0  
Goodwill $ 21,359,000   21,359,000   $ 21,359,000
Goodwill changes     0    
Shire's MRT Program [Member]          
Finite Lived Intangible Assets [Line Items]          
Goodwill 21,400,000   21,400,000    
Shire's MRT Program [Member] | Sanofi Agreement [Member]          
Finite Lived Intangible Assets [Line Items]          
Estimated amortization expense of intangible assets for 2021 11,800,000   11,800,000    
Estimated amortization expense of intangible assets for 2022 11,200,000   11,200,000    
Estimated amortization expense of intangible assets for 2023 11,100,000   11,100,000    
Estimated amortization expense of intangible assets for 2024 2,700,000   2,700,000    
OTC Deficiency Program [Member]          
Finite Lived Intangible Assets [Line Items]          
Amortization of Intangible Assets $ 2,600,000 $ 3,600,000 $ 4,600,000 $ 4,300,000  
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Assets:    
Total, assets $ 585,665 $ 585,828
Liabilities:    
Total, liabilities 112,493 152,230
Fair Value, Inputs, Level 1    
Assets:    
Total, assets 0  
Liabilities:    
Total, liabilities 0  
Fair Value, Inputs, Level 2    
Assets:    
Total, assets 585,665 585,828
Liabilities:    
Total, liabilities 0  
Fair Value, Inputs, Level 3    
Assets:    
Total, assets 0  
Liabilities:    
Total, liabilities 112,493 152,230
Money Market Funds    
Assets:    
Total, assets 167,938 273,827
Money Market Funds | Fair Value, Inputs, Level 1    
Assets:    
Total, assets 0  
Money Market Funds | Fair Value, Inputs, Level 2    
Assets:    
Total, assets 167,938 273,827
Money Market Funds | Fair Value, Inputs, Level 3    
Assets:    
Total, assets 0  
U.S. treasuries    
Assets:    
Total, assets 359,871 292,001
U.S. treasuries | Fair Value, Inputs, Level 1    
Assets:    
Total, assets 0 0
U.S. treasuries | Fair Value, Inputs, Level 2    
Assets:    
Total, assets 359,871 292,001
U.S. treasuries | Fair Value, Inputs, Level 3    
Assets:    
Total, assets 0  
U.S. Government Agency Bonds    
Assets:    
Total, assets 57,856 20,000
U.S. Government Agency Bonds | Fair Value, Inputs, Level 1    
Assets:    
Total, assets 0  
U.S. Government Agency Bonds | Fair Value, Inputs, Level 2    
Assets:    
Total, assets 57,856 20,000
U.S. Government Agency Bonds | Fair Value, Inputs, Level 3    
Assets:    
Total, assets 0  
Contingent Consideration    
Liabilities:    
Total, liabilities 112,493 152,230
Contingent Consideration | Fair Value, Inputs, Level 1    
Liabilities:    
Total, liabilities 0  
Contingent Consideration | Fair Value, Inputs, Level 2    
Liabilities:    
Total, liabilities 0  
Contingent Consideration | Fair Value, Inputs, Level 3    
Liabilities:    
Total, liabilities $ 112,493 $ 152,230
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Assets and Liabilities - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 417,692 $ 312,001
Fair Value 417,727 312,001
Due Within One Year [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 305,053 201,606
Fair Value 305,095 201,596
Due After One Year through Two Years [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 112,639 110,395
Fair Value $ 112,632 $ 110,405
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Assets and Liabilities - Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration (Detail) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2021
Dec. 31, 2020
Earnout Payments | Minimum [Member]    
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Projected Year of Payment 2027 2027
Earnout Payments | Maximum [Member]    
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Projected Year of Payment 2039 2039
Milestone Payments | Minimum [Member]    
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Projected Year of Payment 2027 2027
Milestone Payments | Maximum [Member]    
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Projected Year of Payment 2031 2031
Contingent Consideration    
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Fair Value at $ 112,493 $ 152,230
Contingent Consideration | Earnout Payments    
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Fair Value at 103,093 142,250
Contingent Consideration | Milestone Payments    
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Fair Value at $ 9,400 $ 9,980
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Assets and Liabilities - Schedule of Total Acquisition Related Contingent Consideration Liability (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Business Acquisition, Contingent Consideration [Line Items]        
Beginning Balance     $ 152,230  
Discontinuation of MRT5201 and Decrease in fair value of contingent consideration $ 4,242 $ 15,347 (39,737) $ 5,895
Ending Balance $ 112,493   112,493  
Contingent Consideration        
Business Acquisition, Contingent Consideration [Line Items]        
Discontinuation of MRT5201 and Decrease in fair value of contingent consideration     $ (39,737)  
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Assets and Liabilities - Additional Information (Detail)
6 Months Ended 12 Months Ended
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Cash and cash equivalents $ 249,471,000 $ 342,027,000 $ 272,193,000
Contingent Consideration      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Discount Rate 10.8 11.0  
Money Market Funds | Fair Value, Inputs, Level 2      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Cash and cash equivalents $ 167,900,000 $ 273,800,000  
Fair Value, Measurements, Recurring      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Fair Value, assets transfers into (out of) Level 3 0 0  
Fair value,assets transfers from Level 2 to Level 1 0 0  
Fair value,assets transfers from Level 1 to Level 2 0 0  
Fair value, liabilities transfers from Level 1 to Level 2 0 0  
Fair value, liabilities transfers from Level 2 to Level 1 0 0  
Fair Value, liabilities transfers into (out of) Level 3 $ 0 $ 0  
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 29,261 $ 25,492
Less: Accumulated depreciation and amortization (11,012) (10,120)
Property and equipment, net 18,249 15,372
Laboratory Equipment [Member]    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 18,949 12,710
Computer Equipment [Member]    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 932 922
Office Equipment [Member]    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 941 941
Leasehold Improvements [Member]    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 5,557 5,730
Construction In Progress [Member]    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 2,882 $ 5,189
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, Net - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Property, Plant and Equipment [Abstract]        
Depreciation and amortization expense $ 1.0 $ 0.7 $ 1.9 $ 1.4
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accrued employee compensation and benefits $ 5,326 $ 5,600
Accrued external research and development expenses 4,420 2,805
Accrued consultant and professional fees 2,468 1,489
Other 2,865 3,308
Total accrued expenses $ 15,079 $ 13,202
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Expenses - Additional Information (Detail)
$ in Millions
Jun. 30, 2021
USD ($)
Payables and Accruals [Abstract]  
Other accrued expenses $ 2.5
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Incentive Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended
Jan. 01, 2020
Jun. 15, 2018
Jun. 30, 2021
Jun. 30, 2020
Jan. 20, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Unrecognized compensation cost related to unvested stock-based awards     $ 57.4      
Unrecognized compensation cost, period for recognition     2 years 10 months 24 days      
Stock Options [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Intrinsic value of stock options, exercised     $ 3.8 $ 10.7    
Weighted average grant-date fair value     $ 13.56 $ 5.50    
2021 Inducement Stock Incentive Plan [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant         2,612,550  
2018 Stock Incentive Plan [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Number of common shares reserved for issuance     10,471,204     7,457,171
Increase in common stock issued 3,001,185          
Percentage of exercise price per share of fair market value   100.00%        
Expiration period of stock options after grant date   10 years        
2018 Stock Incentive Plan [Member] | Minimum [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Stock options for purchase of common stock held, exercisable period   1 year        
2018 Stock Incentive Plan [Member] | Maximum [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Stock options for purchase of common stock held, exercisable period   4 years        
2018 Employee Stock Purchase Plan [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Number of common shares reserved for issuance     870,096      
Number of stock issued during period under the plan     54,152      
2016 Stock Incentive Plan [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Sharebased Compensation Arrangement by Sharebased Payment Award Shares Cancelled in Period     12,848      
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock Option Activity (Detail) - Stock Options [Member]
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Number of shares    
Number of shares, beginning balance | shares 9,557,391  
Number of shares, granted | shares 3,126,560  
Number of shares, exercised | shares (286,899)  
Number of shares, forfeited | shares (154,303)  
Number of shares, ending balance | shares 12,242,749 9,557,391
Number of shares, exercisable | shares 5,953,908  
Number of shares, vested and expected to vest, ending balance | shares 12,242,749  
Weighted average exercise price    
Weighted average exercise price, beginning balance | $ / shares $ 8.79  
Weighted average exercise price, granted | $ / shares 21.81  
Weighted average exercise price, exercised | $ / shares 8.25  
Weighted average exercise price, forfeited | $ / shares 14.68  
Weighted average exercise price, ending balance | $ / shares 12.06 $ 8.79
Weighted average exercise price, exercisable | $ / shares 8.14  
Weighted average exercise price, vested and expected to vest, ending balance | $ / shares $ 12.06  
Weighted average remaining contractual term    
Weighted average remaining contractual term, ending balance 8 years 25 days 7 years 11 months 1 day
Weighted average remaining contractual term, exercisable 7 years 25 days  
Weighted average remaining contractual term, vested and expected to vest, ending balance 8 years 25 days  
Intrinsic value    
Intrinsic value, ending balance | $ $ 189,483 $ 93,256
Intrinsic value, exercisable | $ 115,421  
Intrinsic value, vested and expected to vest, ending balance | $ $ 189,483  
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Incentive Stock Options and Employee Stock Purchase Plan - Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted (Detail) - Employees And Directors [Member] - Stock Options [Member]
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Risk-free interest rate 1.03% 0.79%
Expected term (in years) 6 years 1 month 6 days 6 years 1 month 6 days
Expected volatility 69.70% 68.60%
Expected dividend yield 0.00% 0.00%
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Stock-based compensation expense $ 5,336 $ 6,014 $ 9,320 $ 9,186
Research and Development Expenses [Member]        
Stock-based compensation expense 2,841 4,091 4,921 5,545
General and Administrative Expenses [Member]        
Stock-based compensation expense $ 2,495 $ 1,923 $ 4,399 $ 3,641
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Operating Loss Carryforwards [Line Items]        
Income tax benefits $ (981) $ 0 $ (727) $ 0
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Numerator:            
Net income (loss) $ 17,144 $ 26,522 $ (36,288) $ (14,282) $ 43,666 $ (50,570)
Denominator:            
Weighted average common shares outstanding—basic 75,254,186   62,282,291   75,222,119 61,145,254
Net income (loss) per share—basic $ 0.23   $ (0.58)   $ 0.58 $ (0.83)
Weighted average common shares outstanding—diluted 80,026,488   62,282,291   79,994,422 61,145,254
Net income (loss) per share—diluted $ 0.21   $ (0.58)   $ 0.55 $ (0.83)
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income (Loss) per Share - Additional Information (Detail) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Antidilutive securities excluded from computation of basic net loss per share   3,608,932 10,496,680
Restricted Common Stock [Member]      
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Antidilutive securities excluded from computation of basic net loss per share   0 1,691
Restricted Common Stock [Member] | Weighted Average [Member]      
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Antidilutive securities excluded from computation of basic net loss per share 3,790   11,149
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Net Income (Loss) per Share - Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail) - shares
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Antidilutive securities excluded from computation of basic net loss per share 3,608,932 10,496,680
Stock Options [Member]    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Antidilutive securities excluded from computation of basic net loss per share 3,608,932 10,494,989
Restricted Common Stock [Member]    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Antidilutive securities excluded from computation of basic net loss per share 0 1,691
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Additional Information (Details)
1 Months Ended 6 Months Ended 12 Months Ended
Nov. 03, 2020
USD ($)
ft²
Mar. 31, 2018
Oct. 31, 2020
USD ($)
Jun. 30, 2017
USD ($)
ft²
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Apr. 30, 2021
USD ($)
Lessee Lease Description [Line Items]                
Lease expiration period   Mar. 31, 2023     Mar. 31, 2023      
Remaining term of lease         5 years 8 years    
Operating lease right of use assets         $ 68,123,000   $ 72,957,000  
Operating lease, liability         57,856,000   62,686,000  
Operating lease commitment         75,953,000   84,049,000  
Operating lease liability due in first year         15,178,000   18,067,000  
Operating lease liability due in second year         15,591,000   15,178,000  
Opearting lease payment         9,593,000 $ 1,320,000    
Increase decrease in right of use assets and lease liabilities         1,400,000      
Waltham Massachusetts [Member]                
Lessee Lease Description [Line Items]                
Office and laboratory space | ft² 138,444              
Operating lease right of use assets         0      
Operating lease, liability         0      
Tenant improvement for lease $ 26,300,000              
Additional tenant allownace per square foot $ 15              
Operating lease liability due in first year             5,700,000  
Operating lease liability due in second year             8,000,000.0  
Restricted cash             3,900,000  
Opearting lease payment         $ 2,300,000      
Operating Lease Term Of Contract 10 years              
Percentage Of Increase In The Monthly Rental Expense 3.00%              
Lexington, Massachusetts [Member]                
Lessee Lease Description [Line Items]                
Office and laboratory space | ft²       59,000        
Monthly lease payments       $ 200,000        
Percentage of annual increase in operating lease       3.00%        
Cash deposit collateral       $ 1,000,000.0        
Remaining term of lease         7 years      
Operating Lease Term Of Contract   5 years   10 years        
Suite Retention And Development Agreement [Member]                
Lessee Lease Description [Line Items]                
Commitment to Build Out Cost         $ 6,000,000.0      
Shared Overage cost commitment         11,000,000.0      
Maximum [Member] | Waltham Massachusetts [Member]                
Lessee Lease Description [Line Items]                
Opearting lease payment             12,500,000  
Minimum [Member] | Waltham Massachusetts [Member]                
Lessee Lease Description [Line Items]                
Opearting lease payment             $ 10,500,000  
Albany Molecular Research, Inc. ("AMRI") [Member] | Suite Retention And Development Agreement [Member]                
Lessee Lease Description [Line Items]                
Monthly lease payments         1,000,000.0      
Payments For Build Out Costs         3,200,000      
Future Build Out Costs         5,600,000      
Operating lease right of use assets         66,600,000      
Operating lease, liability         $ 53,800,000      
Operating Lease Term Of Contract         5 years      
Operating Lease Renewal Term         3 years      
Operating lease option to extend description         the Company has the right to extend for an additional three years.      
Percentage Of Increase In The Monthly Rental Expense         3.00%      
Albany Molecular Research, Inc. ("AMRI") [Member] | Suite Retention And Development Agreement [Member] | Other Noncurrent Assets [Member]                
Lessee Lease Description [Line Items]                
Payments For Build Out Costs         $ 12,800,000      
Biomedical Research Models Inc [Member] | Suite Retention And Development Agreement [Member]                
Lessee Lease Description [Line Items]                
Monthly lease payments     $ 100,000          
Operating lease right of use assets     300,000          
Operating lease, liability     $ 300,000          
Operating Lease Term Of Contract     13 months          
Azzur Cleanrooms on Demand Burlington LLC [Member] | Burlington Massachusetts [Member]                
Lessee Lease Description [Line Items]                
Monthly lease payments         400,000      
Operating lease right of use assets         0      
Operating lease, liability         0      
Operating lease commitment         $ 8,800,000      
Operating Lease Term Of Contract     24 months          
Percentage Of Increase In The Monthly Rental Expense         4.00%      
Richmond Group [Member] | Office And Laboratory Space [Member]                
Lessee Lease Description [Line Items]                
Operating lease, liability               $ 36,800,000
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Lease Cost (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Lease Cost    
Operating lease cost $ 9,597 $ 1,346
Total lease cost 9,597 1,346
Operating cash flows from operating leases 9,593 $ 1,320
Operating lease liabilities arising from obtaining right-of-use assets $ 1,376  
Weighted-average remaining lease term 5 years 8 years
Weighted-average discount rate 12.00% 17.50%
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Leases [Abstract]    
2021 $ 9,971  
2021 and 2022 15,178 $ 18,067
2022 and 2023 15,591 15,178
2023 and 2024 16,050 15,591
2024 and 2025 12,029 16,050
2025   12,029
2026 and thereafter 7,134  
2026 and thereafter   7,134
Total future minimum lease payments 75,953 84,049
Less: imputed interest (18,097) (21,363)
Present value of lease liabilities $ 57,856 $ 62,686
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2019
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Loss Contingencies [Line Items]            
Research agreement, payable amount   $ 4,420   $ 4,420   $ 2,805
Research and development   40,477 $ 29,002 $ 81,617 $ 50,442  
Research agreement, expiration period       2022-12    
Research agreement, payment       $ 2,400 1,200  
Amended Sanofi Agreement [Member] | Sanofi Pasteur Inc [Member]            
Loss Contingencies [Line Items]            
Upfront payment received   2,500   $ 2,500    
Roche Diagnostics Corporation Master Supply Agreement [Member]            
Loss Contingencies [Line Items]            
Agreement extended date       Dec. 31, 2024    
Commitment amount       $ 10,500    
Purchase commitments, year 2022   3,500   3,500    
Purchase commitments, year 2023   3,500   3,500    
Purchase commitments, year 2024   3,500   3,500    
Research and development   1,300 1,300 5,700 2,600  
MIT Research Agreement [Member]            
Loss Contingencies [Line Items]            
Research agreement, payable amount   0   0    
Research and development   300 $ 300 700 $ 700  
Research agreement, committed amount $ 4,100          
Research agreement, expiration period 2022-12          
MIT Exclusive Patent License Agreement [Member]            
Loss Contingencies [Line Items]            
Payment of milestones   700   700    
MIT Exclusive Patent License Agreement [Member] | Sanofi Pasteur Inc [Member]            
Loss Contingencies [Line Items]            
Upfront payment received   3,400   3,400    
MIT Exclusive Patent License Agreement [Member] | Milestone Payment One [Member]            
Loss Contingencies [Line Items]            
License agreement, milestone payments       1,375    
MIT Exclusive Patent License Agreement [Member] | Milestone Payment Two [Member]            
Loss Contingencies [Line Items]            
License agreement, milestone payments       1,250    
MIT Exclusive Patent License Agreement [Member] | Milestone payment Three [Member]            
Loss Contingencies [Line Items]            
Upfront payment received   $ 900   $ 900    
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Event - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
Aug. 02, 2021
Jun. 30, 2021
Dec. 31, 2020
Subsequent Event [Line Items]      
Business combination, contingent consideration, liability   $ 112,493 $ 152,230
Subsequent Event [Member] | Merger Agreement [Member]      
Subsequent Event [Line Items]      
Shares issued, price per share $ 38.00    
Subsequent Event [Member] | Merger Agreement [Member] | Termination of Agreement [Member] | Vector Merger Sub, Inc [Member]      
Subsequent Event [Line Items]      
Business combination, contingent consideration, liability $ 96,000    
EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 217 355 1 false 69 0 false 9 false false R1.htm 1001 - Document - Cover Page Sheet http://translate.bio/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://translate.bio/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations Sheet http://translate.bio/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Sheet http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 1008 - Statement - Condensed Consolidated Statements of Cash flows Sheet http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash flows Statements 8 false false R9.htm 1009 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentation Nature of the Business and Basis of Presentation Notes 9 false false R10.htm 1010 - Disclosure - Summary of Significant Accounting Policies Sheet http://translate.bio/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 1011 - Disclosure - Collaboration Agreement Sheet http://translate.bio/role/CollaborationAgreement Collaboration Agreement Notes 11 false false R12.htm 1012 - Disclosure - Intangible Assets and Goodwill Sheet http://translate.bio/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 12 false false R13.htm 1013 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilities Fair Value of Financial Assets and Liabilities Notes 13 false false R14.htm 1014 - Disclosure - Property and Equipment, Net Sheet http://translate.bio/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 14 false false R15.htm 1015 - Disclosure - Accrued Expenses Sheet http://translate.bio/role/AccruedExpenses Accrued Expenses Notes 15 false false R16.htm 1016 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan Sheet http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlan Incentive Stock Options and Employee Stock Purchase Plan Notes 16 false false R17.htm 1017 - Disclosure - Income Taxes Sheet http://translate.bio/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 1018 - Disclosure - Net Income (Loss) per Share Sheet http://translate.bio/role/NetIncomeLossPerShare Net Income (Loss) per Share Notes 18 false false R19.htm 1019 - Disclosure - Leases Sheet http://translate.bio/role/Leases Leases Notes 19 false false R20.htm 1020 - Disclosure - Commitments and Contingencies Sheet http://translate.bio/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 1021 - Disclosure - Subsequent Event Sheet http://translate.bio/role/SubsequentEvent Subsequent Event Notes 21 false false R22.htm 1022 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://translate.bio/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://translate.bio/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 1023 - Disclosure - Collaboration Agreement (Tables) Sheet http://translate.bio/role/CollaborationAgreementTables Collaboration Agreement (Tables) Tables http://translate.bio/role/CollaborationAgreement 23 false false R24.htm 1024 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://translate.bio/role/IntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://translate.bio/role/IntangibleAssetsAndGoodwill 24 false false R25.htm 1025 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilities 25 false false R26.htm 1026 - Disclosure - Property and Equipment, Net (Tables) Sheet http://translate.bio/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://translate.bio/role/PropertyAndEquipmentNet 26 false false R27.htm 1027 - Disclosure - Accrued Expenses (Tables) Sheet http://translate.bio/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://translate.bio/role/AccruedExpenses 27 false false R28.htm 1028 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan (Tables) Sheet http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables Incentive Stock Options and Employee Stock Purchase Plan (Tables) Tables http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlan 28 false false R29.htm 1029 - Disclosure - Net Income (Loss) per Share (Tables) Sheet http://translate.bio/role/NetIncomeLossPerShareTables Net Income (Loss) per Share (Tables) Tables http://translate.bio/role/NetIncomeLossPerShare 29 false false R30.htm 1030 - Disclosure - Leases (Tables) Sheet http://translate.bio/role/LeasesTables Leases (Tables) Tables http://translate.bio/role/Leases 30 false false R31.htm 1031 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) Sheet http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail Nature of the Business and Basis of Presentation - Additional Information (Detail) Details 31 false false R32.htm 1032 - Disclosure - Collaboration Agreement - Additional Information (Detail) Sheet http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail Collaboration Agreement - Additional Information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Collaboration Agreement - Summary of Collaboration Revenue (Detail) Sheet http://translate.bio/role/CollaborationAgreementSummaryOfCollaborationRevenueDetail Collaboration Agreement - Summary of Collaboration Revenue (Detail) Details 33 false false R34.htm 1034 - Disclosure - Collaboration Agreement - Balance of Contract Liabilities Related to Collaboration Agreements (Detail) Sheet http://translate.bio/role/CollaborationAgreementBalanceOfContractLiabilitiesRelatedToCollaborationAgreementsDetail Collaboration Agreement - Balance of Contract Liabilities Related to Collaboration Agreements (Detail) Details 34 false false R35.htm 1035 - Disclosure - Intangible Assets and Goodwill - Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets (Detail) Sheet http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail Intangible Assets and Goodwill - Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets (Detail) Details 35 false false R36.htm 1036 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) Sheet http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail Intangible Assets and Goodwill - Additional Information (Detail) Details 36 false false R37.htm 1037 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 37 false false R38.htm 1038 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail) Sheet http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail Fair Value of Financial Assets and Liabilities - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail) Details 38 false false R39.htm 1039 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration (Detail) Sheet http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail Fair Value of Financial Assets and Liabilities - Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration (Detail) Details 39 false false R40.htm 1040 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Total Acquisition Related Contingent Consideration Liability (Detail) Sheet http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail Fair Value of Financial Assets and Liabilities - Schedule of Total Acquisition Related Contingent Consideration Liability (Detail) Details 40 false false R41.htm 1041 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail) Sheet http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail Fair Value of Financial Assets and Liabilities - Additional Information (Detail) Details 41 false false R42.htm 1042 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) Sheet http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) Details 42 false false R43.htm 1043 - Disclosure - Property and Equipment, Net - Additional Information (Detail) Sheet http://translate.bio/role/PropertyAndEquipmentNetAdditionalInformationDetail Property and Equipment, Net - Additional Information (Detail) Details 43 false false R44.htm 1044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 44 false false R45.htm 1045 - Disclosure - Accrued Expenses - Additional Information (Detail) Sheet http://translate.bio/role/AccruedExpensesAdditionalInformationDetail Accrued Expenses - Additional Information (Detail) Details 45 false false R46.htm 1046 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Sheet http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail Incentive Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Details 46 false false R47.htm 1047 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock Option Activity (Detail) Sheet http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock Option Activity (Detail) Details 47 false false R48.htm 1048 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted (Detail) Sheet http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail Incentive Stock Options and Employee Stock Purchase Plan - Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted (Detail) Details 48 false false R49.htm 1049 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock-Based Compensation Expense (Detail) Sheet http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock-Based Compensation Expense (Detail) Details 49 false false R50.htm 1050 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://translate.bio/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 50 false false R51.htm 1051 - Disclosure - Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) Sheet http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) Details http://translate.bio/role/NetIncomeLossPerShareTables 51 false false R52.htm 1052 - Disclosure - Net Income (Loss) per Share - Additional Information (Detail) Sheet http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail Net Income (Loss) per Share - Additional Information (Detail) Details http://translate.bio/role/NetIncomeLossPerShareTables 52 false false R53.htm 1053 - Disclosure - Net Income (Loss) per Share - Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail) Sheet http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail Net Income (Loss) per Share - Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail) Details http://translate.bio/role/NetIncomeLossPerShareTables 53 false false R54.htm 1054 - Disclosure - Leases - Additional Information (Details) Sheet http://translate.bio/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 54 false false R55.htm 1055 - Disclosure - Leases - Schedule of Lease Cost (Details) Sheet http://translate.bio/role/LeasesScheduleOfLeaseCostDetails Leases - Schedule of Lease Cost (Details) Details 55 false false R56.htm 1056 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) Sheet http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) Details 56 false false R57.htm 1057 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 57 false false R58.htm 1058 - Disclosure - Subsequent Event - Additional Information (Detail) Sheet http://translate.bio/role/SubsequentEventAdditionalInformationDetail Subsequent Event - Additional Information (Detail) Details 58 false false All Reports Book All Reports d192980d10q.htm d192980dex101.htm d192980dex102.htm d192980dex103.htm d192980dex311.htm d192980dex312.htm d192980dex321.htm d192980dex322.htm tbio-20210630.xsd tbio-20210630_cal.xml tbio-20210630_def.xml tbio-20210630_lab.xml tbio-20210630_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d192980d10q.htm": { "axisCustom": 4, "axisStandard": 25, "contextCount": 217, "dts": { "calculationLink": { "local": [ "tbio-20210630_cal.xml" ] }, "definitionLink": { "local": [ "tbio-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "d192980d10q.htm" ] }, "labelLink": { "local": [ "tbio-20210630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tbio-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "tbio-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 507, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 3, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 7 }, "keyCustom": 53, "keyStandard": 302, "memberCustom": 42, "memberStandard": 25, "nsprefix": "tbio", "nsuri": "http://translate.bio/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://translate.bio/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Summary of Significant Accounting Policies", "role": "http://translate.bio/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Collaboration Agreement", "role": "http://translate.bio/role/CollaborationAgreement", "shortName": "Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Intangible Assets and Goodwill", "role": "http://translate.bio/role/IntangibleAssetsAndGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Fair Value of Financial Assets and Liabilities", "role": "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Property and Equipment, Net", "role": "http://translate.bio/role/PropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Accrued Expenses", "role": "http://translate.bio/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan", "role": "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlan", "shortName": "Incentive Stock Options and Employee Stock Purchase Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Income Taxes", "role": "http://translate.bio/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Net Income (Loss) per Share", "role": "http://translate.bio/role/NetIncomeLossPerShare", "shortName": "Net Income (Loss) per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Leases", "role": "http://translate.bio/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Commitments and Contingencies", "role": "http://translate.bio/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Subsequent Event", "role": "http://translate.bio/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "tbio:RecentlyadoptedaccountingpronouncementPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://translate.bio/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "tbio:RecentlyadoptedaccountingpronouncementPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Collaboration Agreement (Tables)", "role": "http://translate.bio/role/CollaborationAgreementTables", "shortName": "Collaboration Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Intangible Assets and Goodwill (Tables)", "role": "http://translate.bio/role/IntangibleAssetsAndGoodwillTables", "shortName": "Intangible Assets and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "role": "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesTables", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://translate.bio/role/PropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Accrued Expenses (Tables)", "role": "http://translate.bio/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan (Tables)", "role": "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables", "shortName": "Incentive Stock Options and Employee Stock Purchase Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Net Income (Loss) per Share (Tables)", "role": "http://translate.bio/role/NetIncomeLossPerShareTables", "shortName": "Net Income (Loss) per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Leases (Tables)", "role": "http://translate.bio/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "0", "first": true, "lang": null, "name": "tbio:NumberOfWhollyOwnedSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Subsidiary", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)", "role": "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "0", "first": true, "lang": null, "name": "tbio:NumberOfWhollyOwnedSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Subsidiary", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Collaboration Agreement - Additional Information (Detail)", "role": "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "shortName": "Collaboration Agreement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Collaboration Agreement - Summary of Collaboration Revenue (Detail)", "role": "http://translate.bio/role/CollaborationAgreementSummaryOfCollaborationRevenueDetail", "shortName": "Collaboration Agreement - Summary of Collaboration Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Collaboration Agreement - Balance of Contract Liabilities Related to Collaboration Agreements (Detail)", "role": "http://translate.bio/role/CollaborationAgreementBalanceOfContractLiabilitiesRelatedToCollaborationAgreementsDetail", "shortName": "Collaboration Agreement - Balance of Contract Liabilities Related to Collaboration Agreements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Intangible Assets and Goodwill - Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets (Detail)", "role": "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail", "shortName": "Intangible Assets and Goodwill - Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail)", "role": "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "shortName": "Intangible Assets and Goodwill - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)", "role": "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Fair Value of Financial Assets and Liabilities - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail)", "role": "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail", "shortName": "Fair Value of Financial Assets and Liabilities - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "tbio:FairValueInputsProjectedYearOfPayment", "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021_EarnoutPaymentsMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "tbio:FairValueInputsProjectedYearOfPayment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration (Detail)", "role": "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "tbio:FairValueInputsProjectedYearOfPayment", "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021_EarnoutPaymentsMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "tbio:FairValueInputsProjectedYearOfPayment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Total Acquisition Related Contingent Consideration Liability (Detail)", "role": "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Total Acquisition Related Contingent Consideration Liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021_ContingentConsiderationMemberusgaapContingentConsiderationByTypeAxis", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)", "role": "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "shortName": "Fair Value of Financial Assets and Liabilities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021_ContingentConsiderationMemberusgaapContingentConsiderationByTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:AlternativeInvestmentMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)", "role": "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Property and Equipment, Net - Additional Information (Detail)", "role": "http://translate.bio/role/PropertyAndEquipmentNetAdditionalInformationDetail", "shortName": "Property and Equipment, Net - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)", "role": "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Accrued Expenses - Additional Information (Detail)", "role": "http://translate.bio/role/AccruedExpensesAdditionalInformationDetail", "shortName": "Accrued Expenses - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Additional Information (Detail)", "role": "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "shortName": "Incentive Stock Options and Employee Stock Purchase Plan - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock Option Activity (Detail)", "role": "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail", "shortName": "Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021_EmployeesAndDirectorsMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted (Detail)", "role": "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "shortName": "Incentive Stock Options and Employee Stock Purchase Plan - Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021_EmployeesAndDirectorsMembersrtTitleOfIndividualAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock-Based Compensation Expense (Detail)", "role": "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail", "shortName": "Incentive Stock Options and Employee Stock Purchase Plan - Summary of Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "role": "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)", "role": "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "shortName": "Net Income (Loss) per Share - Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Net Income (Loss) per Share - Additional Information (Detail)", "role": "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail", "shortName": "Net Income (Loss) per Share - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2020To06_30_2020_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WeightedAverageMembersrtRangeAxis", "decimals": "0", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Net Income (Loss) per Share - Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)", "role": "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail", "shortName": "Net Income (Loss) per Share - Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Leases - Additional Information (Details)", "role": "http://translate.bio/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "-5", "lang": null, "name": "tbio:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Leases - Schedule of Lease Cost (Details)", "role": "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails", "shortName": "Leases - Schedule of Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1056 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)", "role": "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "tbio:AccruedExternalResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1057 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "lang": "en-US", "name": "tbio:ResearchCollaborativeArrangementExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1058 - Disclosure - Subsequent Event - Additional Information (Detail)", "role": "http://translate.bio/role/SubsequentEventAdditionalInformationDetail", "shortName": "Subsequent Event - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn08_02_2021_MergerAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "decimals": "2", "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "role": "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P04_01_2021To06_30_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008 - Statement - Condensed Consolidated Statements of Cash flows", "role": "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Nature of the Business and Basis of Presentation", "role": "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d192980d10q.htm", "contextRef": "P01_01_2021To06_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://translate.bio/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [ "r202", "r204", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r379", "r381" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r202", "r204", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r379", "r381" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r191", "r202", "r204", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r379", "r381" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Range" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r191", "r202", "r204", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r379", "r381" ], "lang": { "en-us": { "role": { "label": "Range [Domain]", "terseLabel": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r86", "r87", "r88", "r89", "r90", "r103", "r139", "r140", "r237", "r254", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "label": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r86", "r87", "r88", "r89", "r90", "r103", "r139", "r140", "r237", "r254", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "label": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r127", "r128", "r187", "r190", "r380", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r127", "r128", "r187", "r190", "r380", "r392", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r130", "r319" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r327", "r329", "r332" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_AccruedConsultantAndProfessionalFees": { "auth_ref": [], "calculation": { "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued consultant and professional fees.", "label": "Accrued Consultant And Professional Fees", "terseLabel": "Accrued consultant and professional fees" } } }, "localname": "AccruedConsultantAndProfessionalFees", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "tbio_AccruedExternalResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued external research and development expenses current.", "label": "Accrued External Research And Development Expenses Current", "terseLabel": "Accrued external research and development expenses", "verboseLabel": "Research agreement, payable amount" } } }, "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_AdditionalTenantImprovementAllowanceForLeasePerSquareFoot": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional tenant improvement allowance for lease per square foot.", "label": "Additional Tenant Improvement Allowance For Lease Per Square Foot", "terseLabel": "Additional tenant allownace per square foot" } } }, "localname": "AdditionalTenantImprovementAllowanceForLeasePerSquareFoot", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tbio_AdditionalUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional upfront payment.", "label": "Additional Upfront Payment", "terseLabel": "Additional Upfront Payment" } } }, "localname": "AdditionalUpfrontPayment", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_AdditionalUpfrontPaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional upfront payment receivable.", "label": "Additional Upfront Payment Receivable", "terseLabel": "Additional Upfront Payment Receivable" } } }, "localname": "AdditionalUpfrontPaymentReceivable", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_AggregateResearchFundingCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend for research funding under the collaboration agreement.", "label": "Aggregate Research Funding Commitment Amount", "terseLabel": "Research agreement, committed amount" } } }, "localname": "AggregateResearchFundingCommitmentAmount", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_AgreementOneAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement One [Axis]" } } }, "localname": "AgreementOneAxis", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tbio_AgreementOneDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement One [Domain]" } } }, "localname": "AgreementOneDomain", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_AgreementTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement Type [Axis]" } } }, "localname": "AgreementTypeAxis", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tbio_AgreementTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement Type [Domain]" } } }, "localname": "AgreementTypeDomain", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_AlbanyMolecularResearchIncamriMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Albany Molecular Research IncAMRI [Member]", "terseLabel": "Albany Molecular Research, Inc.\u00a0(\"AMRI\") [Member]" } } }, "localname": "AlbanyMolecularResearchIncamriMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_AmendedSanofiAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Sanofi Agreement.", "label": "Amended Sanofi Agreement [Member]", "terseLabel": "Amended Sanofi Agreement [Member]" } } }, "localname": "AmendedSanofiAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_AmountPayableOnMilestoneAchievementPursuantToALicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable on milestone achievement pursuant to a license agreement.", "label": "Amount Payable On Milestone Achievement Pursuant To A License Agreement", "terseLabel": "Payment of milestones" } } }, "localname": "AmountPayableOnMilestoneAchievementPursuantToALicenseAgreement", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_AmountPayableOnSublicenseIncomePursuantToALicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable on sublicense income pursuant to a license agreement.", "label": "Amount Payable On Sublicense Income Pursuant To A License Agreement", "terseLabel": "Upfront payment received" } } }, "localname": "AmountPayableOnSublicenseIncomePursuantToALicenseAgreement", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement And Related License Agreement [Abstract]", "label": "Asset Purchase Agreement And Related License Agreement [Abstract]" } } }, "localname": "AssetPurchaseAgreementAndRelatedLicenseAgreementAbstract", "nsuri": "http://translate.bio/20210630", "xbrltype": "stringItemType" }, "tbio_AzzurCleanroomsOnDemandBurlingtonLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Azzur Cleanrooms on Demand Burlington LLC [Member].", "label": "Azzur Cleanrooms on Demand Burlington LLC [Member]", "terseLabel": "Azzur Cleanrooms on Demand Burlington LLC [Member]" } } }, "localname": "AzzurCleanroomsOnDemandBurlingtonLlcMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_BiomedicalResearchModelsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biomedical research models, Inc [Member].", "label": "Biomedical Research Models Inc [Member]", "terseLabel": "Biomedical Research Models Inc [Member]" } } }, "localname": "BiomedicalResearchModelsIncMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_BuildOutCostCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Build Out Cost Commitment.", "label": "Build Out Cost Commitment", "terseLabel": "Commitment to Build Out Cost" } } }, "localname": "BuildOutCostCommitment", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tbio_BurlingtonMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Burlington Massachusetts [Member].", "label": "Burlington Massachusetts [Member]", "terseLabel": "Burlington Massachusetts [Member]" } } }, "localname": "BurlingtonMassachusettsMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_CashPaymentOfResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Payment Of Research And Development Expense", "label": "Cash Payment Of Research And Development Expense", "terseLabel": "Research agreement, payment" } } }, "localname": "CashPaymentOfResearchAndDevelopmentExpense", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_CollaborationReceivableMilestonePaymentsAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaboration receivable milestone payments achieved.", "label": "Collaboration Receivable Milestone Payments Achieved", "terseLabel": "Collaboration receivable milestone payments achieved" } } }, "localname": "CollaborationReceivableMilestonePaymentsAchieved", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_CollaborativeAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement [Axis]", "label": "Collaborative Agreement [Axis]", "terseLabel": "Collaborative Agreement" } } }, "localname": "CollaborativeAgreementAxis", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tbio_CollaborativeAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Agreement [Domain]", "label": "Collaborative Agreement [Domain]", "terseLabel": "Collaborative Agreement" } } }, "localname": "CollaborativeAgreementDomain", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_CollaborativeArrangementMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement Milestone Payment", "label": "Collaborative Arrangement Milestone Payment", "terseLabel": "License agreement, milestone payments" } } }, "localname": "CollaborativeArrangementMilestonePayment", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "domainItemType" }, "tbio_DevelopmenTandRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development and Regulatory Milestone Payments.", "label": "Developmen tAnd Regulatory Milestone Payments", "terseLabel": "Maximum development and regulatory milestone payment receivable" } } }, "localname": "DevelopmenTandRegulatoryMilestonePayments", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_EarnoutPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnout payments.", "label": "Earnout Payments [Member]", "terseLabel": "Earnout Payments" } } }, "localname": "EarnoutPaymentsMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "domainItemType" }, "tbio_EmployeesAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and directors.", "label": "Employees And Directors [Member]" } } }, "localname": "EmployeesAndDirectorsMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail" ], "xbrltype": "domainItemType" }, "tbio_EstimatedMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated milestone payments.", "label": "Estimated Milestone Payments", "terseLabel": "Estimated milestone payments" } } }, "localname": "EstimatedMilestonePayments", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_EstimatedReimbursableDevelopmentCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated reimbursable development costs.", "label": "Estimated Reimbursable Development Costs", "terseLabel": "Estimated reimbursable development cost" } } }, "localname": "EstimatedReimbursableDevelopmentCosts", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_EstimatedReimbursableEmployeeCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated reimbursable employee costs.", "label": "Estimated Reimbursable Employee Costs", "terseLabel": "Estimated reimbursable employee cost" } } }, "localname": "EstimatedReimbursableEmployeeCosts", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_FairValueInputsProjectedYearOfPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value inputs projected year of payment.", "label": "Fair Value Inputs Projected Year Of Payment", "terseLabel": "Projected Year of Payment" } } }, "localname": "FairValueInputsProjectedYearOfPayment", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "gYearItemType" }, "tbio_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "label": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "terseLabel": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]" } } }, "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "tbio_FinancingReceivablesDueAfterOneYearThroughTwoYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing Receivables Due After One Year Through Two Years", "label": "Financing Receivables Due After One Year Through Two Years [Member]", "terseLabel": "Due After One Year through Two Years [Member]" } } }, "localname": "FinancingReceivablesDueAfterOneYearThroughTwoYearsMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "domainItemType" }, "tbio_FinancingReceivablesDueWithinOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing Receivables Due Within One Year", "label": "Financing Receivables Due Within One Year [Member]", "terseLabel": "Due Within One Year [Member]" } } }, "localname": "FinancingReceivablesDueWithinOneYearMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "domainItemType" }, "tbio_FuturePaymentsForBuildOutCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future payments for build out costs.", "label": "Future Payments For Build Out Costs", "terseLabel": "Future Build Out Costs" } } }, "localname": "FuturePaymentsForBuildOutCosts", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tbio_IncreaseDecreaseInLeaseLiability": { "auth_ref": [], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in lease liability.", "label": "Increase Decrease In Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInLeaseLiability", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tbio_IncreaseDecreaseInRightOfUseAssets": { "auth_ref": [], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in right-of-use assets.", "label": "Increase Decrease In Right Of Use Assets", "negatedLabel": "Right-of-use assets" } } }, "localname": "IncreaseDecreaseInRightOfUseAssets", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tbio_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in right of use assets and lease liabilities.", "label": "Increase Decrease In Right Of Use Assets And Lease Liabilities", "terseLabel": "Increase decrease in right of use assets and lease liabilities" } } }, "localname": "IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilities", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tbio_IncreaseDecreaseInShortTermCollaborationReceivables": { "auth_ref": [], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in short term collaboration receivables.", "label": "Increase Decrease In Short Term Collaboration Receivables", "terseLabel": "Collaboration receivables" } } }, "localname": "IncreaseDecreaseInShortTermCollaborationReceivables", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tbio_IncreaseDecreaseInTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase/Decrease in transaction price.", "label": "Increase Decrease In Transaction Price", "negatedLabel": "Increase in transaction price" } } }, "localname": "IncreaseDecreaseInTransactionPrice", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_InitialPublicOfferingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering [Line Items]", "label": "Initial Public Offering [Line Items]", "terseLabel": "Initial Public Offering [Line Items]" } } }, "localname": "InitialPublicOfferingLineItems", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tbio_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "tbio_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after Year four.", "label": "Lessee Operating Lease Liability Payments Due after Year Four", "terseLabel": "2026 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "tbio_LexingtonMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lexington Massachusetts.", "label": "Lexington Massachusetts [Member]", "terseLabel": "Lexington, Massachusetts [Member]" } } }, "localname": "LexingtonMassachusettsMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_LumpsumOrOnetimeManufacturingMilestoneAmountReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lumpsum or onetime manufacturing milestone amount receivable.", "label": "Lumpsum Or Onetime Manufacturing Milestone Amount Receivable", "terseLabel": "Lumpsum or one time manufacturing milestone amount receivable" } } }, "localname": "LumpsumOrOnetimeManufacturingMilestoneAmountReceivable", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MIT Exclusive patent license agreement.", "label": "Massachusetts Institute Of Technology Exclusive Patent License Agreement [Member]", "terseLabel": "MIT Exclusive Patent License Agreement [Member]" } } }, "localname": "MassachusettsInstituteOfTechnologyExclusivePatentLicenseAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_MaximumNumberOfInfectiousDiseasePathogensForVaccineDevelopment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum \u200bnumber \u200bof infectious \u200bdisease pathogens \u200bfor\u200b vaccine \u200bdevelopment.", "label": "Maximum Number Of Infectious disease Pathogens For Vaccine Development", "terseLabel": "Maximum number of infectious disease pathogens for vaccine development" } } }, "localname": "MaximumNumberOfInfectiousDiseasePathogensForVaccineDevelopment", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "tbio_MergerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger agreement.", "label": "Merger Agreement [Member]", "terseLabel": "Merger Agreement [Member]" } } }, "localname": "MergerAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_MilestonePaymentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment One [Member]", "label": "Milestone Payment One [Member]", "terseLabel": "Milestone Payment One [Member]" } } }, "localname": "MilestonePaymentOneMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_MilestonePaymentReceivableUponTheSatisfactionOfAdditionalSpecifiedCommercialRegulatoryAndManufacturingMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment receivable upon the satisfaction of additional specified commercial regulatory and manufacturing milestones.", "label": "Milestone Payment Receivable Upon The Satisfaction Of Additional Specified Commercial Regulatory And Manufacturing Milestones", "terseLabel": "Milestone payment receivable upon the achievement of additional specified regulatory development manufacturing and commercial milestones" } } }, "localname": "MilestonePaymentReceivableUponTheSatisfactionOfAdditionalSpecifiedCommercialRegulatoryAndManufacturingMilestones", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_MilestonePaymentThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Milestone payment Three [Member]", "terseLabel": "Milestone payment Three [Member]" } } }, "localname": "MilestonePaymentThreeMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_MilestonePaymentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment Two [Member]", "label": "Milestone Payment Two [Member]", "terseLabel": "Milestone Payment Two [Member]" } } }, "localname": "MilestonePaymentTwoMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_MilestonePaymentsAchieved": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments achieved.", "label": "Milestone Payments Achieved", "terseLabel": "Milestone payments achieved" } } }, "localname": "MilestonePaymentsAchieved", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_MilestonePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments [Member]", "terseLabel": "Milestone Payments" } } }, "localname": "MilestonePaymentsMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "domainItemType" }, "tbio_MitResearchAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MIT research agreement.", "label": "Mit Research Agreement [Member]", "terseLabel": "MIT Research Agreement [Member]" } } }, "localname": "MitResearchAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_MrtProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MRT Product.", "label": "Mrt Product [Member]", "terseLabel": "MRT Product [Member]" } } }, "localname": "MrtProductMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "tbio_NatureOfBusinessAndBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of business and basis of presentation.", "label": "Nature Of Business And Basis Of Presentation [Table]", "terseLabel": "Nature Of Business And Basis Of Presentation [Table]" } } }, "localname": "NatureOfBusinessAndBasisOfPresentationTable", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tbio_NonRefundableUpfrontFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-refundable upfront fees.", "label": "Non Refundable Upfront Fees", "terseLabel": "Non-refundable upfront payment" } } }, "localname": "NonRefundableUpfrontFees", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_NumberOfInfectiousDiseasePathogensForVaccineDevelopment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of infectious disease pathogens for vaccine development.", "label": "Number Of Infectious Disease Pathogens For Vaccine Development", "terseLabel": "Number of infectious disease pathogens for vaccine development" } } }, "localname": "NumberOfInfectiousDiseasePathogensForVaccineDevelopment", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "tbio_NumberOfWhollyOwnedSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of wholly owned subsidiaries.", "label": "Number Of Wholly Owned Subsidiaries", "terseLabel": "Number of wholly owned subsidiaries" } } }, "localname": "NumberOfWhollyOwnedSubsidiaries", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "tbio_OTCDeficiencyProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OTC deficiency program.", "label": "O T C Deficiency Program [Member]", "terseLabel": "OTC Deficiency Program [Member]" } } }, "localname": "OTCDeficiencyProgramMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_OfferingCostsIncludedInAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs included in accrued expenses.", "label": "Offering costs included in accrued expenses", "terseLabel": "Offering costs included in accrued expenses" } } }, "localname": "OfferingCostsIncludedInAccruedExpenses", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tbio_OfficeAndLaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and laboratory space.", "label": "Office And Laboratory Space [Member]" } } }, "localname": "OfficeAndLaboratorySpaceMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_OpenMarketSaleAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Open Market Sale Agreement [Member]" } } }, "localname": "OpenMarketSaleAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_OperatingLeasesAnnualIncreaseInRentExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Leases Annual Increase In Rent Expense", "label": "Operating Leases Annual Increase In Rent Expense", "terseLabel": "Percentage of annual increase in operating lease" } } }, "localname": "OperatingLeasesAnnualIncreaseInRentExpense", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tbio_OriginalSanofiAgreementAndSecondSanofiAmendmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Original Sanofi Agreement And Second Sanofi Amendment Agreement.", "label": "Original Sanofi Agreement And Second Sanofi Amendment Agreement [Member]", "terseLabel": "Original Sanofi Agreement And Second Sanofi Amendment Agreement [Member]" } } }, "localname": "OriginalSanofiAgreementAndSecondSanofiAmendmentAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_PaymentOfIssuanceCommissions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of issuance commissions.", "label": "Payment Of Issuance Commissions", "terseLabel": "Payment of issuance commissions" } } }, "localname": "PaymentOfIssuanceCommissions", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_PaymentsForBuildOutCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for build out costs.", "label": "Payments For Build Out Costs", "terseLabel": "Payments For Build Out Costs" } } }, "localname": "PaymentsForBuildOutCosts", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tbio_PaymentsOfPublicOfferingCosts": { "auth_ref": [], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments Of Public Offering Costs.", "label": "Payments Of Public Offering Costs", "negatedLabel": "Payments of public offering costs" } } }, "localname": "PaymentsOfPublicOfferingCosts", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tbio_PercentageOfIncreaseInTheMonthlyRentalExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in the monthly rental expense", "label": "Percentage Of Increase In The Monthly Rental Expense", "terseLabel": "Percentage Of Increase In The Monthly Rental Expense" } } }, "localname": "PercentageOfIncreaseInTheMonthlyRentalExpense", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tbio_PropertyAndEquipmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property And Equipments [Abstract]", "label": "Property And Equipments [Abstract]" } } }, "localname": "PropertyAndEquipmentsAbstract", "nsuri": "http://translate.bio/20210630", "xbrltype": "stringItemType" }, "tbio_RecentlyadoptedaccountingpronouncementPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RecentlyAdoptedAccountingPronouncement", "label": "RecentlyAdoptedAccountingPronouncement policy", "terseLabel": "Recently Adopted Accounting Pronouncement" } } }, "localname": "RecentlyadoptedaccountingpronouncementPolicy", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "tbio_RemainingPerformanceObligationExpectedToBeRecognizedAsRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining Performance Obligation Expected To Be Recognized As Revenue.", "label": "Remaining Performance Obligation Expected To Be Recognized As Revenue", "terseLabel": "Remaining performance obligation, expected to be recognized as revenue" } } }, "localname": "RemainingPerformanceObligationExpectedToBeRecognizedAsRevenue", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_ResearchCollaborativeArrangementExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research Collaborative Arrangement Expiration Period", "label": "Research Collaborative Arrangement Expiration Period", "terseLabel": "Research agreement, expiration period" } } }, "localname": "ResearchCollaborativeArrangementExpirationPeriod", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "tbio_RichmondGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Richmond Group [Member]" } } }, "localname": "RichmondGroupMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_RocheDiagnosticsCorporationMasterSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roche Diagnostics Corporation master supply agreement.", "label": "Roche Diagnostics Corporation Master Supply Agreement [Member]", "terseLabel": "Roche Diagnostics Corporation Master Supply Agreement [Member]" } } }, "localname": "RocheDiagnosticsCorporationMasterSupplyAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_SaleOfStockAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of stock, authorized amount.", "label": "Sale Of Stock Authorized Amount", "terseLabel": "Market sale aggreement of common stock" } } }, "localname": "SaleOfStockAuthorizedAmount", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_SanofiAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanofi agreement.", "label": "Sanofi Agreement [Member]", "terseLabel": "Sanofi Agreement [Member]" } } }, "localname": "SanofiAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_SanofiCollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sanofi Collaboration And License Agreement [Member]" } } }, "localname": "SanofiCollaborationAndLicenseAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_SanofiPasteurIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanofi pasteur.", "label": "Sanofi Pasteur Inc [Member]", "terseLabel": "Sanofi Pasteur Inc [Member]" } } }, "localname": "SanofiPasteurIncMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_SarsCov2LicensedFiledMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sars Cov2 Licensed Filed.", "label": "Sars Cov2 Licensed Filed [Member]" } } }, "localname": "SarsCov2LicensedFiledMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_SecondSanofiAmendmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Second Sanofi Amendment Agreement [Member]" } } }, "localname": "SecondSanofiAmendmentAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePricePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options grant date exercise price percent.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Percent", "terseLabel": "Percentage of exercise price per share of fair market value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePricePercent", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Abstract]", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Abstract]", "terseLabel": "Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "tbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted average remaining contractual term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "tbio_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesCancelledInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, shares cancelled in period.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Shares Cancelled in Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardSharesCancelledInPeriod", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "tbio_SharedOverageCostCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shared Overage Cost Commitment.", "label": "Shared Overage Cost Commitment", "terseLabel": "Shared Overage cost commitment" } } }, "localname": "SharedOverageCostCommitment", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tbio_ShiresMrtProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shires Mrt Program.", "label": "Shires Mrt Program [Member]", "terseLabel": "Shire's MRT Program [Member]" } } }, "localname": "ShiresMrtProgramMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "tbio_ShortTermCollaborationReceivablesCurrent": { "auth_ref": [], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) related to a collaboration, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Short Term Collaboration Receivables Current", "terseLabel": "Collaboration receivables" } } }, "localname": "ShortTermCollaborationReceivablesCurrent", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "tbio_SpecificAdditionalMilestonePaymentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specific Additional Milestone Payment.", "label": "Specific Additional Milestone Payment [Axis]" } } }, "localname": "SpecificAdditionalMilestonePaymentAxis", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "tbio_SpecificAdditionalMilestonePaymentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specific Additional Milestone Payment.", "label": "Specific Additional Milestone Payment [Domain]" } } }, "localname": "SpecificAdditionalMilestonePaymentDomain", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_StockAvailableToBeSoldUnderSalesAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock available to be sold under sales agreement.", "label": "Stock Available To Be Sold Under Sales Agreement", "terseLabel": "Stock available to be sold under sales agreement" } } }, "localname": "StockAvailableToBeSoldUnderSalesAgreement", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_StockIssuedDuringPeriodIncludingValueOfPremiumPaidOnStockValueNewIssuesUnderSecuritiesPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period including value of premium paid on stock under securities purchase agreement.", "label": "Stock Issued During Period Including Value Of Premium Paid On Stock Value New Issues Under Securities Purchase Agreement", "positiveLabel": "Shares issued during the period value" } } }, "localname": "StockIssuedDuringPeriodIncludingValueOfPremiumPaidOnStockValueNewIssuesUnderSecuritiesPurchaseAgreement", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_StockIssuedDuringPeriodSharesNewIssuesPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Shares New Issues Public Offering.", "label": "Stock Issued During Period Shares New Issues Public Offering", "terseLabel": "Issuance of common stock in connection with public offerings, net of underwriting discounts and commissions and offering costs, Shares", "verboseLabel": "Issuance of common, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesPublicOffering", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "tbio_StockIssuedDuringPeriodValueNewIssuesPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value New Issues Public Offering.", "label": "Stock Issued During Period Value New Issues Public Offering", "terseLabel": "Issuance of common stock in connection with public offerings, net of underwriting discounts and commissions and offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesPublicOffering", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "tbio_SublicenseSecondAmendmentAgreementWithSanofiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublicense second amendment agreement with sanofi [Member].", "label": "Sublicense Second Amendment Agreement With Sanofi [Member]" } } }, "localname": "SublicenseSecondAmendmentAgreementWithSanofiMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_SuiteRetentionAndDevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Suite Retention And Development Agreement [Member]" } } }, "localname": "SuiteRetentionAndDevelopmentAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tbio_SupplyAgreementExtendedPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supply Agreement Extended Period", "label": "Supply Agreement Extended Period", "terseLabel": "Agreement extended date" } } }, "localname": "SupplyAgreementExtendedPeriod", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "tbio_TechnologyAndProcessTransferMilestonePaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of milestone payments on completion of technology and process transfer.", "label": "Technology And Process Transfer Milestone Payment Receivable", "terseLabel": "Technology and process transfer milestone payment receivable" } } }, "localname": "TechnologyAndProcessTransferMilestonePaymentReceivable", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_TenantImprovementAllowanceForLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance for lease.", "label": "Tenant Improvement Allowance For Lease", "terseLabel": "Tenant improvement for lease" } } }, "localname": "TenantImprovementAllowanceForLease", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tbio_TerminationOfAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of agreement.", "label": "Termination Of Agreement [Member]", "terseLabel": "Termination of Agreement [Member]" } } }, "localname": "TerminationOfAgreementMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_TwoThousandAndEighteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 employee stock purchase plan.", "label": "Two Thousand And Eighteen Employee Stock Purchase Plan [Member]", "terseLabel": "2018 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandAndEighteenEmployeeStockPurchasePlanMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_TwoThousandEighteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen Stock Incentive Plan [Member]", "label": "Two Thousand Eighteen Stock Incentive Plan [Member]", "terseLabel": "2018 Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenStockIncentivePlanMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_TwoThousandSixteenStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Stock Incentive Plan.", "label": "Two Thousand Sixteen Stock Incentive Plan [Member]", "terseLabel": "2016 Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandSixteenStockIncentivePlanMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_TwoThousandTwentyOneInducementStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty One Inducement Stock Incentive Plan.", "label": "Two Thousand Twenty One Inducement Stock Incentive Plan [Member]", "terseLabel": "2021 Inducement Stock Incentive Plan [Member]" } } }, "localname": "TwoThousandTwentyOneInducementStockIncentivePlanMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_UpfrontPaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payments received", "label": "Upfront Payments Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentsReceived", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tbio_VectorMergerSubIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vector merger sub, inc.", "label": "Vector Merger Sub, Inc [Member]", "terseLabel": "Vector Merger Sub, Inc [Member]" } } }, "localname": "VectorMergerSubIncMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tbio_WalthamMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Waltham, Massachusetts [Member].", "label": "Waltham Massachusetts [Member]", "terseLabel": "Waltham Massachusetts [Member]" } } }, "localname": "WalthamMassachusettsMember", "nsuri": "http://translate.bio/20210630", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail", "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r25", "r162" ], "calculation": { "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r39", "r41", "r42", "r368", "r387", "r391" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r38", "r42", "r43", "r76", "r77", "r79", "r276", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r237" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r76", "r77", "r79", "r234", "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r205", "r207", "r240", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r207", "r230", "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestmentMeasurementInput": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure alternative investment.", "label": "Alternative Investment, Measurement Input", "terseLabel": "Discount Rate" } } }, "localname": "AlternativeInvestmentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r65", "r148", "r155" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of basic net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Office and laboratory space" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r73", "r115", "r118", "r124", "r137", "r274", "r277", "r291", "r352", "r366" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r35", "r73", "r137", "r274", "r277", "r291" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total, assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r134", "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Amortized\u00a0Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r132", "r135", "r143", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r208", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "verboseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "verboseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r201", "r203" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r201", "r203", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r64", "r269" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "disclosureGuidance": "Discontinuation of MRT5201 and Decrease in fair value of contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows", "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r264", "r265", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Business combination, contingent consideration, liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability [Abstract]" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r264", "r266" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r75", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r68", "r69", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r23", "r67" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r62", "r67", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "terseLabel": "Total cash, cash equivalents and restricted cash at end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]", "terseLabel": "Cash, cash equivalents and restricted cash at end of period:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r62", "r292" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r72", "r73", "r93", "r94", "r95", "r97", "r99", "r107", "r108", "r109", "r137", "r291" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r270", "r271", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Sanofi Collaboration and License Agreement" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r32", "r170", "r358", "r372" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 3 and 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r166", "r167", "r169", "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of common shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r180" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 75,343,712 shares and 75,029,625 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r47", "r48", "r51", "r361", "r375" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction In Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Balance of Contract Liabilities Related to Collaboration Agreements" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract": { "auth_ref": [ "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract", "terseLabel": "Revenue recognized as a cumulative catch-up adjustment" } } }, "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r182", "r183", "r188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementBalanceOfContractLiabilitiesRelatedToCollaborationAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementBalanceOfContractLiabilitiesRelatedToCollaborationAgreementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r182", "r183", "r188" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r182", "r183", "r188" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized from contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r65", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r65", "r113" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Incentive Stock Options and Employee Stock Purchase Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r52", "r82", "r83", "r84", "r85", "r86", "r91", "r93", "r97", "r98", "r99", "r103", "r104", "r362", "r376" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net income (loss) per share\u2014basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r52", "r82", "r83", "r84", "r85", "r86", "r93", "r97", "r98", "r99", "r103", "r104", "r362", "r376" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net income (loss) per share\u2014diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r100", "r101", "r102", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Unrecognized compensation cost related to unvested stock-based awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Unrecognized compensation cost, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r76", "r77", "r79", "r81", "r87", "r90", "r106", "r138", "r180", "r181", "r234", "r235", "r236", "r253", "r254", "r293", "r294", "r295", "r296", "r297", "r298", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r281", "r282", "r283", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Fair value,assets transfers from Level 1 to Level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Fair value,assets transfers from Level 2 to Level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r287", "r289" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r281", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r282", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r281", "r282", "r285", "r286", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r192", "r193", "r198", "r200", "r282", "r324" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r192", "r193", "r198", "r200", "r282", "r325" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r282", "r326" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Fair value, liabilities transfers from Level 1 to Level 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Fair value, liabilities transfers from Level 2 to Level 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r287", "r289" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Unobservable Inputs and Fair Value Components of Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Fair Value, assets transfers into (out of) Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Fair Value, liabilities transfers into (out of) Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r288", "r290" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueAxis": { "auth_ref": [ "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by time period financial asset is past due.", "label": "Financial Asset, Period Past Due [Axis]" } } }, "localname": "FinancingReceivablesPeriodPastDueAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period in which financial asset is past due. Element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater Than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less Than [high end numeric value] [date measure] Past Due [Member] formats.", "label": "Financial Asset, Period Past Due [Domain]" } } }, "localname": "FinancingReceivablesPeriodPastDueDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Definite-lived intangible assets, estimated life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r154" ], "calculation": { "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Definite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Estimated amortization expense of intangible assets for 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Estimated amortization expense of intangible assets for 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Estimated amortization expense of intangible assets for 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Estimated amortization expense of intangible assets for 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r149", "r151", "r154", "r158", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r154", "r336" ], "calculation": { "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Definite-lived intangible assets, gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r149", "r153" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r154", "r335" ], "calculation": { "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Definite-lived intangible assets, net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expenses [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r144", "r145", "r351" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLossNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of loss recognized that results from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss, Net of Tax", "terseLabel": "Goodwill, Impairment Charges" } } }, "localname": "GoodwillImpairmentLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Goodwill changes" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r49", "r115", "r117", "r120", "r123", "r125", "r349", "r359", "r363", "r377" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r247", "r249", "r251", "r255", "r257", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r74", "r89", "r90", "r114", "r246", "r256", "r258", "r378" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax benefits", "terseLabel": "Income tax benefits" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r64" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r64" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r64" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r64" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidRent": { "auth_ref": [ "r64" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Rent", "negatedLabel": "Long-term prepaid rent" } } }, "localname": "IncreaseDecreaseInPrepaidRent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r150", "r157" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets, gross carrying amount/net carrying amount" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r150", "r157" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Total intangible assets, gross carrying amount" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r147", "r152" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "verboseLabel": "Total intangible assets, net carrying amount" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r313", "r315" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease expiration period" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of maturities of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Operating lease commitment", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "2026 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2021 and 2022", "verboseLabel": "Operating lease liability due in first year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2024 and 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2023 and 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2022 and 2023", "verboseLabel": "Operating lease liability due in second year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r314" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease option to extend description" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating Lease Renewal Term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "verboseLabel": "Operating Lease Term Of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r73", "r119", "r137", "r275", "r277", "r278", "r291" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r73", "r137", "r291", "r353", "r370" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31", "r73", "r137", "r275", "r277", "r278", "r291" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "positiveLabel": "Fair Value at", "terseLabel": "Total, liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Commitment amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputsAndFairValueComponentsOfContingentConsiderationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r62", "r63", "r66" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r44", "r46", "r50", "r66", "r73", "r80", "r82", "r83", "r84", "r85", "r89", "r90", "r96", "r115", "r117", "r120", "r123", "r125", "r137", "r291", "r360", "r374" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows", "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r115", "r117", "r120", "r123", "r125" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r308", "r315" ], "calculation": { "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease, liability", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r304" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r304" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r305", "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "verboseLabel": "Opearting lease payment" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r303" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets, net", "verboseLabel": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r312", "r315" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r311", "r315" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term", "verboseLabel": "Remaining term of lease" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesRentExpenseMinimumRentals": { "auth_ref": [ "r300", "r301", "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.", "label": "Operating Leases, Rent Expense, Minimum Rentals", "terseLabel": "Monthly lease payments" } } }, "localname": "OperatingLeasesRentExpenseMinimumRentals", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r30" ], "calculation": { "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/AccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r357", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/AccruedExpensesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r36", "r39" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized gains (losses) on available-for-sale securities, net of tax of $0", "verboseLabel": "Unrealized gains (losses) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r37", "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax", "verboseLabel": "Unrealized gains (losses) on available-for-sale securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Payments of other offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r59" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r58" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r208", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020; no shares issued and outstanding as of June 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r21", "r22" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r60" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from public offerings, net of underwriting discounts and commissions" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Gross proceeds from issuance of public offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r60", "r233" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r56", "r57", "r133" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Sales and maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r60", "r233" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r25", "r163" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r165", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r24", "r161" ], "calculation": { "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r163", "r371" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r161" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of recorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Recorded Unconditional Purchase Obligation Due in Second Year", "terseLabel": "Purchase commitments, year 2023" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of recorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Recorded Unconditional Purchase Obligation Due in Third Year", "terseLabel": "Purchase commitments, year 2024" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months", "terseLabel": "Purchase commitments, year 2022" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r199", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r199", "r317", "r320", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r243", "r405" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expenses [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r71", "r350", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Cash deposit collateral" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r8", "r67", "r71", "r350", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r2", "r8", "r71" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "periodEndLabel": "Restricted cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Common Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r181", "r237", "r369", "r386", "r391" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r76", "r77", "r79", "r81", "r87", "r90", "r138", "r234", "r235", "r236", "r253", "r254", "r382", "r384" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r111", "r112", "r116", "r121", "r122", "r126", "r127", "r129", "r186", "r187", "r334" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementSummaryOfCollaborationRevenueDetail", "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r310", "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesScheduleOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesSummaryOfEstimatedAmortizedCostsAndFairValueOfTheDebtSecuritiesAvailableForSaleAndHeldToMaturityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfTotalAcquisitionRelatedContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Total Acquisition Related Contingent Consideration Liability" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]", "terseLabel": "Summary of Collaboration Revenue" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r93", "r94", "r97", "r99", "r104" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareAdditionalInformationDetail", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfPotentialCommonSharesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r149", "r153", "r335" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillSummaryOfDefiniteLivedIntangibleAssetsSubjectToAmortizationAndIndefiniteLivedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Summary of Definite-Lived Intangible Assets Subject to Amortization and Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r25", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r208", "r232" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r212", "r218", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Assumptions Used in Black-Scholes Option-Pricing Model to Determine Grant-Date Fair Value of Stock Option Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Arrangements with Employees and Nonemployees [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r64" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock options for purchase of common stock held, exercisable period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock options, exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of shares, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Intrinsic value, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r214", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares, ending balance", "periodStartLabel": "Number of shares, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, ending balance", "periodStartLabel": "Weighted average exercise price, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Intrinsic value, vested and expected to vest, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of shares, vested and expected to vest, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, vested and expected to vest, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Number of stock issued during period under the plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r206", "r211" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period of stock options after grant date" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r224", "r238" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineGrantDateFairValueOfStockOptionGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, vested and expected to vest, ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r11", "r354", "r355", "r365" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r72", "r73", "r93", "r94", "r95", "r97", "r99", "r107", "r108", "r109", "r137", "r180", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r34", "r76", "r77", "r79", "r81", "r87", "r90", "r106", "r138", "r180", "r181", "r234", "r235", "r236", "r253", "r254", "r293", "r294", "r295", "r296", "r297", "r298", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r76", "r77", "r79", "r106", "r334" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockBasedCompensationExpenseDetail", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r13", "r14", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "verboseLabel": "Issuance of common stock under employee stock purchase plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Issuance of common, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the number of shares issued.", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "terseLabel": "Increase in common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r180", "r181", "r216" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of shares, exercised", "terseLabel": "Exercise of stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r13", "r14", "r180", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "negativeTerseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r34", "r180", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r73", "r131", "r137", "r291" ], "calculation": { "http://translate.bio/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balances", "periodStartLabel": "Beginning balances", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets", "http://translate.bio/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r299", "r322" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r299", "r322" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r299", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r299", "r322" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/LeasesAdditionalInformationDetails", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CollaborationAgreementAdditionalInformationDetail", "http://translate.bio/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://translate.bio/role/IntangibleAssetsAndGoodwillAdditionalInformationDetail", "http://translate.bio/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://translate.bio/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. Government Agency Bonds" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r192", "r200", "r364" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasuries" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/IncentiveStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r92", "r99" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding\u2014diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r91", "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding\u2014basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://translate.bio/role/CondensedConsolidatedStatementsOfOperations", "http://translate.bio/role/NetIncomeLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922355-210448" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25383-109308" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121595440&loc=d3e34039-112682" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r406": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r407": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r408": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r409": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r410": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r411": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 82 0001193125-21-237889-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-237889-xbrl.zip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�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end

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�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